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ABSTRACT
The Bhutanese traditional medicine (BTM) has been integrated with biomedicine
since 1967 and serves as one of the important health care delivery systems in Bhutan.
Therefore, the need to imrpove its quality through scientific studies have become
paramount. In our efforts to address this important issue, we authenticated the botanical
names of low altitude medicinal plants, determined the major classes of phytochemicals
of 25 selected species, evaluated the bioactivities of the crude extracts of seven of them,
and finally isolated the phytochemicals from six of these plants. We have established
the antimalarial, anti-inflammatory, antimicrobial, and cytotoxicity activities of these
phytochemicals and also identified five novel drug lead compounds.
In our ethnobotanical study; we resolved the traditional and taxonomical
discrepancies for Bhutanese medicinal plants, assessed the current BTM formulations,
and carried out the field survey for the low altitude medicinal plants (LAMP), which is
described in Chapter 2. Out of 113 LAMP, 92 species are used in the current multiingredient formulations produced by Manjong Sorig Pharmaceuticals (MSP) and 28 of
them are currently imported from India. Out of these 28 species, 16 of them are found
growing abundantly in Bhutan and most of them have not been studied for their
phytochemicals and pharmacological properties. In this study, we have selected 25 of
these plants and assessed them for their major classes of phytochemicals which we
have described in Chapter 3. Of these, the crude extracts of seven selected plants
(Corydalis

crispa,

C.

dubia,

Ajania

nubegina,

Meconopsis

simplicifolia,

Pleurospermum amabile, Aconitum laciniatum and Codonopsis bhutanica) were
investigated for their biological activities and we found that five of them possessed
significant antiplasmodial activities, one species showed moderate cytotoxicity, two
species exhibited moderate anti-Trypanosoma brucei rhodesiense activity, six species
exhibited significant to mild TNF-α inhibitory activities, and all seven plants exhibited
mild antimicrobial activity. The highest antiplasmodial activity was exhibited by the
chloroform extract of M. simplicifolia with an IC50 value of 0.40 g/mL against the
TM4/8.2 strain without cytotoxicity. The chloroform extract of C. crispa showed
moderate cytotoxicity with an IC50 value of 12.5 g/mL and the highest antiinflammatory activities. The chloroform extracts of P. amabile and also C. crispa
exhibited moderate anti-Trypanosoma brucei rhodesiense activity with IC50 values of
16.1 and 4.6 g/mL, respectively. The dichloromethane extract of P. amabile showed
the highest antibacterial activity with a MIC value of 312 µg/mL or a MIZ value of 14
xix

mm against B. subtilis. Guided by these preliminary bioactivity results, we have carried
out the isolation of the phytochemicals from six of the seven aforementioned plants.
A total of 43 compounds were isolated from these plants. Of these, 25 were
alkaloids, nine were terpenoids, six were furanocoumarins, two were flavones and one
was a glycosylated flavone. From C. crispa (described in Chapter 4), nine isoquinoline
alkaloids 1-9 were isolated and protopine (1) was identified as the major alkaloid
component. The characterization of compounds 2 and 3 with complete NMR data
analysis was achieved by us for the first time. Similarly, from C. dubia (described in
Chapter 5), another group of isoquinoline alkaloids 10-15 were isolated along with the
alkaloids 1 and 9. Alkaloid 15 was isolated as a new natural product which we named
as dubiamine after the plant’s name (C. dubia) and its structure was confirmed from its
single crystal X-ray structural analysis. From A. nubigena (Chapter 6), nine
compounds, 19-26 belonging to terpenoids, flavonoids and glycosylated flavones were
isolated from the essential oil and crude methanol extract. While luteolin (25) was the
major constituent of the MeOH extract, (3R,6R)-linalool oxide acetate (19) was the
major constituent (75.8 %) of the essential oil. Out of 53 constituent peaks detected by
GC/GC-MS, 45 of them were identified with chamazulene (20) as a new subchemotype of the genus Ajania. From the MeOH extract of M. simplicifolia, one new
protoberberine alkaloid (27), with protopine (1) as the major alkaloid, and four
benzophenanthridine type alkaloids (29-32) were isolated. The new alkaloid was named
as simplicifolianine after its plant species, M. simplicifolia. The GC/GC-MS identified
37 constituents from its essential oil with 14 of them (38% of total oil) being fatty acid
esters and dimethyl 1,4-benzenedicarboxylate (29.2%) as the major constituent. From
P. amabile, 10 known compounds were isolated for the first time. Its essential oil
yielded terpenoids (37-40) with (E)-isomyristicin (37) as the major constituent, and the
crude MeOH extract yielded furanocoumarins (41-46) with bergapten as the major one.
Through GC/GC-MS analysis, we have also identified 52 compounds from the essential
oil component of this plant. From A. laciniatum, five known lycoctonine-type C19diterpenoid alkaloids (54-58), with pseudaconitine (54) as the major compound, were
isolated.
Following the same bioassay methods conducted for the crude extracts of the
selected seven plants, we tested 32 of the total of 43 compounds isolated from the six
plants investigated. Of these, 18 compounds showed interesting biological activities.
Among these 18 active compounds, protopine (1), cheilanthifoline (11), scoulerine
xx

(14), luteolin-7-O-β-D-glucopyranoside (26) and simplicifolianine (27) exhibited
highly significant antiplasmodial activities against chloroquine sensitive and multidrug
resistant strains of P. falciparum and were identified as antimalarial drug lead
compounds. Scoulerine (14) significantly inhibited acetylcholinesterase with a
minimum inhibitory requirement of 0.0015 nmol which is almost twofold better than
that of galanthamine (0.003 nmol), the currently used standard drug to treat Alzheimer
disease. Only protopine showed anti-inflammatory activity against TNF-α with a
statistically significant p-value of p<0.05. Apart from compounds 25 and 26, which
exhibited mild cytotoxicity, the other compounds were not cytotoxic.
In general, the biological activities of the crude extracts of the seven selected
medicinal plants and the 18 pure compounds that we have studied were in alignment
with their ethnopharmacological uses. Thus, our studies have validated the use of these
plants in BTM either individually or in combination with other medicinal ingredients to
treat diseases (especially malaria) as described in the pharmacopoeia and the formulary
compendium of BTM.
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CHAPTER 1
INTRODUCTION

Photograph courtesy: Google.com

"Until man duplicates a blade of grass, nature can laugh at his so-called scientific
knowledge. Remedies from chemicals will never stand in favour compared with the
products of nature, the living cell of the plant, the final result of the rays of the sun, the
mother of all life… The doctor of the future will give no medicine, but will interest his
patients in the care of the human frame, in diet, and in the cause and prevention of
disease."
-Thomas A. Edison, Inventor.
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1.1. General Introduction
Disease and suffering mark the impermanence of human life. Despite the
advancement in medical sciences, innumerable people are affected by diseases and
millions die every year. Of the 57 million global deaths documented by the World
Health Organization (WHO) in 2008, 36 million (63%) were due to non-communicable
disease (WHO, 2013a). In 2012, the WHO recorded 6.6 million deaths under the age of
5 and 58% of mortality was due to communicable diseases (WHO, 2013b). The
microbial infections, malaria, cardiovascular diseases and cancer are the leading causes
of premature death worldwide. While the sexually transmitted diseases (499 million),
HIV-AIDS (35.3 million), tuberculosis (8.7 million) and other unaccounted microbial
infections, top the morbidity and mortality chart, about 219 million cases of malaria,
including 660,000 deaths were reported in 2010 (WHO, 2013c). Cancer accounted for
7.6 million deaths in 2008 (WHO, 2013d).
These mortality and morbidity statistics suggest that either the treatment regimens
have not been effective in treating the diseases or that the advanced medical facilities
were not accessible to many people. Many people continue to face a scarcity of
medicines especially in the developing countries. Surveys undertaken from 2007 to
2012 indicated that the average availability of selected generic medicines in the public
sector in low- and middle-income countries was only 57% (WHO, 2013e). Patients who
cannot afford the expensive modern hospital treatments or whose diseases did not
respond to modern medicines often resort to traditional and complementary medicines
(TCM), which often include a spiritual component.
It is reasonable to classify TCM into folk medicine, scholarly medical and
spiritual healing systems. While it is difficult to establish an accurate origin and
chronology of TCM, it was found that the personal belongings of a 5000 years old
frozen ‘ice man’ discovered in the Swiss Alps, included medicinal plants which were
apparently used for treating intestinal parasites (Gewali, 2008). Many ancient
civilizations including the Mesopotamian, Egyptian, Chinese, Indian, Greek, Roman
and Tibetan developed scholarly medical systems (Wangchuk, 2004) with rich herbal
traditions. Today, TCM caters to almost 70-80% of the world’s population in their
primary health care services (WHO, 2008). The selected country-wise percentages of
the population which have used TCM are: 80% in Africa, 77% in Germany, 75% in
France, 74% in Belgium, 71% in Chile, 70% in Canada, 60-70% in Japan, 48% in
Australia, 46% in Switzerland and the United Kingdom, 42% in USA, 40% in China,
2
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Colombia and Indonesia, 30% in Vietnam (WHO, 2002) and about 60% in Bhutan. The
Bhutanese traditional medicine belongs to the larger corpus of Tibetan So-wa-rig-pa
medicine.
Due to this widespread use of TCM for primary health care and its rich medicinal
plant traditions, it has recently captured the attention of the pharmaceutical industry and
the medical research community, both of which have sought to capitalize on the
knowledge contained therein (Vos, 2010). Natural products used in TCM have been the
primary source of early drug discovery and still continue to provide new therapeutic
chemical entities against various pharmacological targets including cancer, malaria,
Alzheimer’s disease, inflammatory pain, and microbial infections. An analysis by
Fabricant and Farnsworth (2001) on the origin of the drugs developed between 1981
and 2001 showed that 80% of 122 plant-derived drugs were related to their original
ethnopharmacological purposes. Between 2000-2005, about five medicinal plant-based
drugs were introduced in the United States market and another seven plant-derived
compounds are currently in clinical trials around the world (Balunas and Kinghorn,
2005; Chin et al., 2006).
It is estimated that about 50,000 plants species are believed to be used in TCM
(Gewali, 2008) and one can only admire how many bioactive chemical entities with
potential for drug development must be present in them. Gewali (2008) generated a
general breakdown of the availability of higher plant species and medicinal plants for
the selected countries shown in Table 1.1. While nations like the USA, Indonesia and
Malaysia have a high number of higher plant species, their utilisation as medicinal
plants are low (Table 1.1). India ranked first with 20.0% in the utilisation of medicinal
plants and China closely followed it with 18.9%. Countries like Thailand, Sri Lanka
and Vietnam use about 15.5-17.1 % of their floral biodiversity as medicinal plants. A
number of initiatives including the International Collaborative Program (ICP) and the
National Cooperative Drug Discovery Group (NCDDG) funded by the U.S. National
Cancer Institute (NCI) were set up to discover new drugs from medicinal plants. The
ICP studied 800 medicinal plants from the tropical biodiversity of Vietnam and Laos
and discovered at least 25 biologically active compounds including 13 new anti-HIV
agents and three new antimalarial compounds (Soejarto et al., 2002). The NCDDG
project collected 5886 plant accessions primarily in tropical forests representing 2582
species from 1358 genera in 288 families and numerous bioactive compounds were
isolated from them (Balunas and Kinghorn, 2005).
3
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Table 1.1. Number of medicinal plants reported from selected countries.
Country
China
Bhutan
India
Indonesia
Malaysia
Nepal
Pakistan
Philippines
Sri Lanka
Thailand
USA
Vietnam

Higher plant species
26092
5603
15000
22500
15500
6973
4950
8931
3314
11625
21641
10500

Medicinal plant species
4941
600
3000
1000
1200
700
300
850
550
1800
2564
1800

%
18.9
10.7
20.0
4.4
7.7
10.0
6.18
9.5
16.5
15.5
11.8
17.1

In the case of Bhutan, of more than 5603 higher plant species, only 600 plants are
used in the Bhutanese form of So-wa-rig-pa medicine (popularly known as Bhutanese
traditional medicine (BTM)). The plants used in folk and spiritual healing systems were
not documented and thus are not included in Table 1.1. Unlike other scholarly
medicines such as Chinese, Indian and Thai traditional medicines, the BTM has not
been subjected to in-depth scientific analysis. There is scarcity of scientific information
on the medicinal plants of Bhutan.

1.2

Bhutanese traditional medicine (BTM)

1.2.1. Overview of BTM
In ancient times, Bhutan was known as ‘bruk-tsen-dhen-b.kod-pai-rgyal-khab or
the Dragon kingdom of bountiful medicinal sandal wood and sman-jong or the land of
medicinal plants (Dorji, 2005). The ascribing of such appropriate names is today
authenticated by the living tradition of a rich traditional medical knowledge that is
being supported by the country’s unique biodiversity. With 72% of the country under
forest cover and harbouring fauna within, Bhutan is considered as one of the ten global
biodiversity-hotspots par excellence in the world. The diverse landlocked ecological
zones with notable differences in altitude ranging from 150 meters above sea level
(masl) in the sub-tropical south to 7500 masl in the alpine north (MOA, 2009), has
facilitated the development of rich biodiversity and cultural heritages. One of the pillars
of the Bhutanese cultural heritage is the traditional healing systems (THS). This
includes the scholarly medical system, known as BTM, folk medicine and the spiritual
healing system. Until the advent of modern allopathic medicine in the 1960s, the THS
practitioners were the sole health care providers and even today their practices are
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widespread in the country. Recently, Pelden (2012) reported the existence of 1,683
Folk Healers and 112 BTM practitioners alongside 1,593 modern health care providers.
Since preservation of culture is one of the four pillars of the country’s
development policy called ‘Gross National Happiness’, it has gained much attention
over recent years both in the national and international arena. Within Bhutan, the BTM
is protected by the constitutional rights and other national policies. Section 21 and 22
under Article 9 of the constitution of the Kingdom of Bhutan states that, “The state
shall provide free access to basic public health services in both modern and traditional
medicines”. Bhutan 2020: A Vision for Peace, Prosperity and Happiness also states
that, “We must continue to provide a place for traditional medicine in our system of
health care. Traditional medicine embodies knowledge that has been accumulated over
centuries and which draws upon the nation’s rich bio-diversity and of plants with
proven medical qualities. As these qualities become substantiated by scientific research,
there is a growing need to integrate more effectively traditional medicine with the
modern system of health care. The maintenance of traditional medicine not only adds
dimensions to the nation’s system of health care, but provides an alternative for those
who seek one. It should also be regarded as a conscious decision to conserve a part of
our rich and varied cultural heritage”. The national health policy of the Ministry of
Health in Bhutan states that, “Focused efforts shall be directed towards making
Bhutanese So-wa-rig-pa the centre of excellence in providing quality traditional
medical services including wellness centre that is recognizable at an international level
and that the identification, demarcation and protection of areas rich with medicinal
plants be managed judiciously by the relevant district administration in conformity with
the conservation regulations of the Ministry of Agriculture and Forestry”. The inclusion
of BTM in the country’s constitution and policy frameworks stand as a testament to the
Government’s commitment in preserving and promoting the sustainable traditional
medicine and that alone is a great achievement and source of inspiration for the BTM
practitioners and communities.
While the history of BTM (Dorji and Morisco, 1989; Wangdi and Wangdi, 2007;
Wangchuk et al., 2007a; Wangchuk, 2008) noted many Bhutanese leaders and BTM
practitioners, there are four important figures that are prominent due to their paramount
influence and contributions to the inception and development of this medical system in
the country. They are medicine Buddha (Sangay Manlha, 2500 B.C), Guru Rimpoche
(Mahayana Buddhist saint of 8th Century A.D), Zhabdrug Rimpoche (Bhutanese
5
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political and religious leader of 13th Century A.D) and Jigme Singye Wangchuk (fourth
king of Bhutan) (Figure 1.1A-D).

A

B

C

D

Figure 1.1. Important figures in the history of BTM: A) The medicine Buddha, B)
Guru Rimpoche, C) Zhabdrung Rimpoche, D) Jigme Singye Wangchuk (4th King)
(Photograph by Wangchuk, 2008).
The BTM uses Rgyud-zhi (Four Root Medical Tantras) (Choeda, 1989; M.gonpo,
1992), Shel-gong-shel-phreng (Phuntshok, 1994) and as many as 26 other Tibetan
contemporary So-wa-rig-pa related books as reference and teaching materials. Since
BTM follows Tibetan textual traditions, many similarities including philosophy,
concepts and principles of the BTM ethnopharmacology and the ethnobotany were
apparent. Philosophically, the BTM adheres to the tenets of the mainstream Buddhist
philosophy.
Ethnopharmacologically, this medical system observes four universal principles:
1) the principle of five cosmo-physical elements (byung-ba-nga); 2) the principle of
three humors (nad-pa-g.sum); 3) the principle of astrology (rtsi); and 4) the principle of
binary opposition of intrinsic hot-cold quality (tsha-brang-byung-ba). Etiologically,
about 404 disorders are recognised which are classified into four major categories: 1)
afflictions by spirits (kuen-rtag-g.don-gyi-nad); 2) sufferings originating from bad
karmic actions of a previous life (g.shen-d.bang-sgon-les-kyi-nad); 3) minor ailments
that heal by themselves without requiring major medical intervention (star-snang׳phrel-gyi-nad); and 4) life threatening diseases based on the principles of the three
humors (yongs-grub-tsheyi-nad). The kuen-rtag-g.don-gyi-nad and the g.shen-d.bangsgon-les-kyi-nad are mainly dealt within the Local Healing Systems (not described
here), the star-snang-׳phrel-gyi-nad and the yongs-grub-tsheyi-na are principally
treated by BTM. These diseases are diagnosed through pulse reading, urine analysis,
and examination of the physical changes and studies of the patient’s medical history.
6
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Ethnobotanically, both BTM and the Tibetan medicine consider the five cosmophysical elements such as earth, water, fire, air, and space as the vital components
responsible for the healthy growth of medicinal plants. It is only the matter of balance
in these elements that would determine whether the plant is healthy, diseased, toxic or
medicinal.
While there are many similarities between the mainstream Tibetan medicine and
BTM, the local beliefs, culture and traditions, and the constant processes of review,
adaptation, innovation and evolution made the BTM particular to Bhutan. Such
variations are to be expected as the materia medica of the mainstream Tibetan medicine
should not be considered as standard and static both in time and space, but as a tradition
that has been constantly evolving in several countries with its adaptations to local
vegetation, culture and foreign influences (Boesi, 2006). The language of a community
or a country is also an important factor that can affect description, identification and
classification of a plant. For example, the So-wa-rig-pa medical practitioners in Bhutan
are known as Drung-tshos and Man-pas, in Tibet as Gso-gyad and Man-pa, and in
Dolpo (Nepal) and Mongolia as Am-chis and Olamjila Amchi, respectively.
One notable difference is the BTM have segregated the medical services, training,
and the collection and processing of medicines. The National Institute of Traditional
Medicine (NITM), under the Royal University of Bhutan, develops human resources
required for providing the traditional health care services. The Traditional Medicine
Hospitals (TMH) provides primary health care services to the people through different
BTM hospitals and Basic Health Units in the country. The Manjong Sorig
Pharmaceuticals (MSP) under the Ministry of Health of Bhutan carries out an
independent identification, collection, formulation and production of medicines. Other
examples of BTM specific practices as defined by the participants of this study are: 1)
acupressure therapy that mainly uses G.ser-khab (gold needle) (Figure 1.2) which was
innovated by a Bhutanese Drung-tsho Sherab Jorden based on the principle of a
Tibetan procedure called Spra-ba (moxibustion) (Dorji and Morisco, 1989); and 2)
some health problems, the current formulations and the medicinal ingredients, and the
processing methods are slightly different to the mainstream Tibetan medicine.
Currently, large-scale production equipment and methods have replaced the
ancient small-scale mortar and pestle-based preparation of medicines. The recent
Bhutanese traditional classification of diseases and related health problems (Gayleg et
al., 2010), identified and recognized only 79 diseases. Similarly, out of the thousands
7
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prescribed in the mainstream Tibetan pharmacopoeia, only 103 formulations were
selected and modified to suit the current needs of the formulation in Bhutan (Tenzin,
2007). The selection of these 103 formulations was strictly based on the prevalence and
the trend of the diseases (79 types of diseases) in the country. These formulations use
only about 300 types of locally available medicinal ingredients, the bulk (229 types)
being medicinal plants (Tenzin, 2007).

A

B

Figure 1.2. Bhutanese golden needle therapy: A) Golden needle (80-90% pure gold),
B) Application of heated golden needle in the affected meridian point of a patient
(Photograph by Wangchuk, 2008).
The Drung-tshos and sman-pas generally classify the medicinal plants as: 1)
high altitude medicinal plants (HAMP) (sngo-smen) comprising 116 species; 2) low
altitude medicinal plants (LAMP) (khrog-smen) comprising 113 species; and 3) plant
exudates (rtsi-smen) (Wangchuk et al., 2008a, 2009). The BTM practitioners estimated
that about 30-40% of these medicinal plants are different from the mainstream Tibetan
medicine formulations. Another distinction is that, unlike Tibetan medicine, the BTM
was officially recognized by the government of Bhutan and was integrated with the
mainstream biomedicine health care services in 1967 to provide better health care
choices to the people.

1.2.2.

Treatments and medications
A recent study by Lhamo and Nebel (2011) on the perception and attitudes of the

Bhutanese towards the BTM health care services reported that 51% of 155 respondents
of the study were being treated by the So-wa-rig-pa practitioners and about 83% of
them were satisfied with the traditional services provided by BTM. This finding
8
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suggested that the BTM is still an effective tool for treating various diseases in Bhutan.
In fact, it was reported that the NTMH caters to 20-30% of the daily out-patients within
49 traditional medicine units attached to 20 district modern hospitals and 29 basic
health units (BHU) in the country (Wangchuk et al., 2007a).
To treat diseases, the BTM practitioners (Drung-tshos and Man-pas) generally
employ four main treatment procedures such as correction of diet, modification of
behavior, medication and the five accessory physiotherapies (Les-nga-pyad-nga)
(Wangchuk et al., 2007a). Among these treatment services, les-nga-pyad-nga (five
accessory physiotherapies) was the most popular among patients and they have proven
effective for treating chronic diseases such as sinusitis, arthritis, rheumatism and the
diseases related to the digestive and nervous systems. In 2011 patient records
maintained by the National Traditional Medicine Hospitals (NTMH) (NTMH, 2011)
listed the top five diseases as: neurological problems (tsa-d.kar), sinusitis (ya-khrag),
stomach disorders (pho-nad), arthritis and rheumatism (brum-bu), and skin diseases
(chuser-pak-nad).
The medications for treating diseases are prepared using medicinal ingredients
belonging to five major categories: 1) medicinal plants (shing-sman) (bulk ingredient);
2) precious gem stones and metals (rin-po-che-sman); 3) minerals (rdo-sman); 4)
medicinal soils (sa-sman); and 5) animal parts (srog-chags-sman). The gem stones
include cat’s eye, turquoise, emerald, ruby and sapphire. The precious metals include
gold, silver, copper, bronze and iron. The minerals include stones, ores, rock exudates
and base minerals including rock and sea salts. About 18 types of medicinal ingredients
belonging to precious gem stones, metals, minerals and medicinal soils are used in the
current formulations. The animal parts include the parts and products of four footed
animals (mainly milk, blood, bile, bone and horn), birds (mainly meat), insects (whole
parts), insect-fungi (whole parts), reptiles (mainly meat and skin) and marine organisms
(mainly crab, pearls, seashells and corals). About 35 different types of animal products
are used in the current formulation of BTM. Some rare animal parts such as rhinoceros
horn, tiger bone, elephant tusk and musk are banned from use in the herbal
formulations. Our analysis of the current formulations revealed that different types of
medicinal ingredients are mixed in specific proportion and then processed into different
dosage forms including pills (ril-bu, 40 %), tablets (gor-lab, 31 %), capsules (13 %),
powders (phye-ma, 4 %), ointments (byug-sman, 3 %), decoctions and syrups (thang, 3
%) and un-established dosage forms (6%). Except for capsules and tablets (both
9
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modern dosage forms), the other dosage forms are traditionally described and
prescribed. All these medicines are recommended to be taken with hot water.
If an ailment persists, even after prolonged adherence to the prescribed
medications, patients are generally referred to undergo the five accessory therapies
which include emesis, purgation, nasal irrigation, enema and minor surgical procedures.
The minor surgical procedures include bloodletting, cauterization, moxibustion and
needle acupressure therapy. The Drung-tshos and sman-pas believe that such therapies
can remove toxins, combat the latent disorder fully and act as a prophylactic by
improving the bodily system to avoid future recurrence. Another popular treatment
regimen is herbo-mineral water treatment which comprises bathing in four categories of
water: 1) medicinal water (Sman-chu); 2) hot springs (Tsha-chu); 3) sanctified spring
water (Drub-chu); and 4) five herbal elixir steam water (B.dud-rtsi-nga-lum).
While Tsha-chu is hot spring water usually found in volcanically active areas,
Sman-chu is cool medicinal water rich in natural minerals such as sulphur, phosphorus
and iron that are associated with a pungent aroma and are usually found in marshy
areas. Drup-chu is holy spring water believed to be unearthed by Drub-thops
(enlightened beings) or eminent Lamas through their arduous meditation or miraculous
activities (Wangchuk, 2010). These three healing types of water (Tsha-chu, Sman-chu
and Drup-chu) are therefore regarded sacred and are generally believed to cleanse away
sins and heal mental and bodily disorders. So far, about 10 Tsha-chu, 14 Sman-chu and
16 Drup-chu have been recorded in Bhutan (Wangchuk, 2010) and the search for other
sacred sources is continuously pursued by the Drung-tshos and sman-pas. Although
visits by patients to these three water treatment sources are popular, no patient records
have been maintained to date by the Drung-tshos and Man-pas.
B.dud-rtsi-nga-lum is man-made medicated water, which is prepared by the
Drung-tshos and sman-pas using herbal ingredients. It is of four types: herbal bath
(chu-lums), herbal steaming (rlang-lums), localized steaming (rlang-dhugs) and herbal
compress (ching-lums). The 2011 patient records of NTMH (NTMH, 2011) showed
that 11,280 patients were treated by localized steaming, 4,136 patients by herbal
steaming, 3,338 patients by herbal bath and 165 patients by herbal compress. Judging
by the number of patients, it appeared that the localized steaming method was the most
popular type of b.dud-rtsi-nga-lum.
While providing the traditional medical services, the BTM practitioners adhere to
their compassionate approach to treating the disease and patients together. For the
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safety of patients, the practitioners have to undergo a rigorous 5 years (for Drung-tshos
course) and 3 years (sman-pas course) of training at NITM and then they have to
register themselves with the Bhutan Medical Health Council, which legalises their
profession as clinical traditional physicians. While in service, they have to undergo
mandatory training on good clinical practice, patient information confidentiality,
hospital management, safety and sanitation, good dispensing practices and adverse drug
reactions (ADR) reporting processes. The medicines that they prescribe to patients have
to be registered with the Drug Regulatory Authority of Bhutan. In order to provide the
same, consistent and efficient traditional health care services, these practitioners have
to follow the standard operating procedures set by the Ministry of Health in Bhutan.
In terms of monitoring the quality of production of BTM medicines, the MSP
oversees it through the enforcement of locally adapted Good Manufacturing Practices
(GMP), Good Laboratory Practices and Good Collection Practices, which are still
under adaptation, modification and development stages. While modern quality
parameters such as macroscopy, microscopy, physiochemical (total ash value, moisture
content, loss on drying, essential oil content) and comparative thin layer
chromatography analysis were recently adapted, the ancient methods for assessing the
quality of medicinal ingredients are still practiced at the MSP.
The traditional methods to identify, evaluate and grade the quality of medicinal
ingredients are achieved mainly through the observation of: a) the macroscopic features
such as shape, size, cutting appearances and texture; b) the organoleptic properties such
as color, aroma and taste; and c) the characteristics of the plants such as smooth, heavy,
warm, oily, cold, blunt, cool, flexible, fluidity, dry, non-oily, hot, light, sharp, coarse
and mobility. Often the medicinal parts are burnt or placed in water to determine their
authenticity. For distinguishing and grading the quality of medicinal plants, the BTM
practitioners rely on six different types of tastes such as sweet (ngar), sour (kyur), salty
(tsha), bitter (kha-ba or khag-tra), pungent (tsha-ba) and astringent (ka). For example,
Glycyrrhiza glabra L. (shing-m.ngar) is distinguished by its sweet taste, Phyllanthus
emblica (kyu-ru) by its sour taste, Piper pedicellatum DC. (pi-pi-ling) by its acrid taste,
Neopicrorhiza scrophulariiflora Hong (hong-len) by its bitter taste and Terminalia
chebula Retzius (a-ru) by its astringent taste.
Generally, the medicinal plants or formulations with acrid, salty, sour and sweet
taste are used for treating wind disorders; bitter, sweet and astringent taste for treating
bile disorders; and acrid, sour, and salty taste for treating phlegm disorders. Therefore,
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Chapter 1: Introduction

the grading of the quality of medicinal plants is also undertaken in accordance to these
needs and formulations. For example, the reddish seeds of Punica granatum L., with a
sour taste, is believed to be of high medicinal value for treating air disorders affecting
the stomach and digestive system as opposed to its seeds which have a sweet taste.
For the finished products, the quality parameters include stringent adherence to 1)
appropriate colour, aroma, taste and solubility of the products, 2) standard dosage
forms, 4) pH values, 5) testing the products for friability, disintegration and bulk
density, and 5) packaging with appropriate materials. While the laboratory quality test
protocols are considered important, the quality, safety, and effectiveness of any
medicines depended largely on the quality of their raw materials and how they are
handled through collection and production processes. Therefore, much emphasis has
been given to monitoring the quality at their sources of collections, which is being
achieved by adherence to g.ches-pai-yan-lag-b.dun or seven branches of quality
practices.

1.2.3. Traditional concepts, classification and characterisation of medicinal plants
Conceptually, the BTM considers the five cosmo-physical elements: earth or
land, water, fire, air, and space to make up the biological manifestation in all living
forms including, humans, disease and medicinal plants. It is only the matter of balance
in these elements that would determine whether the life form is healthy or diseased or
medicinal. For example, the growth of a healthy plant and its properties (yon-tan)
including taste (ro), smell (grim), main constituents (zes-׳jor), potency (ngo-bo-nus-pa)
and quality (pue-tshey) are determined by the combinations of these five cosmophysical elements which usually manifest into balanced plant nutrients (see Table 1.2).
Table 1.2. Effects of the five cosmo-physical elements on the taste, nutrients and
therapeutic effects of medicinal plants (Krug, 2008).
Elements

Taste

Potency

Contraindication

Earth + water

Sweet

Improves air and bile

Exacerbates phlegm

Earth + fire

Sour

Improves phlegm

Exacerbates bile

Water + fire

Salty

Improves air and phlegm

Exacerbates bile

Water + air

Bitter

Improves bile

Exacerbates air and phlegm

Fire + air
Earth + air

Hot (pungent)
Astringent

Improves air and phlegm
Improves bile

Exacerbates bile
Exacerbates air and phlegm
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The combination of the earth and water cosmo-physical elements is believed to nurture
a sweet taste for a plant which is claimed to improve the defective air and bile, or
associated disorders, but may exacerbate phlegm disorders if the proper balance is not
achieved in the medication. The details of the effects of the five proto-elements on the
taste and therapeutic effects of medicinal plants, including their potency and
contraindications, are given in Table 1.2.
The Drung-tshos and sman-pas must comprehend the medicinal plants in relation
to these five cosmo-physical elements since different plants influence the three
principle energies in a body differently, depending on the inherent nature and the
properties of the plants. For example, a plant of sweet nature, which is mainly nurtured
by the combination of water and earth elements (Table 1.2), is medicinal but can
exacerbate the phlegm disorders. Therefore, a Drugn-tsho’s skills to reduce or at least
neutralize that side effect through exclusion or in combination with other plant
ingredients of different nature would be crucial in formulating safe and effective
medicines. The BTM practitioners characterize medicinal plants by four properties as
nature, taste, potency and quality, which they assess before a patient is considered for
treatment. In relation to the classification and characterisation of medicinal plants, the
BTM have well documented traditional texts. The BTM mode of naming, description,
identification and classification of the medicinal plants are based mainly on the altitude,
habitat, morphology, uses, cultural and religious significance, resemblances with
human parts or other objects and organoleptic properties.
The Drung-tshos and sman-pas identify eight main components of a plant as the
root (tsa-ba), stem (dong-po), branch (shel-lag), bark (pa-ko), shoot (nyung), leaf
(dhab-ma), flower (me-tog) and fruit (dre-bu). They group all medicinal plants under
the broad category of the plant kingdom (shing). The plant kingdom is divided into two
main divisions as flowering plants (me-tog-chen-gi-shing) and non-flowering plants
(me-tog-med-pai-shing). Each of the two divisions is considered to have mainly six
orders as herbaceous plants (sa-g.ter-sngo-shing), erect plant with woody trunk or stem
(dong-po-chen-gi-shing), plants with thorns (tsher-shing), climber (thri-shing), grass
(tsa-shing) and fungi (sha-mui-rigs) and lichens.
The medicinal plants belonging to these six orders are then segregated into three
main categories as high altitude medicinal plants (sngo-smen), low altitude medicinal
plants (khrog-smen) and plant exudates (rtsi-smen). The high altitude medicinal plants
(HAMP) are generally considered herbaceous and grow in the alpine snowy mountains
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in an altitude range of 2000 to 5000 metres above sea level (masl). The low altitude
medicinal plants (LAMP) are mostly woody types, which grow in the temperate and
tropical zones in an altitude range of 150 to 1999 masl. The plant exudates, although
considered as a separate class, are mostly extracted from the LAMP and seldom from
HAMP.
These three categories are further sub-categorized into seven origins based on the
seven habitats types, including forests (g.nag-tshel), grasslands (spang-zhi), mountain
tops (la), enclosure of valleys (loong-pa), cultivable dry lands (tse-ri), marshy or
wetlands (chu-zhi) and plants growing on rocky cliffs (byag). For example, Polygonum
macrophyllum D. Don is locally named as spang-ram after its habitat type spang
(meadows) and therefore it can be grouped under the origin spang-smen (medicinal
plants growing in the meadows). Similarly, Juniperus indica Bertol, grows in the
habitat type la (often called gangs-ri) and is named as la-shug and Lepisorus contortus
Ching grows in the habitat type rocky cliffs and is thus named as brag-spos-pa.
Medicinal plants of these seven origins are divided into many types (rigs). Since
the plants under these types are related morphologically, it correlates to the botanical
class of genus. For example, medicinal plants constituting the type ba-lu-rigs showed a
relationship to the species from the genus Rhododendron, while the type bong-nga-rigs
correlated to the species from the genus Aconitum. Other types include dyi-mong-rigs
(species from the genus Clematis), kyi-lchi-rigs (species from the genus Gentiana),
udpel-rigs (species from the genus Meconopsis) and skyer-pa-rigs (species from the
genus Berberis). Each type is graded as a medicinal plant of superior quality (smenm.chog) or of inferior quality (smen-smen-pa). When there is a shortage of the superior
plant types, inferior or similar sub-types are often used as substitutes for preparing
multi-ingredient formulations.
The colour of the flower such as white (d.kar-po), black (g.nag-po), red (d.marpo), yellow (g.ser-po), blue (ngon-po) and purple (smug-po) are often joined with the
local names to give more specific plant names. For examples, Rhododendron
anthopogon D. Don is locally named as dva-li-d.kar-po after its white flower (Figure
1.3A), Cavea tanguensis Smith as ming-chen-g.nag-po after its dark flower (Figure
1.3B), Rhodiola crenulata J. D. Hooker & Thomson as sro-lo-d.mar-pa after its red
flower (Figure 1.3C), Inula grandiflora Willd. as ming-chen-g.ser-po after its yellow
flower (Figure 1.3D), M. simplicifolia Walpers as ud-d.pel-sngon-po after its blue
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flower (Figure 1.3E) and Onosma hookeri Clarke as bri-smug after its purple flower
and purple roots (Figure 1.3F).
Medicinal plants are also named based on the resemblances of the plant parts
with the appearances of human and animal body parts. For example, a Dactylorhiza
hatagirea D. Don. usually has five tubers arising from the main rootstock which
resembles a human hand (lag-pa) and therefore, this plant is named as d.bang-po-lagpa (Figure 1.4A). Similarly, Erythriana arborescens Roxb. is named as m.khal-ma-zhosha-g.nag-po after its kidney-shaped seed (m.khal-do) (Figure 1.4B), Pedicularis
flagellaris Benth. as glang-sna after its flower which resemble an elephant trunk
(glang-sna) (Figure 1.4C), Pedicularis longiflora D. Don as lug-ru after its flower
which resemble a sheep horn (lu-gi-raow) (Figure 1.4D), Ranunculus tricuspis Maxim.
as chu-rug-lbal-lag after its leaves which resemble a frog’s webbed feet (lbal-lag)
(Figure 1.4E) and Delphinium drepanocentrum Munz as bya-rkang after its flower
which resemble a bird’s leg (bya-gi-rkang-pa) (Figure 1.4F).

1.2.4. Seven branches of affectionate practices (g.ches-pai-yan-lag-b.dun) and the
collection of medicinal plants in Bhutan
The Drung-tshos and sman-pas believe that the inherent potency and the quality
of medicinal plants depend largely on the adherence to the ethnoquality doctrine called
‘seven branches of affectionate practices’ (g.ches-pai-yan-lag-b.dun). Failing to
observe and adhere to this ethnoquality doctrine would result in losing their medicinal
efficacy. These seven branches of affectionate practices are discussed briefly in the
following sections.

1.2.4.1. Correct identification of ingredients (medicinal plants)
Historically, the Drung-tshos and sman-pas identified, collected and processed
medicinal plants and formulated the potent medicines themselves. This trade was
treated as a clandestine code to the success and the popularity of the elite BTM
practitioners and therefore remained as a secret in the hands of a few physicians. The
ingredient identification knowledge was mostly passed down in a lineage form as an
oral tradition (׳dam-ngag) either through father to son or master to faithful student.
Even now, some Drung-tshos and sman-pas believe that many medicinal plants, which
they consider as secretive and sacred, may lose their potencies if revealed openly to the
public.
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Figure 1.3. Medicinal plants named after the colour of their flowers: A) R. anthopogon
named as dva-li-d.kar-po, B) C. tanguensis as ming-chen-g.nag-po, C) R. crenulata as
sro-lo-d.mar-pa, D) I. grandiflora as ming-chan-g.ser-po, E) M. simplicifolia as udd.pel-sngon-po, F) O. hookeri as bri-smug [Photographs by P. Wangchuk, 2009].
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Figure 1.4. Medicinal plants named based on their appearances and resemblances with
human and animal body parts: A) D. hatagirea named as dbang-po-lag-pa, B) E.
arborescens as m.khal-ma-zho-sha-g.nag-po, C) P. flagellaris as glang-sna, D) P.
longiflora as lug-ru, E) R. tricuspis as chu-rug-lbal-lag, F) D. drepanocentrum as byarkang [Photographs by P. Wangchuk, 2009].
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However, as a requirement of the course curriculum of the Royal University of
Bhutan, this sacred knowledge is today taught openly to the trainees or students at the
NITM. Although descriptions of medicinal plants can be found in old texts and taught
to the students, this information is not sufficient to identify the plants correctly without
having considerable field experience. The students are provided apprenticeships by the
MSP responsible for the identification, collection and formulation of medicines. They
are also taken for annual field trips to equip them with the field identification skills and
experiences. Therefore, unlike modern medical courses, the traditional medical students
in Bhutan have to master both the medical and pharmacy skills. The pharmacy skills
includes throrough knowledge of plant uses and potency, field identification of
medicinal plants, preparations and prescriptions of disease-specific polyherbal
formulations, and management of adverse herbal reactions.
Some elderly Drung-tshos and sman-pas received their field identification
trainings from masters of a different lineage system. As a result, a few disparities
existed in the medicinal plant nomenclatures which were recently standardized in a
seminar involving senior Drung-tshos and sman-pas, who all had vast experience in
field identifications. The BTM morphology-based identification was not effective to
distinguish closely related medicinal plants that have similar morphological features,
especially from the same genus. Medicinal plants belonging to different genera or
species were often collected under the same Bhutanese names. For example, it is likely
that Chrysosplenium nudicaule Bunge var. intermedium Hara and C. forrestii Diels
were both collected for medicinal use at ITMS under the same traditional name of
g.ya’-kyi-ma. All these disparities hinder proper monitoring of the quality of BTM and
there is need for correct botanical identification of medicinal plants at the species level.

1.2.4.2.

Acceptable habitat and collection centres

The BTM practitioners believe that habitat plays an important role in plantnutrient dynamics, which ultimately determines the intrinsic properties (macroscopic
feature, organoleptic property and 17 plant traits) and the therapeutic potency of a
plant. Therefore, plants collected from the acceptable habitat are believed to possess the
highest curative potency. According to the seven branches of affectionate practices of
the BTM, the collection site should be a clean, pleasant and fertile place endowed with
the balance of sunshine, wind and water elements and preferably blessed by
Boddhisattvas or enlightened beings. Depending upon the therapeutic nature of a plant,
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collection should be done from the shady or the sunshine areas. Drung-tshos and smanpas believe that the collection site must not be affected by frost, hailstorm, drought,
fire, insects, harmful and hazardous substances nor should it be a burial or cemetery
ground, waste disposal or polluted site, a place of human dwellings, or the dwelling
place of local deities or spirits.
According to the BTM, the medicinal plants growing in the habitats characterized
as pristine, higher elevation, shady, facing north and surrounded by snowy mountains
are considered to be more potent and beneficial for treating the hot disorders arising
from pathogenic bile. When a plant of cool quality grows in a warm place, it is believed
to have less curative power when compared to those growing in the cooler places. This
belief is logical since the production of secondary metabolites by a plant varies from
place to place and region to region depending upon the habitat types, vegetation zones
and climatic conditions. For this reason, when the same species of plants are found
growing both in the alpine and the temperate vegetation zones or habitat, the MSP let
their farmers to preferentially collect medicinal plants from the alpine vegetation zones
or habitat. On the contrary, plants used for treating cold disorders arising from
pathogenic phlegm and air must be collected from habitats characterized by abundant
sunshine, a warm climate, lower elevation and facing south.
Lingzhi, under the Thimphu district, and Lanthel, under the Trongsa district,
serve as the main collection centres for HAMP and LAMP, respectively, for the simple
reason that these places were notable for purity and pristine environments with pleasant
climate and fertile land which supported abundant medicinal plants growth. While
almost all the 116 HAMP are sourced from within Bhutan from an altitude range of
2000 to 5000 meters above sea level (masl), not many species of LAMP are sourced
within Bhutan (see Chapter 2 for details). While traditional practices of collection from
those pristine collection sites seem logical and sound, no study has been undertaken to
determine the variations in active marker components in those plants collected from
different habitats and locations.

1.2.4.3.

Appropriate collection season and timing
According to BTM practitioners, the collection time of medicinal plants

depends upon the nature of the disease for which the plant is used, the nature of the
plant parts used and the type of herbal preparations. Bhutan has four seasons and
therefore, medicinal plants should be collected corresponding to these four seasons. In
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the past, Drung-tshos carried out the collection of medicinal plants by themselves on an
auspicious day at the waxing period of the moon (tshey) and most preferably on the
ascending date of the month of the Bhutanese calendar year as the 8th, 10th and 15th day
(yar-sngo). In general, medicinal plants cannot be collected during rain, storm, solar or
lunar eclipse and bad days as deemed by the Bhutanese calendar year such as the
meeting the nine evils (ngyan-pa-d.gu-'zom).
Currently, the bulk collections of medicinal plants are carried out by the MSP
with the help of the trained farmers from two different collection centres. There are
many reason for doing this way: 1) the quantities of medicinal plants required by MSP
are high and it is impossible to collect the required amounts by the practitioners or MSP
collection team; and 2) the MSP framed a policy to improve the income and livelihood
of the farmers living in and around the catchment areas of medicinal resources by
engaging them in the collection and cultivation programs. During the collection season,
the collection team from MSP meets with the farmers or yak herders and distributes the
list of medicinal plants to be collected among the collectors (Figure 1.5A) at the
meeting.
The appropriate harvesting periods depends on the part of the plants to be harvested and
varies from plant to plant. For example:
i)

Fruits should be harvested in late summer or autumn when they are mature.

ii)

Flowers should be harvested in the spring at the pollination time and when the
aroma is intense.

iii) Buds and tender shoots should be harvested in the late spring.
iv) Leaves and milky saps should be harvested in early summer.
v)

Inner bark, cambium, cortex and resin must be harvested in early spring (March).

vi) The underground components, e.g. roots, rhizomes, tubers, bulbs and stolons
should be harvested in late autumn when the aerial parts are dried and when the
bulk of the plant nutrients are stored in them.
vii) The branches, stems and trunks should be harvested in late autumn when the
vegetative and propagation processes have ceased.
viii) Purgative medicinal plants are harvested at the end of autumn or winter when the
earth and water elements within the plants are believed to be predominant and
when these elements descend to the bottom of the plant.
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ix)

Plants of emetic nature are harvested in mid or at the end of spring or summer
when the fire and air elements are predominant and when these elements rise to
the top of the plant.

A

C
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D

Figure 1.5. Collecting and pre-processing of medicinal plants: A) Farmers collecting
medicinal plants, B) Washing, C) Sorting, D) Sizing [Photographs by Manjong Sorig
Pharmaceuticals, 2009].
The medicinal plants are treated as sacred and the Bhutanese in general believe
that the cultivation and collection of medicinal plants are good deeds and one gains
good merit by doing it mindfully and with respect. Polluting medicinal plants and its
habitat with feces, urine or other dirty materials and also trampling on it are considered
sinful and can compromise its therapeutic efficacy. Disturbing or polluting the plants
and environment possessed by subterranean spirits (klu) are considered offensive and
may herald incurable infectious diseases (klu-nad). When collecting these plants,
libation to appease the subterranean spirits must be performed. Some medicinal plants
require picking at a specified time of the day, for example, at night in the presence of
moonlight. If such plants are picked at other times, it is believed that they would lose
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their healing properties and therefore these plants are still being picked by the BTM
practitioners themselves. It is possible that all the empirical knowledge described above
could have a scientific basis but studies on the variations of chemical components
collected at different seasons and timings could shed real light on these practices.

1.2.4.4.

Pre-processing, smoothening and detoxification of poisonous plants

The medicinal plants collected from the field are first pre-processed and
detoxified prior to the preparation of medicines. The pre-processing methods include
sorting (Figure 1.5B), washing (Figure 1.5C) and sizing (Figure 1.5D). The sizing or
chopping involved removal of believed to be harmful parts such as bark, nodes,
petioles, sepals, piths, hard part of fruits, seed covers and dead plant parts.
The smoothening and detoxification process is performed to enhance the potency
of some medicinal plants depending upon the type of medications and formulations it is
to be used for. Hence, these processes vary from plant to plant. For example,
Polygonatum verticillatum is first boiled with milk and then dried in the sun for
formulating the nutraceutical products. If poisonous plants, such as Aconitum species,
are to be used for formulating medicinal products, their toxic matters are either reduced
or neutralized or sometimes even removed completely from the plant using traditional
detoxification methods. The detoxification methods includes: a) boiling the roots of
Aconitum in the milk of a cow or a goat, b) burning the roots in a closed airtight pan
under a charcoal fire until the smoke from the burnt aconite makes paper wet or moist
(traditional Tibetan method).

1.2.4.5.

Appropriate drying methods of medicinal plants

While the use of fresh plant materials in BTM is rare, Drung-tshos and sman-pas
justify that the dried plant materials have a longer shelf life allowing them to be stored
for a longer duration and further, they are easier to grind and formulate. The BTM
employs three techniques to dry the medicinal plants. They are: 1) sunshine drying, 2)
shade drying, 3) and oven drying. The plants with cool quality that are sensitive to light
are dried in cool, shady, dry and well ventilated places. The plants of warm qualities
must be dried in the sunlight or in a hot air (oven). These methods need to be
substantiated through scientific studies on the chemical compositions and variations of
the crude drugs which are obtained by drying in different environments.
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1.2.4.6.

Suitable storage conditions of medicinal plants

The dried plant materials are stored separately in a well-ventilated room in
airtight containers protected from dirt, moisture, smoke, worms, rodents and insects.
Every ingredient has an inherent expiration time and must be used within one year after
collection. They are issued for manufacturing on the basis of a first-in, first-out process
(g.so-ma-rnying-pa). Generally, the Drung-tshos and sman-pas consider flowers and
leaves to have a shorter shelf life than woody parts or seeds.

1.2.4.7.

Spiritual empowerment

It is customary for BTM practitioners to offer any freshly harvested medicinal
items to the medicine Buddha (Sangs-rgyas-smen-lha) as a gesture of gratitude for
endowment of a bountiful harvest of medicinal plants and safeguarding the health of
the people. They also offer every batch of new polyingredient preparation first to the
medicine Buddha for spiritual empowerment. Offering is accompanied by a medical
ritual conducted every month wherein the Drung-tshos, sman-pas and students of
NITM gather to visualize and pray to the medicine Buddha for empowering the
medicines with added potency and curative powers and also seek blessing with sound
health and long life for themselves and their patients.

1.2.5. Scopes and challenges facing BTM
The BTM is one of the rich cultural heritages of Bhutan and has cultural,
economic and medical importance. Knowing that this medical system plays a
significant role in the health care services, the government has integrated it into the
mainstream health care delivery system. The medicines used in providing traditional
health care services also need to be registered with the Drug Regulatory Authority of
Bhutan (DRAB). For any medicines, the core component is the quality of production
and clinical studies involving both the ingredients and finished products. Without such
scientific data, the population willing to accept the formulations would dwindle over
time. For public health professionals, such scientific data, despite its limitations, can
help create the basis for a health system that is more respectful towards local practices
and fosters better collaborations across medical systems including different health care
providers. From these perspectives, one can imagine the magnitude of importance of
research on improving the quality, safety and efficaciousness of medicines. Both the
multi-ingredient formulations as well as the rare medicinal plants used in BTM are
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rarely studied for phytochemical and pharmacological activities.
However, initiating and sustaining research and development activities on BTM
and natural products have been a difficult and challenging task. First, there was no
adequate laboratory infrastructure, expertise and financial resources at MSP. Second,
this research requires a multi-disciplinary approach involving traditional medical
practitioners, ethnobotanists, pharmacognosists, phytochemists, pharmacologists and
modern doctors. Third, it often involves designing novel strategies and research
protocols to suit the complexities of traditional medicines. What makes it even harder is
the complexity in the formulations of BTM. Some formulations contain as many as 35
ingredients and establishing quality control parameters and doing clinical trials to prove
their efficacy and mechanism of drug action can be complex, time consuming and
costly.
Moreover, being a Buddhist country, there is a strong culture of respect for
animals and conducting in vivo studies have been not well received by the employees at
the Institute of Traditional Medicine Services. It was not possible to convince and
involve the Drung-tshos in research as they are the practitioners of So-wa rig-pa that
has so much to do with Buddhism which requires oath taking to not kill but to save all
forms of life (humans and animals). Whatever research has been carried out at MSP so
far has focused on surveying and authentication of species, developing monograph and
documenting the product profiles, establishing quality control parameters and daily
monitoring of both raw materials and finished products through analytical methods, and
standardization of the production processes.
Developing and establishing quality parameters for both the raw materials and the
finished products involves separate and extensive studies. Since the quality, safety, and
effectiveness of any multi-ingredient formulations depends on the quality of their
source raw materials and how they are handled through collection and the production
processes, it would be important to focus on an individual plant studies rather than on
the currently used multi-ingredient/polyherbal formulations. Some of these polyherbal
formulations contain as many as 35 ingredients and monitoring their quality including
the identification of marker compounds and their biological activities becomes
complex, difficult to achieve and is an expensive process. Furthermore, the preparation
of the polyherbal formulations have additional challenges including: a) some plant
materials are used in multiple formulations which often exerts pressure on the wild
plant population through persistent collection practices; b) some of the ingredients are
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becoming rare to find and its exclusion from the prescribed formulations could
compromise the quality of the polyherbal formulations; and c) the cost of
manufacturing the polyherbal TM is rising and a few have even become more
expensive than the modern allopathic drugs thereby undermining its affordability.
The above challenges can be resolved if a single plant can be applied for use as
an alternative treatment regimen which is comparatively cheaper, easier to find and far
less complex to monitor for their quality. More than 229 medicinal plants are currently
used in BTM and their therapeutic indications has been explicitly described and
reported in the pharmacopoeia and the other traditional medical texts. This makes the
possibility of using individual plants much easier, safer and practicable. What is
required urgently is the creation of scientific knowledge including botanical
standardization and accurate identification of medicinal plants, phytochemical and
toxicity evaluation, and the verification of the ethnopharmacological uses of plants. The
correct identification of medicinal plants is the first stage in assuring the quality, safety
and efficacy of any herbal medicines and is also a crucial stage for the successful
metabolomic fingerprinting, the verification of ethnopharmacological uses and the
discovery of new drug leads from the medicinal plants. Although, the botanical
standardization and the development of quality parameters have been carried out with
the assistance from European Union projects, there is much more to be done especially
in

the

areas

of

phytochemical

screening

and

the

verifications

of

the

ethnopharmacological uses of medicinal plants. In order to generate scientific data that
could help substantiate the ethnopharmacological uses of plants, the government of
Bhutan, recently (in 2002-2004) funded the research project on the “Bioactive alkaloids
from the three selected medicinal plants of Bhutan”, which resulted in the isolation of
some novel antimalarial alkaloids (Wangchuk, 2004). In continuity to this and in line
with the Bhutan government initiatives to scientifically validate the BTM as well as
carry out bioprosecting based on its rich ethnomedical knowledge, this PhD research
project carried out in-depth phytochemical and biological activity studies of another
seven medicinal plants.

1.2.6. Objectives of the study.
i.

To describe and botanically identify the low altitude medicinal plants
(LAMP) used in BTM.
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ii.

To determine the major classes of phytochemicals and bioactivities of
the crude extracts of selected medicinal plants.

iii.

To isolate, purify and elucidate the structures of the phytochemicals of
the six medicinal plants.

iv.

To determine the antimalarial, anti-inflammatory, antimicrobial, and
cytotoxicity activities and identify novel drug lead compounds.

v.

Ultimately to develop quality parameters for the studied medicinal
plants and create a scientific basis to BTM.

1.3. Logical framework approach (LFA)
This study had two components (see the LFA in Figure 1.6): field work for
identification and collection of medicinal plants and the laboratory work for carrying
out the phytochemical and biological activity studies. The field work was executed in
Bhutan at MSP, also known as the Pharmaceutical and Research Unit (PRU) and
included a literature review of traditional medical texts, standardizing botanical
nomenclature, selecting medicinal plants, collecting them, establishing their herbarium,
carrying out preliminary phytochemical screening for major classes of phytochemicals,
doing a methanol/ethanol extraction of seven selected medicinal plants, getting
approval including phytosanitory certificates for the extracts from the Bhutan
Agriculture and Food Regulatory Authority, and signing material transfer agreement
with the National Biodiversity Centre, Bhutan.

Figure 1.6. Logical framework approach of the study.
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About twenty five medicinal plants that are currently in use in the Bhutanese
traditional medicine were collected from two collection sites: Lingzhi under the
Thimphu district and Langthel under the Trongsa district. Lingzhi was five days walk
from a motorable road and Langthel is located at the motorable road point. Some
medicinal plants grow in far flung mountain screes that take 1-2 days to reach from the
centre of these two collection sites. These collected plants were dried, extracted and
screened for their major classes of phytochemicals at MSP. The extracts of seven
medicinal plants were transported to the University of Wollongong (UOW), Australia
for in-depth phytochemical and pharmacological activity studies. While the main
laboratory works were executed at UOW, other bioassay works including antimicrobial,
anti-inflammatory, antimalarial and cytotoxicity testings were carried out at
Srinakhornwirot University and BIOTEC in Thailand.
Depending upon the results of the biological activities of the crude extracts and
the isolated compounds, the verifiable indicators that help substantiate the
ethnopharmacological uses of the plants in BTM, and the novel drug lead compounds
were to be identified. Further commercialization, if possible, is expected to be followed
up by the National Biodiversity Centre of Bhutan (Figure 1.6).
1.4.
Study limitations
The biological activities were carried out in vitro in the laboratory and will require
further studies on in vivo models.

1.5.

Structure of this thesis
This thesis comprises eleven chapters. Chapter 2 presents the botanical

identification of low altitude medicinal plants in Bhutan which addresses the first
objective of the study. Chapter 3 describes the evaluation of ethnopharmacologically
selected Bhutanese medicinal plants for their major classes of marker compounds and
biological activities which addresses the second objective of the study. Based on the
preliminary results of the crude extracts of the seven medicinal plants, in-depth
phytochemical and biological activity studies were carried out for six of these plants.
Chapter 4, therefore, deliberates on the phytochemical and biological activity studies
of Corydalis crispa. Chapter 5 describes the antimalarial, anti-inflammatory and antiacetylcholinesterase alkaloids from Corydalis dubia. While Chapter 6 reports on the
phytochemicals and the biological activities of the essential oil and the methanol extract
of Ajania nubigena.
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Chapter 7 describes the isolation of one new antimalarial compound along with
other known protoberberine alkaloids from Meconopsis simplicifolia. The oil
components of M. simplicifolia was also analysed using GC/GC-MS and described in
this chapter. Chapter 8 presents the phytochemical and biological activities of the
methanol extract and the essential oil of the Pleurospermum amabile. Chapter 9 is on
the diterpenoid alkaloids isolated from Aconitum laciniatum. In Chapter 10, the overall
conclusions and future directions are discussed and all the experimental protocols of the
study are detailed in Chapter 11.
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CHAPTER 2
STANDARDIZATION AND BOTANICAL IDENTIFICATION OF
BHUTANESE MEDICINAL PLANTS

Top row: Drynaria propingua (epiphytic plant) and Bombax ceiba (tree).
Bottom row: Euphorbia royleana (thorny cactus) and Beaumontia grandiflora (woody
twine) [Photographs by P. Wangchuk]

“Everything that exists in this world, whether in the microcosm or macrocosm is
composed of four elements. Therefore, there is not a single thing which has no
medicinal value.”
-Gyud-zhi (Four Tantra)
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2.1. Introduction
Medicinal plants are the bulk ingredients used in the multi-ingredient BTM
formulations. In 2009, the ITMS procured about 13 metric tons of dried medicinal
plants and more than 5 metric tons were LAMP (ITMS, 2009). In monetary values, the
PRU spent Bhutanese currency Nu. 4 million (USD 97,600 approximately) for the
procurement of medicinal plants in Bhutan and out of that about Nu. 0.6 million was
spent for collecting the LAMP. This medicinal plant collection program is one of the
main income generating activities in Langthel (one of our study areas) in Bhutan. While
it may be safer to assume that the current collection and utilization of medicinal plants
in Bhutan are sustainable, in future this trend may change if not managed judiciously.
Eminent risk factors for the sustainability of medicinal plants in Bhutan were described
by Wangchuk et al. (2008b). The wild species of medicinal plants are currently
managed through establishment of Community Herb Gardens, Community Forests,
Nature Reserves and Protected Biological Corridors. Farmers or medicinal plants
collectors are also provided training by the Manjong Sorig Pharmaceuticals (MSP) on
the traditional identification and safe removal of medicinal plant parts.
Traditionally, the identification of medicinal plants is performed based on the
descriptions made available through the ancient traditional medical texts, Shel-gongshel-phreng (Phuntshok, 1994) and the Medicinal Flora of Bhutan (Anonymous, 1999).
As discussed in Chapter 1, the BTM classify the medicinal plants into two major
groups: sngo-sman (Higher Altitude Medicinal Plants) and Khrog-sman (Low Altitude
Medicinal Plants) (Dorji and Morisco, 1989; Wangchuk et al., 2008a). The generations
of Drungtshos and sman-pas have mastered these texts and gained skills in field
identification of medicinal plants. The plant identifications were purely based on their
morphological descriptions (shape, size, touch, texture and state) and their organoleptic
properties (colour, taste and smell). Slight differences existed in the identification and
collection of medicinal plants by the Drungtshos and sman-pas coming from different
medical lineage groups.
In addition, the traditional mode of plant identification at the species level was
non-existent. When there were plants of similar morphological characters, the
traditional methods failed to distinguish them and often resulted in collecting two or
three different species under same Bhutanese name thereby affecting the quality of
BTM. It is likely, for example, that Chrysosplenium nudicaule Bunge var. intermedium
Hara and Chrysosplenium forrestii Diels were both collected for medicinal use at ITMS
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under the same traditional name of g.ya’-kyi-ma.
These disparities have hindered the proper monitoring of the quality of BTM and
therefore became necessary to standardize both the traditional and the botanical names
of the medicinal plants at the species level. A series of surveys and botanical
identification of the high altitude medicinal plants (HAMP), which were carried out in
between 1994-2008, with the technical and financial assistance from EU, resolved the
discrepancies at the species level (Wangchuk et al., 2008a). However, not much focus
has been given to LAMP and there existed some disparities in their traditional and
botanical names.
The LAMP grows in the eco-floristic zones of warm temperate, subtropical and
tropical (altitudinal range of 150 to 1999 masl). While the tropical lowland zone (150600 masl, 2500-5500 mm rainfall/annum) supports evergreen sal forests, riverine
forests and dense savannah grasslands; the subtropical zone (600-1800 masl, 12002500 mm rainfall/annum) supports evergreen oak forests and cool broadleaf forests;
and the warm temperate zone (1800-2600 masl, 850-1200 mm rainfall/annum) supports
blue pine, chirpine and mixed conifer forests (MOA, 2009). This study was carried out
in the 10 low altitude districts (Figure 2.1) from where the LAMP were collected.

Figure 2.1. Map of Bhutan showing study areas.
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Most of these 10 districts were classified as protected areas and the biological
corridors of Bhutan. Field trips were made to the study areas especially in Trongsa,
Zhemgang, Sarpang, Wangdi Phodrang, Punakha, Lhuntse and Chukha in 2008/2009
for field observations, photographing and herbarium specimen collections and the
findings are discussed here.

2.2. Traditional and botanical authentication of LAMP
This study was carried out by myself as a Principal Investigator (PI) and my
team comprised of Pharmacognosist (Mr. Samten as my colleague), Ethnobotanist (Mr.
Ugyen as my colleague), Traditional Physicians (as interview participants, field
work/survey team and as workshop participants), Ecologist and Foresters (as botanical
authentication workshop participants). The approval (including ethical aspects) for this
study proposal was obtained from the Traditional Medicine Research and Development
Committee of Bhutan. Initially, an inventory of the currently used LAMP was
developed based on the current traditional medicine formulary book (Tenzin, 2007) and
the list of plants obtained from the medicinal plants procurement sections of Manjong
Sorig Pharnmaceuticals (MSP). The assessment of the current formulary book (Tenzin,
2007) indicated that 92 of these plants are used in the formulation of BTM. Out of these
92 plants, only 64 of them were said to be collected from within the country while 28 of
them were imported from India. Based on this analysis, a list of 113 LAMP with
traditional names was generated. The field work proceeded with the characterization
and the spot identification of the listed LAMP. The locations of field work and the
altitudes were recorded using a hand-held Garmin Etrex GPS unit. Other standard data
such as vegetation, habitat description, other medicinal plants present, local plant name,
locality name and species abundance were also recorded at each field site on preprepared forms. Herbarium specimens, pressed and prepared in triplicate, were
preserved at the Pharmaceutical and Research Unit (PRU), ITMS in Bhutan after
assigning an accession number (Table 2.1).
Our field survey of the 10 study areas found that, out of the 113 plants, about 101
were growing in Bhutan. Out of 28 imported species, 16 of them were in fact found
growing abundantly in our study areas in Bhutan (Table 2.2). Twelve of these 16 plants
were found cultivated and the remaining four were found growing wild in the forests.
Prior to our research, no one from MSP including the Drungtshos and sman-pas knew
about the local availability of these plants.
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The medicinal plants identified in the field were then confirmed and authenticated
at the ITMS by organizing the BTM nomenclature standardization and authentication
workshop. Eighteen professional participants took part in the workshop and included
other Drungtshos and sman-pas from the National Institute of Traditional Medicine
(NITM) and National Traditional Medicine Hospital (NTMH). During the workshop,
the medicinal plants photographs and the herbarium specimens were numbered and
displayed. Each participant was then asked to identify them using the BTM names.
Their answer sheets were collected, compiled and analysed with those of the other
participants. Our field identification results were then shown to the participants and
compared with those of the other participants. Many discrepancies and disagreements
were observed and resolved through an open forum debate among the participants and
through consultation of ancient BTM (g.so-ba-rig-pa) texts. The final list of 113
medicinal plants with authentic and standard BTM names was produced at the end of
the workshop.
After authenticating and confirming the BTM names, botanical identification of
the medicinal plants was carried out based on the herbarium specimens, plant
photographs and other recorded field information such as specimen voucher number,
life forms, parts collected, altitudes and the habitat. The medicinal plants identified
were cross-checked, confirmed and standardized by organizing another workshop under
the banner ‘Botanical Nomenclature Standardization and Authentication Workshop’.
Twenty professional participants including one or more ecologist, taxonomist,
ethnobotanist, pharmacognosist, phytochemist, pharmacist, Drungtshos, sman-pas,
forest official and other researchers took part in the 4 day workshop.
Through these academic deliberations and authentication workshops, we
authenticated the traditional and botanical names of those 113 LAMP. Relevant
botanical literature (Anonymous, 1971; Grierson and Long, 1983, 1984, 1987, 1991,
1999, 2001; Naithani, 1990; Noltie, 1994, 2000; Pandey, 2000; Polunin and Stainton,
1997; Watanabe et al., 2005) were referred to aid in the botanical identification. All the
medicinal plants identified in the present study were ascribed their BTM name,
botanical name, family, part used and their ethnomedical uses were translated into
equivalent English terminologies from the BTM literature (Anonymous, 1975; Tenzin,
1985; Phuntshok, 1994; Anonymous, 1999). The translated uses were further confirmed
by consulting the experienced and most senior five Drungtshos of the ITMS. This final
list of LAMP is shown in Table 2.1.
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Table 2.1. Final list of 113 species of LAMP authenticated and botanically identified by this study.
Botanical name and Family

g.so.ba.rig.pa name

Abelmoschus manihot (L.) Medikus
(Malvaceae)
Accacia catechu (L.f) Willdenow
(Leguminosae)

Uses (Anonymous, 1975; Tenzin, 1985; Phuntshok, 1994; Anonymous,
1999; Wangchuk and Samten, 2010).
Allays leprosy and skin disorders. Heals rheumatism and gout by drying
out the pathogenic plasma or serum affecting the joints.
Haemantinic and depurative for impure blood and blood related disorders.
Heals rheumatism by drying the pathogenic plasma or serum affecting the
body. Alleviates leprosy.
Eupeptic and allays indigestion. Generates bodily heat and heals laryngitis.
Anti-diarrhoeal, anti-dysenteric, emetic, vulnerary and allays lung
disorders.
Anticoagulant, carminative and cardiac tonic. Cures disorders arising from
defective bile and air.
Restores stomach heat and aids in digestion. Optimizes the temperature of
spleen in case of cold disorders.
Nervine and refrigerant for connective tissues of heart.

Altitude in
(masl)
600-1100

Life form

Part used

so-ma-ra-d.za

Voucher No. and
Places recorded
L-281, Langthel

Shrub

Seed

stod-ja

L-211, Gaylephu

200-500

Tree

Wood

Acorus calamus L. (Acoraceae)
Aegle marmelos (L.) Correia
(Rutaceae)
Allium sativum L. (Alliaceae)

shu-dag-nag-po
bul-ba

L-236, Langthel
L-212, Gaylephu

600-2800
200-500

Herb
Tree

Rhizome
Fruit

sgog-cha

L-237, Langthel

200-2400

Herb

Bulb

Amomum subulatum Roxb.
(Zingiberaceae)
Aquillaria malaccensis Lam.
(Thymelaeaceae)
Areca catechu L. (Arecaceae)
Aristolochia griffithii Duchartre
(Aristolochiaceae)
Asparagus racemosus Willdenow
(Asparagaceae)

ka-ko-la

L-238, Langthel

700-2100

Herb

Fruit

a-ga-ru

L-219, Goshing

150-500

Tree

Wood

gu-yu
ba-le-ka

L-213, Gaylephu
L-239, Langthel

200-700
1400-2500

Tree
Climber

Fruit
Stem

nyi-shing

L-220, Goshing

300-2100

Woody
vine

Root

Beaumontia grandiflora (Roxb.)
Wall. (Apocynaceae)
Begonia annulata K. Koch
(Begoniaceae)
Boehmeria penduliflora Long
(Urticaceae)
Bombax ceiba L. (Malvaceae)
Brassica juncea (L.) Czern.
(Brassicaceae)
Brassica rapa L. (Brassicaceae)
Buddleja bhutanica Yamazaki
(Buddlejaceae)

dug-mo-nyung

L-240, Langthel

150-1400

Seed

su-me-ser-po

L-201, Dungkar

500-2600

Woody
vine
Herb

Tuber

Cures kidney disorders and strengthen gum and teeth.
Febrifuge, analgesic, antisepsis, antipyretic, blood purifier and anodyne
for blood disorders. Refrigerant for lung, liver, and intestinal disorders.
Anti-ageing and prolongs lifespan. Allays disorders arising from defective
air, pathogenic serum, and cold conditions. Also allays inflammation
affecting the internal body parts, tissues and organs without apparent signs
and symptoms.
Antitoxin, anthelmintic and vermifuge. Refrigerant for defective bile and
related disorders. Allays poisoning and diarrhoea associated with fever.
Antidote and detoxifier.

spos-rtsi

L-241, Langthel

300-1500

Bark

Useful binding agent especially for making incense stick.

pad-ma-ge-sar
yung-d.kar

L-242, Langthel
L-243, Langthel

150-1300
200-2500

Woody
vine
Tree
Herb

Flower
Seed

nung-ma
chang-rtsi

L-221, Goshing
L-222, Goshing

600-2000
600-2000

Herb
Shrub

Root
Leaf

Cardiac tonic and febrifuge for heart disorders.
Aphrodisiac, antitoxin, antiseptic and heals defective serum and its related
diseases. Allays affliction by evil spirits.
Antidote and restores vitality.
Dyspepsia, nervine and regenerates nerves. It is used for preparing yeast.
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Table 2.1. Continued.
Butea parviflora Roxb.
(Leguminosae)
Caesalpinia bounduc (L.) Roxb.
(Leguminosae)
Camellia sinensis (L.) Kuntze
(Theaceae)
Canarium strictum Roxb.
(Burseraceae)
Capsicum annuum L. (Solanaceae)

ma-ru-rtse

L-244, Langthel

1200-1400

Shrub

Seed

'jam-'bras

L-282, Lingmithang

500-1000

Vine

Seed

Anthelmintic, vermifuge and antibacterial. Eupeptic and optimizes
stomach heat for good digestion.
Allays kidney disorders.

ja-shing

L-289, Phuntsholing

150-600

Shrub

Leaf

Has cooling effect and serves as good febrifuge for typhoid.

spos-d.kar

L-245, Langthel

600-800

Tree

Oleoresin

tsi-tra-ka

L-298, Tsirang

200-1500

Herb

Fruit

Carthamus tinctorius L.
(Asteraceae)
Cassia fistula L. (Leguminosae)

gur-gum

L-299, Tsirang

200-900

Herb

Flower

dong-ga

L-214, Gaylephu

300-1200

Tree

Seed

Cassia tora L. (Leguminosae)

thal-ka-rdo-rje

L-223, Goshing

200-800

Herb

Seed

Cautleya spicata (Smith) Baker
(Zingiberaceae)
Choenomeles lagenaria (Loisel.)
Koidzumi. (Rosaceae)
Choerospondias axillaries (Roxb.)
Burtt & Hill (Anacardiaceae)

sga-skya

L-246, Langthel

300-2000

Herb

Rhizome

b.se-yab

L-247, Langthel

1600-2400

Shrub

Fruit

sning-zho-sha

L-248, Langthel

300-1600

Tree

Fruit

Cinnamomum camphora Nees &
Eberm. (Lauraceae)
Cinnamomum granduliferum
(Wall.) Meisn. (Lauraceae)
Cinnamomum impressinervium
Meisn. (Lauraceae)
Cinnamomum zeylanicum Nees
(Lauraceae)

ga-bur

L-291, Punakha

200-1200

Tree

Oil

Allays chu-ser-nad (serous/serum diseases), defective air (rlung-nad) and
unnatural enlargement of testicles (rlig-rlugs). Also used in incense.
Antibacterial. Generate stomach heat which optimizes digestion. Allays
piles and leprosy.
Tonic to liver and heart, styptic and haemostatic. It is also a nerve
constrictor.
Purgative, laxative, demulcent and de-obstruent especially when suffering
from constipation. Allays liver disorders.
Aphrodisiac, allays skin diseases (ringworm, wounds, abscess, and skin
itching) and g.za’-nad (with symptoms including vertigo, body tremor,
facial contortion, deformities and paralysis).
Anticoagulant, attenuant, febrifuge and cures a complicated disorder
arising due to the combination of defective phlegm and air (bad-rlung).
Febrifuge especially for disorders caused by defective phlegm, e.g.
stomach ulcer.
Febrifuge and cardiac tonic. Heals heart disorders characterized by fever,
drowsiness, darkening of tongue, chest pain, loss of appetite, thirstiness
and petulance when using thick warm clothes.
Antimalarial, febrifuge and refrigerant. Heals heart disorders.

a-gar-go-snod

L-249, Langthel

1500-2400

Tree

Wood

shing-tsa

L-224, Goshing

1200-2500

Tree

Bark

rgya-gar-shing-tsa

L-283, Lingmithang

800-1000

Tree

Bark
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Febrifuge and anticephalagic. Heals defective air energy characterized by
headache, yawning, nausea, blurred vision, dizziness, and shivering.
Anti-diarrhoeal, carminative, restores stomach heat and heals flatulence.
Drains out pus resulting from lung infection (glo-rnag).
Anti-diarrhoeal, carminative, generates stomach heat and allays flatulence.
Also drains out pus resulting from lung infection.
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Table 2.1. Continued.
Clematis buchananiana DC.
(Ranunculaceae)
Commiphora mukul L.
(Burseraceae)
Coriandrum sativum L.
(Umbelliferae)
Crocus sativus L. (Iridaceae)
Cuminum cyminum L.
(Umbelliferae)
Curcuma longa L. (Zingiberaceae)
Datura stramonium L. (Solanaceae)
Diospyros lotus L. (Ebenaceae)

d.yi-mong-nag-po

L-202, Dungkar

200-1400

Climber

Aerial

gu-gul

Not found in Bhutan

Imported

Shrub

Oleoresin

hu-su

L-250, Langthel

200-2500

Herb

Seed

dri-zang
ze-ra

Not found in Bhutan
Not found in Bhutan

Imported
Imported

Herb
Herb

Stigma
Seed

yung-ba
dha-du-ra
rgun-‘brum-nag-po

L-225, Goshing
L-292, Punakha
L-251, Langthel

400-1200
1200-2500
300-2500

Herb
Herb
Tree

Rhizome
Seed
Fruit

Drynaria propingua (Wall. ex
Mett.) J. Sm. ex Bedd.
(Polypodiaceae)
Elettaria cardamomum Malton
(Zingiberaceae)
Entada rheedii Spreng.
(Leguminosae)
Equisetum arvense L.
(Equisetaceae)
Erythriana arborescens Roxb.
(Leguminosae)

re-rel

L-252, Langthel

500-1900

Epiphytic

Stem

sug-smel

Not found in Bhutan

Imported

Herb

Fruit

Heals kidney disorders and cold related diseases.

m.chin-pa-zho-sha

L-253, Langthel

600-1500

Climber

Seed

smyug-m.tse

L-203, Dungkar

1200-2400

Herb

Aerial

m.khal-ma-zho-shanag-po

L-254, Langthel

200-1200

Tree

Seed

Erythriana variegate L.
(Leguminosae)
Euphorbia royleana Boissier
(Euphorbiaceae)
Ferula asafoetida L. (Umbelliferae)

m.khal-ma-zho-shad.kar-po
shri-m.khan-tra

L-215, Gaylephu

150-500

Tree

Seed

Detoxifier and heals liver poisoning (m.chin-dug). Allays neuralgia,
paralysis and other nerves disorders.
Used for wounds, injuries, fever, liver and spleen inflammation. Stops
bleeding and also rejuvenates body.
Febrifuge for kidney disorders (m.khal-tshad) associated with sympotoms
of irregular urination, vaporizing reddish urine, back pain, giddiness,
hearing disability and inability to walk.
Replenishes and rejuvenates kidney. Heals kidney disorders.

L-255, Langthel

900-2100

Shrub

Stem

shing-kun

Not found in Bhutan

Imported

Herb

Oleoresin

Laxative, hydragogue, and purgative. Demulcent and heals skin diseases.
Allays defective serum (chu-ser-nad). Also generates bodily heat.
Antimicrobial. Heals cold diseases, heart disorders, and allays toothache.

Foeniculum vulgare Miller
(Umbelliferae)

la-la-phud

Not found in Bhutan

Imported

Herb

Seed

Heals stomach and cold disorders

36

Anti-tumour, aperitive, prevents unwanted serous fluid accumulation and
allays indigestion.
Expectorant and anodyne for sepsis and infection. Heals liver disorders
and the infectious skin disorders.
Lithontriptic and disintegrates pebble like mass formed in the stomach as a
result of defective phlegm.
Febrifuge, liver tonic and heals liver disorders.
Antipyretic and heals fever arising due to lung disorders.
Tonic, antidote, anti-inflammatory, antiseptic and good preservative.
Antimicrobial, vermifuge and alleviates toothache.
Febrifuge, astringent and cholagogue. It purges excessive and defective
bile from the body. Expectorant and heals lung disorders.
Antidote and detoxifier especially when suffering from meat poisoning
and intentional man-made poisons (sbyar-dug).
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Table 2.1. Continued.
Fraxinus paxiana Lingelsheim
(Oleaceae)
Glycyrrhiza glabra L.
(Leguminosae)
Gossypium hirsutum L.
(Malvaceae)
Hordeum vulgare L. (Poaceae)

stabs-seng

L-256, Langthel

1200-2700

Tree

Bark

shing-m.ngar

Not found in Bhutan

Imported

Climber

Root

Heals bone fracture and alleviates fever arising from bone infection (ruetshad). Allays eye disorders. Also vulnerary and heals old wounds.
Nervine. Heals nervous and lung disorders.

re-‘bras

L-226, Goshing

600-1400

Shrub

Seed

Anti-epistaxis and heals nose disorders.

so-ba

Not found in Bhutan

Imported

Herb

Seed

Jatropha curcas L. (Euphorbiaceae)
Juglans regia L. (Juglandaceae)

dan-rog
star-ga

L-257, Langthel
L-204, Dungkar

300-1400
1200-2700

Shrub
Tree

Seed
Nut

Justicia adhatoda L. (Acanthaceae)

khrog-ba-sha-kad.kar-po
du-ru-ka

L-258, Langthel

500-1600

Shrub

Leaf

L-227, Goshing

300-800

Tree

Heart
Wood

Lagenaria siceraria (Molina)
Standley (Cucurbitaceae)
Luffa aegyptiaca Miller
(Cucurbitaceae)
Mahonia napaulensis DC.
(Berberidaceae)
Mangifera indica L.
(Anacardiaceae)
Mentha piperita L. (Labiatae)

ka-bed

L-259, Langthel

300-1200

Climber

Seed

Allays bile related disorders, progresses child delivery, and aids in easy
removal of foreign body from wounded muscle parts.
Purgative and laxative. Allays constipation.
Heals disorders arising from defective air (rlung-nad). Straightens and
aligns crooked limbs or allays stiffness of limbs.
Febrifuge and allays fever arising from blood, liver and bile infections.
Used as anodyne for blood infection and blood pressure (khrag-g.zir).
Heals heart disorders characterized by fever, drowsiness, darkening of
tongue, chest pain, loss of appetite, thirstiness and petulance with thick
warm clothes (snying-tshad). Allays disorders arising from defective air
(rlung-nad).
Anti-diarrhoeal and anti-dysenteric.

g.ser-gyi-phud-bu

L-290, Punakha

200-1000

Climber

Seed

skyer-sgod

L-205, Dungkar

1200-2600

Shrub

Bark

am-‘bras

L-260, Langthel

400-1000

Tree

Seed

u-shi-la

L-293, Punakha

500-1800

Herb

Oil

Millettia pachycarpa Bentham
(Leguminosae)
Mirabilis himalaica (Edgew.)
Heimerl (Nyctaginaceae)

a-‘bras

L-261, Langthel

900-1400

Vine

Seed

ba-spru

L-284, Lingmithang

800-2500

Climber

Root

Knema tenuinervia Wilde
(Myristicaceae)
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Emetic, detoxifier and astringent. Used especially for jaundice to extract
excessive bile from the body.
Anti-diarrhoeal, febrifuge, heals eye disorders and soaks up poison inside
the body. Hydragogue and dries out defective serum.
Replenishes and rejuvenates kidney and allays kidney disorders.
Appetizer, digestive, analgesic, anti-rashes, anti-inflammatory (ulcer),
alleviates fever induced by air disorders and relieves throat disorders.
Allays kidney disorders.
Allays cold disorders (grang-nad) induced by diet, lifestyle, medication,
therapy, cold climate and cold environment. Also allays disorders induced
by defective serum (chu-ser-nad) that affects lower abdomen.
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Table 2.1. Continued.
Monachosorum henryi Christ.
(Dennstaedtiaceae)
Morus mucroura Miquel
(Moraceae)
Mucuna imbricata Baker
(Leguminosae)

khyung-der-d.kar-po

L-206, Dungkar

1200-2000

Fern

seng-ldeng

L-262, Langthel

900-2000

Tree

Nodal
lump
Wood

gla-gor-zho-sha

L-228, Goshing

200-800

Climber

Seed

Myristica fragrans Houtt.
(Myristicaceae)
Myrsine semiserrata Wall.
(Myrsinaceae)
Nymphaea sp. (Nymphaeaceae)

za’-ti

Not found in Bhutan

Tree

Seed

byi-tang-ga

L-263, Langthel

Not
available
1200-2500

Shrub

Fruit

pad-rtsa

L-294, Punakha

200-1200

Herb

Root

Oroxylum indicum L.
(Bignoniaceae)
Oryza sativa L. (Poaceae)

tsam-pa-ka-me-tog

L-295, Punakha

200-1500

Tree

Seed

‘bras

L-264, Langthel

200-2500

Herb

Seed

Otochilus lancitabius Seibenfaden
(Orchidaceae)
Phlogacanthus thyrsiformis
(Hardwicke) Mabberley
(Acanthaceae)
Phyllanthus emblica L.
(Euphorbiaceae)
Piper nigrum L. (Piperaceae)

pu-shel-rtse

L-265, Langthel

600-1900

Epiphytic

Stem

khrog-ba-sha-kad.mar-po

L-229, Goshing

200-1100

Shrub

Leaf

skyu-ru

L-266, Langthel

600-1800

Shrub

Fruit

pho-ba-ri-nag-po

Not found in Bhutan

pi-pi-ling

L-230, Goshing

Woody
vine
Shrub

Fruit

Piper pedicellatum DC.
(Piperaceae)

Not
available
200-1800
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Fruit

Febrifuge when suffering from poisoning (dug-tshad).
Blood purifier. Desiccates defective blood and serum accumulated in and
around wounds, abscess or boil.
Febrifuge and allays spleen disorders characterized by stomach swelling,
breathlessness, whitening of tongue, darkening of lip, swelling of knees,
severe backache, numbness and tingling sensation (m.cher-tshad).
Anticephalagic and adaptogen. Heals vertigo, dysphoria, insomnia,
giddiness, headache and heart disorders.
Antimicrobial. Restores stomach heat and improves digestion. Also allays
skin dullness and parched face (skya-rbab). Improves skin radiance.
Nourishes body, progresses skin glow and heals skin allergies.
Haemostatic and febrifuge for blood disorders.
Febrifuge and antimalarial.
Anti-diarrhoeal, anti-emetic, demulcent, adaptogen, relaxant, aphrodisiac
and restores youthfulness. Progresses skin glow and texture. Heals all
types of disorders arising from the defective air (rlung), bile (m.khris-pa)
and phlegm (bad-d.kan).
Anti-emetic, febrifuge for stomach inflammation (bad-tshad), and allays
hyperdipsia and dehydration.
Febrifuge and heals blood disorders like feverish blood infection (khragtshad) and painful blood pressure (khrag-g.zir). Also allays feverish liver
inflammation (m.chin-tshad) and feverish bile disorders (m.khris-tshad).
Febrifuge and heals all disorders related to defective phlegm and bile
(bad-m.khris).
Heals phlegm and cold related disorders.
Aphrodisiac, anti-flatulence, anti-asthmatic, digestive, haemantinic, and
blood purifier. Replenishes kidney and alleviates dry cough. Heals cold
disorders (grang-nad) associated with backache, abdominal pain,
difficulty in passing urine and swelling of testicles. Also allays disorders
arising from the combination of defective phlegm and air.
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Table 2.1. Continued.
Pisum sativum L. (Leguminosae)
Prunus persica (L.) Batsch.
(Rosaceae)
Pterocarpus santalinus L.
(Fabaceae)
Punica granatum L. (Punicaceae)

sran-ma-d.kar-po
kham-bu

L-267, Langthel
L-268, Langthel

1200-2800
250-2800

Climber
Shrub

Seed
Nut

tsan-dan-d.mar-po

L-285, Lingmithang

600-1000

Tree

Wood

se-‘bru

L-269, Langthel

900-2400

Shrub

Seed

Quercus griffithii Miquel
(Fagaceae)
Raphanus sativus L. (Cruciferae)

mon-cha-ra

L-270, Langthel

1300-2500

Tree

Nut

la-phug

L-296, Punakha

200-2800

Herb

Root

Rhus chinensis Miller
(Anacardiaceae)
Ricinus communis L.
(Euphorbiaceae)
Rubia manjith Roxb. ex Fleming
(Valerianaceae)
Rubus ellipticus Smith (Rosaceae)

da-trig

L-271, Langthel

900-2700

Tree

Fruit

dan-khra

L-272, Langthel

200-1700

Shrub

Seed

b.tsod

L-273, Langthel

1200-2700

Climber

Stem

ga-bra

L-231, Goshing

800-1900

Shrub

Bark

Saccharum officinarum L.
(Poaceae)
Santalum album L. (Santalaceae)

bur-shing

L-216, Gaylephu

200-900

Herb

Stem

tsan-dan-d.kar-po

L-286, Lingmithang

800-1000

Tree

Wood

Sapindus rarak DC. (Sapindaceae)

po-so-cha

L-274, Langthel

350-1400

Tree

Fruit

Sapria himalayana Griffith
(Rafflesiaceae)

na-ga-ge-sar

L-207, Dungkar

200-900

Endophytic

Flower

Schoenoplectus mucronatus (L.)
Palla (Cyperraceae)
Selaginella involvens (SW.) Spring
(Selaginellaceae)

sho-zur

L-208, Dungkar

300-1800

Herb

Aerial

sngo-chu-srin-sdermo

L-300,
Wangdue Phodrang

500-1000

Herb

Leaf
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Cures disorders arising from defective air.
Cholagogue and heals bile disorders. Hydragogue and dries out defective
serum. Seed promotes hair growth.
Refrigerant and alleviates feverish blood disorders (khrag-tshad).
Restores stomach heat and heals all ranges of stomach disorders. Allays
phlegm and cold diseases (grang-nad).
Anti-diarrhoeal.
Restores stomach heat, allays asthma and resolves vocal hoarseness (skad‘gag) arising due to defective phlegm and lung infection.
Purgative, emetic and appetizer. Allays asthma and also replenishes and
strengthens lung.
Purgative and emetic. Heals indigestion and all orders of stomach
disorders.
Haematinic and heals blood disorders. Allays debilitating fever (‘gramstshad).
Allays common cold and heals blood disorders resulting from defective air
(rlung-khrag).
Analgesic and astringent. Heals hyperdipsia and dehydration. Allays
nausea, vertigo and fainting. Oppresses excessive bile secretion.
Febrifuge. Expectorant and allays dry cough. Heals skin diseases if its oil
is applied on the affected areas.
Excellent emetic. Also locally used for washing hair and getting rid of
head lice.
Allays liver disorders accompanied by fever (m.chin-tshad). It is used as
main ingredient in preparing medicines for treating the disorders afflicted
by the underworld spirits (klu-sman).
Nourishes and builds body. Progresses flesh growth. Improves intelligence
and memory. Antitoxin and heals man-made poisoning (gyur-dug).
Anti-dropsy, heals bone fracture and allays stiffness of limbs.
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Table 2.1. Continued.
Sesamum indicum L. (Pedaliaceae)

til-d.kar

L-232, Goshing

500-1000

Herb

Seed

Stephania glabra (Roxb.) Miers
(Menispermaceae)
Strychnos nux-vomica L.
(Loganiaceae)
Swertia chirayita (Roxb.) Karsten
(Gentianaceae)
Symplocos sumuntia D. Don.
(Symplocaceae)
Syzygium aromaticum (L.) Merrill
& Perry (Myrtaceae)
Syzygium cumini (L.) Skeels
(Myrtaceae)
Terminalia bellerica (Gaertner)
Roxb. (Combretaceae)

d.po’-ser-po

L-233, Goshing

600-1600

Climber

Tuber

Nourishes and replenishes body. Heals disorders arising from defective
air. Improves spermatogenesis and oogenesis.
Febrifuge and heals fever arising from poisoning (dug-tshad).

ko-byi-la

Not found in Bhutan

Tree

Seed

Febrifuge, antidote and antitoxin.

rgya-tig

Herb

Aerial

Febrifuge and antimalarial.

zhu-m.khan

L-297,
Shingkhar Lauri
L-275, Langthel

Not
available
800-2000
900-2200

Shrub

Leaf

li-shi

Not found in Bhutan

Tree

Flower

sra-‘bras

L-276, Langthel

Not
available
200-1600

Tree

Fruit

Febrifuge and heals fever arising due to incapacitation of seven bodily
constituents, chronic lung infection and kidney diseases (‘gram-tshad).
Heals nervous disorders (srog-rtsai-nad). Allays complicated disorders
arising from cold and defective air (grang-rlung).
Replenishes kidney and heals kidney disorders.

ba-ru

L-277, Langthel

150-1500

Tree

Fruit

Terminalia chebula Retzius
(Combretaceae)

a-ru

L-278, Langthel

300-1900

Tree

Fruit

Thysanolaena latifolia Honda
(Thysanolaeneae)
Tinospora cordifolia Hook. f. &
Thomson (Menispermaceae)
Tribulus terristris L.
(Zygophyllaceae)

rtsa-ku-sha

L-217, Gaylephu

200-1800

Herb

Flower

sle-tres

L-279, Langthel

200-1500

Climber

Stem

g.ze-ma

L-301, Wangdue
Phodrang

800-950

Herb

Fruit

Triticum aestivum L. (Poaceae)

dro

L-280, Langthel

150-3000

Herb

Seed

Typha elephantina Roxb.
(Typhaceae)

shu-dag-d.kar-po

L-209, Dungkar

300-1800

Herb

Root
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Cholagogue and hydragogue. Heals defective plasma and serous fluid
especially associated with gout, arthritis and leprosy (chu-ser-nag-po).
Allays air disorders and also complicated disorders arising from defective
phlegm and bile (bad-m.khris). Prevents hair loss.
Restores three defective humours (air, bile and phlegm) and replenishes
bodily constituents. It is also an expectorant, anti-dysenteric and antidiarrhoeal. Heals chronic lung and kidney diseases.
Anti-ageing. Nourishes body and increases longevity.
Cures fever arising from air disorders (rlung-tshad). Allays air disorder
characterized by chill and severe pain in the bone (rlung-rims).
Anti-diuretic. Allays strangury, arthritis and kidney disorders. Nourishes
and replenishes kidney. Also useful for treating cold disorder caused by
defective air affecting lower abdominal parts (grang-rlung).
Aphrodisiac, nourishes body and allays a complicated disorder arising due
to combination of defective air and bile (rlung-m.khris).
Nourishes and builds body. Progresses flesh growth. Improves intelligence
and memory. Antitoxin and heals man-made poisonings (gyur-dug).
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Table 2.1. Continued.
Vitis vinifera L. (Vitaceae)

rgun-‘brum-d.kar-po

L-287, Lingmithang

500-1000

Vine

Fruit

Withania somnifera L. (Solanaceae)

lcha-ba

L-288, Lingmithang

150-1000

Shrub

Root

Xanthium indicum Roxb.
(Compositae)
Zanthoxylum armatum DC.
(Rutaceae)
Zingiber officinale Roscoe
(Zingiberaceae)

byi-tsher

L-210, Dungkar

200-2500

Herb

Fruit

g.yer-ma

L-234, Goshing

500-2500

Shrub

Fruit

sman-sga

L-235, Goshing

300-1500

Herb

Rhizome

Ziziphus mauritiana Lam.
(Rhamnaceae)

rgya-skyegs-shing

L-218, Gaylephu

200-1000

Shrub

Sticlac
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Febrifuge. Replenishes lung and heals lung disorders (glo-tshad)
accompanied by fever, cough, breathlessness, simultaneous chest and back
pain, dizziness and difficulty in speaking.
Heals kidney disorder (m.khel-rkid) with backache and numbness in the
leg region. Also heals cold disorders (grang-nad) with backache,
abdominal pain, urine and swelling of testicles.
Febrifuge and heals fever associated with common cold and flu, poisoning
(dug-tshad), kidney disorders (m.khel-tshad) and air disorders.
Allays indigestion, food poisoning, itching and sepsis. Dispels alcohol
hang-over and progresses melodious voice.
Restores bodily heat and appetizer. Refrigerant for spleen infection
(m.cher-tshad). Heals disorder arising due to the combination of defective
air and phlegm (bad-rlung). Also allays infections and the cold disorders
due to defective air affecting the lower abdomen (grang-rlung).
Heals lung, kidney and blood disorders. Normalises disturbances in the
bodily constituents and three defective humours (air, bile and phlegm)
(‘gram-‘khrug) and also allays associated debilitating fever (gram-tshad).
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Table 2.2. List of 28 imported medicinal plants and their availability status in Bhutan.
Botanical name

Availability status in Bhutan

Botanical name

Availability status in Bhutan

Accacia catechu (L.f.) Willdenow
Caesalpinia bounduc (L) Roxb.
Camellia sinensis (L.) Kuntze
Carthamus tinctorius L.
Cinnamonum camphora (L.) Nees and Eberm.
Cinnamonum zeylanicum Nees
Commiphora mukul L.
Coriandrum sativum L.
Crocus sativa L.
Cuminum cyminum L.
Elettaria cardamomum Malton
Ferula asafoetida L.
Foeniculum vulgare Miller
Glycyrrhiza glabra L.

Grows wild in Gaylephu
Cultivated in Lingmithang
Cultivated in Phuntsholing
Cultivated in Tsirang
Cultivated in Punakha
Cultivated in Lingmithang
Not available
Cultivated in Bhutan
Not available
Not available
Not available
Not available
Not available
Not available

Hordeum vulgare L.
Mentha piperita L.
Mirabilis himalaica (Edgew.) Heimerl
Myristica fragrans Houtt.
Piper nigrum L.
Pterocarpus santalinus L.
Saccharum officinarum L.
Santalum album L.
Sesamum indicum L.
Strychnos nux-vomica L.
Syzygium aromaticum (L.) Merrill and Perry
Tribulus terristris L.
Vitis vinifera L.
Withania somnifera Dunal

Not available
Grows wild in Bhutan
Cultivated in Lingmithang
Not available
Not available
Cultivated in Lingmithang
Cultivated in Bhutan
Cultivated in Lingmithang
Cultivated in Goshing
Not available
Not available
Grows wild in Punakha and Wangdi Phodrang
Cultivated in Lingmithang
Grows wild in Bhutan

Table 2.3. Distribution of LAMP by ecological zones.
Ecological zone
Snow-capped mountains

Altitude range
(metre)
5000 above

Annual range of temperature
(degree Celsius)
Not recorded

Annual range of rainfall
(mm per year)
Not recorded

Number of medicinal plants reported in each
zones
Not recorded

Alpine

3600-5000

–0.9 - 12.0

<650

Higher elevation plants

Sub-alpine/cool temperate

2600-3600

0.1- 22.3

650-850

Higher elevation plants

Warm temperate

1800-2600

0.1-26.3

650-850

14

Dry subtropical

1200-1800

3.0-28.7

850-1,200

28

Humid subtropical

600-1200

4.6-33.0

1,200-2,500

46

Tropical

150-600

11.6-34.6

2,500-5,500

13
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Table 2.4. Distribution of plant species in different families.
Family
Leguminosae
Zingiberaceae
Euphorbiaceae
Lauraceae
Poaceae
Umbelliferae
Anacardiaceae
Malvaceae
Rosaceae
Solanaceae
Acanthaceae
Brassicaceae
Burseraceae
Combretaceae
Cucurbitaceae
Menispermaceae
Myristicaceae
Myrtaceae
Piperaceae
Rutaceae
Acoraceae
Alliaceae
Apocynaceae

Number of species
12
5
4
4
4
4
3
3
3
3
2
2
2
2
2
2
2
2
2
2
1
1
1

Family
Arecaceae
Aristolochiaceae
Asparagaceae
Asteraceae
Begoniaceae
Berberidaceae
Bignoniaceae
Buddlejaceae
Compositae
Cruciferae
Cyperraceae
Dennstaedtiaceae
Ebenaceae
Equisetaceae
Fabaceae
Fagaceae
Gentianaceae
Iridaceae
Juglandaceae
Labiatae
Loganiaceae
Moraceae
Myrsinaceae

43

Number of species
1

Family
Nyctaginaceae

Number of species
1

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

Nymphaeaceae
Oleaceae
Orchidaceae
Pedaliaceae
Polypodiaceae
Punicaceae
Rafflesiaceae
Ranunculaceae
Rhamnaceae
Santalaceae
Sapindaceae
Selaginellaceae
Symplocaceae
Theaceae
Thymelaeaceae
Thysanolaeneae
Typhaceae
Urticaceae
Valerianaceae
Vitaceae
Zygophyllaceae

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
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2.2.1. Medicinal plant distribution by ecological zones
Out of 101 LAMP that were found growing in Bhutan, 74 species were observed in
the sub-tropical zone (600 to 1800 masl), followed by the temperate zone (14 species) and
the tropical zone (13 species) (Table 2.3). It is likely that the agro-climatic conditions of
the sub-tropical zone (annual mean temperature of 19° C and an annual mean rainfall of
1850 mm per year) supports the luxurious growth of medicinal plants.

2.2.2. Medicinal plant distribution by family
The 113 LAMP that were identified by this study belonged to 104 genera and 68
families (Table 2.4). The highest number of medicinal plants (12 species) belonged to the
family Leguminosae followed by Zingiberaceae (5 species) and others (1 species each).

2.2.3. Medicinal plant distribution by places (study areas)
Out of the 10 study areas listed (Figure. 2.1) for the availability of LAMP, Langthel
was found to host the maximum number of LAMPs (46 species) followed by Goshing (17
species) and Dungkar (10 species) (Figure 2.2). Phuntsholing and Shingkhar Lauri had
only one species each: Camellia sinensis (L.) Kuntze (Theaceae) and Swertia chirayita
(Roxb.) Karsten (Gentianaceae), respectively. Camellia sinensis is now grown in Trongsa
district and marketed as green tea.

Figure 2.2. Distribution of medicinal plants by area.
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More detailed survey needs to be undertaken in these two areas and also other
southern parts of Bhutan (Samtse, Phuntsholing, Dagana, Sarpang, Samdrup Jongkhar) in
the future. Some plant species were found growing widely across the study areas and only
those places with abundant growth of medicinal plants were selected. For example, Justicia
adhatoda L. (Acanthaceae) is a cosmopolitan plant that is found growing on the fringes of
cultivated lands in almost all our study areas. However, since this plant is abundantly
found in Langthel (Trongsa) and is also presently collected for current use from this area, it
is placed under Langthel.

2.2.4. LAMP segregation by life forms and parts used
The life forms of LAMP are statistically represented in Figure 2.3 and include:
climbers (Figure 2.4A), herbaceous plants (Figure 2.4B), holoparasitic or endophytic plants
(Figure 2.4C), epiphytic plants (Figure 2.4D), ferns (Figure 2.4E), shrubs (Figure 2.4F),
trees (Figure 2.4G) and woody vines (Figure 2.4H). Among these life forms, the majority
of them belong to the category of herbaceous plants with 35 species, followed by trees (32
species), shrubs (23 species), climbers (12 species), woody vines (7 species) and epiphytics
(2 species). The life forms that had the least number of species were ferns and endophytic
or holoparasitic plants with one species each.

Figure 2.3. Distribution of medicinal plant species in life forms.
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Figure 2.4. Different life forms represented by some of the identified LAMP:
A) Climber (Entada rheedii), B) Herbaceous (Cassia tora), C) Holoparasitic (Sapria
himalayana), D) Epiphytic (Otochilus lancilabius), E) Fern (Monachosorum henryi), F) Shrub
(Piper pedicellatum), G) Tree (Quercus griffithii), H) Woody vine (Millettia pachycarpa)
[Photographs by P. Wangchuk, 2009].

Sapria himalayana, Monachosorum henryi and Millettia pachycarpa were identified
for the first time by our study. An interesting finding was of Sapria himalayana which is a
rare holoparasitic flowering Himalayan plant related to Rafflesia. This plant represents the
extreme manifestation of the parasitic mode, being completely dependent on its host plant
for water, nutrients and products of photosynthesis which it procures through a specialised
root system called haustoria.
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2.2.5. Segregation of LAMP by components used
The plant components that were collected by MSP include aerial parts, roots, bulbs,
rhizomes, tubers, woods, heart woods, stems, barks, infected parts, parasitic plant parts,
nodal lumps, leaves, flowers, fruits, seeds, nuts, oils and resins. The maximum numbers of
plant parts collected for use at MSP were the seeds (31 species) followed by fruits (21
species), roots (9 species), stems (7 species) and leaves (6 species) (Figure 2.5).

Figure 2.5. Number of LAMP used for their plant parts

At present, the collection of seeds, fruits, stems and leaves from these LAMP
(although of higher collection rate as compared to other parts of a plant) were found
sustainable and manageable. However, continuous removing or collecting a large
proportion of such parts in the long run may likely have a significant impact on the species
resiliency. To sustain a consistent population pattern, sufficient seeds or other reproductive
materials should be available for future regenerations. The extraction of roots or bulbs or
any underground parts are the most damaging to the plants since it may affect the whole
life cycle of the individual plant and produce a number of ecological impacts. For instance,
persistent harvesting of the root of a single stemmed, sparsely distributed plant may
threaten the survival of the species.
We also observed that the sustainability pressures were specific to the species. Some
plants have multi-pronged values including, social, cultural, economical, religious and
medicinal. For example, the hard wood Fraxinus paxiana (stab-seng) is used for various
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purposes including traditional medicines, firewood, making houses, and in making the
plough for farming. Because of this, the rate of collection of this particular species is
increased manifold, thereby undermining its long-term sustainability. Another high value
medicinal plant is Aquillaria malaccensis (a-ga-ru, Thymelaeaceae). Its resinous aromatic
heartwood is in high demand both within and across the borders of Bhutan and as a result,
there are highly executed operational networks of illegal traders around the borders putting
extreme pressure on this species. It is fortunate that this plant can be cultivated quite easily
as demonstrated in the localities of Goshing (Zhemgang district). However, the farmers
reported that the infection of the heartwood to form a resinous matter in the cultivated
species occurs very rarely compared to the wild type. From this perspective, the wild
species of this plant is still the preferred choice in Bhutan and other neighboouring
countris.

2.3. Conclusions
Out of 113 LAMP, 92 species were found to be used in the current multi-ingredient
formulations (102 Essential Traditional Medicines and 18 commercial products) produced
by MSP. Of these 92 species, 28 of them were imported from India and 16 of these
imported species were found growing abundantly in Bhutan. Cultivating and collecting
these 16 imported LAMP species from within Bhutan, in the future, is expected to be of
benefit to the rural farmers. It would be also easier for MSP to monitor the quality of these
medicinal plants at their source if grown within Bhutan. Most of the LAMP have also not
been studied for their phytochemical and pharmacological values and this presents a huge
scientific and bioprospecting potential. The concern is how to move forward with such
initiatives. Perhaps, a systems biology approach as proposed by Verpoorte et al. (2009),
which considers observation based science without hypothesis, could be an appropriate
starting point.
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CHAPTER 3
EVALUATION OF SEVEN BHUTANESE MEDICINAL PLANTS FOR
THEIR MAJOR PHYTOCHEMICALS AND BIOACTIVITIES

"The damage this disease [malaria] does is quite incredible… The parasite has been
killing children and sapping the strength of whole populations for tens of thousands of
years…Now we can chart a course to end it."
-Bill Gates
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3.1. Introduction
An effective scientific study of traditional medicines fundamentally begins with a
sound understanding of the mode of usage and the therapeutic indications of the associated
medicinal plants. This helps researchers to devise appropriate strategies and protocols for
studying the medicinal plants at various levels including the crude plant extracts, the
individual phytochemicals and their biological activities. While a study of crude plant
extracts relates closest to the materials used in traditional practice, identifying the
individual natural products would give important insights into the way traditional
medicines act. The bioactivities of plant extracts, and the type of compounds these extracts
may contain, largely depends upon their biosynthetic pathways expressed and the
metabolites they have manufactured under the given environment. Metabolites can be of
primary or secondary in functions. While the primary metabolites include the
carbohydrates, proteins, nucleic acids, lipids, fatty acids and steroids which play a pivotal
role in the metabolism and reproduction of cells, the secondary metabolites include
phenols, flavonoids, saponins and alkaloids that serve in defense, predation and
communication of an organism (Zivanovic, 2012). The secondary metabolites are often
specific to the range of species and are largely induced by the environment that the plants
are exposed to. When medicinal plants are subjected to phytochemical screening,
researchers often target only one compound, or a limited number of compounds, and often
lose many important metabolites. Owing to this, the activities of the crude extracts are
often different to that of the single isolated compound. Synergistic effects of the total
chemicals present in the crude extracts are thought to be of importance in the overall
biological activities of crude extracts. This theory is often common in the traditional
medical practices.
In the case of the BTM, the traditional physicians (Drung-tshos) strongly believe that
the potency of a plant largely depends on the ‘seven branches of affectionate practices’
(detailed in Chapter 1) and that the effectiveness of multi-ingredient formulations has
better efficaciousness than that of a single ingredient or an individual plant. They believe
that while some ingredients reduce the toxicity, others enhance the therapeutic potency.
Therefore, only prepared multi-ingredient formulations are popularly used in BTM and the
use of a single plant for treating the disease is rare. However, due to the complexities of the
multi-ingredient formulations (as detailed in Chapter 1), we have focused on studying the
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crude extracts of individual plants. This is a second stage level of our approach to
scientifically validate BTM. We first selected 25 interesting medicinal plants based on
certain selection criteria, translated their ethnomedical uses (Table 3.1) and screened them
for their major classes of chemical compounds. These medicinal plants selected were
collected from two collection areas in Bhutan: a) Lingzhi (high altitude, 2000 to 6000
masl) in Thimphu district; and b) Langthel (low altitude, 150 to 1999 masl) in Trongsa
district. Finally, we assessed the biological activities of the crude extracts of seven of these
medicinal plants with the aim of generating scientific data that could substantiate the
ethnopharmacological uses of these plants and to help us in prioritizing the plant species
for further phytochemical and pharmacological studies.

3.2. Selection, collection and the ethnopharamacological uses of medicinal plants
The pharmacopoeia, Shelgong shelphreng (Phuntshok, 1994), the current formulary
book (Tenzin, 2007), and the recently published scientific articles related to BTM
(Wangchuk et al., 2008a, 2009; Wangchuk and Samten, 2010) were analyzed to find the
approaches, the number of plants used and their therapeutic indications. We listed down
229 medicinal plants indicated for treating various diseases in the BTM and streamlined
the selection of plants based on certain selection criteria represented in Scheme 3.1. Out of
these, 55 species were found endemic either to Bhutan or the Himalayas. The scientific
literature review of these 55 species revealed that 33 of them have been not studied before.
Most of the unstudied medicinal plants belonged to the traditional category of HAMP. Out
of 33 plants that were rarely investigated, 25 of them representing 19 different families
were short listed (see Table 3.1).
The traditional uses of the 25 selected medicinal plants were translated into
equivalent English terminologies as shown in Table 3.1. In doing so, the BTM disease
signs and symptoms were compared with those of the western medical diseases. For
example, chin-tshad, chin means liver and tshad means fever, is traditionally used for
describing the fever associated with liver disorders. Direct translation becomes liver-fever
which is not described and therefore chin-tshad becomes incomprehensible. It is to be
understood in the context of liver inflammation since it is characterized by tsha-ba (pain)
with a rise in body temperature. Scientifically, liver inflammation occurs when the hepatic
Kupffer cells (macrophages) of the liver respond to foreign antigens by regulating the pro51
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inflammatory cytokine, TNF-α. Its over production can trigger the production of reactive
oxygen species (ROS) and plays an important role in the inflammation and pathogenesis of
many forms of liver disease. Similarly, srin or bub is a general BTM medical term used for
describing worms as well as infection-causing germs. This srin/bub can cause a variety of
infections which reflect disease states bearing relevance to immunity, skin disorders,
inflammation, wounds, and parasitic and microbial infections. Therefore, this BTM terms
should be inclusive of all these relevant western medical terms when the diseases related to
srin or bub, that are described in BTM, are translated. The selected 25 medicinal plants
were collected in the period of June to December 2009 and were dried in accordance to the
traditional methods prescribed by the BTM pharmacopoeia (Phuntshok, 1994). Digital
photographs of these live plants were taken and their locations including the altitudes were
recorded in the prepared Herbarium specimens which were preserved in Bhutan after
assigning an accession number. The collected plants were then assessed for their contents
of different phytochemicals.

Free listing of currently used medicinal plants (229 species)

Medicinal plants used as antiparasitics, tumor and infections (100 species)

Medicinal plants endemic to the Himalayas and Bhutan (55 species)

Unstudied medicinal plants (33 species)

Qualitative screening for major classes of phytochemicals (25 species)

Medicinal plants representing different families (19 species)

Final list of medicinal plants (7 species)

Scheme 3.1. Number of plant species identified against each selection criteria.
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Table 3.1. Twenty five selected plants with local name, specimen number, reported altitude range, and their ethnopharmacological uses.

b.san-dug

Specimen
No.
93

Altitude
(meters)
3500-4570

Ajania nubigena DC.
(Compositae)
Androsace strigillosa Franchet
(Primulaceae)
Aster flaccidus Bunge
(Asteraceae)
Butea parviflora Roxb.
(Leguminosae)
Capsella bursa pastoris (L.)
Medik. (Brassicaceae)
Cavea tanguensis (Drumm.) Smith
& Small (Asteraceae)
Chrysosplenium nudicaule Bunge
(Saxifragaceae)
Codonopsis bhutanica
Ludlow (Campanulaceae)

'khen-d.kar

73

3600-4800

Part (s)
used
Tuber,
leaf,
flower
Aerial

sga-tig-nag-po

15

2400-4300

Aerial

Allays abscess, swelling of limbs, benign tumor and kidney infection. It is a
vulnerary, expectorant, styptic and anti-epistaxis
Used in edema, fever, wound and urinary tract blockage

me-tog-lug-mig

20

3500-4200

Flower

Used in fever, chronic cough and as a general antidote

ma-ru-rtse

L-244

1200-1400

Seed

so-ka-pa

24

2300-4200

Aerial

Anthelmintic, vermifuge and antibacterial. Eupeptic and optimizes stomach heat
responsible for digestion
Used as an anti-emetic and febrifuge

ming-chen-nagpo

31

4250-4570

Aerial

Used in wound and fever

g.yaa’-kyi-ma

1

3600-4800

Aerial

Allays infections and disorders resulting from malfunctioning of bile (m.khris-pa)

klu-b.dud-rdor-rjenag-po

71

4200-4800

Aerial

Corydalis crispa Prain
(Fumariaceae)
Corydalis dubia Prain
(Fumariaceae)

sngo-ba-sha-ka

78

4000-4600

Whole

re-skon

14

4500-4900

Whole

Fraxinus paxiana Lingelsheim
(Oleaceae)
Gentiana urnula H. Smith
(Gentianaceae)

stabs-seng

L-256

1200-2700

Bark

gang-ga-chung

40

3900-5700

Whole

Allays disorders including leprosy caused by the subterranean beings (Klus) and
evil spirits (g.don). Also heals tingling sensation, nephritis, numbness and gout. It
can nourish blood and help in normalizing blood circulation
Febrifuge. Allays blood disorders including high blood pressure and feverish
blood infections, and heals liver infections and bile disorders.
Febrifuge for fever arising from the infections of liver, heart, lung, pancreas and
kidney. Detoxifies impure blood and also allays neuralgia and complicated
disorders including tuberculosis (bad-d.kan-mug-po) that have resulted from the
combination of defective air, bile and phlegm
Heals bone fracture and alleviates fever arising from bone infection (rue-tshad).
Allays eye disorders. Also vulnerary and heals old wounds
Allays fever associated with poisoning (dug-tshad), blood infection (khrag-tshad),
malfunctioning of bile (m.khris-tshad), tubercolosis (bad-d.kan-smug-po) and
fitful coughing. Also hydragogue, deobstruent, attenuant and anti-diarrheal

Botanical name

g.so-ba-rig-pa name

Aconitum laciniatum Stapf
(Ranunculaceae)
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Ethnopharmacological uses (Wangchuk et al, 2009; Wangchuk and Samten,
2010)
Anthelmintic and allays chronic infection including leprosy. Also allays bone
diseases, mumps and gout
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Table 3.1. Continued.
Knema tenuinervia de Wilde
(Myristicaceae)

du-ru-ka

L-227

300-800

Meconopsis simplicifolia Walpers
(Papaveraceae)
Myricarea rosea Smith
(Tamaricaceae)
Myrsine semiserrata Wall.
(Myrsinaceae)
Otochilus lancitabius Seibenfaden
(Orchidaceae)
Pedicularis integrifolia Hooker
(Scrophulariaceae)
Pedicularis longiflora Rudolph
(Scrophulariaceae)
Phlogacanthus thyrsiformis
(Hardwicke) Mabberley
(Acanthaceae)
Pleurospermum amabile Craib &
W.W.Smith (Umbelliferae)
Polygonum macrophylla D.Don
Sapria himalayana Griffith
(Rafflesiaceae)

up-pel-sngon-po

2

3500-4600

Resinous
heartwood
Aerial

chu-shing-ombu

92

3350-4250

Aerial

byi-tang-ga

L-263

1200-2500

Fruit

pu-shel-rtse

L-265

600-1900

Stem

me-tog-glang-sna

22

3500-4800

Aerial

lug-ru-ser-po

26

3050-5560

Aerial

khrog-ba-sha-kad.mar-po

L-229

200-1100

Leaf

rtsad

29

3950-4700

Aerial

spang-ram
na-ga-ge-sar

23
L-207

3500-4200
200-900

Rhizome
Flower

Veronica cephaloides Pennell
(Scrophulariaceae)

ldum-nag-domm.khris

13

4000-4600

Aerial

54

Heals heart disorders characterized by fever, drowsiness, darkening of tongue,
chest pain, loss of appetite, thirstiness and petulance with thick warm clothes
(snying-tshad). Allays disorders arising from defective air (rlung-nad).
Allays fever associated with cough and cold and malaria. Also heals the blood,
liver and lung infections.
Allays fever associated with poisoning (dug-tshad), blood infection (khrag-tshad),
cough and cold, and dropsy. Also useful for treating wound and chicken pox
Antimicrobial. Restores stomach heat and improves digestion. Also allays skin
dullness and parched face (skya-rbab). Improves skin radiance
Anti-emetic, febrifuge for stomach inflammation (bad-tshad), and allays
hyperdipsia and dehydration
Anti-dropsy, anti-diuretic, anti-asthmatic and anti-rheumatic. Also allays wounds
and edema and can nourish body
Anti-diuretic, anti-rheumatic, coagulant and anti-hypertensive agent. Allays
dehydration, wounds and irregular menstruation
Febrifuge and heals blood disorders like feverish blood infection (khrag-tshad)
and painful blood pressure (khrag-g.zir). Also allays feverish liver inflammation
(m.chin-tshad) and feverish bile disorders (m.khris-tshad)
Antidote, febrifuge and useful for dyspepsia
Allays diarrhea, stomach pain and dysentery
Allays liver disorders accompanied by fever (m.chin-tshad). It is used as main
ingredient in preparing medicines for treating the disorders afflicted by the
underworld spirits (klu-sman)
Haemostatic, allays ulcer, and regenerates damaged cells. Also allays fever
associated with wound (rma-tshad)
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3.3. Classes of major phytochemicals present in 25 medicinal plants
It is generally found that plants containing diverse classes of phytochemicals are of
superior biological activities (Cowan, 1999; Geyid et al., 2005). Thus, it may be also
deduced that the higher the diversity and the quantity of these chemical classes that a plant
may contain, the stronger and broader the spectrum of biological activities a plant may
exhibit. In general, tests for the presence or absence of different classes of phytochemical
or marker compounds using the below methods involved the addition of appropriate
chemicals and reagents to the concentrated methanol extracts of a plant in a test tube
(Scheme 3.2). The changes in the appearance of the solution, as the case may be,
confirmed the presence or an absence of alkaloids, flavonoids, tannins, terpenoids and
saponins. Dragendorff’s reagent was used to confirm the presence of alkaloids. Piperine
isolated from Piper pedicellatum was used as a standard for the alkaloid tests. An extract
of Terminalia chebula was used as a standard for the flavonoid test while that of Punica
granatum was used as a standard for the tannin test. A terpene extract of Juniperus indica
was used as a standard for the terpenoid test while an extract of Sapindus rarak was used
as a standard for the saponin test.
Grounded plant material (20 g)
-Extracted with hot methanol (4 x 100 mL)
-Filtered
Methanol extract (50 mL)
-Methanol extract concentrated and divided into
5 parts (5 × 1 mL).
Part 1: Alkaloid test
Portion 1: Added NH3
and Dragendorf’s
reagent.
Portion 2: Added
Mayer’s reagent.
Portion 1: Orange
color, Portion 2:
white precipitate
indicated the presence
of alkaloids.

Part 2:
Flavonoid test
Hydrolyzed with
KOH and then
added basic lead
acetate (25%).
A yellow
precipitate
indicated the
presence of
flavonoids.

Part 3:
Tannin test
Added FeCl3
(10% in H2O)
and observed
changes.
Blue green
colouration
indicated
the presence
of tannins.

Part 4:
Terpenoid test
Added
LibermannBuchard
reagent.
A blue-violet
colouration
indicated the
presence of
terpenoids.

Part 5:
Saponin test
Added water
and shaken.
vigorously.
Presence of
more than
1 cm foam
indicated
the presence
of saponins.

Scheme 3.2. Test methods for screening the plants for major classes of phytochemicals.
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Table 3.2. Twenty five medicinal plants with their major classes of phytochemicals.
Botanical name
A. laciniatum
A. nubigena
A. strigillosa
A. flaccidus
B. parviflora
C. bursa pastoris
C. tanguensis
C. nudicaule
C. bhutanica
C. crispa
C. dubia
F. paxiana
G. urnula
K. tenuinervia
M. simplicifolia
M. rosea
M. semiserrata
O. lancitabius
P. integrifolia
P. longiflora
P. thyrsiformis
P. amabile
P. macrophylla
S. himalayana
V. ciliate
Punica granatuma
Terminalia chebulab
Piperinec
Juniperus indicad
Sapindus rarake

Part tested
Tuber
Aerial
Aerial
Flower
Seed
Aerial
Aerial
Aerial
Aerial
Whole
Whole
Bark
Whole
Wood
Aerial
Aerial
Fruit
Stem
Aerial
Aerial
Leaf
Aerial
Rhizome
Flower
Aerial

Tannin
–
++
+
+
+
++
++
++
++
–
+
++
++
–
–
++
+
–
+
–
–
–
–
+
+

Flavonoid
–
+
–
–
–
++
–
+
–
–
–
+
–
–
–
–
+
–
–
+
–
+
–
–
–

Alkaloid
Dragendorf
Mayer’s
+++
+++
–
–
–
–
–
–
+
+
–
–
–
–
–
–
+
+
++
++
++
++
–
–
–
–
–
–
+
+
–
–
–
–
–
–
+
+
+
+
–
–
–
+
–
–
–
–
–
–

Terpenoid
–
–
–
–
–
–
–
–
+
–
–
–
–
+
–
–
–
–
–
+
–
–
+
–
–

Saponin
–
–
–
–
–
–
–
–
–
–
++
–
–
–
–
–
–
–
–
–
–
–
+
–
–

Note: + : Mild positive; ++: Positive; +++: Highly positive; –:Negative, a Positive control/standard for tannins test,
Positive control/standard for flavonoids test, c Positive control/standard for alkaloids test, d Positive control/standard for
terpenoids test, e Positive control/standard for saponins test.
b

Out of 125 test samples prepared from the above 25 medicinal plants, 16 tested
positive for tannins, nine for alkaloids, six for flavonoids, four for terpenes or terpenoids
and two for saponins (Table 3.2). Codonopsis bhutanica, Corydalis dubia and Pedicularis
longiflora showed the highest diversity of phytochemicals belonging to at least three
chemical classes. C. dubia contained tannins, alkaloids and saponins. P. longiflora
contained flavonoids, alkaloids and terpenes. Ajania nubegina, Capsella bursa pastoris,
Chrysosplenium nudicaule, Myrsine semiserrata and Fraxinus paxiana all contained
tannins and flavonoids. Polygonum macrophylla contained terpenes and saponins.
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3.4. Ethno-directed bioassays of the crude extracts of seven plants
Based on the above preliminary chemical screening results, seven plants: Aconitum
laciniatum, Codonopsis bhutanica, Corydalis crispa, C. dubia, Meconopsis simplicifolia,
Pleurospermum amabile and Ajania nubegina were finally selected for in-depth
phytochemical and biological activity studies (Figure 3.1; Table 3.3). The methanol
extracts of these seven plants were brought to the University of Wollongong with
approvals from various regulatory bodies in Bhutan including Manjong Sorig
Pharmaceuticals and Bhutan Agriculture and Food Regulatory Authority. A material
transfer agreement was signed between the National Biodiversity Centre of Bhutan and the
PI of this study. Approval from Australian Quarantine was obtained.

A

D

B

E

C

F

G

Figure 3.1. Seven selected medicinal plants for this study: A) Corydalis crispa, B)
Corydalis dubia, C) Meconopsis simplicifolia, D) Ajania nubigena, E) Pleurospermum
amabile, F) Aconitum laciniatum, G) Codonopsis bhutanica [Photographs by P.
Wangchuk, 2009]
Traditionally, these seven plants accounted for the formulation of 52 of the total 103
multi-ingredient formulations used in BTM. P. amabile (rtsad) or most preferably
Delphinum brunonianum (bya-rgod-spos) has been used as the substitute for the musk
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(g.lar-rtsi) which makes up 29 multi-ingredient formulations. We have observed that
wherever A. laciniatum has been used in formulations, musk was used as a neutralizer for
reducing the toxic content of A. laciniatum. C. crispa was used for making 20 multiingredient formulations followed by A. laciniatum (14 formulations), M. simplicifolia (11
formulations), C. dubia (four formulations), A. nubegina (one formulation) and C.
bhutanica (one formulation). The therapeutic indications of these seven plants (Table 3.3)
bore relevance to the symptoms of microbial infections, cancer, inflammations, malaria
and other parasitic infections. Therefore, the crude plants extracts were directed for
antimicrobial, antiplasmodial, cytotoxicity, anti-inflammatory, and anti-Trypasoma brucei
rhodesiense assays. The verifiable indicators for the ethno-directed bioassay are given in
Table 3.3.
For the bioassays, crude plant extracts were prepared using the alcoholic extraction
and acid-base fractionation methods as illustrated in Scheme 3.3. Four solvent extracts
including hexane, CH2Cl2, CHCl3 and water extracts of each plant were obtained after
drying. A total of 35 crude extracts were obtained including the original methanol extracts
and were despatched to our collaborators in Thailand for bioactivity testing.
Chopped/grounded plant material (2 kg)
Soaked in methanol (4 days)
Filtered
Residues (stored)
MeOH extract (Filtrate)
Extracted with hexane (10 g)

Hexane extract

Aqueous fraction
5% HCl in H2O
Aqueous fraction

CH2Cl2 extract

NH4OH, pH 9-11
CHCl3 extract

Aqueous extract

Scheme 3.3. Fractionation scheme used for preparing biological assay test samples.
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Table 3.3. Bioassay directions, sample weights and the verifiable indicators for the ethnopharmacological uses of seven medicinal plants
Botanical name

Traditional therapeutic indications/uses

A. laciniatum

Anthelmintic (srin-bub-nad) and allays chronic
infection including leprosy. Also allays bone
diseases, mumps and gout.
Allays abscess, swelling of limbs, benign tumor
and kidney infection. It is a vulnerary,
expectorant and febrifuge, styptic and antiepistaxis.
Heals tingling sensation, nephritis, numbness,
gout, leprosy, blood infections and help in
normalizing blood circulation.

A. nubigena

C. bhutanica

C. crispa

Febrifuge. Allays blood disorders including high
blood pressure and feverish blood infections, and
heals liver infections and bile disorders.

C. dubia

Febrifuge for liver, heart, lung, pancreas and
kidney infections. Detoxify impure blood and
also allays neuralgia and complicated disorders
including tuberculosis (bad-d.kan-mug-po).

M. simplicifolia

Allays fever associated with cough and cold and
malaria. Also heals the blood, liver and the lung
infections

P. amabile

Antidote, general febrifuge and useful for
dyspepsia

MeOH
extracts (g)
Antimicrobial. srin-bub and leprosy bear relevance to the 165.0
symptoms and disease state of microbial infections.

Verifiable indicators for
ethnopharmacological uses
Exhibited weak antibacterial activity
against two bacterial strains.

Antimalarial, antimicrobial and cytotoxicity. Abscess,
vulnerary, expectorant and febrifuge, kidney infection and
benign tumor bear relevance to malarial and microbial
infections and cancer.
Antimicrobial. Leprosy and blood infections bear
relevance to microbial infections.

80.1

Exhibited
significant
antimalarial
activities and weak antibacterial activity
against three bacterial strains.

170.1

Showed weak antibacterial activity
against four bacterial strains.

Antimicrobial,
antimalarial,
cytotoxicity,
antiinflammatory and anti-Trypanosoma brucei rhodesiense.
Febrifuge, blood and liver infections bear relevance to
parasitic and cytotoxicity assay. Leprosy is related to
microbial infections.
Antimicrobial, anti-inflammatory, antimalarial and
anti-Trypanosoma brucei rhodesiense. Febrifuge, blood
and liver infections, tuberculosis and the leprosy bear
relevance to parasitic and microbial infections.

160.0

Showed significant antimalarial and
anti-inflammatory activities, moderate
cytotoxicity and anti-Trypanosoma
brucei rhodesiense property and weak
antimicrobial activity against all strains.
Exhibited
significant
antimalarial
activity and mild antibacterial activity
against three bacterial strains.

Antimicrobial,
antimalarial,
anti-inflammatory,
cytotoxicity and anti-Trypanosoma brucei rhodesiense.
Febrifuge and malaria bear relevance to parasitic and
microbial infections, and also cytotoxicity assay.
Antimicrobial, antimalarial, anti-inflammatory and
anti-Trypanosoma brucei rhodesiense. Febrifuge bear
relevance to parasitic and microbial infections.

43.1

Direction for bioassay
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65.1

190.0

Demonstrated the highly significant
antimalarial activity without any cell
cytotoxicity and mild antibacterial
activity against four bacterial strains.
Showed moderate antimalarial, antiinflammatory and anti-Trypanosoma
brucei rhodesiense and antibacterials
activities.
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Table 3.4. Antiplasmodial, Anti-Trypanosoma brucei rhodesiense and cytotoxicity activities of seven medicinal plants of Bhutan (all IC50 ±
SD were in µg/mL and for standard positive controls IC50 reported in µM).
Antiplasmodial activity
K1CB1

MeOH
Hexane

>25
>25

>25
>25

>25
>25

CH2Cl2

>25

>25

>25

>25

>25

820±35

32

CHCl3

>25

>25

>25

>25

>25

30

H2O
MeOH
Hexane

>25
9.84 ±1.55
>12.5*

>25
8.71 ±1.14
6.22 ±3.55

>25
>10
>10

>25
>10
>10

>25
>10
>10

806±81
NT
399±28
614±34

-36†
-1

CH2Cl2

>12.5

9.51 ±1.30

>10

>10

>10

220±1

-65‡

CHCl3

20.00 ±4.22

18.70 ±0.59

>25

>25

>25

-39†

H2O
MeOH
Hexane

>25
>6.25
>1.56

>25
>6.25
>1.56

>25
>5
>1

>25
>5
>1

>25
>5
>1

381±65
NT
726±66
570±14

17
-8

CH2Cl2

>6.25

>6.25

>5

>5

>5

503±42

-19

CHCl3

>6.25

>6.25

>5

>5

>5

-32†

H2O
MeOH
Hexane

>25
11.53 ±4.83
14.57 ±1.76

>25
13.24 ±0.59
15.82 ±3.94

>25
>10
>10

>25
>25
>25

>25
>25
>25

422±22
NT
778±3
142±17

25
-77‡

CH2Cl2

12.09 ±0.58

11.27 ±3.14

>25

>25

>25

71±17

-89‡

CHCl3

2.11 ±0.55

1.89 ±0.20

4.63 ±0.53

12.5

>25

-54†

H2O
MeOH
Hexane

>25
6.38 ±0.62
NT

>25
9.50 ±0.84
NT

>25
>10
NT

>25
>10
NT

>25
>10
NT

284±102
NT
236±45
NT

-62‡
NT

CH2Cl2

>3.13

>3.13

>1

>1

>1

669±19

8

CHCl3

2.21 ±0.43

2.84 ±0.32

>10

>10

>10

258±42

-58‡

H2O

>12.5

>12.5

>10

>10

>10

NT

A. laciniatum

C. bhutanica

C. crispa

C. dubia

Anti-inflammatory activity
Level of TNF-α
% inhibition/
production**
stimulation
582±20
-6
763±74
23

TM4/8.2

Crude extracts

A. nubigena

Cytotoxicity

Anti-Tbr
Activity

Plant name

60

KB cells
>25
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Vero cells
>25
>25
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Table 3.4. Continued.
M. simplicifolia

P. amabile

MeOH

>12.5

>12.5

>10

>10

>10

568±31

-8

Hexane

>12.5

>12.5

>10

>10

>10

513±32

-17

CH2Cl2

15.50 ±1.95

12.80 ±2.63

>25

>25

>25

399±14

-36†

CHCl3

0.40 ±0.00

6.39 ±2.73

>25

>25

>25

-2

H2O

>25

>25

>25

>25

>25

610±63
NT

MeOH

>25

>25

>25

>25

>25

672±95

8

Hexane

>25

>25

>25

>25

>25

206±10

-67‡

CH2Cl2

12.10 ±0.37

10.90 ±2.34

14.83 ±0.81

>25

>25

300±35

-52†

CHCl3

7.81 ±1.84

7.34 ±2.61

16.10 ±3.61

>25

>25

-32†

H2O

>12.5

>12.5

>10

>10

>10

421±65
NT

Chloroquinea

0.03

0.28

Cycloguanila

0.03

3.24

Pyrimethaminea

0.08

30.9

PB113b

0.19

Elliptricinec

0.38

Doxorubicinc

1.04

Dexamethasoned
RPMIe
DMSOf

258±65
502±43
620±54

a

-58‡
Media
Solvent

Positive controls for antiplasmodial activity, b Positive control for anti-Trypanosoma brucei rhodesiense activity, c Positive controls for cytotoxicity activity, d positive control
drug at 1 µg/mL concentration; e culture media control; f solvent control (1% DMSO). * Due to solubility problems a number of extracts were tested at their maximum
concentration. For example at 12.5 μg/mL. If at this concentration no activity was observed then activity is given as >12.5 μg/mL.**Secretion value of TNF-α of resting cells = 0<0.5 pg/mL and the level of TNF-α production were determined for the optimized dose/concentration of 50 µg/mL of each solvent extracts of the plants; †statistical significance (in
relative to solvent control) was p<0.05; ‡statistical significance with p<0.01; − : inhibited; +: activated; NT: Not tested.
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Anti-inflammatory and antimicrobial assays were carried out by Dr. Malai
Taweechotipatr of

Srinakharinwirot

University,

Bangkok.

Antiplasmodial,

anti-

Trypanosomal and cytotoxicity assays were carried out by Dr. Aunchalee Tonsomboon,
Roonglawan Rattanajak and Sumalee Kamchonwongpaisan of BIOTEC Central Research
Unit, Pathumthani. Overall, these seven plants showed good biological activities.

3.4.1. Antiplasmodial activity
To test for antiplasmodial activity, the crude extracts were made up in DMSO
solution and the in vitro testing was carried out using the Microdilution Radioisotope
Technique (as detailed in the experimental section) against the two Plasmodium
falciparum strains, TM4/8.2, which is a wild type chloroquine and antifolate sensitive
strain, and K1CB1 which is a multidrug resistant strain. From the results in Table 3.4, it
appears that different solvent extracts of C. crispa, C. dubia, A. nubigena, M. simplicifolia
and P. amabile exerted significant antiplasmodial activities against both the P. falciparum
strains. The highest activity was exhibited by that of M. simplicifolia with an IC50 value of
0.40 g/mL against the TM4/8.2 strain. Extracts of A. laciniatum and C. bhutanica were
found inactive even at the highest concentration of 25 g/mL. In general, C. crispa showed
better inhibitory activity, with four of its solvent extracts (methanol, hexane, CH2Cl2 and
CHCl3) exhibiting promising antiplasmodial activities.
Amongst these four extracts of C. crispa, the CHCl3 extract showed the highest
activity with an IC50 of 2.11 g/mL and 1.89 g/mL against TM4/8.2 and K1CB1 strains,
respectively. Similarly, the CHCl3 extract of C. dubia showed promising antiplasmodial
activities with IC50 values of 2.21 g/mL and 2.84 g/mL against the TM4/8.2 and K1CB1
strains, respectively. In the case of A. nubigena, four of its solvent extracts (methanol,
hexane, CH2Cl2 and CHCl3) significantly inhibited K1CB1 strains while only two of its
extracts (methanol and CHCl3) inhibited the TM4/8.2 strain, but only moderately. The
commonly observed pattern was that the CHCl3 extracts of all five plant species tested
positive for antiplasmodial activities and also showed better activities as compared to the
hexane, CH2Cl2 and water extracts (no activity at all). The reason could be that the CHCl3
extracts from basified aqueous extracts, are most likely rich in alkaloids which are
responsible for the bioactivities.
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Amongst the CHCl3 extracts, that of C. crispa, C. dubia, and M. simplicifolia showed
highly significant antiplasmodial activities against both the TM4/8.2 and K1CB1 strains
(see Table 3.4). Such strong antiplasmodial activities could be attributed to the fact that all
these three plants contain alkaloids which are generally significant contributors to the
bioactivities. This is of particular interest in view of the BTM use of these plants as
febrifuge in general and more specifically for the treatment of malaria. It provides a
scientific basis for their use in BTM for treating malaria in Bhutan.

3.4.2. Anti-Trypanosoma brucei rhodesiense activity
Using the Alamar blue test method, the crude extracts of the plant extracts were
tested for their inhibitory activity against Trypanosoma brucei rhodesiense which causes
African sleeping sickness. Out of the 35 crude extracts tested, only those from C. crispa
and P. amabile exhibited anti-Trypanosoma brucei rhodesiense activity (see Table 3.4).
Among these plants, the CHCl3 extract of C. crispa exhibited highest anti-Trypanosoma
brucei rhodesiense activity with an IC50 value of 4.61 g/mL. The CHCl3 and CH2Cl2
extracts of P. amabile showed significant anti-Trypanosoma brucei rhodesiense activities
with IC50 values of 14.8 g/mL and 16.1 g/mL, respectively.

3.4.3. Cytotoxicity
Cytotoxicity was evaluated by the sulforhodamine B (SRB) assay (OD510 nm) using
the Vero cells of the kidney epithelial cells of African green monkey, Cecopithecus
aethiops and KB cells of human oral carcinoma (detail methods described in the
experimental section). Out of 35 solvent extracts tested, only the CHCl3 extract of C.
crispa showed moderate cytotoxicity to the KB mammalian cell line with an IC50 value of
12.4 μg/mL. The other solvent extracts were found to be non-toxic to both KB and Vero
cells (see Table 3.4). This is a good result since the antiplasmodial and antimicrobial
agents in these extracts should be non-cytotoxic to human cell lines.

3.4.4. Anti-inflammatory activity
The cell viability or the cytotoxic effects of the crude extracts in THP-1 cells were
determined by the Trypan-blue (Gibco-Invitrogen, USA) stain exclusion assay and the
TNF-α production in THP-1 cell culture supernatants were measured using cytokine63
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specific sandwich quantitative enzyme-linked immunosorbent assays (ELISAs) according
to the manufacturer’s instructions (R & D Systems, USA). A total of 27 extracts were
assessed for their anti-inflammatory activity. Prior to the TNF-α bioassay, the
concentration of the test sample was optimized through a cell viability study. This
optimization was carried out on one representative test sample, the methanol extract of C.
dubia at different concentrations (0-200 µg/mL, Figure 3.2). At 50 µg/mL, there was no
significant cell reduction/death and this concentration showed the highest inhibitory
activity (better than at 25 µg/mL) of TNF-α secretion. Thus, this concentration was
selected as the optimum dose for determining the inhibitory activity of the other crude
extracts on TNF-α production in LPS-activated THP-1 cells. This further established that at
this concentration, the inhibition of TNF-α production was not associated with cytotoxic
effects to the THP-1 cells. In addition, the THP-1 cells in RPMI and THP-1 cells incubated
with the crude plant extracts alone (without LPS) did not activate TNF-α production which
established that their inhibition of TNF-α production was not associated with the cytotoxic
effects to THP-1 cells. The secretion values of TNF-α of resting cells are generally very
low at 0-<0.5 pg/mL.
120
Cell viability (%)

100

80
60
40
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(µg/mL)

Figure 3.2. Cytotoxic effects of varying concentrations of representative crude extracts of
C. dubia to THP-1 monocytic cells as determined by Trypan Blue dye exclusion assay.
The results of the inhibition of TNF-α secretion and the percentage of TNF-α
inhibition of the 27 crude extracts by THP-1 monocytic cells are listed in Table 3.4. In the
presence of each of the plant extracts, TNF-α production was mostly inhibited and in a few
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cases, stimulated. Of the seven plants studied, the crude extracts of six of them inhibited
the production of TNF-α cytokine with varying degrees and effects. Amongst the six
plants, C. crispa gave the best inhibitory activity followed by P. amabile, A. nubigena, C.
dubia, M. simplicifolia and C. bhutanica (Table 3.4). The hexane and CH2Cl2 extracts of C.
crispa displayed the most potent TNF-α inhibitory activity by inhibiting/suppressing the
TNF-α production to the level of 142 pg/mL (77% inhibition) and 71 pg/mL (89%
inhibition), respectively.
Analysis of statistical significance or variances using the Student’s t-test with onetailed distribution showed that these two crude extracts had the significance p-value of
p<0.01 indicative that this extract may contain good anti-TNF-α compounds (Figure 3.3).
Similarly, the hexane and CH2Cl2 extracts of P. amabile showed significant TNF-α
inhibitory activity with the production values of 206 pg/mL (67% inhibition) and 300
pg/mL (52% inhibition), respectively. The methanol and CHCl3 extracts of C. dubia
displayed good TNF-α inhibitory activity with the suppression of TNF-α production to the
level of 236 pg/mL (62% inhibition) and 258 pg/mL (58% inhibition), respectively. The
CH2Cl2 extract of A. nubigena showed the TNF-α inhibitory value of 220 pg/mL (65%
inhibition). A. laciniatum did not inhibit the production of TNF-α cytokine but instead
stimulated the production of TNF-α cytokine.
Segregating the activities by the level of statistical significance, 13 of the 27 crude
extracts inhibited the TNF-α production in LPS-activated THP-1 cells with the statistical
significance of p<0.05 and p<0.01 (in comparison to DMSO solvent control and the RPMI
culture media control) (Figure 3.3) for inhibition values). Of these 13 extracts, six of them
inhibited the production of pro-inflammatory cytokine TNF-α with 58-89% percent
inhibition which gave the statistical significance of p<0.01. Another seven extracts (out of
13) suppressed the production of pro-inflammatory cytokine TNF-α with 32-52% percent
inhibition which gave the statistical significance of p<0.05. The positive control drug,
dexamethasone (1 µg/mL), significantly inhibited the secretion/production of TNF-α at the
values of 258 pg/mL (58% of inhibition) with the statistical significance of p<0.01.
Amongst the four different solvent extracts, the CHCl3 extract consistently showed the best
TNF-α inhibitory activity closely followed by the CH2Cl2 and hexane extracts. This
indicated that CHCl3 was the best solvent for extracting the bioactive secondary
metabolites from these plants. Since the CHCl3 extracts contained basic components (see
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the extraction procedures), it may be also deduced that basic compounds are responsible
for the better biological activities.

Figure 3.3. Statistical analysis of the anti-inflammatory effects of different solvent extracts
(50 µg/mL) of seven plants on TNF-α production in LPS-activated THP-1 monocytic cells.
Asterisks denote statistical significance in relative to solvent control; *(p<0.05);
**(p<0.01); error bars indicate standard deviations. Hexane extract of C. crispa was not
tested due to solubility problem. RPMI as cell culture media control; DMSO as solvent
control; Dexamethasone as positive control drug (10 µg/mL).
3.4.5. Antimicrobial activities
The investigation of the antimicrobial activity of the plant extracts was initially
performed using the modified Agar Well Diffusion (AWD) method where the zone of
inhibition was measured. Subsequently, it was followed by measuring the Minimum
Inhibitory Concentration (MIC) of each extract under a series of two fold dilutions using
the broth microdilution method as detailed in the experimental section. Both antimicrobial
assays were performed on seven bacterial and one fungal strain: Escherichia coli (ATCC
25922), Bacillus subtilis (ATCC 6633), Staphylococcus aureus (ATCC 6538), methicillin
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resistant Staphylococcus aureus (MRSA), (DMST 20651), Staphylococcus epidermidis
(ATCC 12228), Vibrio cholerae (DMST 2873), Helicobacter pylori (H40) and Candida
albicans (ATCC 10231). There has been no specific cut-off value reported as a reference
point or standard for analyzing the antimicrobial activity of plant extracts. In many cases,
both forms of Minimum Inhibition Zone (MIZ) and MIC that were reported had set their
own standards for result interpretation. The evidence and criteria for such standards are
often vague (Mohamad et al., 2011).
According to the liquid dilution screening method for antimicrobial activity of higher
plants a prominent antibacterial effect worthy of further investigation is not only when the
1/2 but also the 1/8 and 1/32 dilutions show inhibitory activities (Vanden-Berghe and
Vlietinck, 1991; Kokoska et al., 2002). In previous studies, plant extracts were considered
bioactive antimicrobials if the MIZ was ≥3 mm well diameter (Rojas et al., 1992) and
when reported in the form of MIC, if their MIC were ≤1000 µg/mL (Svetaz et al., 2010);
≤1600 µg/mL (Mohamad et al., 2011); and ≤2000 µg/mL for antimicrobial and ≤4000
µg/mL for antifungal (Geyid et al., 2005).
In this study, 35 plant extracts were tested for antimicrobial activity at the highest
test concentration of 2500 µg/mL and only if MIZ was ≥5 mm well diameter or if their
MIC were ≤2500 µg/mL, their activities were considered noteworthy. Some extracts
showed a mild antimicrobial zone of inhibition in the Agar Well Diffusion method but
when the MIC was determined for the same extracts, few inhibitory activity values did not
fall within the cut off test concentration value of ≤2500 µg/mL and were considered as
inactive. The results of the antimicrobial screening of the 35 crude extracts using five
different solvents is shown in Table 3.5.
The results shown in Table 3.5 indicated that all seven plant species exhibited
activity against one or more of the bacterial strains at an inhibitory concentration range of
312 – 1250 µg/ml. C. crispa showed activity against all the seven bacterial strains at
different gradient dilutions. Thus, it was evident that C. crispa extracts showed better
antimicrobial activity when compared to the other six plant extracts. Only its crude extracts
showed moderate activities against V. cholerae and E. coli. Crude extracts of C. bhutanica
and P. amabile both inhibited four bacterial strains, A. nubegina inhibited three, C. dubia
and M. simplicifolia both inhibited two and A. laciniatum showed the least inhibitory
activity.
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Table 3.5. Antimicrobial activities of crude extracts of the seven selected plants (inhibition zone in mm and MIC in µg/mL).
Antifungal
activity

Antibacterial activity
Plant name

A. laciniatum

Crude
extracts

V. cholerae

S. aureus

MIZ

MIC

MIZ

MIC

MIZ

MIC

MIZ

E. coli

B. subtilis

S. epidermidis

H. pylori

C. albicans

MIC

MIZ

MIC

MIZ

MIC

MIZ

MIC

MIZ

MIC

MeOH
Hexane
CH2Cl2
CHCl3
H2O
MeOH
Hexane
CH2Cl2
CHCl3
H2O
MeOH
Hexane
CH2Cl2
CHCl3
H2O

-

----------------

5
5
5
5.5
5.5
6
5
-

-NT
---2500
1250
---1250
1250
1250
2500
--

5
6.5
5.5
5.5
5.5
7.5
6
6
-

-NT
---1250
1250
2500
--1250
1250
2500
1250
--

-

----------------

6.5
5
5
5
5
5
5.5
5
6.5
5
5
-

2500
NT
2500
--2500
1250
2500
--1250
625
625
NT
--

6
5.5
-

-------------NT
--

5.25
5.25
5.75
5.25
5
5.25
-

2000
2000
-2000
2000
------1000
----

-

----------------

C. crispa

MeOH
Hexane
CH2Cl2
CHCl3
H2O

5.5
6
5
7
-

1250
2500
1250
625
--

6
6
7
-

-2500
2500
1250
--

6
5.5
7
-

-2500
1250
1250
--

6
5.5
6
7
-

1250
1250
1250
1250
--

5.75
7
-

--625
625
--

5
6
6
7
-

1250
2500
1250
625
--

5.25
6.5
6.25
6.5
-

500
500
500
500
--

5.5
-

---312.5
--

C. dubia

MeOH
Hexane
CH2Cl2
CHCl3
H2O

NT
-

-NT
----

5
NT
5
-

2500
NT
-1250
--

5
NT
5
-

-NT
-625
--

NT
NT
-

-NT
-NT
--

5
NT
5
NT
-

2500
NT
2500
NT
--

6
NT
5
NT
-

NT
NT
NT
NT
--

NT
-

-NT
----

NT
-

-NT
----

A. nubigena

C. bhutanica

-

MRSA
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Table 3.5. Continued.
M. simplicifolia

P. amabile

References
Amoxicillin
Vancomycin
Amphotericin B

MeOH
Hexane
CH2Cl2
CHCl3
H2O
MeOH
Hexane
CH2Cl2
CHCl3
H2O

16

----------7.8

5
6
6
6.5
6
7
NT
31

2500
2500
-2500
--2500
1250
NT
-<0.97

6
6
6
6.5
12
6
-

-1250
---2500
2500
1250
1250
--

15

3.9

9

----------7.8

6.5
5
7
6
7
14
NT
10

2500
1250
1250
---2500
312
NT
-62.5

5
5
5.5
5.5
NT
20

-----NT
NT
625
NT
-15.6

5
5
5.25
5
5.5
7

1000
1000
2000
---NT
2000
--15.6

-

-----------

18

<0.97

MIZ: Minimum Inhibition Zone in well diameter (mm). MIC: Minimum Inhibition Concentration. NT: Due to solubility problems a number of extracts were not tested for their MIC values.
- : no zone inhibition. --: No inhibitory activity at the highest cut off concentration of 2500 µg/mL.

69

Chapter 3: Major phytochemicals and bioactivities of crude extracts

Analyzing the inhibition results by extracts; out of 35 crude extracts, 15 extracts
exhibited antibacterial activity with a MIC of 1250 µg/mL, three extracts with a MIC of
1000 µg/mL, six with a MIC of 625 µg/mL, and four with a MIC of 500 µg/mL (Table
3.5). Comparing the activities of the five different solvent extracts, CHCl3 and CH2Cl2
extracts exhibited better activities and the water extract did not show any activity. The
CH2Cl2 extract of P. amabile exhibited the highest activity with a MIC value of 312

µg/mL or MIZ value of 14 mm against B. subtilis. Similarly, the CHCl3 extract of C. dubia
exhibited comparatively better activity against MRSA (20651) with a MIC value of 625
µg/mL. Out of the 35 plant extracts, only the chloroform extract of C. crispa exhibited
antifungal activity against the opportunistic pathogen C. albican (ATCC 10231) with a
MIC value of 312.5 µg/mL (see Table 3.5).

3.5. Conclusions
The preliminary phytochemical screening of 25 plants indicated that some of them
contained as much as three classes of phytochemicals and the majority of them were
tannins, alkaloids and flavonoids. The crude extracts of five of the seven plants bioassayed, the CHCl3 extract of M. simplicifolia showed the highest antiplasmodial activity
with an IC50 value of 0.40 g/mL against the TM4/8.2 strain without cytotoxicty. The
CHCl3 extract of C. crispa showed moderate cytotoxicity with an IC50 value of 12.5
g/mL and the highest anti-inflammatory activities. The CHCl3 extracts of P. amabile and
also C. crispa exhibited moderate anti-Trypanosoma brucei rhodesiense activity with IC50
values of 16.1 and 4.6 g/mL, respectively. The CH2Cl2 extract of P. amabile showed the
highest antibacterial activity with a MIC value of 312 µg/mL or a MIZ value of 14 mm
against B. subtilis. Among the five different solvent extracts, the CHCl3 extract
consistently showed the best and the broadest activities. All the results obtained above
helped us in the prioritization of candidate plant species for further in-depth
phytochemical and pharmacological investigations, which will be described in the ensuing
chapters.
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CHAPTER 4
PHYTOCHEMICAL COMPOSITIONS AND BIOLOGICAL
ACTIVITIES OF CORYDALIS CRISPA

Botanical classification
Kingdom

: Plantae

Phylum

: Magnoliophyta

Class

: Magnoliopsida

Order

: Ranunculales

Family

: Fumariaceae (Papaveraceae)

Genus

: Corydalis

Species

: crispa

Synonyms

: Corydalis stracheyoides Fedde

Bhutanese name

: Ba-sha-ka
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4.1. Introduction
The Bhutanese traditional medicine describes three types of Ba-sha-ka. They are
called sngo-ba-sha-ka, khrog-ba-sha-ka-d.kar-po and khrog-ba-sha-ka-d.mar-po (not in
current use). The khrog-ba-sha-ka-d.kar-po (Justicia adhatoda L., Adhatoda vasica Nees,
A. zeylanica Medikus) and the khrog-ba-sha-ka-d.mar-po (Phlogacanthus thyrsiformis
Mabberley, P. thyrsiflorus Nees) belongs to the Bhutanese medicinal plant classification
system of Khrog-sman (LAMP) and grows between 200-1600 masl. The sngo-bashaka,
which is studied here, belongs to the Bhutanese medicinal plant classification system of
sngo-sman (HAMP).
The BTM classify Ba-sha-ka as superior and inferior types. The superior ones are:
khrog-ba-sha-ka-d.kar-po (Justicia adhatoda L.) and sngo-ba-sha-ka (Corydalis crispa).
While there is no clear cut distinction and details as to how to differentiate between the
superior and inferior types of Ba-sha-ka; plants like ldum-nag-dom-m.krhis (Veronica
ciliata Fisch.) and Tongril-zil-pa (C. calliantha) are considered as inferior types (Dawa et
al., 2001).
The plant sngo-ba-sha-ka (botanically identified as C. crispa Prain) is also known
by its synonym as ldum-ba-sha-ka. Its botanical synonym is Corydalis stracheyoides
Fedde. It belongs to the family Fumariaceae and genus Corydalis. Corydalis is a close
relative of the poppy family (Papaveraceae) and more than 300 species grow worldwide
(Caius, 1986). Out of the 280 species that occur in the Sino-Himalayan region (Kubitzki,
1993), about 32 species, including eight endemic species, have been reported to grow in
Bhutan (Grierson and Long, 1984; Wangchuk et al., 2010a).
Corydalis species are a rich source of isoquinoline alkaloids which mediate
chemical defence against a variety of micro-organisms and herbivores (Schmeller et al.,
1997; Majak et al., 2003). The isoquinoline alkaloids have various structural types and
can be classified into twenty categories including, simple isoquinolines, emetines,
benzylisoquinolines, proaporphines, aporphines, protoberberines, benzophenanthridines,
dibenzopyrrocolines, protopines, rhoeadines, narceines, phthalideisoquinolines, pavines,
isopavines,

spirobenzylisoquinolines,

benzylisoquinolines,

morphines

and

protostephanines,
the

hasubanonines,

phenethylisoquinolines

(Southon

bisand

Buckingham, 1989). Although these alkaloids are quite often typical and restricted to
certain genera of the family as in the case of rhoeadine alkaloids, which are encountered
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only in the Papaver genus, more than one class of alkaloids have been observed
commonly even within a genus. These isoquinoline alkaloids, if ingested in large
concentrations, can be toxic. For example, C. caseana and C. aurea, both containing high
concentrations of isoquinoline alkaloids, have been implicated in cattle and sheep
poisoning in western Canada (Majak et al., 2003). However, many species of this genus
have been generally regarded as non-toxic and are used in Asian folklore medicines for
treating different types of ailments (Li et al., 2006; Ma et al., 2008). The BTM currently
uses three species: C. calliantha Long, C. dubia Prain and C. crispa Prain for formulating
as many as 30 multi-ingredient Essential Traditional Medicinal Drugs (ETMD) (Tenzin,
2007; Wangchuk et al., 2010a).
Owing to the interesting inherent properties of this genus, and the wide range of
biological activities exhibited by its isoquinoline alkaloids, Corydalis species have been
extensively studied. More than 58 Corydalis species have been studied phytochemically
with over 190 isoquinoline alkaloids reported from this genus (Southon and Buckingham,
1989). Some of the biological activities exhibited by the isoquinoline alkaloids of
Corydalis includes; acetylcholinesterase inhibition (Adsersen et al., 2007), cytotoxicity
(Kim et al., 2005), fungitoxicity (Ma et al., 1999), antitumour and chemopreventative (Ito
et al., 2001), antimicrobial (Orhana et al., 2007), antihepatitis B (Wu et al., 2007),
antihypertensive (Bhakuni and Chaturvedi, 1983), antimalarial (Wangchuk et al., 2010a)
and insecticidal activities (Miyazawa et al., 1998).
Despite the breadth of reports, no phytochemical study on the Bhutanese medicinal
plant, C. crispa has been reported. C. crispa occurs in an altitude range of 3834-4851
masl and a density range of 0.3-7.9 plants/m2 in Bhutan (Krug, 2008). This plant is a
perennial, decumbent, much branched and flowering herb that grows to about 10-23 cm
tall arising from stout woody rootstock. It has numerous ovately pinnate leaves (2-3 x 22.5 cm) terminating into many leaflets (1-2 mm broad) and about 10-20 yellow broad
rounded flowers (upper petal 10-14 mm) appearing in dense rounded racemes (Grierson
and Long, 1984). Its specific habitat is characterized by sandy-loam soil covered with
shallow gravels, damp mountain screes and stream sides. Other medicinal plants recorded
to grow in close association with C. crispa are Polygonum sp., Eriophyton wallichi,
Tanacetum nubigenum, Erysimum bhutanicum and Phlomis rotata. It is distributed in
Lingshi, Dagala, Bumthang, Laya and Lhuntse in Bhutan.
73

Chapter 4: Corydalis crispa

The crude drug for use in BTM consists of stem, leaves and yellow flowers. The
material is fragile and has an aromatic smell. The assessment of BTM formulation
(Tenzin, 2007) indicated that it contributes to the preparation of as many as 21 important
multi-ingredient ETMDs or polyherbal formulations. They are: a-gar-35, bol-sman-7 pa,
brag-skya-5-thang, ghi-vang-9 pa, gong-sman-a-ru-18, g.tso-bo-8 pa, g.tso-bo-25, gu-yu28, g.yu-ril-13, klu-b.dud-18, man-ngag-b.sil-sbyor, rga-lo-sman-d.mar, ru-rta-6 pa, rurta-13, se-‘bru-kun-phan-b.de-byed, seng-ldeng-23, skyu-ru-25, spang-rgyan-15, sposd.kar-10 pa, thang-chen-25, and ya-sman-rdo-rje-rab-‘jom.
As an individual plant, C. crispa is used in BTM as a febrifuge and for treating
infections in the blood, liver and bile which correlates to the signs and symptoms of
parasitic and microbial infections, cancer and inflammatory conditions. The crude extracts
of this plant showed significant antiplasmodial, anti-inflammatory, antimicrobial, antiTrypanosoma brucei rhodesiense and cytotoxicity activities (discussed in Chapter 3) and
encouraged by this finding, we carried out in-depth phytochemical and bioassay studies of
this plant.

4.2. Isolation and identification of alkaloids
A preliminary test for alkaloids on the dried whole parts of C. crispa was performed
following the Culvenor and Fitzgerald method (Culvenor and Fitzgerald, 1963) and a
positive alkaloid test was obtained. Enough methanol extract was obtained from 2 kg of
air-dried plant material. Through a sequential acid-base fractionation and extraction
process (shown in Scheme 4.1), three fractionated organic solvent extracts were obtained.
Each extract was then subjected to repeated separation and purification processes using
column chromatography on silica gel (mobile phase: gradient eluant of increasing solvent
polarities mainly using MeOH and CHCl3) and preparative Thin Layer Chromatography
(PTLC). Every final fraction was subjected to fractional crystallization, often using
methanol/chloroform.
Finally, nine isoquinoline alkaloids 1–9 (Figure 4.1) were isolated and
characterized. These were identified as protopine (1), 13-oxoprotopine (2), 13oxocryptopine (3), stylopine (4), coreximine (5), rheagenine (6), ochrobirine (7),
sibiricine (8) and bicuculline (9). Compounds 1-4 belong to the class of protopine
alkaloids; compound 5 to the class of protoberberine alkaloids; compound 6 to the class of
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rhoeadine alkaloids; compounds 7 and 8 to the class of spirobenzylisoquinoline alkaloids;
and compound 9 to the class of phthalideisoquinoline alkaloids. Compounds 2 and 3
lacked full NMR characterisation in the literature and are presented here for the first time
(see Table 4.1).
13-Oxoprotopine (2) was isolated previously from Papaveraceae (Papaver
atlanticum) (Preininger and Santavy, 1970), Hypecoaceae (Hypecoum procumbens) (Onur
et al., 1986), and Fumariaceae (C. ophiocarpa, C. platycarpa, C. pallida var. tenuis, and
C. ochotensis var. raddeana) (Iwasa et al., 1988). It was characterized only by melting
point, UV, IR and MS data (Guinaudeau and Shamma, 1982) with no 1D or 2D-NMR
data recorded. In this study, compound 2 was isolated as a white amorphous solid which
was found to be optically inactive. Analysis of the LR-ESI-MS spectrum indicated a peak
at m/z 368 assigned to the [M+H+] ion of 2. An analysis of the HR-ESI-MS spectrum
supported a molecular formula of C20H17NO6. In the LR-EI-MS, the major ions observed
corresponded to the reported favored fragmentation pattern of protopine-type alkaloids
(Hanus et al., 1967).

MeOH extract
5% HCl in H2O
Aqueous portion

Hexane extract
Protopine (1)

CH2Cl2 extract

Aqueous portion
NH4OH, pH 9-11

Rheagenine (6)
Ochrobirine (7)
Sibiricine (8)
Bicuculline (9)

CHCl3 extract

Aqueous

Protopine (1)
13-Oxoprotopine (2)
13-Oxocryptopine (3)
Stylopine (4)
Coreximine (5)

Scheme 4.1. Extraction and isolation of alkaloids from C. crispa.
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Figure 4.1. The structures of compounds 1-9.
The 1H-NMR spectrum of compound 2 showed the signals at δ 7.22 (s, 1H), 6.64 (s,
1H), 7.00 (d, J = 8.3 Hz, 1H), and 7.72 (d, J = 8.3 Hz, 1H) which were assigned to the
four aromatic protons (Table 4.1). Analysis of the APT spectrum indicated the presence of
one CH3 group, five CH2, four CH and ten quaternary carbons. From the gHSQC spectral
correlation analysis, the aromatic protons (CH) were found linked to C-1, C-4, C-11 and
C-12 carbons with signals resonating at δ 110.8, 108.4, 109.8 and 125.9, respectively. 1HNMR signals observed at δ 5.96 (s, 2H) and 6.17 (apparent d, J = 11.5, 2H) were assigned
to the two methylenedioxy groups, while their respective carbons resonated at δ 102.5 and
104.5, respectively. The methyl protons attached to the nitrogen resonated at δ 2.71 (s,
3H). The methylene (CH2) protons attached to the C-atoms, C-5, C-6 and C-8, resonated
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as very broad peaks in the region of δ 2.99-4.55. In the APT spectra, the C-13 and C-14
carbonyl groups resonated at δ 187.2 and δ 191.7, respectively. The intensity of the

13

C-

NMR signals assigned to the C-8 and C-10 carbonyl groups, and those of the quaternary
carbons C-4a, C-8a, and C-12a were weak and barely visible in the APT spectra but they
were observed clearly in the gHMBC spectrum (Table 4.1). This long range gHMBC
correlation established the C→H and H→C cross-correlations among the H-atoms and Catoms of the structure 2 which was identified as 13-oxoprotopine (2). This alkaloid is
derived from protopine (1) by oxidation at the C-13 position. To further confirm the
structure 2, we synthesized it by the oxidation of compound 1 with mercuric acetate
(Leonard and Sauers, 1957). The compound synthesized was identical by TLC, MS and
1

H-NMR analysis to the natural product 2.
The isolation of 13-oxocryptopine (3) has been reported from Papaveraceae (P.

somniferum) (Guinaudeau and Shamma, 1982; Taylor and Francis, 2013) and thus far has
not been isolated from the genus Corydalis (Fumariaceae). Compound 3 was previously
identified based on its melting point, and its MS and 1H-NMR spectroscopic data
(Brochmann-Hanssen et al., 1970; Guinaudeau and Shamma, 1982). We report here for
the first time, its

13

C-NMR data and full characterization based on its 2D-NMR spectra.

Compound 3 was obtained as an optically inactive pale green solid. In the LR-ESI-MS, a
peak was observed at m/z 384 which was assigned as the [M+H+] ion. The HR-ESI-MS
supported a molecular formula of C21H21NO6. In the LR-EI-MS spectrum, the main
fragment ions observed were found to be consistent with those reported for 13oxocryptopine (3) (Guinaudeau and Shamma, 1982).
The 1H-NMR spectrum of compound 3 was found to be in agreement with that
reported for 13-oxocryptopine (Brochmann-Hanssen et al., 1970). The APT spectra
indicated the presence of three CH3 groups, four CH2, four CH and ten quaternary carbons
(Table 4.1). From the gHSQC spectrum the aromatic protons (CH) correlated to C-1, C-4,
C-11 and C-12 whose

13

C-NMR signals resonated at δ 111.8, 112.4, 107.3, and 125.9,

respectively. A signal at δ 42.19 was assigned to the carbon of the CH3 group attached to
nitrogen and the signals at δ 56.0 and 55.9 were assigned to the two methoxy groups. The
carbon of the methylenedioxy group was assigned to the peak at δ 101.9. The intensity of
the 13C-NMR signals assigned to the two carbonyl groups (C-13 and C-14), C-6, and the
other quaternary carbon C-14a were weak in the APT spectra but they were clearly seen
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in the gHMBC spectrum. The long range gHMBC spectrum analysis established the
C→H and H→C cross-correlations among the H-atoms and C-atoms of the structure 3
and the gNOESY correlations confirmed its structure.
Table 4.1. 1H (500 MHz) and
Compounds 2 and 3.

C-NMR (125 MHz) data (obtained in CD3OD) of

Carbon no.

Compound 2 (CD3OD)
13
1
C NMR
H NMR
δ (ppm)
δ (ppm), mult., J (Hz)

1

110.8

2
3

145.9
148.0

4

108.4

4a

122.0*

5

25.7

6

7.22 (s)

53.0

150.6

120.0

9

149.7

112.4

6.64 (s)

*

8a

Compound 3 (CDCl3)
13
1
C NMR
H NMR
δC (ppm)
δH (ppm), mult., J (Hz)
111.8
7.50 (s)
147.0

53.3

8

*

13

6.71 (s)

130.1
2.99 (bs)**

29.2

1.64 (m)

4.55 (bs)

46.0*

2.64 (m)

3.54 (bs)

50.1

3.67 (m)

*

120.0
145.2

*

149.9

10

142.0

11

109.8

7.00 (d, J = 8.3)

107.3

6.83 (d, J = 8.5)

12

125.9

7.72 (d, J = 8.3)

125.9

7.49 (d, J = 8.5)

12a

126.0*

128.1

13, C=O

187.2*

182.0 *

14, C=O

191.7

191.9

14a

131.5

131.0*

N-CH3

43.0

2-OCH3

42.1

1.86 (s)

–

56.0

3.96 (s)

3-OCH3

–

55.9

3.91 (s)

2,3-OCH2O

102.5

5.96 (s)

–

9,10-OCH2O

104.5

6.17 (d, J = 11.5)

–
101.9

2.71 (s)

6.06 (s)

Signal only observed in the gHMBC spectrum; ** broad singlet.

The other known compounds were first identified through MS library matching
techniques (NIST08s) and then confirmed through comparison of their melting points,
optical rotations, and mass spectra with those reported. For some major compounds, their
structures were elucidated first using 1D and 2D NMR spectra and then further confirmed
through the comparison of their structural NMR data with those in the literature. Although
compounds 1-9 are quite often typical and restricted to certain genera of the family, the
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presence of more than one class of alkaloids from a genus or even within a species have
been sometimes observed. For example, different alkaloids belonging to the protopine,
protoberberine, phthalideisoquinoline and spirobenzylisoquinoline classes of alkaloids
have been reported from C. sibirica (Manske et al., 1969a).
Protopine (1) was crystallized as prisms using MeOH/CHCl3 and was the major
compound isolated from C. crispa. This compound melted at 209-211 °C which was close
to the literature value of 203.7-207.8 °C (Wangchuk et al., 2010a). The LR-ESI-MS
showed a peak at (m/z) 354 [M+H+] and the HR-ESI-MS established the molecular
formula as C20H19NO5 (calculated for 354.1336 [M+H]+)). The LR-EI-MS showed the ion
fragmentation pattern as (m/z): 353 [M+], 295, 281, 267, 251, 237, 223, 209, 190, 177,
163, 148 (100%), 134 which matched that of protopine reported in the MS library
(NIST08s, Entry # 26245, CAS: 130-86-9, RetIndex: 2943). The 1H-NMR and 13C-NMR
data of the isolated compound 1 (see experimental section) agreed with those reported for
protopine (Takahashi et al., 1985; Seger et al., 2004). Protopine is the principal alkaloid
found in a number of plant families including, Fumariaceae (Corydalis, Dactylicapnos,
Dcentra, Fumaria), Papaveraceae (Argemone, Bocconia, Chelidonium, Eschscholtzia,
Glaucium, Hunnemannia, Hylomecon, Macleaya,

Meconella, Meconopsis, Papaver,

Roemeria, Romeya, Sanguinaria, Stylomecon), Hypecoaceae, Berberidaceae (Berberis),
Sapindaceae (Pterodophyllum), Nandinaceae, and the Pteridophyllaceae.
Stylopine (4) was isolated as an amorphous solid and had a melting point of 197199 °C (Lit. 163-165 °C (Wangchuk et al., 2010a)). The LR-ESI-MS showed the [M+H+]
ion peak at (m/z) 324 and the HR-ESI-MS calculated the molecular formula as C19H18NO4
for the (m/z): 324.1231 [M+H+]. The LR-EI-MS showed the ion fragmentation pattern as
323 [M+], 204, 174, 148 (100%) which matched that of stylopine reported in the MS
library (NIST08, Entry # 127880, CAS: 4312-32-7, RetIndex: 2612). The 1H-NMR and
the

13

C-NMR data of the isolated compound 4 (see experimental section) agreed with

those reported for stylopine (Narasimhan et al., 1983; Chrzanowska, 1995; Lee et al.,
2005).
Coreximine (5) was isolated as a papery shiny solid which had a melting point of
238-242 °C (Lit. 240-241 °C (Costa et al., 2009)). The LR-ESI-MS showed a [M+H+]
peak at 328 and the HR-ESI-MS calculated the molecular formula for 328.1225 [M+H+]
as C19H22NO4. The LR-EI-MS displayed the ion fragmentation pattern as (m/z): 327 [M+],
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310, 298, 178 (100%), 163, 150, 135, 121, 107, 91, 77 which matched those of
coreximine reported in the MS library (NIST08.LIB, Entry # 130643, CAS: 483-45-4,
RetIndex: 2744).
Rheagenine (6) was isolated as a red solid which melted at 203.7-207.8 °C (Lit.
236-238 °C (Forgacs and Provost, 1985)). The LR-ESI-MS displayed the [M+H+] peak at
m/z 370 and the HR-ESI-MS calculated molecular formula for (m/z): 370.1277 [M+H+] as
C20H20NO6. The LR-EI-MS showed the ion fragmentation pattern as m/z 369 [M+], 308,
279, 206 (100%), 192, 177, 162, 148, 135, 91, 77 which matched that of rheagenine
reported in the MS library (NIST08.LIB, Entry # 154981, CAS: 5574-77-6, RetIndex:
2971). Compound 6 has been reported previously from the genus of Papaver,
Meconopsis, Glaucum, Roemeria, Bocconia and Fumaria (Forgacs and Provost, 1985;
Taylor and Francis, 2013). However, it was not previously reported from the genus
Corydalis (Fumariaceae) and this is the first example of a rhoeadine-type alkaloid being
isolated from this genus. Its presence in C. crispa is not that surprising since: a) rhoeadine
alkaloids have been reported from its close relative Fumaria parviflora belonging to the
same family of Fumariaceae; and b) rhoeadine alkaloids are the biogenetic derivatives of
protopine (Forgacs and Provost, 1985). Furthermore, direct evidence for the incorporation
of labeled protopine into rhoeadine in P. rhoeas has been documented (Shamma and
Moniot, 1977).
Ochrobirine (7) was crystallized as prisms from MeOH/CHCl3 which melted at 203207 °C (Lit. 198 °C (Preisner and Shamma, 1980)). This compound was optically active
with []D25 + 38.7° (c 0.36, CHCl3) which was close to the literature value of []D21 +36o
(c 1.8, CHCl3) (Preisner and Shamma, 1980). Its LR-ESI-MS showed a peak at 370
[M+H+] and the HR-ESI-MS calculated the molecular formula for 370.1252 [M+H+] as
C20H20NO6. The LR-EI-MS exhibited the ion fragmentation pattern as (m/z): 369 [M+],
351, 336, 322 (100%), 293, 264, 204, 190 which matched that of ochrobirine in the MS
library (NIST08.LIB, Entry # 154984, CAS: 24181-64-4, RetIndex: 3185). The 1H-NMR
and the

13

C-NMR data (see experimental section) agreed with those reported for

ocrhobirine in the literature (Manske et al., 1969b; Margvelashvili et al., 1978; Shah et al.,
1989).
Sibiricine (8) was isolated as an amorphous solid which had the melting point of
213.7-216.8 °C (Lit. 225 °C (Manske et al., 1969a)). The LR-ESI-MS detected a [M+H+]
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peak at m/z 368 and the HR-ESI-MS determined the molecular formula for m/z 368.1109
[M+H+] as C20H18NO6. The LR-EI-MS showed the ion fragmentation pattern as (m/z):
367 [M+] (100%), 352, 336, 322, 295, 264, 204, 190, 149 which matched that of sibiricine
reported in the MS library (NIST08.LIB, Entry # 153896, CAS: 24181-66-6, RetIndex:
3168). The 1H-NMR data (see experimental section) agreed with those reported in the
literature (Manske et al., 1969a; Preisner and Shamma, 1980).
Bicuculline (9) was isolated as an amorphous solid which melted at 204.5-205.6 °C
(Lit. 199-200 °C (Basha et al., 2002)). This compound was optically active with []D25
+127.2° (c 0.07, CHCl3) which was close to the literature value of []D25 +131° (c 1.6,
CHCl3) (Edwards and Handa, 1961). The LR-ESI-MS showed the [M+H+] peak at m/z
368 and the HR-ESI-MS determined the molecular formula for (m/z): 368.1091 [M+H+]
as C20H18NO6. The LR-EI-MS exhibited the ion fragmentation pattern as (m/z): 367 [M+],
206, 190 (100%), 175, 149 which matched that of bicuculline reported in the MS library
(NIST08.LIB, Entry # 153894, CAS: 485-49-4, RetIndex: 3142). The 1H-NMR and

13

C-

NMR spectroscopy data (see experimental section) agreed with those reported (Edwards
and Handa, 1961).

4.3. Biological activities of the isolated alkaloids
Guided by the promising biological activities of the crude extracts of C. crispa
described in Chapter 3 and reproduced in Table 4.2, we also investigated the biological
activities of six of the nine isolated compounds. While some pharmacological and
biological activities of the compounds 1, 4, 5 and 9 have been reported, the biological
activities of the compounds 2, 3, 6, 7, and 8 have not previously been studied. In our
present study, we have investigated six of these compounds 1, 2, 4, 5, 7 and 9 for their
anti-inflammatory, acetylcholinesterase inhibition, antiplasmodial, anti-Trypanosoma
brucei rhodesiense, cytotoxicity and antimicrobial activities. The quantities of the minor
compounds 3, 6 and 8 were insufficient for determining their biological activities. None
of the pure alkaloids exhibited anti-Trypanosoma brucei rhodesiense and cytotoxicity
activities. However, some crude extracts and compounds interestingly showed other
biological activity which we have given in Table 4. 2.
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Table 4.2. Bioactivities of the crude extracts and the pure compounds 1, 2, 4, 5, 7, and 9 isolated from C. crispa.
Anti-inflammatory
Samples

MeOH extract*
Hexane extract*
CH2Cl2 extract*
CHCl3 extract*
Protopine (1)
13-Oxoprotopine (2)
Stylopine (4)
Coreximine (5)
Ochrobirine (7)
Bicuculline (9)
RPMI (media control)
1% DMSO (solvent control)
Dexamethasone1
Galanthamine2
Chloroquine3
Cycloguanil3
Pyrimethamine3
PB1134
Ellipticine5
Doxorubicinc

TNF-α
(pg/ml)
778 ± 3
142 ± 17
71 ± 17
284 ± 102
467 ± 4
862 ± 141
679 ± 28
632 ± 4
606 ± 30
791 ± 117
502 ± 43
620 ± 54
258 ± 65

Activity (%)
+ (25)
− (77)
− (89)
− (54)
− (25)
+ (39)
+ (10)
+ (1)
− (2)
+ (28)

AChEa
MIR
(nmol)
Nt
Nt
Nt
Nt
0.14
1.31
0.15
0.53
0.14
>2.72

Antiplasmodial

Anti-Tbrb

Cytotoxicity

TM4/8.2
IC50 ( μg/ml)

K1CB1
IC50 ( μg/ml)

IC50 ( μg/ml)

Vero cells
IC50 ( μg/ml)

KB cells
IC50 ( μg/ml)

11.53 ± 4.83
14.57 ± 1.76
12.09 ± 0.58
2.11 ± 0.55
1.45 ± 0.53
>4.6
>4.0
5.56 ± 0.63
>9.2
>9.2

13.24 ± 0.59
15.82 ± 3.94
11.27 ± 3.14
1.89 ± 0.20
1.38 ± 0.31
>4.6
>4.0
6.87 ± 1.09
>9.2
>9.2

>10.0
>10.0
>25.0
4.63 ± 0.53
>3.5
>3.7
>3.2
>8.2
>9.2
>9.2

>25.0
>25.0
>25.0
>25.0
>3.5
>3.7
>3.2
>8.2
>9.2
>9.2

>25.0
>25.0
>25.0
12.5
>3.5
>3.7
>3.2
>8.2
>9.2
>9.2

0.003
0.0096
0.0095
0.0200

0.089
0.810
7.7 00
0.064
0.093
0.56

a

Acetylcholinesterase inhibitory activity.
Anti-Trypanosoma brucei rhodesiense activity.
Nt: Not tested; +: activated; −: inhibited.
* biological activities of crude extracts reproduced from Chapter 4 for easy comparison.
1
Reference drug for anti-inflammatory activity.
2
Reference drug for acetylcholinesterase activity.
3
Reference drugs for antiplasmodial activity.
4
Positive control for anti-Trypanosoma brucei rhodesiense activity.
5
Positive controls for cytotoxicity activity.
b
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4.3.1. Anti-inflammatory activity
Since C. crispa is used in the BTM as a febrifuge and for treating infections in the
blood, liver and bile. Its crude extracts showed potent anti-inflammatory activity against
the pro-inflammatory cytokine (TNF-α) in LPS activated THP-1 cells, the present study
explored the pure alkaloids of the plant in a similar mode. The anti-inflammatory
activities of different crude extracts are reproduced in Table 4.2 to allow a direct
comparison of their inhibitory values with those of the pure compounds. The cytotoxic
effects of the pure compounds (Figure 4.2) against THP-1 cells were determined first on
all the test samples at different concentrations using the Trypan Blue dye exclusion assay.

Concentrations of pure compounds (µg/mL)

Figure 4.2. Cytotoxic effects of different concentrations of pure compounds (1, 2, 4, 5, 7
and 9) against THP-1 monocytic cells as determined by Trypan Blue dye exclusion assay.
The cell viability results indicated that at 3.9 µg/mL concentration, there was no
significant cell reduction and acceptable high inhibitory activities. The percentage of
viable cells in each sample was >90%. The percentage cell viability of RPMI was 97%,
DMSO was 98% and dexamethasone was 97% (composite % of all concentrations tested
but not shown here). This suggested that the inhibition of TNF-α production by the test
samples were not associated with cytotoxic effects on the THP-1 cells. Thus, this
concentration value (3.9 µg/mL) was selected as the concentration for determining the
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inhibitory activities of the six pure compounds on TNF-α production in LPS-activated
THP-1 cells.
The THP-1 cells in RPMI and THP-1 cells incubated with pure compounds alone
(without LPS) did not activate TNF-α production. The positive control drug,
dexamethasone, exhibited an anti-inflammatory response by suppressing the production of
TNF-α to 258 pg/mL which was very high as compared to the secretion levels of TNF-α
production of RPMI culture media control (502 pg/mL) and the DMSO solvent control

Secreted TNF-α (pg/ml)

(620 pg/mL, insignificant effect).

1200
1100
1000
900
800
700
600
500
400
300
200
100
0

*P<0.05
*p<0.05
**P<0.01
**p<0.01

*
*

Controls and test samples (pure compounds)

Figure 4.3. Anti-inflammatory effects of pure alkaloids at 3.9 µg/mL on TNF-α
production in LPS-activated THP-1 monocytic cells. Asterisks denote statistical
significance in relative to solvent control (1% DMSO), *(p<0.05), **(p<0.01); error bars
indicate standard deviations; media control was RPMI.
In the presence of each of the individual alkaloids, the TNF-α production was either
suppressed or stimulated in varying degrees (see Table 4.2). Of the six alkaloids (1, 2, 4,
5, 7 and 9) tested, the major plant alkaloid, protopine (1) exhibited significant antiinflammatory activity by inhibiting TNF-α production to the level of 467 pg/mL (25 %
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inhibition over the DMSO control). Analysis of statistical significance or variances using
the Student’s t-test with one-tailed distribution showed that compound 1 had the p-value
of p<0.05 (Figure 4.3). This compound was previously reported to have an antiinflammatory effect (29% inhibition) in the carrageenan-induced paw oedema at the dose
of 50 mg kg-1 and was found three times more potent than aspirin (Saeed et al., 1997).
Compound 7 exhibited weak anti-inflammatory activity with a TNF-α production level of
606 pg/mL (2% inhibition but not statistically significant). Compound 4 was previously
reported to have an inhibitory effect on lipopolysaccharide (LPS)-induced inflammatory
mediators in a concentration dependent manner (Jang et al., 2004). Compounds 2, 5 and 9
displayed stimulated inflammatory activity (see Table 4.2).

4.3.2. Acetylcholinesterase inhibitory activity
The acetylcholinesterase inhibitory activity for the crude extracts of C. crispa was
not studied as it was traditionally not used for treating mental disorders or symptoms
related to dementia or the Alzheimer’s disease. However, since the expertise and facilities
were readily available at UOW, the individual compounds 1, 2, 4, 5, 7 and 9 (see Table
4.2) isolated from this plant were assessed for their acetylcholinesterase inhibitory
activity. Among the six alkaloids studied here, compounds 1, 4, 5 and 7 exhibited
moderate inhibitory activity with minimum inhibitory requirement (MIR) values of 0.14–
0.53 nmol. Compound 1 was previously reported to have acetylcholinesterase inhibitory
activity (Vacek et al., 2010). Compound 2 showed weak acetylcholinesterase inhibitory
activity with a MIR value of 1.31 nmol and compound 9 was found to be inactive.
Compounds 5 and 9 were previously reported to show affinity for GABA-receptors
(Debarbieux et al., 1998; Eisenreich et al., 2003).

4.3.3. Antiplasmodial activity
The crude extracts (hexane, CH2Cl2, CHCl3, MeOH) of C. crispa were previously
reported in Chapter 3 to possess significant in vitro antiplasmodial activity against P.
falciparum strains: TM4/8.2 (a wild type chloroquine and antifolate sensitive strain) and
K1CB1 (multidrug resistant strain). Their reported antiplasmodial inhibitory activities are
reproduced in Table 4.2 for comparative studies. Among six of its isolated alkaloids (1, 2,
4, 5, 7 and 9) assayed for their antiplasmodial activities, compound 1 significantly
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inhibited TM4/8.2 and K1CB1 strains with IC50 values of 1.45 ± 0.19 μg/mL and 1.38 ±
0.31 μg/mL, respectively (see Table 4.2). These activities were in line with the values (1.5
μg/mL for both parasite strains) reported previously (Wangchuk et al., 2010a). Compound
5 also inhibited TM4/8.2 and K1CB1 strains with IC50 values of 5.56 ± 0.63 μg/mL and
6.87 ± 1.09 μg/mL, respectively.
These activities were marginally better than that of the crude extracts. Thus,
protopine (1) and coreximine (5) may be responsible for the major antiplasmodial activity
of this plant and have the potential to be candidates for antiplasmodial drug leads. This
finding is timely as resistance to the front line agent, artesunate, appears to be emerging
(Dondorp et al., 2009). Due to the poor solubility of compounds 2 and 4, they were found
inactive at the highest concentration of 4–4.6 μg/mL. Indeed, previous studies indicated
that compound 4 was inactive against P. falciparum and P. berghei (Dreyfuss et al., 1987;
Cunha et al., 2005). The other compounds did not show activity even at the highest tested
concentration of 9.2 μg/mL.

4.3.4. Antimicrobial activity
The crude extracts of C. crispa were reported in Chapter 3 to have moderate
inhibitory activity on all the eight test strains: E. coli, B. subtilis, S. aureus, methicillin
resistant S. aureus, S. epidermidis, V. cholerae, H. pylori and C. albicans. These microbial
strains were selected purely based on what types of strains our collaborators in Thailand
had when we first contacted them. The activities are reproduced in Table 4.3. Guided by
the result, similar antimicrobial assays were performed for the compounds 1, 2, 4, 5, 7 and
9. The antimicrobial activities of these compounds were determined first by the modified
agar well diffusion method using a well diameter of 4 mm. The activity was expressed as
minimum inhibition zone (MIZ) in mm.
Among the compounds tested, compound 1 showed the highest MIZ against S.
aureus (MIZ 8 mm), V. cholera (MIZ 7.5 mm) and E. coli (MIZ 7 mm). The MIZ (7 mm)
of this compound observed against E. coli was significant but not as good as that of the
positive control, amoxicillin (MIZ of 9 mm). Compound 1 has been also previously
reported for its antibacterial (Mahady et al., 2003), antifungal (Vacek et al., 2010) and
antiviral (Orhana et al., 2007) activities. The MIZ of compound 5 with a 6 mm zone
against H. pylori was the highest among all the six alkaloids tested.
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Table 4.3. Antimicrobial activities of the crude extracts and pure compounds of C. crispa (Minimum Inhibition Zone (MIZ) in mm, well
diameter = 4 mm; Minimum Inhibitory Concentration (MIC) in µg/mL).
Bacterial and fungal strains
Samples

V. cholerae

S. aureus

MRSA

E. coli

MIZ

MIC

MIZ

MIC

MIZ

MIC

MIZ

MeOH extract

5.5

1250

−

−

−

−

6

Hexane extract

6

2500

6

2500

6

2500

CH2Cl2 extract

5

1250

6

2500

5.5

CHCl3 extract

7

625

7

1250

Protopine (1)

7.5

250

8

13-Oxoprotopine (2)

Nt

Nt

Stylopine (4)

Nt

Coreximine (5)

B. subtilis

H. pylori

C. albicans

MIZ

MIC

MIZ

MIC

MIZ

MIC

MIZ

MIC

1250

−

−

5

1250

5.3

500

−

−

5.5

1250

−

−

6

2500

6.5

500

−

−

1250

6

1250

5.8

625

6

1250

6.3

500

−

−

7

1250

7

1250

7

625

7

625

6.5

500

5.5

313

250

5.5

250

7

250

−

−

−

−

5.3

125

Nt

Nt

4.5

500

4.5

500

6

250

5

250

Nt

Nt

5

125

Nt

Nt

Nt

5.5

250

5

500

6

250

5

250

Nt

Nt

5

125

Nt

Nt

Nt

Nt

5.5

250

4.5

250

6

250

5

125

Nt

Nt

6

125

Nt

Nt

Ochrobirine (7)

Nt

Nt

4.5

500

4.5

250

5

250

5

250

Nt

Nt

5

125

Nt

Nt

Bicuculline (9)

Nt

Nt

6

500

4.5

250

5

250

5

250

Nt

Nt

5

125

Nt

Nt

16

7.8

31

<1

9

8

10

20

16

7

16

18

<1

Amoxicillin

1

Vancomycin

1

Amphotericin B

15

MIC

S. epidermidis

63

4

2

1

Standard drug as a positive control for antibacterial testing.
Standard drug as a positive control for antifungal testing.
Nt: Not tested, −: Not active.
2
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These active compounds when assessed for their minimum inhibition concentration
(MIC) using a modified broth microdilution method following a serial two-fold dilution in
96-well microtiter plates, did not show significant activity. Overall, the alkaloids
exhibited very poor MIC values against the entire eight microbial test strains with the
highest MIC being 125 µg/mL against H. pylori and B. subtilis.

4.4. Conclusions
C. crispa was found to contain at least nine isoquinoline alkaloids with protopine
(1) as the major alkaloid. The characterization of compounds 2 and 3 with complete NMR
data analysis was achieved here for the first time. The bioassays of these selected pure
alkaloids gave interesting and promising biological activities. Although, the hexane and
CH2Cl2 crude extracts of the plant showed significant anti-inflammatory activities when
compared to the DMSO control and positive control drug, dexamethasone, only one
isolated alkaloid 1 showed anti-inflammatory activity with a statistically significant pvalue of p<0.05. Compound 7 showed only weak anti-inflammatory activity perhaps due
to its crystalline nature which rendered solubility problems. Since compound 1 was the
major alkaloid component of C. crispa, it can be deduced at least in part, that this
compound is responsible for the marked anti-inflammatory effects of the crude extracts of
C. crispa. Compounds 1 and 5 exhibited significant antiplasmodial activity and can be
considered as the candidates for development of new antimalarial drugs. These
compounds also showed moderate acetylcholinesterase inhibitory activity indicating their
broad spectrum bioactivities. All the alkaloids tested showed weak antibacterial activities
against H. pylori with MIC values of 125 µg/mL. Although the crude CHCl3 extract of
this plant showed moderate anti-Trypanosoma brucei rhodesiense and cytotoxicity
activities as described in Chapter 3, none of the individual alkaloids exhibited these
activities.
In general, the anti-inflammatory, antiplasmodial and antimicrobial activities of the
crude extracts and some pure alkaloids (1, 5, and 7) were in alignment with the
ethnopharmacological uses of C. crispa. Thus, our studies have validated the use of this
plant in BTM either individually or in combination with other medicinal ingredients to
treat infections of the blood, liver and bile.
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CHAPTER 5
PHYTOCHEMICAL COMPOSITIONS AND BIOLOGICAL
ACTIVITIES OF CORYDALIS DUBIA

Photograph by P. Wangchuk, 2009.

Botanical classification
Kingdom

: Plantae

Phylum

: Magnoliophyta

Class

: Magnoliopsida

Order

: Ranunculales

Family

: Fumariaceae (Papaveraceae)

Genus

: Corydalis

Species

: dubia

Bhutanese name

: Re-kon
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5.1. Introduction
Corydalis dubia Prain (Fumariaceae), which is locally known as Re-skon, is an
annual yellow-flowering glabrous herb of lower stature arising from tuberous rootstock.
This plant is endemic to Bhutan, Sikkim (India) and the Chumbi Valley of Tibet (Grierson
and Long, 1984). In Bhutan, it grows sparsely with a recorded density of 0.6 to 3.6
plants/m2 in the wild in localized parts of the Lingzhi and Bumthang region at an altitude
range of 4294-5039 masl (Wangchuk et al., 2009; Krug, 2008).
C. dubia is closely related to C. crispa (Chapter 4). Owing to the interesting
isoquinoline alkaloids, the Corydalis species has been subjected to many pharmacological
studies. It has been also used in many traditional medicines, e.g. in Bhutan, it is used for
formulating as many as six multi-ingredient medicines as Gyu-ril-13, Hong-len-9-pa,
Khrag-smen-11, Rma-sman-reg-pa-bde-ster, Sman-sna-phyema and Sman-grub. The
crude drug comprises the whole dried plant. The leaf and the flower parts are present in
small quantities compared to the roots. Most of the roots are crushed and the inner
component is removed and only the bark of the roots, measuring from 4-6 cm in length, is
present in the crude dried drug.
As an individual plant, this plant is indicated for treating impure blood (detox),
fever arising from the infections of liver, heart, lung, pancreas and kidney, and in
alleviating neuralgia and complicated disorders that have resulted from a combination of
defective air, bile and phlegm (Wangchuk et al., 2009). These are symptoms which
correlate to both malarial and microbial infections. A preliminary phytochemical
screening demonstrated the presence of alkaloids and the crude MeOH and CHCl 3
alkaloid extracts showed significant antiplasmodial activity against chloroquine and
antifolate resistant Plasmodium falciparum strains: TM4/8.2 and K1CB1 as detailed in
Chapter 3. This prompted us to further investigate the alkaloid constituents of C. dubia.

5.2. Isolation and structure elucidation of isoquinoline alkaloids from C. dubia
Acid-base fractionations of the crude MeOH extract yielded three different solvent
extracts; CH2Cl2 extract, the CHCl3 extract and butanol (BuOH) extract (see Chapter 5,
Scheme 5.1). Focusing on the alkaloids, these extracts were repeatedly chromatographed
on silica gel columns eluting with various gradient solvent systems (mainly MeOHCHCl3, 1:1). Further purification processes using flash column chromatography, PTLC,
90

Chapter 5: Corydalis dubia

and crystallization (CHCl3/MeOH and ethyl acetate/hexane) yielded eight alkaloids:
protopine (1) (the major alkaloid of the plant), bicuculline (9), capnoidine (10),
cheilanthifoline (11), corydecumbine (12), hydrastine (13), scoulerine (14), and a new
natural product which we named dubiamine (15) after the plant’s name.
MeOH extract (60 g)
5% HCl in H2O

Aqueous

CH2Cl2 Extract
Fatty acids/neutrals (17.87 g)

NH OH, pH 9-11
4

CHCl3 Extract (1.14 g)
Protopine (1)
(1)
Bicuculline (9)
Capnoidine (10)
(1)
Cheilanthifoline (11)
Corydecumbine (12)

Aqueous

BuOH extract (1.48 g)
g)Coreximine (5)
Hydrastine (13)
Scoulerine (14)
Dubiamine (15)

Protopine (1)
13Capnoidine
(10)
Oxoprotopine
Capnoidine
(2)
(10)Aqueous

H2O/Salt
Stylopine
(4)

Scheme 5.1. Isolation of alkaloids from Corydalis dubia.

Dubiamine (15) was obtained as colorless needle-like crystals with mp 192.8-194.6
°C and had a molecular ion of (m/z) 300 [M+H+]. The EI-MS of this compound showed
the ion fragmentations as (m/z): 299 [M+], 298, 192, 176, 164, 148 (base peak), 134, 121,
107 and through HR-ESI-MS on (m/z) 300.1597 [M+H]+, its molecular formula was
determined as C18H21NO3. While compound 15 has been synthesized as an intermediate
product in vitro from the enzymatic oxidation of d,l-N-norarmepavine which was assigned
the IUPAC name as 4-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)phenol
(Inubushi et al., 1969), this is the first time it has been isolated as a natural product. No
NMR spectroscopic data was published for this compound. The 1H- and

13

C-NMR

spectroscopic data are given in Table 5.1. The structure of 15 (Figure 5.1) was also
confirmed from the analysis of its single crystal X-ray crystallographic data based on the
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molecular formula C18H21NO3 and the mass of 299.37. (Figure 5.2). The crystal structure
has been deposited at the Cambridge Crystallographic Data Centre and allocated the
deposition number CCDC 872799. Compound 15 is closely related in structure to
sendaverine and its derivatives (Pandey and Tiwari, 1980; Kametani and Ohkubo, 1965;
Suau et al., 1994).

Figure 5.1. Alkaloids isolated from Corydalis dubia.

Figure 5.2. Single crystal structure of dubiamine (15) with CCDC 872799.
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Table 5.1. 1H (500 MHz) and
compound 15.

13

C-NMR (125 MHz) data (obtained in CDCl3) of

Carbon no.

13

1

1
2
3
4
4a
5
6
7
8
8a
1'
2'
3'
4'
5'
6'
6-OCH3
7-OCH3

55.6
62.2
50.7
28.7
126.7
111.6
147.6
147.6
109.7
126.3
130.1
130.7
115.3
155.1
115.3
130.7
56.0
56.1

3.53 (s)
3.60 (s)
2.73 (t, J = 5.8 Hz)
2.81 (t, J = 5.8 Hz)

C NMR, δ (ppm)

H NMR, δ (ppm), multiplicity, J in Hz

6.58 (s)

6.48 (s)

7.22 (d, J = 7.5 Hz)
6.75 (d, J = 8.0 Hz)
6.75 (d, J = 8.0 Hz)
7.22 (d, J = 7.5 Hz)
3.83 (s)
3.80 (s)

Other known compounds (see Figure 5.2) were identified through MS library
matching techniques (NIST08s) and subsequent comparison of their melting point, optical
rotation, mass spectra and NMR spectra (1H and

13

C) with those reported. Protopine (1)

was identified by comparing its NMR data with the one isolated from C. crispa (described
in Chapter 4) and with the data previously published (Abou-Donia et al., 1980; Takahashi
et al., 1985; Seger et al., 2004). Similarly, bicuculline (9) was identified by comparing its
NMR data with the one isolated from C. crispa described in Chapter 4 and also with those
reported (Edwards and Handa, 1961; Abou-Donia et al., 1980; Blasko et al., 1982;
Elango, et al., 1982; Basha et al., 2002).
Capnoidine (10) was obtained as colourless crystals and had an optical rotation of
[]D20 ─116.2 (c 0.41, CHCl3) (Lit. []D20 ─116 (c 0.52, CHCl3) (Blasko et al., 1982))).
The LR-ESI-MS showed its [M+H+] peak at (m/z): 368 and the HR-ESI-MS supported its
molecular formula of C20H17NO6 from the (m/z): 368.1120 [M+H+]. The LR-EI-MS
exhibited the ion fragmentation pattern as (m/z): 367 [M+], 207, 190 (100%), 175, 160,
149, 131, 117, 103 which matched that of capnoidine reported in the MS library
(NIST08.LIB, Entry # 153894, CAS: 485-49-4, RetIndex: 3142). The 1H-NMR and
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NMR data of the isolated capnoidine (10) agreed with those reported in the literature
(Blasko et al., 1982; Ribar and Meszaros, 1991; Pilar et al., 2010).
Cheilanthifoline (11) was isolated as an amorphous solid which melted at 168.9170.8 oC (Lit. 183-184 oC (Haisova and Slavik, 1973)) and had an optical rotation of
[]D20 ─206 (c 0.37, MeOH) (Lit. []D20 ─331 (c 0.1, MeOH) (Haisova and Slavik,
1973))). The LR-ESI-MS showed its [M+H+] peak at m/z 326 and the HR-ESI-MS for
(m/z): 326.1315 [M+H+] supported a molecular formula of C19H20NO4. The LR-EI-MS
exhibited the ion fragmentation pattern as (m/z): 325 [M+], 310, 190, 176, 162, 149, 148
(100%), 133, 119 which matched that of cheilanthifoline reported in the MS library
(NIST08.LIB, Entry # 129214, CAS: 483-44-3, RetIndex: 2678). The 1H-NMR and

13

C-

NMR spectroscopic data agreed with those reported in the literature for cheilanthifoline
(11) (Okamoto et al., 1971; Yeola and Mali, 1984; Rucker et al., 1994; Cheng et al.,
2008).
Corydecumbine (12) was isolated as an amorphous creamy crystalline solid. The
LR-ESI-MS showed the [M+H+] peak at m/z 370 and the HR-ESI-MS for this peak (m/z):
370.1294, supported its molecular formula of C20H19NO6. The 1H-NMR and

13

C-NMR

spectroscopic data of the isolated compound 12 agreed with those reported in the
literature (Basnet et al., 1993).
Hydrastine (13) was isolated as an amorphous solid. The LR-ESI-MS showed its
[M+H+] at m/z 384 for which a molecular formula was established as C21H21NO6 by the
HR-ESI-MS. The LR-EI-MS showed the ion fragmentation pattern as (m/z): 190 (100%),
149, 117 and this matched that of hydrastine reported in the literature (Blasko et al., 1982;
Elango, et al., 1982) and that recorded in the MS library (NIST08.LIB, Entry # 269564,
CAS: 118-8-1, RetIndex: 3176).
Scoulerine (14) was isolated as a reddish brown solid which melted at 188.5-189.7
o

C (decomposition) (Lit. 197 oC (Brochman-Hanssen and Nielson 1966)) and had the

optical rotation of []D24 ─283.3 (c 0.72, MeOH) (Lit. []D24 ─318 (c 0.41, MeOH)
(Brochman-Hanssen and Nielson 1966))). The LR-ESI-MS showed its [M+H+] peak at
m/z 328 and the HR-ESI-MS supported its molecular formula as C19H21NO4 which was
measured from the [M+H+] peak of m/z 328.1556. The LR-EI-MS of compound 14
showed the ion fragmentation pattern as: m/z 327 (M+), 326, 312, 178 (100%), 176, 163,
150, 150, 135, 121 and 107 that matched with the literature for scoulerine in the MS
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library (NIST08.LIB, Entry # 130643, CAS: 483-45-4, RetIndex: 2744). The 1H-NMR
and

13

C-NMR spectroscopic data of the compound 14 agreed with those reported in the

literature for scoulerine (Brochman-Hanssen and Nielson 1966; Cheng et al., 2008).

Scheme 5.2. The biosynthetic pathway for the Papaver isoquinoline alkaloids.

Compounds 1, 11 and 14, are related biosynthetically. This biosynthetic pathway
(Scheme 5.2) for the above comounds was established by tracer experiments using
Corydalis incisa and Chelidonium majus and demonstrated that protopine (1) was
biosynthesised in plants from tyrosine (16) via (S)-reticuline (17), scoulerine (14),
cheilanthifoline (11) and (S)-stylopine (18) (Battersby et al., 1975 a,b; Takao et al., 1976).
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5.3. Biological activities
Given the traditional use of C. dubia to treat fever and various disorders bearing
relevance to malaria and microbial infections and the evidence that the crude alkaloid
extracts exhibited various biological activities (as detailed in Chapter 3 and some data
reproduced in Table 5.2), we investigated the biological activities of alkaloid constituents
of this plant. Out of the eight alkaloids (compounds 1, 9-15, Figure 5.1) isolated from this
plant, we examined bicuculline (9), capnoidine (10), scoulerine (14), and dubiamine (15)
for their anti-inflammatory, anti-acetylcholinesterase, antiplasmodial and cytotoxicity
activities (Table 5.2) and also the antimicrobial properties (Table 5.3). Due to the smaller
quantities of compounds 12 and 13, their biological activity studies were not carried out.
The new natural product, dubiamine (15), did not exhibit any biological activities. All
alkaloids studied here did not show any significant cytotoxicity thereby suggesting that
the plant is safe for use in BTM.

5.3.1. Anti-inflammatory activity
The anti-inflammatory activity of the pure alkaloids isolated from C. dubia was
determined using the same conditions and methods as described in Chapter 4 and detailed
in the experimental section. Although, the crude extracts showed significant inhibition of
the production of TNF-α (Table 5.2), compounds 10-11 and 14 showed only mild antiinflammatory activity against TNF-α production with insignificant p-values. Among these
three alkaloids, compound 10 showed the maximum inhibition of TNF-α production with
the inhibition value of 532 pg/mL. The inhibition of TNF-α production by protopine (1)
was studied earlier and discussed in Chapter 4. This compound showed significant antiinflammatory activity.

5.3.2. Acetylcholinesterase inhibitory activity
The acetylcholinesterase (AChE) inhibitory activity of the crude extracts of C.
dubia was not studied. However, the individual compounds 1, 9-11 and 14, (see Table
5.2) isolated from this plant were assessed for their AChE inhibitory activity at UOW.
This assay was chosen as it was readily available at UOW and was not based on
ethnomedical direction. Among these alkaloids, scoulerine (14) exhibited highly
significant inhibitory activity with the minimum inhibitory requirement (MIR) value of
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0.0015 nmol which was even better than the reference drug, galanthamine with a MIR
value of 0.003 nmol (Table 5.2). Protopine (1) was previously reported to have AChE
inhibitory activity (Vacek et al., 2010) and our studies support that this compound
possesses significant AChE inhibitory activity with a MIR value of 0.14 nmol. While
capnoidine (10) showed similar activity with the same MIR value as that of compound 1,
cheilanthifoline (11) exhibited AChE activity with a MIR value of 0.31 nmol. Although
bicuculline (9) was previously reported to show affinity for GABA-receptors (Debarbieux
et al., 1998; Eisenreich et al., 2003), it did not show any significant AChE inhibitory
activity in our studies.

5.3.3. Antiplasmodial activity
The antiplasmodial activity of the pure alkaloids was determined as described in
Chapters 3 and 4 and the methods as detailed in the experimental section. The crude
MeOH extract and the CHCl3 crude alkaloid extract (as described in Chapter 3) exhibited
significant antiplasmodial activity (Table 5.2). Chelanthifoline (11) and protopine (1)
were isolated from different plant species, Corydalis calliantha and their antiplasmodial
activity were reported (Wangchuk et al., 2010a) and these values are also included in
Table 5.2 to allow for ready comparisons.
From Table 5.2, it was evident that scoulerine (14) had almost two fold better
activity than the crude CHCl3 extract and seven fold better activity than that of the crude
MeOH extract. Scoulerine (14) demonstrated significant in vitro antiplasmodial activity
against TM4/8.2 and K1CB1 strains with IC50 values of 1.78 µg/mL and 1.04 µg/mL,
respectively. This activity was eight fold better than the conventional antimalarial drug
pyrimethamine (reference drug) (Table 5.2) and therefore, represents a potential new
scaffold based on which the improved antimalarial lead compounds can be drawn. This
compound has been also reported to exhibit other activities such as: anti-topoisomerase I
(Cheng et al., 2008), GABAA receptor agonist (Eisenreich et al., 2003), and antiemetic,
antitussive and antibacterial activities (Taylor and Francis, 2013). While the compounds 1
and 11 have similar antiplasmodial activity (Table 5.2), compounds 9-10 and 15 did not
show antiplasmodial activity even at the highest tested concentration of 10-20 μM.
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Table 5.2. Bioactivities of the crude extracts and the pure alkaloids 1, 9-11 and 14-15, isolated from C. dubia.
Anti-inflammatory
Samples

MeOH extracta
CHCl3 extracta
Protopine (1)b
Bicuculline (9)b
Capnoidine (10)
Cheilanthifoline (11)
Scoulerine (14)
Dubiamine (15)
RPMI
1% DMSO
Dexamethasonec
Galanthamined
Chloroquinee
Cycloguanile
Pyrimethaminee
Ellipticinef
Doxorubicinf

AChE*
MIR (nmol)

TNF-α
(pg/mL)

Activity (%)

236 ± 45
258 ± 42
467 ± 40
723 ± 50
532 ± 47
541 ± 33
566 ± 17
NT
502 ± 43
620 ± 54
258 ± 65

– (62)
– (58)
– (25)
+ (17)
– (14)
– (13)
– (9)
NT
Media
Solvent
– (58)

NT
NT
0.14
>2.72
0.14
0.31
0.0015
NT

Antiplasmodial
TM4/8.2
IC50 ( μg/mL)
6.38 ± 0.62
2.21 ± 0.43
1.45 ± 0.53
>10
>20
16.60 ± 0.8
1.78 ± 0.72
>20

Cytotoxicity

K1CB1
IC50 ( μg/mL)
9.50 ± 0.84
2.84 ± 0.32
1.38 ± 0.30
>10
>20
1.22 ± 0.8
1.04 ± 0.08
>20

Vero cells
IC50 ( μg/mL)
>10
>10
>3.5
>10
>20
>20
>20
>20

KB cells
IC50 (μg/mL)
>10
>10
>3.5
>10
>20
>20
>20
>20

0.003
0.0096
0.0095
0.0200

0.089
0.810
7.700
0.093
0.56

NT: Not tested; +: activated; −: inhibited; * Acetylcholinesterase inhibitory activity.
a
Biological activities of crude extracts reproduced from Chapter 3 for easy comparison.
b
Original activity taken from Chapter 4.
c
Reference drug for anti-inflammatory activity.
d
Reference drug for acetylcholinesterase activity.
e
Reference drugs for antiplasmodial activity.
f
Positive controls for cytotoxicity activity.
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Table 5.3. Antimicrobial activities of the pure compounds of C. dubia in Minimum Inhibition Zone (MIZ) (in mm, well diameter = 4 mm)
and in Minimum Inhibitory Concentration (MIC) (in µg/mL).
V. cholerae
Samples
MeOH
CH2Cl2
CHCl3
Protopine (1)
Bicuculline (9)
Capnoidine (10)
Cheilanthifoline (11)
Scoulerine (14)
Amoxicillin1
Vancomycin1
Amphotericin B2
1
2

AWD
16

MIC
-------7.8

S. aureus

MRSA

E. coli

B. subtilis

S. epidermidis

H. pylori

C. albicans

AWD
5
5

MIC
2500
-1250

AWD
5
5

MIC
--625

AWD
NT

MIC
--NT

AWD
5
5
NT

MIC
2500
2500
NT

AWD
6
5
NT

MIC
NT
NT
NT

AWD
-

MIC
----

AWD
-

MIC
----

31

----<1

-

-----

9

----8

5
10

--1000
-63

20

----16

5
5
6
5
7

250
250
2,000
250
16

-

-----

18

<1

15

4

Standard drug as a positive control for antibacterial testing.
Standard drug as a positive control for antifungal testing.
NT: Due to solubility problems a number of extracts were not tested for their MIC values.
- : no zone inhibition. --: No inhibitory activity at the highest cut off concentration of 2500 µg/mL.
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5.3.4. Antimicrobial activity
The antimicrobial activities of crude extracts of C. dubia, which were reported in
Chapter 3, were determined using the MIZ and MIC testing methods. Some compounds
showed moderate to mild antibacterial activity as shown in Table 5.3. Guided by this
crude extracts results, similar antimicrobial assays were performed for the compounds
listed in Table 5.3 using the modified Agar Well Diffusion (AWD) method with a well
diameter of 4 mm and subsequently determining their minimum inhibition concentration
(MIC). Among the compounds tested, compounds 1, 9-11 and 14 were all active against
H. pylori, the highest being that of compounds 9-10 and 14 with all of these compounds
showing the MIC values greater than 250 μg/mL. Cheilanthifoline (11) also showed weak
activity against the bacterial strain, B. subtilis. None of the compounds tested showed any
antifungal activity.

5.4. Conclusions
In summary, our study found: a) a new natural product (15) which we named as
dubiamine and its structure was confirmed from its single crystal X-ray structure, b)
compound 14 showed significant in vitro antiplasmodial activity without mammalian cell
toxicity and was identified as a potential antimalarial hit scaffold, c) since the compounds
1, 11 and 14 have shown significant antiplasmodial activities and that protopine (1) was
the major alkaloid present, it may be deduced that these three alkaloids (alone or
synergistically) may be responsible for the significant activity of the CHCl3 crude
alkaloid extract of C. dubia, d) the in vitro antiplasmodial activity of the crude extracts
and the pure compounds 1, 11, and 14 is commensurated with the ethnopharmacological
uses of this plant and thus substantiated its usage in BTM for the aforementioned
disorders. However, it may be premature to claim that the plant extract formulated and
administrated according to traditional protocols would be effective for treating humans.
Therefore, in vivo animal model of malaria using methods of traditional preparation and
administration would more confidently support the use of the plants in treating humans.
As resistance to the front line antimalarial drug, artesunate, appears to be emerging
(Dondorp et al., 2009), the above in vivo experiments on crude extracts and also on
compound 1, 11 and 14 which showed significant antiplasmodial activity against
antifolate sensitive and multidrug resistant strains, are essential.
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CHAPTER 6
ESSENTIAL OIL, PHYTOCHEMICALS AND BIOACTIVITIES OF
AJANIA NUBIGENA

Photograph by MSP.

Botanical classification
Kingdom

: Plantae

Phylum

: Angiospermae

Class

: Dicotyledoneae

Order

: Campanulales

Family

: Asteraceae (compositae)

Genus

: Ajania

Species

: nubigena

Synonyms

: Artemisia nubigena, Dendranthema nubigenum,
Chrysanthemum nubigenum and Tanacetum nubigenum

Bhutanese name : Khen-kar
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6.1. Introduction
Ajania is a relatively small genus of the family Asteraceae with only 28-40 species
found in Russia and Asian countries including Bhutan, Nepal, India, Tibet, China and
Japan (Pellicer et al., 2009; Zhao et al., 2010; Zhu et al., 2010). In Bhutan, only two
Ajania species: A. nubigena and A. myriantha have been reported (Grierson and Long,
2001). A. nubigena is locally known as m.khan-d.kar and contributes to the preparation of
at least four popular multi-ingredient or polyherbal formulations, including Bdut-rtsi-5lums, Sman-sna-phyema, Sman-sang and Sman-grub (Tenzin, 2007). While Bdut-rtsi-5lums (Five Herbal Ambrosia) is used in spa related health care practices, the later three
products are used mostly in spiritual, religious and medicinal practices. Sman-sang
(medicinal incense) is used mainly for purification rituals. As an individual plant, A.
nubigena is used in the BTM as an incense, vulnerary, expectorant, styptic and antiepistaxis and also for treating abscesses, swelling of limbs, tumor and kidney infections
(Wangchuk et al., 2009).
A. nubigena is similar to T. mutellinum and has been ascribed different
synonyms/basonyms as Artemisia nubigena, Dendranthema nubigenum, Chrysanthemum
nubigenum and Tanacetum nubigenum (IPNI, 2005). It is a silvery-grey tufted perennial
herb of 18-33 cm in height with usually many stems arising from its slender fibrous
rootstock. Each stem has smaller yellow flower heads of 3-5 mm across and palmate
leaves. This plant grows in alpine mountain rocky slopes and sandy grounds of Bhutan at
an elevation range of 3600–4800 masl (Wangchuk et al., 2009). The crude drug
comprises the whole dried plant, with stems, leaves and flowers usually cut into 5-10 mm
lengths.
Varieties of this plant grow in different regions of India, including Kumaon,
Garwal, Uttarakhand and Uttar Pradesh. These have been classified based on the three
main chemotypes of their essential oils (EO) (Mathela et al., 2008; Chanotiya and
Mathela, 2007; Khetwal and Harbola, 1989; Beauchamp et al, 2001; Chanotiya et al.,
2005). Chemotype I contains bornyl acetate (39.7%) as the major marker constituent of
the EO while chemotypes II and III contain (3R,6R)-linalool oxide acetate (69.4%) and ()-cis-chrysanthenol (37.0%) as their principal components, respectively (Mathela et al.,
2008).
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While the Indian varieties of A. nubigena (ascribed under the basonym Tanacetum
nubigenum) have been studied as mentioned above, a Bhutanese variety growing in the
extreme vegetation and climatic conditions of the Bhutan Himalaya has not been
investigated for its phytochemicals or biological activities, especially for antimalarial
activity and cytotoxicity. Moreover, the studies on these Indian varieties of A. nubigena
reported the analysis of the EO of the fresh plant material, which is contrary to the
manner in which this plant is used by the local people in India, Nepal and Bhutan, who
use it in its dried form. Differences in the quality and the chemical constituents of these
differently prepared plant samples were thus expected. Our earlier studies of various
crude solvent extracts of this dried plant material (described in Chapter 3), indicated that
the plant was a good source of antimalarial and antimicrobial agents. This encouraged us
to investigate the chemical components of the EO and the methanol extract of the dried
plant material. The EO and the isolated major phytochemicals were assessed for their
antimalarial, antimicrobial and cytotoxic activities.

6.2. GC/GC-MS analysis and isolation of the essential oil components
The EO was isolated from the dried plant material (1 kg) using the hydrodistillation
method employing a Clevenger apparatus as described in the experimental section. A
greenish EO (7 mL) with a soothing aroma was obtained. The EO was analysed for its
chemical constituents using GC and GC-MS systems (see experimental section for
details). Kovats retention indices (KI) were obtained by GC-FID analysis of an aliquot of
the EO spiked with an n-alkane mixture (n-C7 to n-C30). The EO constituents were
identified by comparing their mass spectra with those in the NIST and NISTREP mass
spectra library of the GC-MS data system and further confirmed by comparing their
Kovats indices (KI) with those in the literature (Adams, 1995, Mathela et al., 2008,
Beauchamp et al., 2001, Chanotiya et al., 2005, Makadia et al., 2011).
A capillary drop of the EO was analyzed using GC and GC-MS which detected 53
constituent peaks of the chromatographable fraction of the total injected oil (Figure 6.1).
Of these, 45 compounds were identified with (3R,6R)-linalool oxide acetate (75.8 %) as
the major constituent, followed by 6-ethenyldihydro-2,2,6-trimethyl-2H-pyran-3(4H)one (4.6%), epoxylinalol (2.8%), germa-crene-D (1.4%), bisabolol oxide A (1.2%),
chamazulene (0.9%), (E)-2-(2,4-hexadiynylidene)-1,6-dioxa-spiro[4,4]non-3-ene (0.9%),
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and (Z)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (0.9%). The percent
contents of the EO were determined on the basis of their FID responses on GC. All the
identified compounds are presented in Table 6.1. With reference to the Indian varieties
reported, no bornyl acetate or (-)-cis-chrysanthenol were detected in our study thereby
confirming that the major constituent of a Bhutanese variety of A. nubigena was
chemotype II. Through careful purification of the EO using column chromatography and
preparative TLC, we isolated four of its major compounds (19-22). The isolated
compounds included an oxygenated terpene ((3R,6R)-linalool oxide acetate (19) (major
oil constituent), a sesquiterpenelactone (chamazulene (20)), and two spiroethers ((E)-2(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (21) and (Z)-2-(2,4-hexadinylidene)1,6-dioxaspiro[4,4]non-3-ene (22)).

Figure 6.1. GC-FID peaks and the isolated compounds of the EO of A. nubigena.
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Table 6.1. EO constituents of aerial parts of Ajania nubigena.
GC-peak
(Figure 6.1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

Compound name
α-Pinine
β-Citrollene
1-Methylpentyl hydroperoxide
Benzaldehyde
cis-Linalool oxide
β-Linalool
6-Ethenyldihydro-2,2,6-trimethyl-2H-pyran-3(4H)-one
L-Pinocarveol
L-Camphor
Pinocarvone
(-)-Borneol
Epoxylinalol
Homoveratrole
(3R,6R)-Linalool oxide acetate (isolated)
Eugenol
α-Copaene
Aromadendrene
β-Farnesene
Unidentified
5-Ketobornyl acetate
Seychellene
Germacrene D
Patchoulene
Unidentified
α-Muurolene
α-Bisabolene
Epiglobulol
Unidentified
(Z)-α-Bisabolene epoxide (tentatively identified)
Spathulenol
Caryophyllene oxide
Isoaromadendrene epoxide
Unidentified
Unidentified
(E)-6-Hexadecen-4-yne
Unidentified
Cubenol
Unidentified
4-Methylene-1-methyl-2-(2-methyl-1-propen-1-yl)-1-vinyl-cycloheptane*
Eudesm-4(14)-en-11-ol
τ-Cadinol
β-Santalol
1(2H)-Napthalenone, octahydro-4a,8a-dimethyl-7-(1-methylethyl)- [4aR(4a.α.,7β.,8a.α)]
Unidentified
6-Isopropenyl-4,8a-dimethyl-1,2,3,5,6,7,8,8a-octahydro-napthalen-2-ol
Chamazulene (isolated)
Bisabolol oxide A
Unidentified
Benzyl benzoate
1-Octadecyne (tentatively identified)
(E)-2-(2,4-Hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (isolated)
(Z)-2-(2,4-Hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (isolated)
1-Phenylbicyclo[3.3.1]nonan-9-one (tentatively identified)

105

Kovats
indices
934
947
949
957
1090
1098
1108
1141
1147
1164
1168
1175
1240
1291
1359
1381
1426
1459
1463
1470
1473
1482
1493
1500
1506
1513
1522
1529
1560
1585
1592
1595
1600
1613
1619
1636
1636
1650
1650
1659
1662
1669
1683
1689
1694
1720
1754
1766
1776
1844
1887
1931
1960

% oil
0.11
0.07
0.07
0.07
0.27
0.08
4.56
0.11
0.02
0.07
0.34
2.76
0.23
75.80
0.11
0.50
0.22
2.90
0.15
0.08
0.09
1.35
0.09
0.38
0.08
0.07
0.39
0.44
0.14
0.30
0.13
0.32
0.14
0.19
0.23
0.02
0.11
0.07
0.19
0.51
0.34
0.31
0.26
0.01
0.62
0.94
1.21
0.12
0.17
0.32
0.93
0.97
0.11
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(3R,6R)-Linalool oxide acetate (19) was isolated as a colorless liquid. The LR-ESIMS showed a [M+H+] peak at (m/z): 213 and the LR-EI-MS exhibited the ion
fragmentation pattern as (m/z): 213, 197, 195, 154, 153, 136, 114, 101, 94, 79, 68, 43. The
1

H-NMR and

13

C-NMR spectroscopic data of the isolated compound (19) agreed well

with those of (3R,6R)-linalool oxide acetate reported in the literature (Chanotiya et al.,
2005).
Chamazulene (20) was isolated as a characteristic dark blue coloured liquid and was
identified as a new sub-chemotype for the first time from this species. Its LR-ESI-MS
showed the [M+H+] peak at (m/z): 185 and the LR-EI-MS exhibited the ion fragmentation
pattern as (m/z): 184, 183, 169 (base peak), 155, 153, 141, 128, 115, 77, 63, 51, 41, 39
which matched the ion fragmentation pattern of chamazulene in the MS library system
(NIST08.LIB, Entry # 33626, CAS: 529-05-5). The

1

H-NMR and

13

C-NMR

spectroscopic data of this isolated compound (20) agreed well with those of chamazulene
reported in the literature (Adam and Zapp, 1998; Carret et al., 2005; Cruz et al., 2006).
(E)-2-(2,4-Hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (21) was isolated as a
liquid and its LR-ESI-MS showed a [M+H+] peak at (m/z): 201.

The LR-EI-MS

exhibited the ion fragmentation pattern as (m/z): 200 (M+) (base peak), 185, 170, 157,
141, 128, 115, 102, 76 which matched the ion fragmentation pattern of the (E)-spiroether
in the MS library system (NIST08.LIB, Entry # 42992, CAS: 16863-61-9, RetIndex:
1570. The 1H-NMR and

13

C-NMR spectroscopic data of this isolated compound (21)

agreed well with those of the (E)-spiroether reported in the literature (Chanotiya et al.,
2005). The isomer of (E)-spiroether was identified as (Z)-2-(2,4-hexadinylidene)-1,6dioxaspiro[4,4]non-3-ene (22). It was isolated as a liquid and its LR-ESI-MS showed a
[M+H+] peak at (m/z): 201 and the LR-EI-MS exhibited the same ion fragmentation
pattern as its isomer. The 1H-NMR and

13

C-NMR spectroscopic data of this isolated

compound (22) agreed well with those of the (Z)-spiroether reported in the literature
(Chanotiya et al., 2005).

6.3. Isolation and identification of the flavonoids from MeOH extracts
Dried A. nubigena was powdered and was extracted with MeOH which was then
fractionated with hexane to give the hexane extract (28 g) followed by EtOAc to obtain
the EtOAc extract (12.5 g). Through repeated normal and reverse phase silica gel column
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chromatography, reverse phase (RP) silica-coated preparative TLC plates, and fractional
crystallization yielded four compounds 23-26 (Figure 6.2).

Figure 6.2. The structures of compounds isolated from the MeOH extract of A. nubigena.

p-Hydroxyacetophenone (23) was a phenylpropanoid compound isolated as a white
solid. The LR-EI-MS indicated an ion fragmentation pattern as (m/z): 136 (M+), 121
(100%), 107, 93, 77, 65, 39, which matched the ion fragmentation pattern of phydroxyacetophenone in the MS library system (NIST08s.LIB, Entry # 6281, CAS: 9993-4, RetIndex: 1250). The 1H-NMR spectroscopic data of this compound agreed with
those of p-hydroxyacetophenone reported in the literature (Makadia et al., 2011).
Oxyanin B (24) which is also known as quercetagetin 3,7,4'-trimethyl ether was
isolated as a pale yellow solid. The LR-ESI-MS showed a [M+H+] peak at (m/z): 361.
The LR-EI-MS indicated its mass as 360 with the ion fragmentation pattern as (m/z): 360
(M+), 345, 327, 317, 299, 274, 246, 207, 164, 151, 135, 69 and its 1H-NMR spectroscopic
data agreed with those of oxyanin B reported in the literature (Malan and Roux, 1979).
This report lacked

13

C-NMR spectroscopic data, which we have reported in the

experimental section.
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Luteolin (25) was isolated as a white solid and its LR-ESI-MS showed a [M+H+]
peak at (m/z): 281. The LR-EI-MS indicated its mass as 286 with the ion fragmentation
pattern as (m/z): 286 (M+, base peak), 277, 258, 229, 153, 124, 96, 77, 69 which matched
that of luteolin reported in the MS library (NIST08.LIB, Entry # 101825, CAS:491-70-3,
RetIndex:2 854). The 1H-NMR and

13

C-NMR spectroscopic data agreed with those of

luteolin reported in the literature (Peters et al., 1986); Jung et al., 2009).
Luteolin-7-O-β-D-glucopyranoside (26) was isolated as a pale yellow solid with a
molecular weight of 449 that was determined by positive ion LR-ESI-MS (M+H+). This
compound was confirmed by comparing its 1H-NMR and

13

C-NMR spectroscopic data

with those of luteolin-7-O-β-D-glucopyranoside reported in the literature (Wang et al.,
2003).

6.4. Biological activities of the EO, crude extracts and isolated compounds
The crude MeOH, hexane, CH2Cl2 and CHCl3 extracts of A. nubigena were studied
previously for their biological activities and the results were described in Chapter 3 and
reproduced here in Table 6.2 for direct comparison of their activities with those of
isolated compounds. In this study, the EO and the eight terpenoid and flavonoid
compounds 19-26 were investigated for their antiplasmodial, antimicrobial and the
cytotoxicity activities and the results are shown in Table 6.2. Among the four flavonoid
compounds tested, luteolin (25) showed broad spectrum activities against all the tested
organisms. In contrast, its glycolsylated derivative, luteolin-7-O-β-D-glucopyranoside
(26), showed more selectivity, being only active against a subset of the targets (Table
6.2).

6.4.1. Antiplasmodial activity
The antiplasmodial activity study was carried out against a wild type chloroquine
and antifolate sensitive strain, TM4/8.2 and the multidrug resistant strain, K1CB1 of the
Plasmodium falciparum using the Microdilution Radioisotope Technique as detailed in
the experimental section. Chloroquine, pyrimethamine and cycloguanil were used as
reference drugs for both the plasmodial strains. The crude MeOH, hexane, CH2Cl2 and
CHCl3 extracts demonstrated significant antiplasmodial activity against both the test
strains (Table 6.2).
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Table 6.2. Bioactivities of the crude extracts, essential oil and the pure compounds 19-26 isolated from A. nubegina
Samples
MeOH extracta
Hexane extracta
CH2Cl2 extracta
CHCl3 extracta
Essential oil
(3R,6R)-linalool oxide acetate (19)
Chamazulene (20)
(E)-Spiroether (21)
(Z)-Spiroether (22)
p-Hydroxyacetophenone (23)
Oxyanin B (24)
Luteolin (25)
Luteolin-7-O-β-D-glucopyranoside (26)
Chloroquineb
Cycloguanilb
Pyrimethamineb
Ellipticinec
Doxorubicinc
Amoxycillind
Vancomycind
Amphotericin Be

Antiplasmodial (IC50 in μg/mL) Cytotoxicity (IC50 in μg/mL)
TM4/8.2
K1CB1
VERO
KB
9.84 ±1
8.71 ±1
>10
>10
>12.5
6.22 ±3
>10
>10
>12.5
9.51 ±1
>10
>10
20.00 ±4
18.70 ±1
>25
>25
66.10±25
70.60±5
>100
>100
>100
>100
>100
>100
>20
>20
>20
>20
7.38±2
8.84±1
>10
>10
>20
>20
>20
>20
>10
>10
>10
>10
>20
>20
>20
>20
6.23±1
6.26±1
14.52±2 14.30±2
2.82±1
2.09±1
33.28±4
>45
0.0096
0.089
0.0095
0.81
0.0200
7.7
0.093
0.56

Antibacterial (MIZ* in mm)
S. aureus B. subtilis S. epidermidis MRSA
5
5
–
6.5
5
5
–
5.5
–
5
–
5.5
–
5.5
–
–
–
13
–
–
–
8
–
–
Nt
Nt
Nt
Nt
–
7
–
–
–
11
8
–
Nt
Nt
Nt
Nt
–
–
–
–
8
7
10
10
–
6
–
–

34

10

Antifungal (MIZ* in mm)
C. albicans
–
–
–
–
11
5
Nt
5
5
Nt
–
5
–

20
15
20

*MIZ: minimum inhibition zone with a well diameter of 4 mm. Nt: Not tested. −: Not active. a results reproduced from earlier Chapter 3.
activity. c Reference drugs for cytotoxicity. d Reference drugs for antibacterial activity. e Reference drug for antifungal activity.
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Interestingly, these four crude extracts were found to be more active against
multidrug resistant K1CB1 strain with the IC50 values in the range of 6.22-9.51 μg/mL
which suggested that the mixtures could possess good antimalarial compounds.
However, the EO of this plant exhibited only moderate antiplasmodial activities against
TM4/8.2 and K1CB1 strains with IC50 values of 66.1 μg/mL and 70.60±5 in μg/mL,
respectively. The antimalarial activities of the crude extracts were almost seven fold
more potent than that of EO.
Among the pure compounds, luteolin-7-O-β-D-glucopyranoside (26) exhibited
the best (among test samples) and highly significant antimalarial activities with IC50
values of 2.82 μg/mL and 2.09 μg/mL against TM4/8.2 and K1CB1 strains,
respectively. Its antimalarial activity was three fold more potent than that of the parent
crude extracts (Table 6.2). This compound (26), with significant antimalarial activities
and lesser toxicity, would serve as a potential lead for developing an analogue with a
better therapeutic index. Luteolin (25) exhibited good antimalarial activities against
both the TM4/8.2 and K1CB1 strains of P. falciparum with IC50 values of 6.23 μg/mL
and 6.26 μg/mL, respectively. The (E)-spiroether (21) isolated from the EO also
displayed significant antiplasmodial activities similar to the crude extracts with IC 50
values of 7.38 μg/mL and 8.84 μg/mL against TM4/8.2 and K1CB1, respectively. The
other compounds were inactive.

6.4.2. Cytotoxicity
The cytotoxicity assay was carried out using the sulforhodamine B (SRB) assay
method on normal vero cells from kidney of African green monkey, Cecopithecus
aethiops and the human oral carcinoma KB cells. Ellipticine and doxorubicin were used
as reference drugs for the cytotoxicity studies. While the crude extracts and the EO did
not exhibit any significant cytotoxicity (Table 6.2), luteolin (25) and luteolin-7-O-β-Dglucopyranoside (26) showed moderate cytotoxicity. Among these two compounds that
were cytotoxic, luteolin (25) demonstrated the highest cytotoxicity against vero and
human oral carcinoma KB cells with IC50 values of 14.52 μg/mL and 14.30 μg/mL,
respectively. Since compound 25 exhibited broad spectrum bioactivity in this study, it
was implicit to be a general toxin. However, literature confirmed that it was a common
natural antioxidant flavone with a broad range of bioactivities including pro-oxidant,
anti-inflammatory, antimicrobial, anti-angiogenesis, apoptosis inducing, anti-tumour
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and anticancer (leukemia, melanoma and carcinomas of pancreas, ovary, brain, kidney,
lung, colon and stomach) activities (Miguel, 2009). Our study demonstrated the
cytotoxicity of this compound against human oral carcinoma KB cells.
Luteolin-7-O-β-D-glucopyranoside (26) exhibited mild cytotoxicity against vero
cells with an IC50 value of 33.28 μg/mL but with no cytotoxicity to the human oral
carcinoma KB cells. An earlier study showed that this compound was not toxic to
RAW264.7 cells and also demonstrated that its aglycone luteolin (25) was more toxic
than the glycosylated form (Hu and Kitts, 2003). The demonstration that the
cytotoxicity of compound 26 was lower than its aglycone 25, suggests that
glycosylation with a glucose moiety reduces toxicity. This has been substantiated by its
closely related compounds, kaempferol and quercetin, which had higher toxicities
compared to their glycosides (Wang and Mazza, 2002). Higher lipophilicity facilitates
greater penetration into the lipid membrane of organisms and therefore greater
cytotoxicity which may explain the higher toxicity of compound 25 when compared to
its glycosylated derivative 26.

6.4.3. Antimicrobial activity
For the antimicrobial assay, the test organisms including Escherichia coli
(ATCC 25922), Bacillus subtilis (ATCC 6633), Staphylococcus aureus (ATCC 6538),
methicillin resistant S. aureus (MRSA), (DMST 20651), Staphylococcus epidermidis
(ATCC 12228), Vibrio cholerae (DMST 2873) and Candida albicans (ATCC 10231)
were used. However, only those strains sensitive to the crude extracts and compounds
are given in Table 6.2. The antimicrobial investigation was performed using the
modified Agar Well Diffusion (AWD) and broth microdilution methods as detailed in
the experimental section. Amphotericin B, vancomycin and amoxicillin were used as a
reference drugs. The crude MeOH, hexane, CH2Cl2 and CHCl3 extracts demonstrated
weak antimicrobial activity but did not show antifungal activity as reproduced in Table
6.2. However, the EO displayed significant antibacterial activity against Bacillus
subtilis (in comparison to that of the standard, amoxicillin) and moderate antifungal
activity against Candida albicans with minimum inhibition zones (MIZ) of 13 mm and
11 mm, respectively.
Among the pure compounds, the (Z)-spiroether (22) demonstrated the highest
antibacterial activity against B. subtilis and S. epidermidis with MIZ values of 11 mm
111

Chapter 6: Ajania nubigena

and 8 mm, respectively. This compound also inhibited the fungal strain, C. albicans.
Compound (25) illustrated inhibitory activities against all Gram-positive bacteria
including B. subtilis, S. aureus, methicillin resistant S. aureus (MRSA), S. epidermidis)
and fungi (C. albicans) with MIZ values in the range of 5-10 mm (Table 6.2). These
MIZ values were significant when compared to that of the positive controls. However,
when the MIC values of this compound were determined, the best MIC-based activity
observed was 125 µg/mL against MRSA and S. epidermidis. Although, chamzulene (20)
did not exhibit any antimicrobial activity, it was reported to inhibit human cytochrome
P450 which are the principal enzymes for the oxidative metabolism of drugs and other
xenobiotics (Ganzera et al., 2006).

6.5. Conclusions
Our study found that the Bhutanese variety of A. nubigena contained: a) an
essential oil (0.7% w/w) with (3R,6R)-linalool oxide acetate (19) as the

major

constituent (75.8%) (chemotype II) and chamazulene (20) as the new sub-chemotype;
b) luteolin (25) as the major marker compound of the crude MeOH extract which
exhibited a broad range of moderate antiplasmodial, cytoxicity and antimicrobial
activities; and c) luteolin-7-O-β-D-glucopyranoside (26) which showed significant in
vitro antiplasmodial activity with mild cytotoxicity which was identified as a potential
antimalarial scaffold. The in vitro antimicrobial and cytotoxicity activities of the crude
extracts, the EO and the isolated compounds were supportive of this plant’s use in
BTM as a vulnerary, expectorant and for treating abscess, swelling and tumors.
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CHAPTER 7
ESSENTIAL OIL AND A NEW ALKALOID FROM MECONOPSIS
SIMPLICIFOLIA WITH POTENT ANTIMALARIAL ACTIVITIES

Photo courtesy: Margaret and Thorne, 2009.

Botanical classification
Kingdom

: Plantae

Phylum

: Angiospermae

Class

: Eudicots

Order

: Ranunculales

Family

: Papaveraceae

Genus

: Meconopsis

Species

: simplicifolia

Synonyms

: Meconopsis nyingchiensis L. H. Zhou,
Papaver simplicifolium D. Don

Bhutanese name
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7.1.

Introduction
Meconopsis is one of the four genera (Papaver, Meconopsis, Stylomecon and

Roemeria) that belong to family Papaveraceae. There are about 43-49 Meconopsis
species with the majority of these restricted to the Himalaya and only one species,
Meconopsis cambrica, being endemic to Europe (Debnath and Nayar, 1986; Zhou et
al., 2009). The plants of this genus are popularly known as ‘Himalayan blue poppies’. It
is difficult to be precise about the exact natural distribution of plants from this genus as
further botanical exploration is extending the known range of certain species and at
times new species are being discovered. However, the highest concentration of
Meconopsis plants were said to be found in Tibet, while her closest neighbor, Bhutan,
hosts more than 13 species (Grierson and Long, 1984). These Meconopsis species have
been known to contain isoquinoline alkaloids, flavonoids, steroids, triterpenoids,
phenylpropanoids, volatile oils and others (Slavik and Slavikova, 1977; Hemingway et
al., 1981; Xie et al., 2001; Yuan et al., 2003; Wu et al., 2009; Zhou et al., 2009; Yue et
al., 2010). In terms of analysing the oil components of the genus, only five species of
Meconopsis (M. punicea, M. delavayi, M. integrifolia, M. quintuplinervia, M.
horridula) have been investigated (Yuan et al., 2003; Wu et al., 2006; Pan, 1998; Guan
et al., 2007).
All Meconopsis plants are well known for their large, beautifully colored,
charming and graceful posture, and eye-catching flowers. Therefore, the plants of this
genus are prized for their ornamental and medicinal qualities. Efforts were made by the
gardeners and botanists to introduce these beautiful alpine flowers in the gardens as
ornamental plants, but many of the species have been more recalcitrant and have never
been successfully cultivated. Meconopsis species have been also used in the Himalayan
traditional medicines including Tibetan, Nepalese and Bhutanese traditional medicine.
M. paniculata, M. punicea, M. integrifolia, M. horridula, M. racemosa, M.
betonicifolia, M. lancifolia and M. quintuplinervia have been used in Tibetan medicine
for treating various disorders (Luo et al., 1984; Zhou et al., 2009; Yue et al., 2010). For
example, M. integrifolia is traditionally used as a precious medicine for treating
hepatitis, pneumonia and edema (Zhou et al., 2013). Pharmacological studies on the
crude extracts of M. quintuplinervia and M. integrifolia found that these plants have
signiﬁcant hepatoprotective and potent in vitro and in vivo antioxidant activity (Zhou et
al. 2009; 2013).
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In Bhutan, out of 13 Meconopsis species reported to grow in the alpine mountains
(Grierson and Long, 1984), about seven of them including M. horridula, M. paniculata,
M. napaulensis, M. superba, M. primulina, M. discigera and M. simplicifolia are
believed to have medicinal properties. Bhutanese healers traditionally classify these
plants as ‘Khrog-sman’ or the high altitude medicinal plants (HAMP). However, only
two species consisting of M. horridula and M. simplicifolia are currently used in BTM
for various formulations (Tenzin, 2007). Both these plants have blue flowers (Figure
7.1).

A

B

Figure 7.1. Two Meconopsis species used in current formulation of BTM:
A) M. horridula, B) M. simplicifolia [Photograph by P. Wangchuk]

M. horridula, which is locally known as ‘Tsher-ngon’, grows higher up in the
alpine mountain with an altitudinal range of 4466-5400 masl. It has distinguishable
firm, sharp and longer straw-coloured spines on all its parts and grows to a height of 30
cm above the ground of its habitat which includes grassy slopes, scree, rock ledges and
stabilized moraines (Grierson and Long, 1984). This plant is used for treating bone
fractures and wounds and for revitalizing fluids in the joints (Wangchuk et al., 2009).
Six

isoquinoline

alkaloids

including,

8,9-dihydroproxocryptochine,

protopine,

reframoline, amurensinine, amuresinine N-oxide A and amuresinine N-oxide B and also
the essential oil components from Meconopsis horridula has been reported (Xie et al.,
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2001; Wu et al., 2006; Wu et al., 2009). However, M. simplicifolia was not studied
previously.
M. simplicifolia, which is locally known as ud-pel-sngon-po, is a rare plant that
inhabits lower elevation within an altitudinal range of 3300-4500 masl. It has narrowly
elongated seed capsules and hairy stems and leaves and grows to a height of 30-70 cm
(Grierson and Long, 1984). It has a low average population density of 0.6 plants/m2 and
is usually found to grow on damp ground, grassland slopes, shrubberies, rocky alpine
hillsides, streamsides, screes and at the margins of Rhododendron scrub (Krug, 2008).
It is distributed in the Lingzhi, Bumthang and Gasa districts of Bhutan and the eastern
parts of Nepal. Habitat destruction and foraging by yaks in these areas, especially in the
Nepal and Lingzhi region of Bhutan, inconsistent harvesting practices by the farmers,
and the low rate of seed germination and seedling mortality has threatened this species
making its distribution patchy and confined to fewer geographical locations. The
regeneration of plantlets through organogenesis using sub-culture of calluses of M.
simplicifolia has been reported to be successful (Sulaiman and Babu, 1993). However,
other than in vitro laboratory tissue culturing, the idea of ex-situ conservation has not
been realized.
The aerial components (stems, leaves, flowers and fruit) of M. simplicifolia, in
combination with other ingredients, are used for preparing more than eight important
BTM multi-ingredient formulations. As an individual plant, it is indicated for treating
coughs and colds, fever and infections of the liver, lung and blood which show
correlations to the symptoms of cancer, microbial infections and malaria (Wangchuk et
al., 2009). Our recent biological activity studies of different solvent extracts of M.
simplicifolia showed remarkable antiplasmodial activity against a multidrug resistant
strain (K1CB1) and a chloroquine and antifolate sensitive wild type strain (TM4/8.2) of
Plasmodium falciparum with IC50 values of 6.39 g/mL and 0.40 g/mL, respectively
(see Chapter 3).
Based on this earlier finding we further investigated this plant for its
phytochemicals and their biological activities and consequently discovered a new
protoberberine type alkaloid along with five known protopine and benzophenanthridine
type alkaloids with potent antimalarial activities. We have also analyzed the essential
oil (EO) components of this plant using GC and GC-MS.
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7.2.

GC/GC-MS analysis and isolation of the EO components
The hydro-distillation of the dried aerial parts of M. simplicifolia (250 g)

yielded 0.5% w/w of pale green liquid EO which solidified (white) upon standing. The
EO was analysed for its chemical constituents using GC/GC-MS (see general
experimental section for details). The percent contents of the EO were determined on
the basis of their FID responses on GC (Figure 7.2). The Kovats retention indices (KI)
were obtained by GC-FID analysis of an aliquot of the EO spiked with an n-alkane
mixture (n-C8 to n-C30).
The GC and GC-MS detected at least 37 constituents of the chromatographable
fraction of the total injected oil (Figure 7.2, Table 7.1). These 37 constituent peaks were
identified by comparing each mass spectrum with those in the NIST and NISTREP
mass spectra library of GC-MS data system and further confirmed by comparing their
Kovats indices (KI) with those reported (Adams, 1995). Of the 37 compound peaks, 14
(38% of total oil) were identified as fatty acid esters with dimethyl 1,4benzenedicarboxylate (29.2%) as the major constituent.

Figure 7.2. GC-FID of the essential oil of M. simplicifolia.
The second predominant compound was stearic acid, isobutyl ester with 10.3%
followed by (E)-isomyristicin (6.9%); palmitic acid, butyl ester (5.9%); phthalic acid,
diisobutyl ester (4.9%); 1,2-benzenedicarboxylic acid, bis(3,5,5-trimethylhexyl) ester
(4.8%); 15-hexadecanedione (3.2%); (Z)-isoelemicin (2.7%); geranyl isobutyrate
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(2.3%); lauryl acrylate (2.0%); epi-cedrol (2.0%); (E,E)-farnesol (1.8%); methyl 5-(2undecylcyclopropyl)pentanoate (1.7%); and tridecanol (1.5%).

Table 7.1. Essential oil composition of aerial parts of M. simplicifolia
GCP No.a % oilb
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

1.4
29.2
0.9
2.3
2.7
0.6
1.5
2.0
6.9
0.6
0.7
1.1
1.3
2.0
0.9
1.3
1.8
0.6
0.6
3.2
0.9
0.6
1.02
4.9
0.6
1.2
0.6
1.4
1.7
5.9
0.8
0.9
0.6
10.3
0.7
1.3
4.80

GC-RTc

KId

Name of compound identified

18.972
19.550
19.722
19.776
20.990
21.242
21.483
21.723
21.882
22.051
22.623
22.715
23.069
23.251
23.366
23.754
23.832
24.040
25.159
25.960
26.391
26.868
27.312
27.873
28.503
29.580
30.013
30.100
30.310
31.011
31.374
32.211
33.151
33.839
34.221
36.396
39.228

1475
1502
1510
1513
1575
1580
1592
1613
1621
1630
1660
1665
1684
1694
1700
1721
1726
1737
1800
1846
1872
1899
1927
1961
1999
2068
2096
2102
2116
2163
2187
2244
2310
2360
2388
2553
2783

Geranyl-n-propionate
Dimethyl 1,4-Benzenedicarboxylate
(2E)-2-Tridecen-1-ol
Geranyl isobutyrate
(Z)-Isoelemicin
tau-Muurolol
Tridecanol
epi-Cedrol
(E)-Isomyristicin
epi-α-Cadinol
Asarone
(Z,E)-Farnesol
Valeranone
Lauryl acrylate
4-Propionyloxytridecane
Isoapiol
(E,E)-Farnesol
(Z,E)-Farnesol
2,6-Dimethylheptadecane
2,15-Hexadecanedione
Phthalic acid, dipropyl ester
2,6,10,14-Tetramethylheptadecane
Methyl isoheptadecanoate
Phthalic acid, diisobutyl ester
4-Propylheptadecane
2-Octylcyclopropene-1-heptanol
9,12-Octadecadienoic acid, methyl ester
trans-Vaccenic acid, methyl ester
Methyl 5-(2-undecylcyclopropyl)pentanoate
Palmitic acid, butyl ester
3-Methylicosane
Oxalic acid, cyclobutyltridecyl ester
2-Methyltricosane
Stearic acid, isobutyl ester
Oxalic acid, cyclobutyl tetradecyl ester
Oxalic acid, isobutyl heptadecyl ester
1,2-Benzenedicarboxylic acid, bis(3,5,5-trimethylhexyl) ester

Note: Identification of compounds was achieved by comparing the peaks’ FID spectra and Kovats indices (KI)
with those reported in Adams (1995) and the NIST and NISTREP mass spectra library of GC-MS data system.
a
Gas chromatogram peak number as appeared in Figure 7.1.
b
Percentage of oil based on the FID percentage of peak area.
c
Retention time based on the FID responses of the gas chromatography peaks where separation was achieved
using a Rxi-5MS: 30 m × 0.25 mm i.d. and 0.25 μm film thickness.
d
Kovats Indices arithmetically calculated in relation to n-alkane mixture (C8-C30).

Other oxygenated sesquiterpenes present were isoapiol (1.2%), asarone (0.7%),
tau-muurolol (0.6%) and epi-α-cadinol (0.6%). The (Z,E)-farnesol (0.5%), 9,12118
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octadecadienoic acid, methyl ester (0.5%) and 4-propylheptadecane (0.5%) were all
minor components. The phthalates, including dimethyl 1,4-benzenedicarboxylate are
common plasticizers and also occur naturally. For example, dimethyl 1,4benzenedicarboxylate (major component of M. simplicifolia) has been previously
identified from the fruits of Melia azedarach L., a medicinal plant, Adhatoda vasica,
and myxobacteria Stigmatella WXNXJ-B, and was reported to exhibit anti-tumour,
antimicrobial, anti-feedent and stomach-toxic effects (Gu and Liu, 1996; Ahmed et al.,
1999; Wang and Tao, 2009). Dimethyl 1,4-benzenedicarboxylate has never been
identified from its other related Meconopsis species.
Different species of Meconopsis were found to contain other types of esters and
naphthalene as the major components of their oils. The major constituents of M.
quintuplinervia, M. horridula and M. delavayi were 9E,12E-ethyl octadeca-9,12dienoate (26.6%) (Wu et al., 2006), ethyl palmitate (29.1%) (Wu et al., 2006) and
hexadecanoic acid (16.8%) (Yuan et al., 2003), respectively. M. punicea was reported
to contain two different chemotypes, one variety from south-west China contained
hexadecanoic acid (9.9%) (Yuan et al., 2003) as a major constituent while another
unspecified variety contained octadecenate ester (11.8%) and methyl oleate as the
major compounds of the EO (Pan, 1998). Similarly, M. integrifolia contained two
different chemotypes with one variety from Tibet having bombykal (26.0%) (Guan et
al., 2007) as a major oil component while another species from an unspecified location
contained 9E,12E,15E-methyl octadeca-9,12,15-trienoate (27.9%) (Wu et al., 2006) as
a major compound of the EO.

7.3.

Isolation and structure elucidation of alkaloids from the MeOH extracts
Dried M. simplicifolia was powdered and extracted with MeOH which yielded

60 g of crude material. This extract was acidified with 5% HCl and then extracted with
CH2Cl2 yielding 9.8 g of CH2Cl2 extract. The remaining acidified aqueous solution was
basified (pH-9-12) with NH4OH solution and then extracted with CHCl3 which
furnished 446 mg of CHCl3 extract. Focusing on the alkaloids, the crude basic CHCl3
extract was subjected to repeated flash column chromatography (CC) over silica gel
(120 g, 200-300 mesh), eluting with a gradient solvent system of MeOH-CHCl3 (in a
v/v% ratio of 0:100, 2:98, 4:96, 6:94, 8:92, 10:90, 20:80, 30:70, 50:50), yielded
fractions CHCl3-F1 to CHCl3-F8.
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Fractions CHCl3-F7 and CHCl3-F8 were combined and separated by CC with a
gradient solvent system of MeOH-CHCl3 (200 mL, v/v% ratio of 20:80, 30:70) to
obtain sub-fractions CHCl3-F78.1 to CHCl3-F78.5. Final separation of sub-fraction
CHCl3-78.4 using PTLC and the mobile phase system of MeOH-CHCl3 (v/v ratio of
15:85) yielded a new protoberberine type alkaloid, compound 27 (Figure 7.3) which we
named as simplicifolianine after the species name of the plant. It was isolated as a
faintly brown amorphous solid which melted at 170.8-171.3 oC. The LR-ESI-MS
spectrum indicated a [M+] ion peak at m/z 380. Its even molecular ion suggested either
zero or an even number of nitrogens or an iminium species. The HR-ESI-MS spectrum
supported the molecular formulae of C21H18NO6 with an actual m/z of 380.1130
[M+H+] (calculated for 380.1134).
The 1H-NMR spectrum (500 MHz, CD3OD) of 27 showed signals at δ 4.17 (s,
3H) for one methoxy group; two methylenedioxy groups at δ 6.09 (s, 2H) and 6.34 (s,
2H); and three methylenes at δ 3.15 (t, J = 5.8 Hz, 2H), 4.71 (t, J = 5.8 Hz, 2H) and
5.03 (s, 2H); and the four aromatic protons at δ 9.32 (s, 1H), 9.26 (s, 1H), 7.48 (s, 1H),
and 6.71 (s, 1H) (Table 7.2). The gCOSY spectrum showed a three bond vicinal
coupling between the methylene protons resonating at δ 3.15 (H-5) and 4.71 (H-6).
This coupling interaction was also observed in the long range TOCSY spectrum. In
addition, this experiment also indicated a correlation of the H-5 protons with the
aromatic proton resonating at δ 6.71 (H-4) indicating that these protons were in close
proximity. The APT spectrum (125 MHz, CD3OD) confirmed the presence of 11
quaternary carbons, one methoxy, two methylenedioxy, three methylene and four
methine carbons (Table 7.2).
From the gHSQC spectral correlations, the methoxy protons corresponded to
the carbon signal at δ 60.8 and the two methylenedioxy protons to the carbon signals at
δ 103.6 and 105.3, respectively. The three methylene protons were bonded to the
carbons resonating at δ 29.2 (C-5), 55.2 (CH2OH) and 56.4 (C-6). The four aromatic
protons were attached to the methine carbons resonating at δ 104.2 (C-4), 146.2 (C-8),
104.3 (C-9) and 121.7 (C-13). The long range gHMBC correlation established the
C→H and H→C cross-correlations among the H and C-atoms (Figure 7.3 (27A)) and
the gNOESY correlations (Figure 7.3 (27B)) further confirmed the structure 27.
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This alkaloid is structurally related to alborine (28) differing only at the C-10
and C-11 substituents where 28 contained two methoxy moieties at these positions
instead of methylene dioxy group (Figure 7.3) (Haifeng et al., 2011).

27C

Figure 7.3. Structure of simplicifolianine (27), the key gHMBC (27A) and NOESY
(27B) spectral correlations and SPARTAN generated structure (AM1) model (27C);
and the structure of the related compound, alborine (28).
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Table 7.2. 1H NMR (500 MHz, CD3OD-d4), 13C NMR (125 MHz, CD3OD-d4), gCOSY
spectroscopic data of simplicifolianine (27).
δ H in ppm
(multiplicity, J in Hz)

δ C in ppm

Carbon position
1

143.7

2

138.3

3

152.5

4

104.3

4a

134.2

5
6

gCOSY
(1H→1H)

6.71 (1H, s)

3.15

29.3

3.15 (2H, t, 5.75)

4.70

56.4

4.70 (2H, t, 5.75)

3.15

8

146.2

9.31 (1H, s)

7.48

8a

115.6

9

104.3

7.48 (1H, s)

9.31

10

155.6

11

139.6

12

138.4

12a

125.8

13

121.9

13a

153.4

13b

114.2

OMe

60.9

4.17 (3H, s)

2,3-OCH2O

103.7

6.09 (2H, s)

10,11-OCH2O

105.3

6.34 (2H, s)

C (12)-CH2OH

55.2

5.02 (2H, s)

9.26 (1H, s)

The other five known protopine and benzophenanthridine type alkaloids were
isolated from this species for the first time (Figure 7.4). Fractions CHCl3-F5 and
CHCl3-F6 were combined and separated using CC (gradient eluent, MeOH-CHCl3)
followed by preparative thin layer chromatography (PTLC) (mobile phase, MeOHCHCl3 (4:96, 100 mL)) and this yielded compound 1 which was identified as protopine.
Protopine (1) was isolated as a creamy white solid and was the major alkaloid of this
plant. The LR-ESI-MS showed a [M+H+] peak at (m/z): 354 and the LR-EI-MS
indicated its mass as 353 with the ion fragmentation pattern as (m/z): 353 [M+], 295,
281, 267, 251, 237, 223, 209, 190, 177, 163, 148, 134, 104, 89, 76, 63 which matched
that of protopine reported in the MS library (NIST08.LIB, Entry # 146592, CAS:13086-9, RetIndex:2943). The

1

H-NMR and
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C-NMR spectroscopic data (see the
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experimental section) agreed with those reported for protopine in Chapters 4 and 5 and
also the literature (Takahashi et al., 1985; Seger et al., 2004; Wangchuk et al., 2010a).

Figure 7.4. Structures of the five known alkaloids (1, 29-32) isolated from M.
simplificolia
Fraction CHCl3-F1 upon final separation using PTLC and CHCl3 as the mobile
phase, and recrystallization using MeOH/CHCl3 yielded compound 29 as small needles
which was identified as norsanguinarine. The LR-ESI-MS showed a [M+H+] peak at
(m/z): 318 and the LR-EI-MS indicated its mass as 317 with the ion fragmentation
pattern as (m/z): 317 [M+, base peak], 288, 259, 230, 201, 174, 157 and the molecular
formula as C19H11NO4 (calculated for 318.0766 by HR-ESI-MS, M+H+) which
matched that of norsanguinarine (NIST08.LIB, Entry # 124031, CAS:522-30-5,
RetIndex:2892). The 1H-NMR and

13

C-NMR spectroscopic data (see the experimental

section) agreed with those reported for norsanguinarine (Tousek et. al., 2004). This
compound 29 was isolated earlier from M. quintuplinervia) (Shang et al., 2003).
Similarly, the crude acidic CH2Cl2 extract was separated using the flash CC on
silica gel eluting with a gradient solvent system of MeOH-CH2Cl2 (in a v/v% ratio of
0:100, 0.5:99.5, 1.5:98.5, 2.5:97.5, 3.5:96.5, 5:95, 10:90, 20:80, 50:50) which yielded
fractions CH2Cl2-F1 to CH2Cl2-F18. Fraction CH2Cl2-F4 upon crystallization from
CHCl3-MeOH (1:1) gave crystals of compound 30 which was identified as
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dihydrosanguinarine. The LR-ESI-MS showed a [M+H+] peak at (m/z): 334 and the
LR-EI-MS indicated its mass as 333 with the ion fragmentation pattern as (m/z): 333
[M+], 332 (100%), 317, 274, 260, 166, 151, 137, 122, 108, 94 and the molecular
formula as C20H15NO4 which matched that of dihydrosanguinarine. The 1H-NMR and
13

C-NMR spectroscopic data (see the experimental section) agreed with those reported

for dihydrosanguinarine (30) (Williams and Ellis, 1993; Choi et al., 2010; Miao et. al,
2011; Yao et al., 2011).
Fraction CH2Cl2-F10 upon separation using CC with a gradient solvent system of
MeOH-CH2Cl2 (in a v/v ratio of 0:100, 0.5:99.5, 1:99, 2:98, 5:95, 10:90, 100:0) gave
sub-fractions CH2Cl2-F10.1 to CH2Cl2-F10.4. Crystallization of the sub-fraction
CH2Cl2-F10.1 from CHCl3-MeOH (97:3) furnished a crystalline compound 31 which
was identified a 6-methoxydihydrosanguinarine. The LR-ESI-MS showed a [M+H+]
peak at (m/z): 364 and the LR-EI-MS indicated its mass as 363 with the ion
fragmentation pattern as (m/z): 363 [M+], 332 (100%), 317, 274, 201, 166, 147, 137,
115, 101, 94 and the molecular formula as C21H17NO5 which matched that of 6methoxysanguinarine. The

1

H-NMR and

13

C-NMR spectroscopic data (see the

experimental section) agreed with those reported for 6-methoxysanguinarine (31)
(Zhang et al., 1995; Dostal et al., 1998; Choi et al., 2010; Miao et al., 2011).
The mother liquor, from which compound 30 was obtained, was purified by CC
eluting with CHCl3 (100%) to obtain five sub-fractions CH2Cl2-F4.1 to CH2Cl2-F4.5.
The sub-fractions CH2Cl2-F4.4 and CH2Cl2-F4.5 were combined and repeatedly
separated. Final separation of fraction CH2Cl2-F4.45.3.1 by PTLC (CHCl3-ethyl
acetate-MeOH in v/v ratio of 90:8:2), yielded compound 32 which was identified as
oxysanguinarine. The LR-ESI-MS showed a [M+H+] peak at (m/z): 348 and the LR-EIMS indicated its mass as 347 with the ion fragmentation pattern as (m/z): 347 [M+, base
peak], 318, 302, 289, 274, 260, 246, 232, 203, 188, 173, 159, 137, 115, 102 and the
molecular formula as C29H25,NO5 which matched that of oxysanguinarine. The 1HNMR and

13

C-NMR spectroscopic data (see the experimental section) agreed with

those reported for oxysanguinarine (32) (Williams and Ellis, 1993; Miao et al., 2011).
The structures of dihydrosanguinarine (30) and 6-methoxysanguinarine (31) were
confirmed from their single crystal X-ray crystallographic structures (Figure 7.5 (A)
and (B)) which we determined here for the first time. Atomic coordinates, bond lengths
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and angles and displacement parameters have been deposited at the Cambridge
Crystallographic Data Centre (CCDC no. 929725, 929726).

Figure 7.5. Single crystal X-ray structures: (A) dihydrosanguinarine (30), and (B) 6methoxydihydrosanguinarine (31).

7.4. Biological activities of the crude extracts and isolated compounds
The crude extracts of a M. simplicifolia were previously studied for their
biological activities and the findings were described in Chapter 3. The CH2Cl2 and
CHCl3 extracts exhibited significant antiplasmodial activity against a wild type
chloroquine and antifolate sensitive strain, TM4/8.2 and the multidrug resistant strain,
K1CB1 of the Plasmodium falciparum. These activities are reproduced here in Table
7.3 for direct comparison of their activities with the isolated compounds. Out of six
alkaloids isolated, compounds 27 and 29-31 were tested in vitro against the same test
strains of P. falciparum and the cancer cell lines. Since the crude extracts did not
exhibit any antimicrobial, anti-inflammatory and anti-trypanosomiasis activities, the
pure compounds were not tested against these assays.

7.4.1 Antiplasmodial and the cytotoxicity activities
Compounds 27 and 29-31 were tested for their antiplasmodial activities and
cytotoxicity using the Microdilution Radioisotope Technique and the sulforhodamine B
(SRB) assay (OD510 nm) methods, respectively (as detailed in the experimental
section). The results are shown in Table 7.3.

125

Chapter 7: Meconopsis simplicifolia

Table 7.3. Antiplasmodial activity (IC50 in μg/mL) of the alkaloids 27 and 29-31
isolated from M. simplicifolia. Also reproduced in the table are the data previously
reported on the crude extracts and protopine (1).
Samples

Antiplasmodial activity

Cytotoxicity

TM4/8.2

K1CB1

Vero cells

KB cells

MeOH extracta
CH2Cl2 extracta
CHCl3 alkaloid extracta

<12.5
15.50 ± 1.9
0.40 ± 0.0

12.5
12.80 ± 2.6
6.39 ± 2.7

> 10
> 25
> 25

> 10
> 25
> 25

Simplicifolianine (27)

0.78 ± 0.14

1.29 ± 0.54

> 3.79

> 3.79

1.45 ± 0.53
> 0.32
> 3.33
> 3.63
0.010
0.009
0.020

1.38 ± 0.31
> 0.32
> 3.33
> 3.63
0.089
0.810
7.700

> 3.50
> 0.32
> 3.33
> 3.63

> 3.50
> 0.32
> 3.33
> 3.63

Protopine (1)b
Norsanguinarine (29)
Dihydrosanguinarine (30)
6-Methoxydihydrosanguinarine (31)
Chloroquinec
Cycloguanilc
Pyrimethaminec
Ellipticined
Doxorubicind
a
original activity taken from Chapter 3.
b
original activity taken from Chapter 4.
c
reference drugs for antiplasmodial activity.
d
reference drugs for cytotoxicity activity.

0.093
0.56

The new protoberberine alkaloid, simplicifolianine (27) showed the most potent
antiplasmodial activity against the P. falciparum strains, TM4/8.2 and K1CB1 with
IC50 values of 0.78 µg/mL and 1.29 µg/mL, respectively (Table 7.3). This potent
antiplasmodial activity was of similar range to that of the parent crude CHCl3 alkaloid
extract against TM4/8.2 but nearly six times more potent than the crude extracts against
K1CB1. Therefore, we have identified simplicifolianine (27) as a potential new drug
lead on which a patent is being filed. Another potential area is that the Bhutanese
traditional formulae involving this plant can be used as an alternative treatment regimen
for malaria through proper clinical studies. Considering the increased resistance of the
parasites to the conventional artemisinin-based combination therapies (ACT), including
artesunate monotherapy and other drugs (Dondorp et al., 2009; Marti et al., 2010), this
finding is timely as it provides a new potential drug lead targeting malarial infections.
Malaria causes 2-3 million deaths each year (Marti et al., 2010) and in Bhutan, there
were 436 microscopy-confirmed indigenous cases with 140 (32%) cases being due to
P. falciparum (Yangzom et al., 2010).
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Protopine (1) isolated from different plant species was reported to exhibit
significant antiplasmodial activity against the same strains as described in Chapters 4
and 5 (reproduced in Table 7.3). This alkaloid (1) has been also reported to have a
broad range of biological activities (Vacek et al., 2010). Since compounds 1 and 27
exhibited highly significant antimalarial activities and that protopine (1) was the major
alkaloid present, it can be deduced that these two alkaloids, either alone or in
combination, may be responsible for the major antiplasmodial activities of the extract
of this plant.
Due to limitation in solubility of compounds 29-31, the highest concentrations
tested were 0.32, 3.33 and 3.63 µg/mL, respectively. At such concentrations,
compounds 29 and 30 did not show any significant antiplasmodial activities nor
cytotoxicity. Compound 31 exhibited about 10-20% inhibitory effect against both
parasite strains with no cytotoxicity against the mammalian cells. Reports on compound
31 also showed an inhibitory effect on the growth of human colon carcinoma cells and
induced apoptosis (Lee et al., 2004). However, this compound exhibited no cytotoxicity
against KB and vero cells in our study at the highest concentration tested. Compound
(31) was also reported to display anti-platelet aggregation activity (Chen et al., 2001).

7.4.2. Antimicrobial activities as reported
Based on the poor results obtained for the crude extracts of M. simplicifolia
(described in Chapter 3), the pure compounds were not tested for their antimicrobial
activities. However, sanguinarine (29) was reported to have antifungal activity against
the phytopathogenic fungi, A. brassiciola and C. maculans with 75-80% inhibition at
200 µg/mL (Singh et al., 2009). Navaroo and Delgado (1999) and Feng et al. (2011)
reported that dihydrosanguinarine (30) displayed varying antimicrobial activities
against S. aureus, Streptococcus faecalis, Escherichia coli, Pseudomonas aeruginosa,
Proteus mirabilis, Candida albicans, Botrytis cinerea, Phytophthora capsici and
Alternaria solani. It was also reported to exhibit significant antiparasitic effect against
Ichthyophthirius multifiliis in richadsin with an IC50 value of 5.2 µg/mL (Yao et al.,
2011). The other alkaloid, 6-methoxydihydrosanguinarine (31) was reported to have
moderate to weak antimicrobial activity against MRSA (Choi et al., 2010), S. aureus, E.
coli and A. hydrophila with MIC values ranging from 12.5-50 µg/mL (Miao et al.,
2011).
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7.5. Conclusions
In summary, the phytochemical study of M. simplicifolia found the following: 1)
a new protoberberine type alkaloid which we named as simplicifolianine (27); 2)
protopine (1) was identified as the major alkaloid constituent; 3) compound 27 showed
significant in vitro antiplasmodial activity with low cytotoxicity and therefore, we have
identified it as a potential antimalarial drug lead; and 4) the in vitro bioassay results of
the crude extracts and the pure compounds 1 and 27 were proportionate with the
ethnopharmacological uses of this plant in the BTM. The low cytotoxicity of the
compounds and the crude extract against human oral carcinoma KB cells and normal
vero epithelial cells makes the activity more interesting and demonstrated the plant’s
potential safety for use in BTM, individually or in combination with other medicinal
ingredients, to treat malaria.
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CHAPTER 8
BIOACTIVE TERPENES AND FURANOCOUMARINS FROM
PLEUROSPERMUM AMABILE

Pleurospermum amabile [Photograph by P. Wangchuk, 2009]

Botanical classification
Kingdom

: Plantae

Phylum

: Angiospermae

Class

: Equisetopsida

Subclass

: Magnoliidae

Superorder

: Asteranae

Order

: Apiales

Family

: Apiaceae

Genus

: Pleurospermum Hoffm.

Species

: amabile

Synonym

: Hymenidium amabile Pimenov & Kljuykov.

Bhutanese name : Tsad
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8.1. Introduction
The Pleurospermum genus is one of the 347 plant genera in the family Apiaceae
(Umbelliferae) and is closely related to seven other genera including Aulacospermum,
Hymenidium,

Hymenolaena,

Pterocyclus,

Physospermopsis,

Pseudotrachydium

and Trachydium (The Plant List, 2010; Zehui and Watson 2005). The generic
boundaries in these genera become indistinct and the classification of some of the
species remain controversial requiring critical revisions and classifications. More
natural classification involving the controversial species will only be possible following
critical revision in the field aided by herbarium development, chemical marker
identification and genetic profiling of each of the species. Despite the complexities and
the controversy of some species of this genus, about 50 Pleurospermum species have
been reported (Zehui and Watson 2005). However, The Plant List (2010), which is a
recent working list of all known plant species developed collaboratively by the Royal
Botanic Gardens, Kew and the Missouri Botanical Garden, accepted 39 Pleurospermum
species out of 107 scientific plant names of the species to be listed. These species are
native to Eastern Europe and Central Asia. They are more diversely distributed in the
high altitude areas of the Himalayas which include countries like Bhutan, China, India,
Nepal and Pakistan (Zehui and Watson, 2005). While as many as 22 Pleurospermum
species are endemic to China, Bhutan hosts about eight species including P.
angelicoides, P. benthamii, P. pilosum, P. album, P. hookeri, P. dentatum, P. apiolens
and P. amabile (Grierson and Long, 1999).
The Pleurospermum species have been used as vegetables, medicinal plants and
herbal perfumes. For example, in Korea, the aerial portion of P. kamtschaticum is used
as an edible mountain vegetable and for treating colds, arthritis, atherosclerosis and
impotence (Jung et al., 2007). Similarly, the roots of P. angelicoides are used in
Chinese and Himalayan folk medicines for treating typhia, dysentery and as an
antipyretic and a diaphoretic agent (Shibano et al., 2006). P. lindleyanum and P.
rivulorum are the Chinese folk medicinal plants used for the treatment of hypertension,
coronary heart disease, high altitude sickness and hepatitis (Tan et al., 2006) and as an
antipyretic, analgesic and diaphoretic agent, respectively (Xiao et al., 1997). P.
densiflorum is used by the Kumaon Himalayan people (Indian) as one of the best herbal
perfumes in the region and is known for its long lasting pleasant smell (Khetwal et al.,
1994). The aerial components of P. amabile, which are studied and discussed in this
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chapter, are from a rare and exotic medicinal plant used in BTM for treating dyspepsia,
poisoning (as antidote) and fever (as febrifuge) (Wangchuk et al., 2009).
Pharmacologically speaking, Pleurospermum taxa were investigated only on a
few occasions. Recent studies have demonstrated that the crude extract of the Tibetan
P. hookeri had anti-inflammatory and analgesic effects (Ming et al., 2012). The extract
of P. kamtschaticum inhibited hyperlipidemia and hypercholesterolemia in rats,
exhibited an anticarcinogenic effects on colon cancer cells and induced apoptosis via a
mitochondrial pathway and NAG-1 expression in colon cancer cells (Kim et al., 2010,
Lee et al., 2012). Buddlejasaponin IV, an oleanane-type triterpene saponin isolated
from the P. kamtschaticum, inhibited hyperlipidemia and hypercholesterolemia in rats;
exhibited potent anti-inflammatory activity blocking the production of nitric oxide,
prostaglandin E2 and tumour necrosis factor-α in lipopolysaccharide-stimulated Raw
264.7 cells (Jung et al., 2005); was cytotoxic against A549, SK-OV-3, SK-MEL-2 and
HCT15 human tumour cell lines (Lee et al., 2012); and induced cell cycle arrest at the
G2/M phase and apoptosis in immortalized human oral keratinocytes with the potential
to block the progression of HPV-induced oral carcinogenesis (Hwang et al., 2011).
In terms of phytochemical investigations of the Pleurospermum genus, only a few
species have been investigated and the phytochemicals reported include coumarins,
flavonoids, monoterpenes, triterpenes, saponins, triterpene saponins, glycosides,
steroids, fatty acids and their esters (Luo et al., 2002; Lee et al., 2012). Some
structurally interesting compounds are represented in Figure 8.1. From P. lindleyanum,
an unusual novel cyclobutane-type lignan with a six membered lactone ring,
lindleyanin (33) and a novel furocoumarinyl sulphate, bergapten-8-yl sulphate (34)
were isolated (Tan et al., 2006). Condensed furanocoumarins (dimers and trimer), as
represented by the trimer rivulotririn C (35), and novel cyclospirobifuranocoumarins, as
exemplified by cyclorivulobirins A (36), were reported from P. rivulorum (Taniguchi et
al., 1999, 2000).
Beside the complex compounds isolated, many volatile constituents composed of
terpenoids (mono-, sesqui- and di-terpenes), alcohols, ketones, aldehydes, alkanes, and
phenylpropanoids were also reported from the EO of some of the Pleurospermum
species. These volatile compounds are responsible for the protection of plants against
microbes, insects, and herbivores (Bakkali et al., 2008). Since antiquity, mankind has
used EO and the EO-containing plants as medicinals (ethnomedicine), perfumeries,
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incense, fragrances and embalmments and in culinary and the preservation of foods
(Romeilah et al., 2010). While the genus Pleurospermum is rich in volatile oil
constituents, many plants remain unstudied. Only five species; P. lindleyanum
(Ajiaikebaier and Lu, 2002), P. austriacum (Radulovic et al., 2010), P. hookeri (Li and
Wang, 2001), P. wrightianum (Liu and Tian, 2004) and P. giraldii (Liu et al., 1991)
have been investigated for their EO.

Figure 8.1. Representative structures of some interesting compounds isolated from
Pleurospermum species.

From the EO of P. lindleyani, 73 compounds were identified with 1-propoxy-2propanol, myristicine, cis-asarone, n-hexane, apiol, dimethyl ether, acetic acid, ethyl
ester, spathulenol, 4-trimethylbenzene methanol, (E)-methyl isoeugenol and βphellandrene as the main constituents (Ajiaikebaier and Lu, 2002). 1-Propoxy-2propanol, dimethyl ether, and n-hexane would appear to be solvent contaminants or
artifacts. From the EO of P. austriacum, 205 compounds were identified with
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germacrene D, β-caryophyllene, β-farnesene, β-phellandrene, δ-cadinene, epi-cubebol,
bicyclogermacrene, humulene, α-cadinol and hexadecanoic acid as some of the major
components (Radulovic et al., 2010). Out of 72 GC peaks detected, 51 compounds were
identified from the EO of P. hookeri and the major constituents were palmitic acid,
decanoic

acid,

ligustilide,

piperitenal,

(Z)-2-decenaldehyde

and

2,4,5-

trimethylbenzaldehyde (Li and Wang, 2001).
From the EO of P. wrightianum, 49 compounds were identified with (E)-9octadecenoic acid and 1,3,5,7-cyclooctatetraene as the major components of the oil (Liu
and Tian, 2004). Out of 45 compounds identified from the EO of P. giraldii, L-carvone
and limonene were found to be the major components (Liu et al., 1991).
A direct correlation between the amount and chemical composition of the EO
were observed wherein the main volatiles of EO-poor species (oil yields less than
0.1%) are fatty acid and carotenoid-derived compounds or other hydrocarbons
especially germacrene D, while the EO-rich taxa (oil yields higher than 0.1%) are
generally

characterized

by

the

specific

production

of

monoterpenoids

or

phenylpropanoids (Radulovic et al., 2010).
P. amabile Craib & W.W. Smith (synonym Hymenidium amabile) was found rich
in EO. This plant was investigated for the phytochemicals of its EO and MeOH extract,
and successively, their biological activities were determined which is discussed in this
chapter. In the absence of musk (obtained from the Himalayan musk deer) and
Delphinium brunonianum, P. amabile which is locally known as r.tsad, is used as a
substitute in almost 30% of the currently used BTM formulations (Tenzin, 2007). This
plant is rare and is found in the northern part of Bhutan, Sikkim, Chumbi valley
(southern part of Tibet), and China (Grierson and Long, 1999; Zehui and Watson,
2005).
In Bhutan, P. amabile inhabits the open scrub, alpine turf and the semi-stable
screes of the high altitude Himalayan mountains (3950 to 4700 masl including
Dungtsho la, Pele la, Wasa la, Gyophu la, Chhew la, Yak la, Somana, Towli phu,
Marlung, Tolegang and Shingbe (Grierson and Long, 1999; Wangchuk et al., 2009). It
grows to 15-50 cm tall with a stout root, a solitary stem, sheathed broad leaves, white to
dark purple flowers and ovoid-oblong fruit (Grierson and Long, 1999; Zehui and
Watson, 2005).
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8.2.

GC/GC-MS identification and isolation of the EO components
The dried plant material (250 g) of P. amabile was powdered and hydrodistilled

using a Clevenger apparatus to obtain 1.8 mL (0.7 %) of EO. Fifty two component
peaks (Figure 8.2) were detected and the compounds were identified by GC/GC-MS
analysis including MS library matching and Kovats retention indices (KI) comparisons
with Adams (1995) (Table 8.1). The percentage contents of the EO were determined on
the basis of their FID responses upon GC. (E)-Isomyristicin (37) was the major
component (32.5%) of the EO (Figure 8.2) followed by limonene (17.0%), (E)-isoapiol
(7.6%), β-sesquiphellandrene (3.9%), methyl eugenol (3.8%), geranyl pentanoate
(2.4%), (Z)-isomyristicin (2.3%), myrcene (2.3%), β-caryophyllene (2.2%), geraniol
(1.6%), (E)-isoelemicin (1.3%), geranyl isobutyrate (1.3%), myristicin (1.3%),
valeranone (1.2%), β-citronellol (1.2%), β-selinene (1.2%), myrtenyl acetate (1.1%)
and citronellyl acetate (1%). Although a slightly different column and protocol
conditions were used in the EOs analysis, many EO compounds of P. amabile
including limonene, β-caryophyllene, germacrene D, α-cadinol, α-bisabolene, α-pinene,
myrcene, α-phellandrene, β-selinene, geranyl acetate and β-ocimene (see Table 8.1 and
literature for details) were found common to the EO of P. austriacum (Radulovic et al.,
2010).

Figure 8.2. GC-FID peaks and the isolated compounds of EO of P. amabile.
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Table 8.1. Chemical compositions of EO from P. amabile.
GC Peak No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

% oil
0.7
0.3
2.3
0.4
0.2
17.0
0.5
0.6
0.6
0.6
0.4
0.2
0.2
0.2
0.2
0.2
0.8
0.6
1.2
0.2
1.6
0.6
0.3
1.1
1.0
0.5
0.2
0.2
3.8
2.2
0.8
0.3
0.2
0.3
1.2
0.5
1.3
1.3
3.9
2.3
0.2
0.7
0.7
2.4
32.5
1.4
0.3
1.3
0.5
1.2
7.6
0.2

Compound name
α-Pinene
β-Pinene
Myrcene
α-Phellandrene
Isoamyl isobutyrate
Limonene
(Z)-β-Ocimene
(E)-β-Ocimene
Terpinolene
Linalool
Isoamyl valerate
2-Methylbutyl isovalerate
Fenchol
Valeric acid, 3-methylbut-2-enyl-ester
Terpinen-4-ol
α-Terpineol
Myrtenol
Fenchyl acetate
β-Citronellol
2,4-Dimethoxytolouene
Geraniol
Citronellyl formate
Pinocarvyl acetate
Myrtenyl acetate
Citronellyl acetate
Geranyl acetate
2-methyl-5,7-dimethylene-1,8-nonadiene
Benzyl 2-methylbutanoate
Methyl eugenol
β-Caryophyllene
Aromadendrene
Geranyl n-propionate
Citronellyl isobutyrate
Germacrene D
β-Selinene
α-Bisabolene
Geranyl isobutyrate
Myristicin
β-Sesquiphellandrene
(Z)-Isomyristicin
Germacrene D-4-ol
Caryophyllene oxide
Geranyl isovalerate
Geranyl pentanoate
(E)-Isomyristicin
Dillapiole
α-Cadinol
(E)-Isoelemicin
Apiole
Valeranone
(E)-Isoapiol
Hexadecanal

*

KI
934a
977a
991a
1005a
1013b
1030a
1038a
1048c
1090c
1100c
1106a
1109c
1115a
1149b
1179a
1189a
1193a
1223c
1229a
1240b
1256a
1276a
1293a
1329b
1354a
1384c
1388b
1396b
1406d
1427c
1462a
1475a
1484a
1489a
1500c
1507a
1514a
1526a
1529b
1575e
1584a
1587a
1605b
1611c
1624f
1630i
1640a
1654g
1665i
1684a
1722h
1840c

Retention time of the compounds based on GC-FID peaks (see Figure 8.1).
Identified by NIST and NISTREP mass spectra library and agrees with Adams (1995).
b
Identified tentatively by NIST and NISTREP mass spectra library.
c
Identified by NIST and NISTREP mass spectra library and agrees with Radulovic et al. (2010).
d
Identified by comparing its KI, NMR spectra with the literature (Jirovetz et al.,2003; Miyazawa and Kohno, 2005).
e
Identified by NIST and NISTREP mass spectra library and agrees with Tzakou et al. (2010).
f
Identified by NIST and NISTREP mass spectra library and its NMR spectra comparison with Antunes et al. (1995).
g
Identified by 1H and 13C-NMR spectra comparison with Enqiquez et al. (1980).
h
Identified by 1H and 13C-NMR spectra comparison with Jakupovic and Eid (1987).
I
Identified by comparing the calculated KI with Siani et al. (1999).
a
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Subsequent purification of the EO of P. amabile using column chromatography
and preparative TLC resulted in the isolation of four compounds 37-40 (Figure 8.2)
which were identified by KI and NMR spectroscopy data comparison with the
literature. The initial column chromatography of the EO using normal phase silica and
gradient elution with petroleum spirit/CHCl3 produced nine fractions, PAOil-1 to
PAOil-9. Separation of fraction PAOil-1, using reverse phase preparative TLC in a
solvent system of H2O/MeOH (1:9), yielded (E)-isomyristicin (37). Separation of the
fraction PAOil-5 using normal phase preparative TLC in a solvent system of
CHCl3/petroleum spirit (9:1) yielded (E)-isoapiol (38) and methyl eugenol (39).
Separation of the fraction PAOil-8, using normal phase PTLC in a solvent system of
diethyl ether/petroleum spirit (1:4), yielded (E)-isoelemicin (40).
(E)-Isomyristicin (37) was isolated as a colourless oil which was the major
chemical constituent of the EO of P. amabile. Its LR-ESI-MS showed a [M+H+] peak
at (m/z): 193 and the LR-EI-MS exhibited the ion fragmentation pattern as (m/z): 192
(base peak), 177, 165, 161, 147, 131, 119, 103, 91, 77, 65, 53, 39 which matched the
ion fragmentation pattern of isomyristicin in the MS library system (NIST08.LIB,
Entry # 15372, CAS: 607-91-0). The 1H-NMR and 13C-NMR spectroscopic data of this
compound (see the experimental section (Chapter 11)) agreed well with those of
isomyristicin reported in the literature (Antunes et al., 1995; Enqiquez et al., 1980).
(E)-Isoapiol (38) was isolated as an oily compound which showed a [M+H+] peak
at (m/z): 222 based on the LR-ESI-MS. The LR-EI-MS exhibited the ion fragmentation
pattern as (m/z): 222 (base peak), 207, 191, 177, 163, 149, 134, 121, 106, 91, 77, 65,
53, 39. The 1H-NMR and

13

C-NMR spectroscopic data of this compound (see the

experimental section (Chapter 11)) agreed well with those of isoapiol reported in the
literature (Jakupovic and Eid, 1987).
Methyl eugenol (39) was isolated as a colourless oil. Its LR-ESI-MS showed a
[M+H+] peak at (m/z): 179 and the LR-EI-MS exhibited the ion fragmentation pattern
as (m/z): 178 (base peak), 163, 147, 135, 115, 107, 91, 77, 57, 41 which matched the
ion fragmentation pattern of eugenol methyl ether in the MS library system
(NIST08s.LIB, Entry # 13416, CAS: 93-15-2). The

1

H-NMR and

13

C-NMR

spectroscopic data of this compound (see the experimental section (Chapter 11)) agreed
well with those of methyl eugenol reported in the literature (Miyazawa and Kohno,
2005).
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(E)-Isoelemicin (40) was isolated as a colourless oil. Its LR-ESI-MS showed a
[M+H+] peak at (m/z): 209 and the [M+] peak at (m/z): 208. The 1H-NMR spectroscopic
data of this compound (see the experimental section (Chapter 11)) agreed with those of
(E)-isoelemicin reported in the literature (Enqiquez et al., 1980).

8.3. Isolation and identification of furanocoumarins from the MeOH extract
Subsequent to the analysis of an EO of P. amabile, its dried powdered material
was extracted with MeOH which yielded 190 g of crude MeOH extract. This extract
was dissolved in MeOH/water (1:9) and fractionated first with hexane and petroleum
spirit to obtain their respective extracts. The remaining aqueous portion was acidified
with 5% HCl and fractionated with CH2Cl2 to obtain the acidic fraction. The aqueous
component was again basified with NH4OH to pH 9-12 and then fractionated with
CHCl3 to obtain a basic CHCl3 extract followed by EtOAc and n-butanol giving EtOAc
and BuOH extracts, respectively. The remaining aqueous layer was dried to obtain H20
extract.
All the crude extracts were purified repeatedly using silica gel column
chromatography and PTLC in different solvent systems which finally yielded
compounds 37-46 (Figure 8.3). Compounds 37-40 were isolated and identified earlier
from the EO of this plant (see Figure 8.2). Compounds 41-46 (Figure 8.3) were
identified as: psoralen (41), bergapten (42), isoimperatorin (43), isopimpinellin (44),
oxypeucedanin hydrate (45) and oxypeucedanin methanolate (46) by MS-library
matching techniques and NMR spectroscopic data comparisions. While compounds 40
(from EO), 42-44 have been reported previously from P. lindleyanum (Tan et al.,
2006), the other compounds, 37-39, 41, and 45-46 were isolated from the genus
Pleurospermum for the first time.
Psoralen (41) was isolated and recrystallised as white needles from
MeOH/CHCl3. Its LR-ESI-MS showed a [M+H+] peak at (m/z): 187 and the LR-EI-MS
exhibited the ion fragmentation pattern as (m/z): 186 [M+] (base peak), 158,
130,102,93, 76, 102, 76, 63, 51 which matched the ion fragmentation pattern of ficusin
(synonym for psoralen) in the MS library system (NIST08.LIB, Entry # 34463, CAS:
66-97-7). The 1H-NMR and

13

C-NMR spectroscopic data of this compound (see the

experimental section (Chapter 11)) agreed well with those of psoralen reported in the
literature (Jiangning et al., 2005). This compound is commonly found in vegetables,
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including parsnip and celery and was previously isolated from Psoralea corylifolia
((Jiangning et al., 2005), Ficus salicifolia, Heracleum leskovii, Ruta chalepensis and
Dictamnus hispanicus (Taylor and Francis, 2013).

Figure 8.3. Furanocoumarin compounds 41-46 isolated from MeOH extract of P.
amabile.
Bergapten (42) was isolated and recrystallised as clear crystals from
MeOH/CHCl3. Its LR-ESI-MS displayed a [M+H+] peak at (m/z): 217 and the LR-EIMS presented the ion fragmentation pattern as (m/z): 216 [M+], 202 (base peak), 192,
173, 158, 145, 131, 118, 102, 89, 74, 69, 63, 51 which matched the ion fragmentation
pattern of heraclin (synonym for bergapten) in the MS library system (NIST08.LIB,
Entry # 53002, CAS: 484-20-8). The 1H-NMR and 13C-NMR spectroscopic data of this
compound (see the experimental section (Chapter 11)) agreed well with those of
bergapten reported in the literature (O’Neill et al., 2013; Kawaii et al., 1999).
Isoimperatorin (43) was isolated and recrystallised from MeOH/CHCl3. Its LRESI-MS indicated a [M+H+] peak at (m/z): 271 and the LR-EI-MS revealed the ion
fragmentation pattern as (m/z): 270 [M+], 202 (base peak), 174, 158, 145, 131, 118,
103, 89, 69, 51 which matched the ion fragmentation pattern of isoimperatorin in the
MS library system (NIST08.LIB, Entry # 90508, CAS: 482-45-1). The 1H-NMR and
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C-NMR spectroscopic data of this compound (see the experimental section (Chapter

11)) agreed well with those of isoimperatorin reported in the literature (Tian et al.,
2013; Jackson et al., 1990).
Isopimpinellin (44) was isolated a white solid. Its LR-ESI-MS presented a
[M+H+] peak at (m/z): 247 and the LR-EI-MS displayed the ion fragmentation pattern
as (m/z): 246 [M+], 232, 216, 202, 188, 173, 160, 148, 139, 116, 194, 91, 74, 60, 50.
The EI-MS, 1H-NMR and

13

C-NMR spectroscopic data of this compound (see the

experimental section (Chapter 11)) agreed well with those of isopimpinellin reported in
the literature (Yoo et al., 2003).
Oxypeucedanin hydrate (45) was isolated as light yellowish needles from
MeOH/CHCl3. Its LR-ESI-MS showed a [M+H+] peak at (m/z): 305 and the LR-EI-MS
demonstrated the ion fragmentation pattern as (m/z): 304 [M+], 244, 215, 202 (base
peak), 174, 145, 118, 89, 59, 51 which matched the ion fragmentation pattern of
oxypeucedanin hydrate in the MS library system (NIST08.LIB, Entry # 114683, CAS:
24724-52-5). The 1H-NMR and 13C-NMR spectroscopic data of this compound (see the
experimental section (Chapter 11)) agreed well with those of isopimpinellin reported in
the literature (Fujioka et al., 1999).
Oxypeucedanin methanolate (46) was isolated as a white solid. Its LR-ESI-MS
indicated a [M+H+] peak at (m/z): 319 and the LR-EI-MS established the ion
fragmentation pattern as (m/z): 318 [M+], 286, 215, 202 (base peak), 185, 174, 157,
145, 118, 99, 85, 73, 59, 51. The 1H-NMR and

13

C-NMR spectroscopic data of this

compound (see the experimental section (Chapter 11)) agreed well with those of
oxypeucedanin methanolate reported in the literature (Fujioka et al., 1999).

8.4. Biological activities of the EO, crude extracts and isolated compounds
Given the traditional use of P. amabile to treat fever and various disorders
bearing relevance to microbial infections and malaria and that its CH2Cl2 and CHCl3
extracts exhibited significant biological activities, as described in Chapter 3 and
reproduced in Table 8.2, we investigated the petroleum spirit, EtOAc and BuOH crude
extracts, the EO and the ten compounds, 37-46, for their antimicrobial, antimalarial and
cytotoxicity activities.
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Table 8.2. Antibacterial, antimalarial and cytotoxicity activities of crude extracts, EO
and compounds 37-46 isolated from P. amabile.
Samples
CH2Cl2 extracta
CHCl3 extracta
Petroleum spirit extract
Ethyl acetate extract
n-Butanol extract
Essential oil (EO)
(E)-Isomyristicin (37)
(E)-Isoapiol (38)
Methyl eugenol (39)
(E)-Isoelemicin (40)
Psoralen (41)
Bergapten (42)
Isoimperatorin (43)
Isopimpinellin (44)
Oxypeucedanin hydrate (45)
Oxypeucedanin methanolate (46)
Amoxicillinb
Vancomycinb
Chloroquinec
Cycloguanilc
Pyrimethaminec
Ellipticined
Doxorubicind

Antibacterial
(MIZ in mm)
B. subtilis
MRSA
14
6
–
–
–
5
5
6
–
–
–
–
–
–
–
9
8

12
NT
–
–
–
–
–
–
–
–
–
–
–
–
–
–

Antiplasmodial
(IC50 in μg/mL)
TM4/8.2
K1CB1
12.1 ± 0.4 10.9 ± 2.3
7.8 ± 1.8
7.3 ± 2.6
27.6 ± 4.3 37.9 ± 14.1
24.3 ± 3.2 25.2 ± 6.5
>100
>100
79.0 ±4.6 72.3 ± 2.1
>100
>100
52.9 ± 2.9 69.9 ± 2.0
>17.8
>17.8
>20
>20
>18.6 16.4 ± 0.3
>10.8
>10.8
19.1 ± 0.9 18.5 ± 0.7
19.5 ± 2.3 15.6 ± 2.5
24.9 ± 2.0 18.7 ± 2.3
7.4 ± 1.3
6.7 ± 1.1

Cytotoxicity
(IC50 in μg/mL)
Vero
KB
>25
>25
>50
>100
>100
>100
>100
>100
>17.8
>20
>18.6
>10.8
>27.0
>24.6
>30.4
>31.8

>25
>25
>50
>100
>100
>100
>100
>100
>17.8
>20
>18.6
>10.8
>27.0
>24.6
>30.4
>31.8

13.5
0.010
0.009
0.020

0.089
0.810
7.700
0.093
0.56

–: Not Active, NT: Not Tested.
a
Original activity taken from Chapter 3.
b
Positive controls for antibacterial activity.
c
Positive controls for antiplasmodial activity.
d
Positive controls for cytotoxicity activity.

8.4.1. Antibacterial activity
The antibacterial investigation was initially performed using the modified Agar
Well Diffusion method (AWD) which measured the activity of the samples in
minimum inhibition zone (MIZ) followed by the broth microdilution methods in 96
well plates that determined the minimum inhibitory concentrations (MIC) as detailed in
the experimental section. Only those strains sensitive to the crude extracts and
compounds are reported in Table 8.2. The EO and compounds 37, 38 and 46 showed
moderate antibacterial activity against only one strain, B. subtilis with minimum
inhibition zones (MIZ) of 5, 6 and 9 mm (Table 8.2). When the MIC of these active
compounds were determined, the highest activity was exhibited by oxypeucedanin
methanolate (46) with the MIC value of 125 µg/mL. Unlike the CH2Cl2 and CHCl3
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extracts that showed activity (reproduced in Table 8.2), the other samples tested and
shown in Table 8.2 did not exhibit any antibacterial or antifungal activity. Although, we
did not test our samples against the bacterial strain, Mycobacterium tuberculosis
(H37Ra), compound 42 (bergapten), that was isolated from Heracleum maximum, was
reported to be active against this bacterium with a MIC value of 200 µg/mL and an IC 50
value of 27 µg/mL (O’Neill et al., 2013).

8.4.2. Antiplasmodial activity
The antiplasmodial activity of the samples were determined for a wild type
chloroquine and antifolate sensitive strain, TM4/8.2 and the multidrug resistant strain,
K1CB1 of Plasmodium falciparum using the Microdilution Radioisotope Technique as
detailed in the experimental section. Among the five crude extracts and the EO, CHCl3
extract exhibited significant and the highest antiplasmodial activity against both P.
falciparum strains, TM4/8.2 and K1CB1, with IC50 values of 7.8 µg/mL and 7.3
µg/mL, respectively which was closely followed by that of the CH2Cl2 extract. The
petroleum spirit and EtOAc extracts showed moderate activity with IC50 values in the
range of 24.3-37.9 µg/mL (Table 8.2). The EO exhibited the lowest antiplasmodial
activity against the P. falciparum strains: TM4/8.2 and K1CB1 with IC50 values of 79.0
µg/mL and 72.3 µg/mL, respectively. The BuOH extract did not show any activity.
The varying activities of the crude extracts and the EO described above suggested
that the more potent chemical components are present in the CH2Cl2 and CHCl3
extracts rather than in the petroleum spirit or EtOAc extracts or the EO. This was
evident from the significant antiplasmodial activity exhibited by oxypeucedanin
methanolate (46) isolated from these two crude extracts. Compound 46 exhibited
significant and the highest activity (amongst the samples tested) against both P.
falciparum strains, TM4/8.2 and K1CB1 with IC50 values of 7.4 µg/mL and 6.7 µg/mL,
respectively. Such activities were similar to that of its parent crude CH2Cl2 and CHCl3
extracts but threefold better than its closely related compound 45 (oxypeucedanin
hydrate) (Table 8.2). Compounds 43-45 also showed moderate antiplasmodial activity
with their IC50 values in a similar range of 15.6-24.9 µg/mL (Table 8.2). Compound 41
was found active against the K1CB1 strain with an IC50 value of 16.4 µg/mL but was
not active against the TM4/8.2 strain. Compound 38, which was isolated from the EO,
showed weak antiplasmodial activity with IC50 values of 52.9 µg/mL and 69.9 µg/mL
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against TM4/8.2 and K1CB1, respectively. Interesting to note here is that the major
component of the EO, (E)-isomyristicin (37), and another major compound of the
MeOH extract, bergapten (42) did not exhibit any biological activities.

8.4.3. Cytotoxicity
Cytotoxicity was evaluated by the sulforhodamine B (SRB) assay method.
Normal Vero cells from the kidney of the African green monkey, Cecopithecus
aethiops, and human oral carcinoma KB cells were used. Ellipticine and doxorubicin
were used as reference drugs. While none of the test samples studied showed any major
cytotoxicity or anticancer activity against human oral carcinoma KB cells, compounds
43 and 45-46 that were isolated from different plant species have been reported to
possess antiproliferative activity by inhibiting the growth of nude mouse-transplantable
human gastric adenocarcinoma (MK-1), human uterus carcinoma (HeLa) and murine
melanoma (B16F10) cells (Fujioka et al., 1999). While compound 43 was also reported
to exhibit moderate cytotoxicity against various tumour cell lines including, L1210,
HL-60, K562, B16F10; compound 41 was found active against only HL-60 and K562
tumour cell lines (Thanh et al., 2004).

8.5. Conclusions
In conclusion, this study found that P. amabile has an EO (0.7% oil w/w) with
(E)-isomyristicin (37) (32.5% oil) as the major constituent. Bergapten (42) was the
major compound isolated from the MeOH extract component of this plant. None of
these two major phytochemicals showed any biological activities. Interestingly, the
furanocoumarin compound, oxypeucedanin methanolate (46), exhibited moderate
antibacterial activity against B. subtilis and had significant antiplasmodial activity
against the P. falciparum strains, TM4/8.2 and the multidrug resistant strain, K1CB1,
without mammalian cell toxicity. This verifies the safety record of P. amabile used in
BTM formulations for treating various disorders.
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CHAPTER 9
DITERPENOID ALKALOIDS FROM ACONITUM LACINIATUM

Aconitum laciniatum [Photograph by P. Wangchuk, 2009]

Taxonomic position and botanical classification
Kingdom

: Plantae

Phylum

: Angiospermae

Subkingdom

: Tracheobionta

Superdivision

: Spermatophyta

Division

: Magnoliophyta

Class

: Magnoliopsida

Subclass

: Magnoliidae

Order

: Ranunculales

Family

: Ranunculaceae

Genus

: Aconitum

Species

: laciniatum

Bhutanese name

: Tsan-dug
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9.1. Introduction
The genus Aconitum belongs to the family of Ranunculaceae and comprises about
300 species in the world with major centres of diversity in the mountains of East and
South-East Asia and Central Europe (Chaudhary and Rao, 1998). From China alone,
about 200 species are reported (Singhuber et al., 2009) and more than 33 species are
found in the Himalayan regions (Sharma and Gaur, 2012). While India hosts 26 of them
(Chaudhary and Rao, 1998), Bhutan is home to 22 species of Aconitum (Grierson and
Long, 1984). Most of the Aconitum species are highly poisonous due to higher
concentration of diterpenoid alkaloids. These alkaloids have complicated structures,
unique chemistry and valuable pharmacological properties (Bessonova and
Saidkhodzhaeva, 2000).
Traditionally, Aconitum species have been used in Asia, Alaska, and Europe for a
wide range of applications (Wink, 1998) ranging from warfare, hunting, covert human
poisons and in traditional medicines. In European homeopathy, and many Asian
traditional medicines, different species of Aconitum are used for treating various
symptoms and diseases such as fainting, syncope, rheumatic fever, painful joints,
gastroenteritis, diarrhoea, oedema, bronchial asthma, various tumours, some endocrinal
disorders like irregular menstruation, neuralgia, gout, hypertension and rheumatism
(Singhuber et al., 2009). Prior to their usage, the toxic components are first reduced
following traditional detoxification methods. In India, the detoxification is usually done
by soaking in cow’s urine for three days or boiling it in cow’s or goat’s milk (Sheokand
et al., 2012). Similarly, in Bhutan, the root of A. laciniatum (poisonous species used in
BTM) is detoxified by boiling in Cow’s milk. In China, about 70 traditional and
modern techniques are applied for the detoxification and processing of Aconitum roots
for medicinal use (Sheokand et al., 2012). It is known that this detoxification process is
bound to a hydrolysis procedure and that the traditional detoxification methods
described above remarkably reduces the toxicity of these alkaloids by converting the
diester diterpene alkaloids (DDA) to their less toxic monoester diterpene alkaloids
(MDA) (Sheokand et al., 2012). While it would be possible to eliminate the DDAs
completely from the aconites by thorough processing, several publications also point
out that a certain amount of DDAs contributes to the desired clinical effects and that
they should not be entirely diminished from the drug (Ameri, 1998; Yang et al., 1997).
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In China, more than 11 species have been used for medicinal purposes
(CPCommission, 2005). For example, A. brachypodum is a well known Chinese
medicine for its anti-rheumatic and analgesic properties and is also used by the local
people for the treatment of abrasions and wounds (Singhuber et al., 2009). In India,
about 14 aconites are used in traditional medicines (Shah, 2005). For example, the
powdered root of Aconitum heterophyllum has been used by the Indians as
antidiarrheal, antidysenteric, anticough, febrifuge, bitter tonic, and in combating
dyspepsia, chronic enteritis and debility after malaria (Chopra et al., 1958; Pelletier et
al., 1968).
In Bhutan, out of the 22 Aconitum species present, only three of them (Figure
9.1): A. laciniatum, A. violaceum and A. orochryseum are used in the formulations of
more than 25 current traditional medicines (Tenzin, 2007). Among these three plants,
A. violaceum and A. orochryseum are mildly toxic as compared to A. laciniatum. They
can be distinguished from the colour of their flowers, and the size and shapes of their
leaves and roots (Figure 9.1).

A

B

C

Figure 9.1. Three medicinal Aconitum species of Bhutan: A) A. laciniatum, B) A.
violaceum, C) A. orochryseum (P. Wangchuk, 2009).

9.2. Pharmacological activities and the diterpenoid alkaloids of the genus
Aconitum
Fujita (1965) carried out the first extensive review on diterpenoid alkaloids and
described 208 of them. Southon and Buckingham (1989) described about 244
diterpenoid alkaloids from 92 different species of Aconitum alone. Recently, Wang et
al. (2010) carried out an extensive review covering the literature from 1998 to 2008
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which described about 364 new diterpenoid alkaloids. Of these, 197 were isolated from
56 Aconitum species. Pelletier and Keith (1970), Dalton (1979), and Southon and
Buckingham (1989) have classified these alkaloids mainly into two major structural
types, the C19- (47) and C20- (48) diterpenoid alkaloids (Figure 9.2).

Figure 9.2. C19- (47) and C20- (48) diterpenoid structural types.

Figure 9.3. C19- and C20-diterpenoid alkaloids isolated from a Bhutanese medicinal
plant, A. orochryseum.
The C19-diterpenoid alkaloids have three structural sub-types, as the aconitines,
the lycoctonines, and the lactones. Among these three, the aconitines accounts for the
majority of the alkaloids and they differ only by substitution with hydroxy, methoxy,
acetyloxy, benzoyloxy and acyloxy groups (Southon and Buckingham, 1989). The C20diterpenoid alkaloids also have three structural sub-types as atidanes, atisanes and
veatchines. While atidanes are the major group, the atisanes represents a smaller group
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with interesting chemical structures. Alkaloids that do not fit into the above structural
types have been classified as the miscellaneous diterpenoid alkaloids. It is known that
an Aconitum plant can have both C19- and C20-diterpenoid alkaloids. For example,
Wangchuk et al. (2007b) isolated four C20-diterpenoid alkaloids (orochrine (49), 2-Oacetylorochrine (50) and 2-O-acetyl-7-α-hydroxyorochrine (51), atisinium chloride
(52)) and one C19 (virescenine (53)) diterpenoid alkaloid from the Bhutanese medicinal
plant, A. orochryseum (Figure 9.3).
The Aconitum extracts and alkaloids have been the subject of extensive
pharmacological investigations and medicinal applications. In biomedicine, aconitecontaining liniments, including AconitysatTM, BrinpaxTM, EtermolTM and PectovoxTM,
have been applied as an anodyne for the treatment of chronic rheumatism, neuralgia
and sciatica (Schemeller and Wink, 1998; Saito et.al., 1982). In traditional medicines,
most of the effects of Aconitum have been examined in the decoctions of traditional
medicine formulations instead of the single plant. For example, a Chinese traditional
medicine (CTM) formulation, called Shenfu which contain aconite and is administered
by injection (Singhuber et al., 2009), has been clinically shown to reduce myocardial
injury in patients undergoing valve replacement operation (Wang et al., 2007), lessen
severity of heart failure when co-administered with conventional medicine in patients
with myocardial infarction (Li, 2006), exert protective effects against atrioventricular
blockage and ventricular arrhythmia caused by cardiopulmonary bypass (Zheng and
Min, 2008), and improve the immunity and general wellbeing of cancer patients by
significantly decreasing the severity of the anaemia (Chen et al., 2007).
The crude extracts of single plants (both processed and unprocessed) have been
also pharmacologically studied. For example, Xue et al. (2007) demonstrated that the
crude total alkaloids of A. excelsum can inhibit morphine-withdrawal syndromes and
down regulate cytochrome P450 2E1 metabolic activity that is heightened by the
withdrawal. Gao et al. (2010) found that the long-time neglected water-soluble nonstarch type polysaccharides of A. carmichaeli and A. kusnezoffii had good antitumour
and immunostimulating activities.
A number of diterpenoid alkaloids isolated from the crude extracts of Aconitum
has been shown to possess a broad range of biological activities. Singhuber et al. (2009)
reviewed the literature from 1981 to 2003 and described the pharmacological activities
of 27 diterpenoid alkaloids with the most commonly observed bioactivities being
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antiarrhythmic, analgesic, anti-inflammatory, antinociceptive, and anti-epileptic
activities. Aconitine, which was isolated as the major component from A. napellus and
was probably the first and thoroughly studied diterpenoid alkaloid for its
pharmacological activities, has been reported to possess a broad range of bioactivities
including: analgesic, anesthetic, anti-inflammatory, anti-arrhythmic, depolarization,
acetylcholine inducer, tachyarrhythmial and bradycardial stimulator, neuronal inhibitor,
and Na+ and Ca2+ channels blocker activity (Singhuber et al., 2009; Ameri et al., 1996).
1-O-Benzoylnapelline, which is a derivative of napelline isolated from A. napellus, A.
karakolicum and A. yesoense, showed maximum antiarrhythmic activity, even
markedly exceeding that of reference Class I antiarrhythmic drugs novocainamide,
quinidine and lidocaine (Shakhidoyatova et al., 2001).
Napalline, hypaconitine, mesaconitine and songorine which were isolated from A.
baicalense, exhibited antidepressant and anti-inflammatory activities (Nesterova et al.,
2011). Lycaconitine, obtained from several Aconitum species was found to be effective
against multi-drug resistant cancers (Kim et al., 1998). Atisinium chloride that was
isolated from a Bhutanese medicinal plant, A. orochryseum showed significant
antimalarial activity against the Plasmodium falciparum strains: TM4/8.2 (wild type,
chloroquine and antifolate sensitive) and K1CB1 (multidrug resistant) (Wangchuk et
al., 2010b).
Our studies on the crude extracts of another Bhutanese medicinal plant, A.
laciniatum found that its crude MeOH extract (see Chapter 3 for details) possessed mild
anti-inflammatory and antibacterial activity against B. subtilis and H. pylori. This plant
is locally known as “bdud-rtsi-lo-ma” or “tsan-dug”. It is an erect biennial herb, of 0.61.5 m in height, with less deeply dissected leaves (up to 15 cm in diameter), bluish
flowers widely spaced in racemes, and paired conical tubers (Grierson and Long,
1984). It grows in grassy alpine mountain slopes of Bhutan among the shrubs within
the altitude range of 3500-4570 masl and is distributed in places including Chelela,
Lingzhi, Phajoding, Rinchenchu, Chamsa, Kohina, Pangla and Dagala. All parts of a
plant including the flowers, leaves and roots (Figure 9.4) are collected annually for use
in BTM.
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A

B

C

Figure 9.4. Different components of A. laciniatum: A) flower, B) leaves and C) roots
used in BTM.
It is noteworthy that for use in BTM the root of this plant is first detoxified by
boiling in the milk of a cow or a goat or by burning the roots in a closed airtight pan
under a charcoal fire until the smoke from the burnt aconite makes paper wet or moist
(traditional Tibetan method). This detoxified component is used, in combination with
other ingredients, for formulating at least five important polyherbal formulations: chimed-srin-sel, khyung-lnga-ril-bu, rin-chen-byu-d.mar-25, seng-ldeng-25 and shingkun-25 (Tenzin, 2007). As an individual plant, it is indicated for treating bone diseases,
gout, leprosy, chronic infections, and as an anthelmintic/vermifuge (Wangchuk et al.,
2009). For this study, we have collected the root component of the plant from Lingzhi
and analysed it for its diterpenoid alkaloids.

9.3.

Isolation and identification of C19-diterpenoid alkaloids from A. laciniatum.
The dried roots of A. laciniatum was powdered and extracted with MeOH which

yielded 165 g of crude MeOH extract. Through an acid-base fraction method, the
DCM-1, DCM-2, EtOAc and BuOH extracts were obtained. The DCM-1 and DCM-2
fractions were repeatedly purified using the silica gel column chromatography and
PTLC plates under different solvent conditions which finally yielded five known C19diterpenoid alkaloids: pseudaconitine (54), 14-veratroylpseudaconine (55), 14-Oacetylneoline (56), neoline (57) and senbusine A (58) (Figure 9.5). Their structures
were first elucidated using 1D and 2D NMR spectroscopic data and then confirmed by
comparing their spectroscopic data with the relevant literature.
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Figure 9.5. C19-diterpenoid alkaloids isolated from A. laciniatum.
Pseudaconitine (54) was recrystallised from CHCl3/MeOH as prisms. Its LR-ESIMS showed a [M+H+] peak at (m/z): 690 and the LR-EI-MS exhibited an ion
fragmentation pattern as (m/z): 689 [M+], 675, 658, 642, 629, 614, 598, 585, 464, 432,
330, 266, 252, 236, 202, 182, 178, 165, 137, 86, 75, 58, 45. The 1H-NMR showed
seven methoxy proton signals (all 3H singlets) at δ 3.16, 3.28, 3.29, 3.53, 3.91 and
3.94; one acetoxyl protons at δ 1.33 (3H, s); and one set of methyl protons at δ 1.10
(3H, t, J = 7.0 Hz). The characteristic H-6 and H-14 proton signals were observed at δ
4.03 (1H, d, J = 6.5 Hz) and 4.86 (1H, d, J = 5.0 Hz), respectively. The veratric acid
(OVr) aromatic protons resonated at the range of δ 6.89-7.71. The

1

H-NMR

spectroscopic data of this alkaloid (54) (detailed in the experimental section) agreed
well with those of pseudaconitine reported in the literature (Hanuman and Katz, 1993).
We identified this alkaloid as the major component of A. laciniatum which was isolated
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earlier from the roots of A. ferox, A. falconeri, A. balfourii, A. deinorrhizum and A.
spicatum (Taylor and Francis, 2013).
14-Veratroylpseudaconine (55) was isolated as an amorphous creamy white solid.
Its LR-ESI-MS displayed the [M+H+] peak at (m/z): 648 corresponding to the
molecular formula of C34H49NO11 (M+H+, calculated for 648.3384). The 1H-NMR
showed six methoxy proton signals (all 3H singlets) at δ 3.25, 3.28, 3.31, 3.42, 3.93 and
3.94, and one set of methyl protons at δ 1.12 (3H, t, J = 7.0 Hz). In this compound, the
characteristic H-6 and H-14 proton signals were shifted a little downfield at δ 4.08 (1H,
d, J = 6.5 Hz) and 5.13 (1H, d, J = 5.5 Hz), respectively. The OVr aromatic protons
resonated at the range of δ 6.89-7.68. Unlike the alkaloid 54, 14-veratroylpseudaconine
(55) contains an OH group instead of an OAc at the C-8 position on the C19lycoctonine-type alkaloid skeleton. Its 1H-NMR spectroscopic data (detailed in the
experimental section) agreed with those of 14-veratroylpseudaconine reported
from another species, A. ferox (Hanuman and Katz, 1993) and A. falconeri (Taylor and
Francis, 2013).
14-O-Acetylneoline (56) was also isolated as an amorphous creamy white solid.
Its LR-ESI-MS showed a [M+H+] peak at (m/z): 690 and the HR-EI-MS exhibited a
molecular formula as C26H41NO7 (calculated from M+H+, 480.2961). When compared
to the first two compounds, 54 and 55, the 1H-NMR data of compound 56 showed only
three set of methoxyl proton signals (all 3H singlets) at δ 3.26, 3.32 and 3.34; one
acetoxyl methyl signal at δ 2.06 (3H, s); and one methyl signal at δ 1.13 (3H, t, J = 7.0
Hz). The characteristic H-6 and H-14 proton signals of C19-diterpenoid type alkaloid
were observed at δ 4.12 (1H, d, J = 6.0 Hz) and 4.86 (1H, d, J = 4.0 Hz), respectively.
Unlike alkaloids 54 and 55, the structure of compound 56 did not contain the C-14 OVr
and C-13 hydroxyl functional groups. Instead, its C-1 and C-3 positions were both
substituted by hydroxyl groups and the OVr group at the C-14 position was replaced by
an acetoxyl group. The structure of 56 was elucidated using APT, gHSQC, gHMBC,
gCOSY and NOESY experimental data and through database searching, the alkaloid
was identified as the known alkaloid, 14-O-acetylneoline (56). The 1H-NMR and 13CNMR spectroscopic data (as detailed in the experimental section) agreed with those of
14-O-acetylneoline isolated from aphids, Brachycaudus aconiti which lives and feeds
on A. napellus (Liu and Katz., 1996).
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Neoline (57) was isolated as an amorphous powder. The LR-ESI-MS showed a
[M+H+] peak at (m/z): 438 and the HR-EI-MS established the molecular formula as
C24H39NO6. This alkaloid differed from 56 only by the C-14 substituent where the
acetoxyl group in 56 has been replaced by a hydroxyl moiety. While this hydroxyl
proton (OH) resonated at δ 7.38 (1H, br s), its germinal proton (H-14) resonated at δ
4.81-4.84 (m). The H-6 proton signal was observed at δ 4.15-4.17 (1H, m); the three
sets of singlet methoxyl protons at δ 3.32, 3.33 and 3.33; and the one set of methyl
protons at δ 1.12 (3H, t, J = 7.0 Hz). These 1H-NMR spectroscopic data agreed with
those of neoline isolated from A. ferox (Hanuman and Katz, 1994).
Senbusine A (58) was isolated as an amorphous powder. The LR-ESI-MS
showed a [M+H+] peak at (m/z): 424 which suggested the loss of one methine (-CH2)
from the structure of 57. This alkaloid differed from that of 57 only at the C-6
substituent where a methoxyl group has been replaced by a hydroxyl moiety which
therefore equates to the difference in loss of a mass of 14 amu or that of a methylene
group. In the 1H-NMR spectrum, a 1H broad singlet was observed at δ 4.20 which was
assigned to a germinal H-6 proton whose splitting pattern and chemical shift was
affected by the attached hydroxyl protons. The APT spectrum showed the C-6 signal at
δC 73.2 which was distinctly a little upfield when compared to the chemical shift of the
methoxyl moiety. The H-14 proton signal was observed at δ 4.78 (1H, d, J = 6.0 Hz).
The methyl of the N-ethyl group resonated at δ 1.14 (3H, t, J = 7.0 Hz) and signals for
the two methoxy groups were observed at δ 3.33 and 3.34 (6H, s). These spectroscopic
data agreed well with those of senbusine A isolated from A. carmichaeli and A. ferox
(Konno et al., 1982; Hanuman and Katz, 1994).

9.4. Conclusions
A. laciniatum is a highly toxic and poisonous plant that requires extreme care but
if administered in the right dose, it has been seen to have desired clinical effects
including in biomedicine. Our phytochemical investigation of the crude MeOH extract
of this plant resulted in the isolation and identification of five known lycoctonine-type
C19-diterpenoid alkaloids (54-58) which are known to be deadly neurotoxins.
Pseudaconitine (54) was established as the major constituent of A. laciniatum. The
crude extracts from this plant did not show any significant biological activities
including cytoxicity.
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“Millions of years of testing by natural selection have made organisms chemists of
superhuman skill, champions of defeating most of the kinds of biological problems that
undermine human health”
- E.O.Wilson, 1994
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10.1.

Conclusions
The BTM, often known as Sowa-rigpa, is one of the oldest surviving scholarly

medical traditions in the world. It embodies knowledge that has been accumulated over
centuries and which draws upon the nation’s rich biodiversity that is nurtured by the
cleanest environment. The maintenance of this traditional medical system not only adds
dimensions to the national health care system but it also generates employment and
commerce to the public, and income to the farmers through cultivation and collection
programs. It is one of the sustainable social services that form one of the four pillars of
the country’s development policy of “Gross National Happiness”.
The government’s commitment and support of BTM is reflected in the inclusion
of traditional medicine in the country’s constitution and health policy frameworks, and
its integration with biomedicine in 1967. With integration, improving the quality of
BTM through scientific studies has become paramount. These required studies include,
the standardization of the traditional health care delivery system, and methods and
processes of manufacturing, the development of quality parameters, the accurate
botanical identification of medicinal plants, phytochemical and toxicity evaluation,
establishment as an evidence-based medicine through clinical trials of the finished
formulations, and verification of the ethnopharmacological uses of plants.
Our study focused on resolving the existing botanical discrepencies, screening of
seven plants for their phytochemicals and verifying the ethnopharmacological uses of
these plants through bioassays of the crude extracts and isolated pure compounds. In
the process, we have also identified five novel drug lead compounds. The traditional
and taxonomical discrepancies, and the botanical identification of LAMP is described
in Chapter 2. Out of 113 LAMP species, 92 are used in the current multi-ingredient
formulations produced by MSP and 28 of them are currently imported from India. Out
of these 28 species, 16 of them are found growing abundantly in Bhutan and most of
them had not been studied for their phytochemicals and pharmacological properties.
After resolving these discrepancies and having correctly identified the
medicinal plants used in the current BTM formulations, we have selected 25 of these
plants based on certain selection criteria and assessed them for their major classes of
phytochemicals which we have described in Chapter 3. Of these plants, seven were
found interesting and indicated that the majority of them contained tannins, alkaloids
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and flavonoids. These seven species were selected for further in-depth phytochemical
and pharmacological activity studies.
The crude extracts of five of the seven plants bio-assayed, showed significant
antiplasmodial activities, one species showed cytotoxicity, two species exhibited antiTrypanosoma brucei rhodesiense activity, six species exhibited TNF-α inhibitory
activities and all of them exhibited mild antimicrobial activity. The highest
antiplasmodial activity was exhibited by the chloroform extract of M. simplicifolia with
an IC50 value of 0.40 g/mL against the TM4/8.2 strain without cytotoxicity. The
chloroform extract of C. crispa showed moderate cytotoxicity with an IC50 value of
12.5 g/mL and the highest anti-inflammatory activities. The chloroform extracts of P.
amabile and also C. crispa exhibited moderate anti-Trypanosoma brucei rhodesiense
activity with IC50 values of 16.1 and 4.6 g/mL, respectively. The CH2Cl2 extract of P.
amabile showed the highest antibacterial activity with a MIC value of 312 µg/mL or a
MIZ value of 14 mm against B. subtilis.
Among the five different solvent extracts obtained from these seven plant species,
the CHCl3 extract consistently showed the best and the broadest range of biological
activities. This indicated that CHCl3 was the best solvent to extract a wide range of
secondary metabolites responsible for the broader spectrum of biological activities.
None of the crude plant extracts studied displayed any significant cytotoxicity thereby
confirming their safety profile for use in BTM. These preliminary phytochemical and
pharmacological results helped us to prioritize the candidate plant species for further indepth phytochemical and pharmacological investigations. These results are described in
detail in Chapters 4-9. Out of the seven plants selected for this study, six of them have
been analysed and described in this thesis.
Phytochemically, a total of 43 compounds were isolated from six medicinal
plants. Of these, 25 were alkaloids, nine were terpenoids, six were furanocoumarins,
two were flavones and one was a glycosylated flavone. From C. crispa (described in
Chapter 4), nine isoquinoline alkaloids 1-9 were isolated and protopine (1) was
identified as the major alkaloid. The characterization of compounds 2 and 3 with
complete NMR data analysis was described for the first time. Similarly, from C. dubia
(described in Chapter 5), another group of isoquinoline alkaloids 10-15 were isolated
along with the alkaloids 1 and 9 that were earlier reported from C. crispa. Alkaloid 15
was isolated as a new natural product which we named as dubiamine after the plant’s
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name (C. dubia) and its structure was confirmed from its single crystal X-ray structural
analysis. From A. nubigena (Chapter 6), nine compounds 19-26 belonging to
terpenoids, flavonoids and glycosylated flavones were isolated from the EO and the
crude methanol extract. While luteolin (25) was the major constituent of the MeOH
extract, (3R,6R)-linalool oxide acetate (19) was the major constituent (75.8 %) of the
EO. Out of 53 constituent peaks detected by GC/GC-MS, 45 of them were identified
with chamazulene (20) as a new sub-chemotype of the genus Ajania. From the MeOH
extract of M. simplicifolia, one new protoberberine alkaloid (27), protopine (1) as the
major alkaloid, and four benzophenanthridine type alkaloids (29-32) were isolated. The
new alkaloid was named as simplicifolianine after its plant species M. simplicifolia.
The GC/GC-MS identified 37 constituents from its essential oil with 14 of them (38%
of total oil) being fatty acid esters and dimethyl 1,4-benzenedicarboxylate (29.2%) as
the major constituent. From P. amabile, 10 known compounds were isolated for the
first time. Its essential oil yielded terpenoids (37-40) with (E)-isomyristicin (37) as the
major constituent, and the crude MeOH extract yielded furanocoumarins (41-46) with
bergapten as the major component. About 52 compounds were also identified by
GC/GC-MS analysis from the essential oil component of this plant. From A.
laciniatum, five known lycoctonine-type C19-diterpenoid alkaloids (54-58), with
pseudaconitine (54) as the major compound, were isolated. This plant is highly
poisonous and the compounds are known to be neurotoxins. Therefore, this plant needs
to be handled carefully and administered in strict doses after detoxification and
formulations with other ingredients.
Pharmacologically, the crude extracts of five of the seven plants studied
demonstrated various biological activities as described earlier and detailed in Chapter 3.
Based on these findings, the pure compounds isolated from the five studied plants were
also tested for various biological activities and the best outcomes are summarised in
Table 10.1. Among the active compounds (Table 10.1), protopine (1), cheilanthifoline
(11), scoulerine (14), luteolin-7-O-β-D-glucopyranoside (26) and simplicifolianine (27)
(highlighted in red and orange) exhibited highly significant antiplasmodial activities
against chloroquine sensitive and multidrug resistant strains of P. falciparum. They
were identified as antimalarial drug lead compounds. The most active was the new
protoberberine alkaloid 27 for which a patent has been filed by the National
Biodiversity of Bhutan.
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Table 10.1. Summary of the biological activities of the compounds isolated from five
medicinal plants.
Compounds

Antimalarial
(IC50 µg/mL)

Anti-Tbra
(IC50
µg/mL)

AChEb
MIR (nmol)

Anti-inflamc
(% inhibition)

Cytotoxicity
(IC50 µg/mL)

TM4

K1CB1

Protopine (1)

1.4

1.3

>10

0.1

25

Vero
>10

>10

KB

13-Oxoprotopine (2)

>12.5

>12.5

>10

1.3

-

>10

>10

Stylopine (4)
Coreximine (5)

>12.5
17.0

>12.5
21.0

>10
>25

0.1
1.5

-

>10
>25

>10
>25

Ochrobirine (7)

>25

>25

>25

0.1

20

>25

>25

Capnoidine (10)

>20

>20

>10

0.1

7

>10

>10

Cheilanthifoline (11)
Scoulerine (14)
(E)-spiroether (21)
Luteolin (25)
Luteolin-7-O-β-Dglucopyranoside (26)
Simplicifolianine (27)

0.9
1.7
7.3
6.2

1.2
1.0
8.8
6.3

>25
>10
NT
NT

0.3
0.001
NT
NT

5
1
NT
NT

>25
>10
>100
14.5

>25
>10
>100
14.3

2.8

2.1

NT

NT

NT

33.3

>45

0.7

1.2

NT

NT

NT

>25

>25

Isoapiol (38)

52.9

69.9

NT

NT

NT

>100

>100

Psoralen (41)

>18.6

16.4

NT

NT

NT

>18.6

>18.6

Isoimperatorin (43)

19.1

18.5

NT

NT

NT

>27.0

>27.0

Isopimpinellin (44)

19.5

15.6

NT

NT

NT

>24.6

>24.6

Oxypeucedanin hydrate (45)

24.9

18.7

NT

NT

NT

>30.4

>30.4

Oxypeucedanin methanolate
7.4
6.7
NT
NT
NT
>31.8
>31.8
(46)
a
b
c
Anti-Tbr: Anti-Trypanosoma brucei rhodesiense activity, AChE: Acetylcholinesterase inhibiton, Anti-inflam: Antiinflammatory activity. Coloured background: most active compounds that were identified as new drug leads.

Scoulerine (14) significantly inhibited acetylcholinesterase with a minimum
inhibitory requirement of 0.0015 nmol which is almost twofold better than
galanthamine (0.003 nmol), the currently used standard drug to treat Alzheimer’s
disease. Only protopine showed anti-inflammatory activity against TNF-α with a
statistically significant p-value of p<0.05. Apart from compounds 25 and 26, which
exhibited mild cytotoxicity, the other compounds were not cytotoxic.
In general, the biological activities of the crude extracts of the seven medicinal
plants and the selected pure compounds that we have studied were in alignment with
their ethnopharmacological uses. Thus, our studies have validated the use of these
plants in BTM either individually or in combination with other medicinal ingredients to
treat diseases (especially malaria) as described in the pharmacopoeia and the formulary
compendium of BTM. The low cytotoxicity of the compounds and the crude extracts
against human oral carcinoma KB cells and normal Vero epithelial cells makes the
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activity more interesting and further demonstrated the potential safety of these plants
for use in BTM.

10.2.

Future directions
Our analysis of the current medicinal plants procurement and consumption

pattern by MSP found that 16 LAMP, which can be collected within Bhutan, are
imported from India. Allowing Bhutanese farmers to collect those 16 species, rather
than importing them from India, would firstly help generate income for the farmers and
secondly, it would be easier to monitor the quality of these medicinal plants as many of
the imported plant materials are known for their adulteration and pesticide residues.
From the safety point of view, Aconites of any types in Bhutan needs regulation and
monitoring. Although, Chinese and Indian researchers have reported that the traditional
methods of detoxification efficiently reduce their toxicity, Bhutanese detoxification
methods need separate standardization and urgent toxicity studies.
From the biodiscovery perspectives, our compounds 1, 11, 14, 26 and 27 showed
the highest antimalarial activities. Thus, modifying their structures and carrying out
structure-activity relationship studies would be worthwhile. It would be also interesting
to carry out the antimalarial testing on various mixtures of these bioactive compounds
(listed in Table 10.1) which could potentially become more potent than the individual
compounds. Scoulerine (14) showed the best acetylcholinesterase inhibitory activity by
the TLC autographic method and its MIC values will be determined in future studies.
There were other minor compounds which we could not readily isolate and future
scale-up isolation of these minor components and determination of their biological
activities are essential. The phytochemical and pharmacological activity data that we
have generated can be used for developing a monograph for those seven studied
medicinal plants and will also serve as important quality parameters.
More than 229 medicinal plants are currently used in BTM and most of them
have not been scientifically studied. The methods that we have used in this study for
analysing seven plants can be applied for investigating these remaining medicinal
plants. It would be also worthwhile to carry out clinical trials on the formulations of
BTM involving those seven studied medicnal plants, as it could generate evidence for
the efficacy of currently prescribed medicines.
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CHAPTER 11
EXPERIMENTAL

Science is defined in various ways, but today it is generally restricted to something
which is experimental, which is repeatable, which can be predicted, and which is
falsifiable.
-Walter Lang
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11.1.

General methodologies for field work
Detailed information on BTM, which were described in Chapters 1 and 2, were

obtained from five selected BTM practitioners called Drung-tshos (Traditional
Physicians or Doctors) and Smen-pas (Traditional Clinical Assistants) with vast
experience in the areas of traditional clinical practices, herbal formulations, field
identification and collection of medicinal plants. They were interviewed using a
convenience sampling method and an open questionnaire followed by informal
discussions. The relevant literature on BTM and Tibetan medicine were consulted and
the current practices of BTM were also observed. The standardizations, botanical
identifications and field surveys of medicinal plants were undertaken in Bhutan
involving two main medicinal plant collection centres, Lingzhi and Trongsa. Lingzhi is
a collection centre for HAMP and Trongsa for LAMP. The standardizations and
botanical identifications described in Chapter 2 are related to LAMP that were collected
from 10 study areas in Bhutan. Prior to the field survey, a list of LAMP was drawn in
consultation with the procurement and formulation sections of Manjong Sorig
Pharnmaceuticals (MSP). During the field survey, the locations of the collection sites
and the altitudes were recorded using a GPS unit. Other standard data such as
vegetation, habitat description, other medicinal plants present, local plant name, locality
name and species abundance were also recorded at each field site on pre-prepared
forms. Herbarium specimens were pressed and prepared in triplicate, and authenticated
by Samten, (pharmacognost at MSP), Rebecca Pradhan (Ecologist at Royal Society for
Protection of Nature), Raling Ngawang (Chief Forest Officer). These specimens were
preserved at the Manjong Sorig Pharmaceuticals (MSP), ITMS in Bhutan after
assigning an accession number as reported in Chapter 2 (Table 2.1). From those
botanically standardized medicinal plants (HAMP and LAMP), 21 species were
selected for screening for their major classes of phytochemicals using the selection
criteria explained in Chapter 3. Based on this preliminary phytochemical screening
result, seven plants: A. laciniatum, A. nubegina, C. bhutanica, C. crispa, C. dubia, M.
simplicifolia, and P. amabile were selected and collected from the wild between JuneAugust 2009 from the Himalayan mountains of Bhutan for further phytochemical and
biological activity studies. The collected plant materials were dried at the drying unit in
Lingshi and transported to the MSP in Thimphu, Bhutan.
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The root of A. laciniatum was collected from the opposite site of Lingshi
Makhang (Altitude: 4183 m; Latitude: 27° 50' 29.9''; Longitude: 89° 25' 41.5''; global
positioning system point number (GPSPN): 138; Site number: P138; Slope: 25°;
Aspect: North-East). The herbarium voucher specimen number 93 was assigned to it.
The aerial components of A. nubegina were collected from Lingzhi in Bhutan and were
ascribed a herbarium specimen voucher number 73. The whole plant components of C.
bhutanica were collected from Lingzhi and this endemic plant of Bhutan was assigned
a herbarium voucher specimen number 71. The whole part of C. crispa was collected
from Thuphu (Altitude: 3962 m; Latitude: 27° 51' 15.4''; Longitude: 89° 27' 12.8'';
GPSPN: 187; Site number: P187; Slope: 40°; Aspect: South-East). The herbarium
voucher specimen number 78 was assigned to it. C. dubia (whole part) was collected
from Thruenchela (Altitude: 4651 m; Latitude: 27° 56' 00.1''; Longitude: 89° 26' 11.6'';
GPSPN: 167; Site number: P167; Slope: 30°; Aspect: North-West). The herbarium
voucher specimen was ascribed an accession number 78. M. simplicifolia (aerial
components) were collected from near the Lingzhi Makhang (Altitude: 4183 m;
Latitude: 27° 50' 29.9''; Longitude: 89° 25' 41.5''; GPSPN: 138; Site number: P138;
Slope: 25°; Aspect: North-East). The plant was ascribed the herbarium voucher
specimen number 2. P. amabile (aerial) was collected from Lingzhi at an altitude of
4200 m and the herbarium specimen voucher number 29 was assigned to it. The
methanol extracts of these seven plants UOW with approvals from various regulatory
bodies in Bhutan and Australia.

11.2. Laboratory experimental procedures
11.2.1. General phytochemical analytical techniques and tools
The screening of 25 selected medicinal plants for their major classes of
phytochemicals was carried out using the modified methods described by Harbourne
(1984). The detailed screening process, along with the reference compounds used, and
the results obtained were described in Chapter 3. Of the seven final plants, three of
them contained EO which were analysed using the methods described below.

11.2.1.1. GC and GC-MS methods for analysing the EO
The EO were obtained by hydrodistillation (temperature at 60 °C) of the dried
aerial plant materials using a Clevenger apparatus for three hours. The EO collected
161

Chapter 11: Experimental

was dried over anhydrous magnesium sulphate. The EO was analysed for its chemical
constituents using GC and GC-MS systems. The GC analysis was performed on a
Shimadzu GC-2010 Plus gas chromatograph. Hydrogen was used as carrier gas (1.5
mL/min at 40 °C in a constant total flow mode) and the separation was achieved using a
Restek fused silica capillary column (Rxi-5MS: 30 m × 0.25 mm i.d., 0.25 μm film
thickness). Injector and detector temperature were set at 260 °C and 300 °C,
respectively. The starting oven temperature was programmed at 40 °C with an
increasing temperature of 6 °C/min until it reached 290 °C. Kovats retention indices
(KI) were obtained by GC-FID analysis of an aliquot of the EO spiked with an n-alkane
mixture (C7 to C30). The GC-MS analysis was performed using Shimadzu QP5050A
GC-MS system (electron impact (EI) mode at 70 eV). The column and the GC-MS
chromatographic conditions were the same as that for GC but He was used as the
carrier gas. The EO constituents were identified by comparing their mass spectra with
the NIST and NISTREP mass spectra library of GC-MS data system and further
confirmed by comparing their Kovats indices (KI) with those reported by Adams
(1995) and other literature described in relevant Chapters.

11.2.1.2. MeOH extraction, fractionation and purification of phytochemicals
The air-dried plant material (2 kg) was chopped into small pieces and was
repeatedly extracted with the analytical grade or HPLC grade methanol (5 x 3 L over
48 h). The extract was filtered and then concentrated using a rotary evaporator at 35 °C50 °C to afford the crude methanol extracts of each of the seven selected medicinal
plants. The MeOH extracts were dissolved in MeOH:H2O (200 mL, 1:9), then
fractionated with different solvents (3 x 100 mL) including hexane, CH2Cl2, CHCl3,
EtOAc, n-BuOH to obtain the respective solvent extracts, and purified repeatedly using
flash column chromatography packed with Merck Kieselgel 60 PF254 (detailed in the
experimental section of each chapter). Aluminium-backed silica plates (0.2 mm silica
thickness, Merck, normal and reverse phase) were used for separating isolates of
smaller quantities. UV light (short wavelength of 254 nm, long wavelength of 366 nm)
was used for visualization of the separated bands on TLC. Dragendorff’s reagent was
prepared (Svendsen and Verpoorte, 1983) for staining the TLC plate loaded with
alkaloid fractions and pure compounds. Ceric ammonium molybdate (CAM) solution
was used for staining non-alkaloid compounds spotted on TLC plates.
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A Reichert hot-stage apparatus was used for determining the melting point of the
compounds and were not corrected. A JASCO 2000 Series polarimeter was used for
measuring the optical rotations of the compounds using a sodium lamp and averages of
ten optical readings were taken to obtain the observed rotation value. IR spectra were
obtained on neat samples using a Smart Omni-Sampler Avator ESP Nicolet
spectrometer. Micromass Waters Platform LCZ (single quadrupole, MeOH as solvent)
was used for obtaining the LR-ESI-MS. Shimadzu GCMS-QP-5050 was used for
recording the LR-EI-MS by the direct insertion technique (at 70 eV). A Micromass
Waters Q-ToF Ultima (quadrupole time-of-flight) mass spectrometer was used for
acquiring HR-ESI-MS.
A 500 MHz Varian Unity Inova, 500 MHz Varian Premium Shield (VNMRS PS
54), and 300 MHz Varian Mercury spectrometer were used for obtaining NMR spectra
(1H-NMR, gCOSY,

13

C-NMR, APT, gHMBC, gHSQC, and gNOESY) using

deuterated solvents (CD3OD or CDCl3) depending upon the solubility of compounds.
Solid compounds were crystallized from a mixed solvent system of
chloroform/methanol unless stated otherwise. The program PLATON was used to
analyse the single crystal structural data. Hydrogen atoms were included at calculated
positions and were initially refined with soft restraints on the bond lengths and angles
to regularize their geometry (C–H in the range 0.93-0.98Å) and on Uiso(H) (in the range
1.2-1.5 times Ueg of the parent atom), after which the positions were refined with riding
constraints and displacement parameters were held fixed. The largest peaks in the final
difference electron density map are located midway along C–C bonds. Computing
details include data collection: COLLECT; cell refinement and data reduction:
DENZO/SCALEPACK; program (s) used to solve structure: USER DEFINED
STRUCTURE SOLUTION; molecular graphics: ORTEP-II in TEXSAN; program(s)
used to refine structure and prepare material for publication: CRYSTALS. The X-ray
diffraction images were measured on a Nonius KappaCCD diffractometer (Mo Kθ
radiation, graphite monochromator, θ = 0.71073 Å) and data extracted using the
DENZO package (Otwinowski and Minor, 1997). Structure solution was by direct
methods (SUPERFLIP, SIR92) (Altomare et al, 1994; Palatinus and Chapuis, 2007).
The structures were refined using the CRYSTALS program package (Betteridge et al.,
2003). Atomic coordinates, bond lengths and angles and displacement parameters have
been deposited at the Cambridge Crystallographic Data Centre (CCDC no. 929725,
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929726). These data can be obtained from www.ccdc.cam.ac.uk/data_requerst/cif or by
emailing

data_request@ccdc.cam.ac.uk,

or

by

contacting

The

Cambridge

Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44
1223 336033.

11.2.2. General bioassay methods
While the antiplasmodial, cytotoxicity and the anti-Trypanosoma brucei
rhodesiense bioassays were performed by Dr. Aunchalee, Dr. Roonglawan and Dr.
Sumalee at BIOTEC of Thailand; the antimicrobial and anti-inflammatory testings were
carried out at Srinakharinwirot University in Thailand by Dr. Malai. The
acetylcholinesterase test was performed at the University of Wollongong.

11.2.2.1. Antiplasmodial test method
The hexane, CH2Cl2, CHCl3, MeOH, and H2O extracts of seven potential plants
and the selected pure compounds which we isolated from the crude extracts were
tested in vitro against Plasmodium falciparum strains, K1CB1 (K1), a multidrug
resistant (chloroquine and antifolate resistant) strain and TM4/8.2 (TM4), a wild type
(chloroquine and antifolate sensitive) strain. The parasites were maintained in human
red blood cells in RPMI 1640 medium supplemented with HEPES (25 mM), sodium
bicarbonate (0.2%), and human serum (8%) in a carbon dioxide (3%) gas incubator
maintained at 37 oC (Trager and Jensen, 1976). The test samples were made up in
DMSO solution and the in vitro antiplasmodial activity testing was carried out using
the Microdilution Radioisotope Technique (as detailed in Kamchonwongpaisan, 2004).
The test sample (25 L, in the culture medium) was placed in triplicate in a 96-well
plate where parasitised erythrocytes (200 L) with a cell suspension (1.5%) of
parasitemia (0.5-1%) were then added to the wells. The ranges of the final
concentrations of the samples varied from 2 x 10-5 to 1 x 10-7 M with 0.1% of the
organic solvent. The plates were then cultured under standard conditions for 24 h after
which 3H-hypoxanthine (25 l, 0.5 µCi) was added to the culture medium. The culture
was incubated (18-20 h) after which the DNA from the parasite was harvested from the
culture onto glass fibre filters and a liquid scintillation counter was used to determine
the

amount

of

3

H-hypoxanthine

incorporation

(Desjardins

et

al.,

1979;

Kamchonwongpaisan et al., 2004). The inhibitory concentration of the sample was
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determined from its dose-response curves or by calculation. The assay was performed
in at least three replicates. Chloroquine (Sigma company), pyrimethamine (Sigma
company) and cycloguanil were used as positive controls for both the plasmodial
strains.

11.2.2.2. Anti-Trypanosoma brucei rhodesiense assay method
Trypanosoma brucei rhodesiense (STIB-900) (Tbr) trypomastigotes (Gros et al.,
2006) were maintained under MEM/EBSS media supplemented with HEPES (25 mM),
glucose (4.5 g/L), NaHCO3 (3.0 g/L), MEM non-essential amino acids (1%), 2mercaptoethanol (0.2 mM), bathocuprionedisulphonic acid (0.05 mM), L-cysteine (0.15
mM), hypoxanthine (0.1 mM), sodium pyruvate (1 mM) and heated (37 °C) fetal
bovine serum (10%) in a CO2 (3%) atmosphere with humidity (95%). To assay antiTbr activity, 20,000 parasites/well with and without drug dilution were incubated (69 h)
in a microplate. Alamar blue (20 µL) was then added and further incubated (3 h). The
plate was read at ex530/em590 nm.

11.2.2.3. Cytotoxicity test method
Vero cells (kidney epithelial cells of African green monkey, Cecopithecus
aethiops) and KB cells (human oral carcinoma cells) were obtained from the bioassay
laboratory, BIOTEC, Thailand. Vero cells were maintained and cultured in
MEM/EBSS supplemented with heated fetal bovine serum (10%), NaHCO3 (2.2 g/L)
and the sodium pyruvate (1%). KB cell lines were cultured in DMEM/low glucose
supplemented with heated fetal bovine serum (10%), NaHCO3 (3.7 g/L) and NEAA
(1%). Cytotoxicity was evaluated by the sulforhodamine B (SRB) assay (OD510 nm).
Ellipticine and doxorubicin were used as positive control drugs for KB and Vero cells.

11.2.2.4. Anti-inflammatory test method
Cell culture and in vitro bioassays were performed as previously described
(Taweechotipatr et al, 2009). The THP-1 human monocytic cell lines (ATCC, TIB 202)
were maintained in RPMI 1640 (Gibco-Invitrogen, USA) supplemented with 10% fetal
bovine serum (Gibco-Invitrogen, USA) in tissue culture flasks (Corning, USA) and
were incubated (37 C in humidified 5% CO2 incubator). For bioassays, cells were
counted with a hemacytometer under an inverted microscope (Nikon TMS No. 300679:
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Nikon, Japan) and diluted to desired cell densities. THP-1 cells (200 µL) were seeded
in 96-well tissue culture plates (Corning, USA) at a final density of 2.5 x105 cells/mL.
Cells were incubated with crude plant extracts alone or in combination with puriﬁed
LPS (100 ng/mL) from Escherichia coli serotype O127 : B8 (Sigma, USA) for 3.5 hr.
Supernatants were collected from individual wells by centrifugation and assayed for
TNF-α.
The cell viability or the cytotoxic effects of crude extracts in THP-1 cells were
determined by the Trypan-blue (Gibco-Invitrogen, USA) stain exclusion assay. Cells
were incubated with varying concentration of crude extracts as 0, 25, 50, 100 and 200
µg/mL and that of pure compounds as 0, 1.95, 3.9, 7.8, 15.6 and 31.25 µg/mL. The
concentration that showed the highest cell viability (without significant cell reduction)
was chosen as the final concentration: for crude extracts (50 µg/mL) and pure
compounds (3.9 µg/mL). Cell suspension was mixed with Trypan Blue which stained
dead cells. The viable and dead cells were counted with a hemacytometer under an
inverted microscope. Cell viability was determined from the ratio of viable cells over
total cells. Results were expressed as means with standard deviations (± SD). The
percentage of cell viability was calculated by the formula: % Cell viability = 100 ×
(1−(dead cells/total cells).
TNF-α production in THP-1 cell culture supernatants were measured using
cytokine-specific

sandwich

quantitative

enzyme-linked

immunosorbent

assays

(ELISAs) according to the manufacturer’s instructions (R & D Systems, USA). The 96well microtiter plates (Corning, USA) were coated overnight with mouse anti-human
TNF-α antibody as capture antibodies. The plates were washed with PBST (0.05%
Tween 20) to remove excess capture antibody. To reduce non-specific binding, wells
were blocked for 2 hr with bovine serum album (BSA) (1% (w/v) of BSA; Sigma,
USA)) and washed with PBST. Recombinant human TNF-α was used as a standard at
the concentration of 15.6, 31.5, 62.5, 125, 250, 500, and 1000 pg/mL. The standard or
samples were added to appropriate wells and plates were incubated overnight. After
washing, biotinylated goat anti-human TNF-α antibodies were added as detection
antibodies and the mixture was incubated for 2 h. The plates were washed with PBST
and incubated for 20 min with streptavidin-horseradish peroxidase conjugate. The
tetramethylbenzidine (TMB) substrate was added to the plates as a color indicator and
was incubated for 20 min. H2SO4 was added to stop the reaction.
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Absorbance was measured at 450 nm using a BioTek® Synergy™ HT (MultiDetection Microplate Reader, USA). Cytokine concentration in each well was
quantified from a standard curve and expressed as pg/ml of culture medium. A
commercial anti-inflammatory drug, dexamethasone (10 µg/mL), (Atlantic LabsComp.
Ltd., Thailand) was used as a positive control. The experiments were performed three
times in triplicate (3x3). Results were expressed as means with standard deviations (±
SD). The percentage of TNF-α inhibition was calculated by the formula: % TNF-α
inhibition = 100 × ((observed/baseline) − 1). Where observed = secreted TNF-α of
experiment (pg/mL) and baseline = secreted TNF-α of DMSO (pg/mL). Statistical
significance or differences were evaluated by GraphPad Prism version 5.01 using
Student’s t-test with one-tailed distribution. A p-value ≤ 0.05 was considered
statistically significant.

11.2.2.5. Antimicrobial test methods.
The antimicrobial assay was prepared and performed using the test organisms:
Escherichia coli (ATCC 25922), Bacillus subtilis (ATCC 6633), Staphylococcus
aureus (ATCC 6538), methicillin resistant S. aureus (MRSA), (DMST 20651), S.
epidermidis (ATCC 12228), Vibrio cholerae (DMST 2873), Helicobacter pylori (H40)
and Candida albicans (ATCC 10231). MRSA and V. cholerae were provided by the
Department of Medical Science, Ministry of Public Health, Thailand. The clinical
isolate of H. pylori was obtained from Chulalongkorn University, Thailand. Fungal
strain, C. albicans was grown on Sabouraud Dextrose Agar (SDA) (Becton Dickinson,
USA) and incubated (25 °C, 24-48 h). H. pylori was grown on Brain Heart Infusion
(BHI) agar (Becton Dickinson, USA) supplemented with horse serum (10%) (GIBCO
Invitrogen, England) and incubated (at 37 °C for 3 days) under micro-aerobic
conditions (5% O2, 10% CO2, 85% N2) generated by using a micro-aerobic GasPak
(Mitsubishi, Japan) in an anaerobic jar (Mitsubishi, Japan). Other bacterial strains were
grown on Mueller Hinton Agar (MHA) (Becton Dickinson, USA) under aerobic
conditions (37 °C, 24 h). The inocula of test organisms were prepared in appropriate
broth by adjusting to the McFarland standard.
Antimicrobial activities of plant extracts were determined by a modified agar well
diffusion method as previously described in the literature (Perez et al., 1990; Mattana et
al., 2010). Based on this method, the culture media for each organism was poured into
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each plate and allowed to solidify. Cultures of E. coli, B. subtilis, S. aureus, S.
epidermidis, MRSA, V. cholerae (approx. 1 x 107 CFU/mL each), C. albicans (1 x 108
CFU/mL) and H. pylori (1 x 109 CFU/mL) were inoculated on the surface plates in an
appropriate broth. Circular wells (4 mm diameter) were made in the agar using a sterile
cork borer. Subsequently, extracts (50 µL each) was filled in each well. The plates were
incubated at appropriate conditions of organisms as described above. The diameters of
the inhibition zones around the well showing no growth of organisms were measured
and recorded in millimeters (mm). The organic solvent extracts of the plants and the
standard antibiotics were diluted in DMSO, and the aqueous extracts of the plants were
diluted in distilled water.
To measure the minimum inhibitory concentration (MIC), a serial two-fold
dilution of each active extract were made in 96-well microtiter plates (Corning, USA)
in an initial concentration of 5 mg/mL. The suspension of each microorganism (1 x 106
CFU/mL) was added in each well in equal volume of extract (50 µL). Microtiter plates
were incubated in appropriate conditions of microorganisms as described above. The
MIC was observed as the lowest concentration of extract, which inhibited growth of
microorganism at that level of concentration. The MIC of active extracts was further
examined by the broth microdilution method as described in the literature (Wayne,
1997; Goyal et al., 2009) but with slight modification. Amphotericin B (SigmaAldrich,USA),

vancomycin

(Edicin,

Slovenia)

and

amoxicillin

(Government

Pharmaceutical Organization, Thailand) were used as standards against fungi, MRSA
and other bacterial strains, respectively. DMSO and distilled water were used as
controls. The experiments were performed three times in duplicate.

11.2.2.6. Acetylcolinesterase inhibitory assay method
A rapid TLC bioautographic method described by Marston et al. (2002) was
used for acetylcholinesterase (AChE) inhibitory testing of pure compounds. A mixture
of two solvents, chloroform (80%) and methanol (20%), was used for a serial two-fold
dilution of each test sample. Galanthamine, which is a frontline AChE inhibitor used to
treat Alzheimer’s disease, was used here as a reference compound. The tests were
performed in triplicate.

168

Chapter 11: Experimental

11.2.3. Experimental section of Chapter 4 (Corydalis crispa)
11.2.3.1. Alkaloid isolation and identification
The MeOH extract (90 g) was acidified with 5% HCl and then subjected to
sequential fractionation and extraction using hexane (5 x 60 mL) and CH2Cl2 (5 x 60
mL) as shown in Scheme 4.1, Chapter 4. Two fractionated extracts were concentrated
resulting in the hexane extract (1.34 g) and the CH2Cl2 extract (2.90 g). The remaining
acidified aqueous solution was basified (pH 9-11) with NH4OH solution, then extracted
with CHCl3 (5  60 mL). The CHCl3 extract was washed (H2O), dried (Na2SO4) and
the solvent was evaporated under reduced pressure to yield a crude CHCl3 alkaloid
extract (1.34 g). Focusing on alkaloids, the crude basic CHCl3 extract was subjected to
fractional crystallization as a first line of separation and purification processes. The
crude alkaloid (CHCl3) extract was dissolved in CHCl3 (~7.0 mL) and added MeOH
(1.5 mL) and left standing for 3 days in air tight container. This yielded white
precipitates which upon further crystallisation with MeOH/CHCl3 (1:1 % v/v) gave
colourless prisms (123 mg), which was identified as protopine (1). The mother liquors
from these different fractional crystallization processes were combined and purified
repeatedly using flash column chromatography (CC) over silica gel (200-300 mesh).
The initial CC over silica gel (120 g), eluting with a gradient solvent system of MeOHCH2Cl2 (250 mL in a v/v% ratio of 0:100, 0.7:99.3, 1.3:98.7, 3.3:96.7, 5.3:94.7,
7.3:92.7, 9.3:90.7, 11.3:88.7, 15.5:84.7, 20.0:80.0, 30.0:70.0), yielded fractions CHCl3F1 to CHCl3-F15. Fraction CHCl3-F15 (60 mg) was separated by CC with a gradient
solvent system of MeOH-CHCl3 (50 mL, v/v ratio of 10:90, 20:80, 25:75, 30:70, 40:60)
to obtain sub-fractions CHCl3-F15.1 to CHCl3-F15.6. Fractions CHCl3-F15.4 and
CHCl3-F15.5 were combined and separated using PTLC and with a mobile phase
system of MeOH-CHCl3-NH4OH (1:3:6 drops) which yielded 13-oxoprotopine (2) and
13-oxocryptopine (3). Fractions CHCl3-F1 gave positive test for alkaloids and upon
separation using CC with a gradient solvent system of MeOH-CHCl3 (200 mL, v/v%
ratio of 0:100, 1:99, 2:98, 3:97, 4:96, 5:95, 10:90, 20:80, 30:70) yielded stylopine (4).
Fractions CHCl3-F4 to CHCl3-F7 contained compounds of same mass (detected by LRESI-MS) and similar Rf values and were combined (161.6 mg combined weight) and
separated by CC with a gradient solvent system of MeOH-EtOAc (200 mL, v/v% ratio
of 0:100, 2:98, 4:96, 8:92, 14:86) to obtain sub-fractions CHCl3-F47.1 to CHCl3-F47.5.
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The final separation of sub-fraction CHCl3-F47-3 (23.1 mg) using PTLC and a mobile
phase system of MeOH-CHCl3 (v/v ratio of 2:98) yielded coreximine (5).
Similarly, the crude CH2Cl2 extract was dissolved in CHCl3 (~10 mL) and MeOH
(~100 µL) was slowly added and left standing for 5 days. Colourless crystals were
obtained from this process and the compound was identified as ochrobirine (7) (61 mg).
The initial CC of the remaining material with a gradient solvent system of MeOHCH2Cl2 (300 mL in a v/v% ratio of 0:100, 1:99, 3:97, 5:95, 7:93, 9:91, 15:85, 20:80,
25:75, 30:70) yielded fractions CH2Cl2-F1 to CH2Cl2-F9. Final separation of subfraction CH2Cl2-F47-2 using PTLC and the mobile phase system of MeOH-CHCl3 (v/v
ratio of 2:98) yielded a reddish solid compound, which was identified as rheagenine
(6). Fractions CH2Cl2-F8 was separated by CC with gradient solvent system (200 mL,
v/v ratio of 1:99, 5:95, 10:90, 15:85, 20:80, 30:70) which yielded sibiricine (8) and
bicuculline (9). These nine isoquinoline alkaloids 1–9 (Figure 4.1) isolated from C.
crispa using Scheme 4.1 described in Chapter 4 and their characterisations are
presented below.

11.2.3.2. Characterisation data for each alkaloid
The chemical shifts of both 1H- and

13

C-NMR (applies to all the experimental

sections) are presented in order of structural numbered format of ascending order. This
is because it is easy to follow while assigning the chemical shift to the numbered
structure of a compound and also while comparing the chemical shifts with the reported
structure in numbered format. As most of the compounds isolated here were known,
following the order of ascending number pattern of the structure of a compound was
easier and can be easily understood.

Protopine (1)
Prisms (MeOH/CHCl3, 1.0 g). mp: 209-211 °C (Lit. 203.7-207.8 °C (Wangchuk
et al., 2010a)). Optically inactive. LR-ESI-MS (m/z) 354 [M + H+]. LR-EI-MS (m/z):
353 [M+], 295, 281, 267, 251, 237, 223, 209, 190, 177, 163, 148 (100%), 134 and this
ion fragmentation pattern matched that of protopine reported in the MS library
(NIST08s, Entry # 26245, CAS: 130-86-9, RetIndex: 2943). HR-ESI-MS (molecular
formula): C20H19NO5. 1H-NMR (500 MHz, CDCl3):  6.90 (1H, s, H-1), 6.64 (1H, s, H4), 2.65 (2H, br s, H-5), 2.59 (2H, br s, H-6), 3.61 (2H, br s, H-8), 6.68 (1H, d, J = 7.5
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Hz, H-11), 6.66 (1H, d, J = 8.0 Hz, H-12), 3.75 (2H, br s, H-13), 5.94 (2H, s, 2,3OCH2O), 5.92 (2H, s, 9,10-OCH2O), 1.96 (3H, s, 7-NCH3).

13

C-NMR (125 MHz,

CDCl3):  108.0 (C-1), 145.9 (C-2), 148.0 (C-3), 110.3 (C-4), 132.7 (C-4'), 31.5 (C-5),
57.6 (C-6), 50.9 (C-8), 117.5 (C-8'), 146.2 (C-9), 146.0 (C-10), 106.8 (C-11), 124.9 (C12), 128.7 (C-12'), 46.1 (C-13), 194.3 (C-14), 136.0 (C-14'), 101.2 (2,3-OCH2O), 41.5
(7-N-CH3), 100.9 (9,10-OCH2O). These 1H-NMR and 13C-NMR data agreed with those
reported in the literature (Takahashi et al., 1985; Seger et al., 2004).

13-Oxoprotopine (2)
Amorphous solid (17.6 mg). mp: 226-228 °C (Lit. 226-230 °C (Hanus et al.,
1967)). Optically inactive. LR-ESI-MS (m/z): 368 [M+H+]. LR-EI-MS (m/z): 367 [M+],
295, 279, 257, 237, 209, 190, 162 (100%), 149, and 134. HR-ESI-MS (molecular
formula): C20H17NO6. 1H-NMR (500 MHz, CD3OD):  7.22 (1H, s, H-1), 6.64 (1H, s,
H-4), 2.92-3.10 (2H, m, H-5), 4.33-4.68 (2H, m, H-6), 3.45-3.63 (2H, m, H-8), 7.00
(1H, d, J = 8.5 Hz, H-11), 7.72 (1H, d, J = 8.5 Hz, H-12), 5.96 (2H, s, 2,3-OCH2O),
6.17 (2H, d, J = 11.5 Hz, 9,10-OCH2O), 2.71 (3H, s, 7-NCH3).

13

C-NMR (125 MHz,

CD3OD):  110.9 (C-1), 145.9 (C-2), 148.1 (C-3), 108.4 (C-4), 122.0 (C-4'), 25.8 (C-5),
53.3 (C-6), 53.0 (C-8), 120.0 (C-8'), 149.7 (C-9), 142.0 (C-10), 109.8 (C-11), 125.9 (C12), 126.0 (C-12'), 191.8 (C-13), 191.8 (C-14), 131.5 (C-14'), 43.1 (7-N-CH3), 102.6
(2,3-OCH2O), 104.6 (9,10-OCH2O).
13-Oxocryptopine (3)
Amorphous solid (4.5 mg). mp: 180-183 °C (Lit. 185-186 °C (Guinaudeau and
Shamma, 1982)). Optically inactive. LR-ESI-MS (m/z): 384 [M+H+]. LR-EI-MS (m/z):
383 [M+], 340, 312, 297, 277, 253, 220, 204, 190, 162 (100%), 149 and 134. HR-ESIMS (molecular formula): C21H21NO6. IR: νmax 792, 939, 1042, 1239, 1365, 1454, 1484,
1656 cm-1. 1H-NMR (500 MHz, CDCl3):  7.50 (1H, s, H-1), 6.71 (1H, s, H-4), 1.241.64 (2H, m, H-5), 2.55-2.75 (2H, m, H-6), 3.47-3.75 (2H, m, H-8), 6.83 (1H, d, J = 8.5
Hz, H-11), 7.49 (1H, d, J = 8.5 Hz, H-12), 1.86 (3H, s, 7-NCH3); 3.96 (3H, s, 2-OCH3),
3.91 (3H, s, 3-OCH3), 6.06 (2H, s, 9,10-OCH2O and these 1H-NMR data agreed with
those reported (Brochmann-Hanssen et al., 1970).

C-NMR (125 MHz, CDCl3): 

13

111.9 (C-1), 147.0 (C-2), 150.6 (C-3), 112.4 (C-4), 130.1 (C-4'): 29.2 (C-5), 46.0 (C-6),
50.1 (C-8), 120.0 (C-8'), 145.2 (C-9), 142.0 (C-10), 109.8 (C-11), 125.9 (C-12), 128.1
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(C-12'), 182.0 (C-13), 191.7 (C-14), 131.5 (C-14'), 42.1 (7-N-CH3), 56.0 (2-OCH3),
55.9 (3-OCH3), 101.9 (9,10-OCH2O).
Stylopine (4)
Amorphous solid (5 mg). mp: 197-199 °C (Lit. 163-165 °C (Wangchuk et al.,
2010a)). LR-ESI-MS (m/z): 324 [M + H+]. LR-EI-MS (m/z): 323 [M+], 204, 174, 148
(100%) and this ion fragmentation pattern matched that of stylopine reported in the MS
library (NIST08, Entry # 127880, CAS: 4312-32-7, RetIndex: 2612). HR-ESI-MS
(molecular formula): C19H17NO4. 1H-NMR (500 MHz, CDCl3):  6.72 (1H, s, H-1),
6.58 (1H, s, H-4), 2.63-3.12 (2H, m, H-5), 2.80-3.22 (2H, m, H-6), 3.53 (2H, d, J =
15.5 Hz, H-8), 6.67 (1H, d, J = 8.0 Hz, H-11), 6.62 (1H, d, J = 8.0 Hz, H-12), 2.81 and
3.23 (2H, dd, J = 15.5, 16.0 Hz, Ha-13, Hb-13), 5.91 (2H, s, 2,3-OCH2O), 5.95 (2H, s,
9,10-OCH2O).

13

C-NMR (125 MHz, CDCl3): δ 105.6 (C-1), 145.0 (C-2), 146.2 (C-3),

108.4 (C-4), 127.8 (C-4'), 29.6 (C-5), 51.2 (C-6), 52.9 (C-8), 116.9 (C-8'), 146.0 (C-9),
149.9 (C-10), 107.3 (C-11), 125.9 (C-12), 128.1 (C-12'), 182.0 (C-13), 191.9 (C-14),
131.0 (C-14'), 100.8 (2,3-OCH2O), 101.1 (9,10-OCH2O). These 1H-NMR and the 13CNMR data were identical to those reported (Narasimhan et al., 1983; Chrzanowska,
1995; Lee et al., 2005).

Coreximine (5)
Papery shiny solid (1 mg). mp: 238-242 °C (Lit. 240-241 °C (Costa et al.,
2009)). LR-ESI-MS (m/z): 328 [M + H+]. LR-EI-MS (m/z): 327 [M+], 310, 298, 178
(100%), 163, 150, 135, 121, 107, 91, 77 and this ion fragmentation pattern matched that
of coreximine reported in the MS library (NIST08.LIB, Entry # 130643, CAS: 483-454, RetIndex: 2744). HR-ESI-MS (molecular formula): C19H21NO4. Material available
was insufficient for NMR analysis.

Rheagenine (6)
Red solid (1 mg). mp: 203.7-207.8 °C (Lit. 236-238 °C (Forgacs and Provost,
1985)). LR-ESI-MS (m/z): 370 [M+H+]. LR-EI-MS: m/z 369 [M+], 308, 279, 206
(100%), 192, 177, 162, 148, 135, 91, 77 and this ion fragmentation pattern matched that
of rheagenine reported in the MS library (NIST08.LIB, Entry # 154981, CAS: 5574-77-
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6, RetIndex: 2971). HR-ESI-MS (molecular formula): C20H19NO6). Material available
was insufficient for NMR analysis.

Ochrobirine (7)
Prisms (MeOH/CHCl3, (60.6 mg)); mp: 203-207 °C (Lit. 198 °C (Preisner and
Shamma, 1980)). []D25 + 38.7° (c 0.36, CHCl3) (Lit. []D21 + 36° (c 1.8, CHCl3)
(Preisner and Shamma, 1980)). LR-ESI-MS (m/z): 370 [M+H+]. LR-EI-MS (m/z): 369
[M+], 351, 336, 322 (100%), 293, 264, 204, 190 and this ion fragmentation pattern
matched that of ochrobirine in the MS library (NIST08.LIB, Entry # 154984, CAS:
24181-64-4, RetIndex: 3185). HR-ESI-MS (molecular formula): C20H19NO6. 1H-NMR
(500 MHz, CDCl3):  6.85 (1H, s, H-1), 6.64 (1H, s, H-4), 2.54 (2H, br s, H-5), 3.25
(2H, br s, H-6), 4.87 (2H, s, H-8), 6.03 (1H, s, H-11), 6.87 (1H, s, H-12), 5.42 (2H, d, J
= 10.5 Hz, H-13), 2.66 (3H, s, N-CH3), 5.83 (2H, s, 2,3-OCH2O), 6.01 (2H, s, 9,10OCH2O). 13C-NMR (125 MHz, CDCl3):  109.4 (C-1), 145.8 (C-2), 146.3 (C-3), 109.8
(C-4), 126.0 (C-4'), 22.5 (C-5),  47.4 (C-6), 73.7 (C-8), 121.0 (C-8'), 144.2 (C-9),
148.3 (C-10), 106.7 (C-11), 116.0 (C-12), 140.0 (C-12'), 79.5 (C-13), 75.0 (C-14),
129.5 (C-14'), 37.5 (N-CH3), 100.8 (2,3-OCH2O), 101.6 (9,10-OCH2O). These 1HNMR and the 13C-NMR data agreed with those reported in the literature (Manske et al.,
1969b; Margvelashvili et al., 1978; Shah et al., 1989).

Sibiricine (8)
Amorphous solid (0.8 mg). mp: 213.7-216.8 °C (Lit. 225 °C (Manske et al.,
1969a)). Optically inactive. LR-ESI-MS (m/z): 368 [M+H+]. LR-EI-MS (m/z): 367
[M+] (100%), 352, 336, 322, 295, 264, 204, 190, 149; this ion fragmentation pattern
matched that of sibiricine reported in the MS library (NIST08.LIB, Entry # 153896,
CAS: 24181-66-6, RetIndex: 3168). HR-ESI-MS (molecular formula): C20H17NO6. 1HNMR (500 MHz, CDCl3):  6.08 (1H, s, H-1, ArH), 6.57 (1H, s, H-4, ArH), 2.28 (2H,
br s, H-5), 3.87 (2H, br s, H-6), 7.01 (d, J = 8.0 Hz, H-11), 7.46 (d, J = 8.0 Hz, H-12),
5.84 (1H, s, H-13, proton geminal to hydroxyl group), 2.43 (3H, s, N-CH3), 5.84 (2H, s,
2,3-OCH2O),

6.18 (2H, s, 9,10-OCH2O). These 1H-NMR data agreed with those

reported in the literature (Manske et al., 1969a; Preisner and Shamma, 1980).
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Bicuculline (9)
Amorphous solid (8 mg). mp: 204.5-205.6 ºC (Lit. 199-200 °C (Basha et al.,
2002)). []D25 + 127.2° (c 0.07, CHCl3) (Lit. []D25 + 131° (c 1.6, CHCl3) (Edwards
and Handa, 1961)). LR-ESI-MS (m/z): 368 [M+H+]. LR-EI-MS (m/z): 367 [M+], 206,
190 (100%), 175, 149 and this ion fragmentation pattern matched that of bicuculline
reported in the MS library (NIST08.LIB, Entry # 153894, CAS: 485-49-4, RetIndex:
3142). HR-ESI-MS (molecular formula): C20H17NO6. 1H-NMR (500 MHz, CDCl3): 
4.03 (1H, d, J = 4.0 Hz, H-1), 2.21-2.85 (4H, m, H-3/H-4), 6.47 (1H, s, H-5), 6.57 (1H,
s, H-8), 5.55 (1H, d, J = 4.0 Hz, H-9), 6.18 (2H, d, J = 8.0 Hz, H-10), 6.91 (2H, d, J =
8.0 Hz, H-11), 2.54 (3H, s, N-CH3), 5.93 (2H, s, OCH2O, Ring A), 6.15 (2H, s,
OCH2O, Ring D).

13

C-NMR (125 MHz, CDCl3, prominent carbon peaks):  45.5 (N-

CH3), 101.1 (OCH2O, Ring A), 103.4 (OCH2O, Ring D), 168.0 (C=O). These 1H-NMR
and

13

C-NMR spectroscopy data agreed with those reported (Edwards and Handa,

1961).

11.2.4. Experimental section for Chapter 5 (Corydalis dubia)
11.2.4.1. Extraction, isolation and identification of alkaloids
The extraction and separation of the alkaloids from the crude methanol extract
(65.12 g obtained from 2 kg dry plant material) was undertaken via an acid/base
extraction procedure described in section 11.2.3.1. This protocol furnished the CH2Cl2
extract (17.87 g) which contained a mixture of acidic and neutral compounds and the
CHCl3 extract (1.13 g) which contained the basic alkaloids. Acid-base fractionations of
the crude MeOH extract yielded three different solvent extracts including the CH2Cl2
extract, the CHCl3 extract and the BuOH extract (see Scheme 5.1). Focusing on the
alkaloids, the basic CHCl3 extract was chromatographed on a silica gel column, eluting
with a gradient solvent system of MeOH-CHCl3 to obtain fractions F1-F11. Fraction
F4, upon crystallization from CHCl3/MeOH (1:1), yielded capnoidine (10). Its mother
liquor was subjected to column chromatography and elution with a gradient solvent
system of MeOH-CHCl3 obtained five sub-fractions F4.1-F4.5. The separation of these
sub-fractions F4.2, F4.3, F4.4 and F4.5 using PTLC plates (mobile phase; CHCl3/ethyl
acetate/NH4OH) (55:45:4 drops) yielded cheilanthifoline (11), bicuculline (9),
corydecumbine (12) and hydrastine (13). Fraction F7 was crystallized from the ethyl
acetate/hexane (1:1) which gave protopine (1), the major alkaloid of this plant.
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Fractions 5 and 6 were combined as F56 and then separated by the column
chromatography with a gradient solvent system of ethyl acetate-CHCl3 to obtain subfractions F56.1-F56.6. Further separation of sub-fraction F56.2 on PTLC plates (mobile
phase; CHCl3/ethyl acetate (55:45)) gave scoulerine (14). Crystallization of the subfraction F56.3 from CHCl3/MeOH (1:1) furnished compound 15 which we identified as
a new natural product and named it as dubiamine after the name of the plant species.

11.2.4.2. Characterisation data for each alkaloid
Protopine (1).
Prismatic crystals (MeOH/CHCl3, 160 g). The melting point, LR-ESI-MS, LREI-MS, HR-ESI-MS and the NMR spectroscopic data were same as those reported in
section 11.2.3.2 for this compound.

Bicuculline (9).
Amorphous solid (18.3 mg). The LR-ESI-MS, LR-EI-MS, HR-ESI-MS and the
NMR spectroscopic data were same as those reported in section 11.2.3.2 for this
compound.

Capnoidine (10)
Orthorhombic crystal (80.3 mg). LR-ESI-MS (m/z): 368 [M+H+]. LR-EI-MS
(m/z): 367 [M+], 207, 190 (100%), 175, 160, 149, 131, 117, 103 and this ion
fragmentation pattern matched that of capnoidine reported in the MS library
(NIST08.LIB, Entry # 153894, CAS: 485-49-4, RetIndex: 3142. HR-ESI-MS
(molecular formula): C20H17NO6. 1H-NMR (500 MHz, CDCl3):  4.02 (1H, d, J = 3.0
Hz, H-1), 3.05-3.07 (2H, m, H-3),  2.44-2.74 (1H, m, H-4), 6.40 (1H, s, H-5), 6.67
(1H, s, H-8), 5.62 (1H, d, J = 3.0 Hz, H-9), 6.94 (1H, d, J = 7.5 Hz, H-10), 7.14 (1H, d,
J = 8.0 Hz, H-11), 2.53 (3H, s, N-CH3), 5.84 (2H, s, OCH2O), 6.10 (2H, s, OCH2O).
C-NMR (125 MHz, CDCl3):  66.2 (C-1), 51.4 (C-3), 29.2 (C-4), 125.2 (C-4a), 108.2

13

(C-5), 146.4 (C-6), 146.0 (C-7), 107.6 (C-8), 130.1 (C-8a), 82.9 (C-9), 140.9 (C-9a),
116.0 (C-10), 113.0 (C-11), 148.9 (12), 144.2 (C-13), 110.0 (C-13a), 45.1 (N-CH3),
100.9 (OCH2O) 103.2 (OCH2O), 167.5 (C=O). These 1H-NMR and

13

C-NMR data

agreed with those reported in the literature (Blasko et al., 1982; Ribar and Meszaros,
1991; Pilar et al., 2010).
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Cheilanthifoline (11)
Amorphous solid (15.1 mg). LR-ESI-MS (m/z): 326 [M+H+]. LR-EI-MS (m/z):
325 [M+], 310, 190, 176, 162, 149, 148 (100%), 133, 119 and this ion fragmentation
pattern matched that of cheilanthifoline reported in the MS library (NIST08.LIB, Entry
# 129214, CAS: 483-44-3, RetIndex: 2678). HR-ESI-MS (molecular formula):
C19H19NO4. 1H-NMR (CDCl3, 500 MHz):  6.59 (1H, s, H-1), 6.81 (1H, s, H-4), 2.633.14 (2H, m, H-5), 2.77 (1H, t, J = 14.5 Hz, Ha-6), 3.25 (1H, d, J = 16.0 Hz, Hb-6), 4.09
(2H, d, J = 15.5 Hz, C-8), 6.67 (1H, d, J = 8.5 Hz, H-11), 6.63 (1H, d, J = 8.5 Hz, H12), 3.53 (2H, d, J = 15.5 Hz, H-13), 3.87 (3H, s, OMe), 5.93 (2H, d, J = 16.5 Hz,
OCH2O), 1.65 (br s, OH). 13C-NMR (125 MHz, CDCl3):  106.8 (C-1), 145.2 (C-2),
145.0 (C-3), 110.7 (C-4), 130.5 (C-4a), 29.3 (C-5), 51.6 (C-6), 53.1 (C-8), 117.0 (C8a), 144.1 (C-9), 143.3 (C-10), 111.5 (C-11), 121.2 (C-12), 128.8 (C-12a), 36.4 (C-13),
59.5 (C-14), 126.1 (C-14a), 101.1 (OCH2O), 56.0 (OMe). These 1H-NMR and

13

C-

NMR spectroscopic data agreed with those reported in the literature (Okamoto et al.,
1971; Haisova and Slavik, 1973; Yeola and Mali, 1984; Rucker et al., 1994; Cheng et
al., 2008; Blasko et al., 1981).

Corydecumbine (12)
Amorphous creamy crystalline solid (12.3 mg). LR-ESI-MS (m/z): 370 [M+H+].
LR-EI-MS (m/z): 367 [M+] and HR-ESI-MS (molecular formula): C20H19NO6. 1HNMR (500 MHz, CDCl3):  3.68 (1H, br s, H-1), 2.52-3.01 (2H, m, H-3), 2.46-3.20
(2H, m H-4), 6.60 (1H, br s, H-5), 5.29 (1H, br s, H-9), 6.84 (H-3', s), 6.84 (H-6', s),
6.25 (H-7', s) 1.95 (3H, s, N-CH3), 5.90 and 5.94 (2 x s, OCH2O, Ring A), 6.04 and
6.08 (2 x s, OCH2O, Ring D). 13C-NMR (125 MHz, CDCl3):  68.7 (C-1), 54.0 (C-3),
29.4 (C-4), 128.7 (C-4a), 108.3 (C-5), 146.5 (C-6), 146.2 (C-7), 107.0 (C-8), 130.7 (C8a), 89.9 (C-9), 135.3 (C-1'), 124.2 (C-2'), 113.9 (C-3'), 148.3 (C-4'), 143.8 (C-5'),
109.0 (C-6'), 97.8 (C-7'), 46.9 (NCH3), 101.0 (OCH2O, Ring A), 102.0 (OCH2O, Ring
D). These 1H-NMR and

13

C-NMR data agreed with those reported in the literature

(Basnet et al., 1993).

Hydrastine (13).
Amorphous solid (1.3 mg). LR-ESI-MS (m/z): 384 [M+H+]. LR-EI-MS (m/z):
190 (100%), 149, 117 and this ion fragmentation pattern matched that of hydrastine
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reported in the MS library (NIST08.LIB, Entry # 269564, CAS: 118-8-1, RetIndex:
3176. HR-ESI-MS (molecular formula) C21H21NO6. Material available was insufficient
for NMR analysis.

Scoulerine (14)
Reddish brown solid (9.4 mg). LR-EI-MS: m/z 327 (M+), 326, 312, 178 (100%),
176, 163, 150, 150, 135, 121 and 107. HR-EIMS (molecular formula): C19H21NO4. 1HNMR (CDCl3, 500 MHz):  6.82 (1H, s H-1), 6.59 (1H, s, H-4), 2.67-3.14 (2H, m, H5), 2.61-3.19 (2H, m, H-6), 3.48 (1H, d, J = 15.5 Hz, Ha-8) and 4.24 (1H, d, J = 15.5
Hz, Hb-8), 6.72 (1H, d, J = 8.0 Hz, H-11), 6.67 (1H, d, J = 8.0 Hz, H-12), 2.78-2.84
(1H, m, Ha-13) and 3.25 (1H, d, J = 16.5, Hb-13), 3.54 (1H, br s, H-13a), 3.86 (3H, s, 3MeO), 3.87 (3H, s, 10-MeO).

13

C-NMR (125 MHz, CDCl3):  109.1 (C-1), 145.1 (C-

2), 144.1 (C-3), 111.5 (C-4), 130.8 (C-4a), 29.3 (C-5), 51.7 (C-6), 53.6 (C-8), 121.3 (C8a), 141.6 (C-9), 144.0 (C-10), 110.8 (C-11), 119.5 (C-12), 128.3 (C-12a), 36.4 (C-13),
59.3 (C-13a), 126.2 (C-13b), 56.3 (3-OCH3), 56.2 (10-OCH3). The 1H-NMR and

13

C-

NMR data agreed with those reported in the literature for scoulerine (BrochmanHanssen and Nielson 1966; Cheng et al., 2008).

Dubiamine (15)
Colorless needle-like crystals (CHCl3/MeOH) (6.9 mg). mp: 192.8-194.6 °C.
ESI-MS (m/z) 300 [M + H+]. EI-MS (m/z): 299 [M+], 298, 192, 176, 164, 148 (100%),
134, 121, 107. HR-ESI-MS (molecular formula): C18H21NO3. For 1H-NMR and

13

C-

NMR see Table 5.1. The structure of 15 (Figure 5.1) was confirmed from the analysis
of its single crystal X-ray crystallographic data (Figure 5.2): (C18H21NO3), Mr 299.37.
Monoclinic, P21/n, a = 6.4140 (1) Å, b = 13.0324 (3) Å, c = 19.2120 (4) Å, β = 98.8791
(11)°, V = 1586.68 (6) Å3, Z = 4, F (000) = 640, Dx = 1.253 Mg m–3, MoKα radiation, λ
= 0.71073 Å, cell parameters from 26826 reflections, θ = 26-27.5°, μ = 0.09 mm–1,
specimen = 0.42 × 0.35 × 0.22 mm (colorless block). 46844 reflections were measured
to 2θmax = 55° and merged to 3625 unique reflections. Final R(3174 reflns with F2 >
2σ(F2)) = 0.037, wR (all data) = 0.101, S = 0.99. The crystal structure has been
deposited at the Cambridge Crystallographic Data Centre and allocated the deposition
number CCDC 872799.
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11.2.5. Experimental section of Chapter 6 (Ajania nubegina)
11.2.5.1. Identification of terpenoids and flavonoids from the EO and MeOH extract
The pale green pleasantly aromatic EO (7 mL) was obtained by hydrodistillation (temperature at 60 °C) from 1 kg of dried plant material of A. nubegina. A
capillary drop of this EO was analyzed using GC and GC-MS which detected 53
constituent peaks of the chromatographable fraction of the total injected oil (see
Chapter 6, Figure 6.1). Of these, 45 compounds were identified with (3R,6R)-linalool
oxide acetate (75.8 %) as the major constituent. The EO (6 mL) was purified using CC
over silica gel with a gradient elution by EtOAc-CH2Cl2 (100 mL in a v/v% ratio of
0:100, 40:60) which yielded fractions ANoil-F1 to ANoil-F9. Fraction ANoil-F6 was
further purified using CC over silica gel with a gradient elution by EtOAc-petroleum
spirit (100 mL in a v/v% ratio of 0:100, 10:90, 20:80 and 50:50) to give sub-fractions
ANoil-F6.1 to ANoil-F6.5. Sub-fraction ANoil-F6.1 upon concentration yielded
((3R,6R)-linalool oxide acetate (19) which was a major oil constituent (1.2 g),
Separation of fraction ANoil-F2 using the PTLC and the mobile phase system of
petroleum spirit (100%) furnished a sesquiterpenelactone (chamazulene (20)). Fractions
ANoil-F3 and ANoil-F4 were combined and separated using the PTLC and the mobile
phase system of CHCl3 (100%) which yielded two spiroethers ((E)-2-(2,4hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (21) and (Z)-2-(2,4-hexadinylidene)1,6-dioxaspiro[4,4]non-3-ene (22)).
Subsequent to the analysis of an essential oil of A. nubigena, its dried powdered
material was extracted with MeOH which yielded crude MeOH extract (80.12 g). This
extract was fractionated with hexane followed by ethyl acetate to obtain the hexane
extract (28 g) and the ethyl acetate extract (12.5 g). The initial silica gel column
chromatography separation of the ethyl acetate extract using gradient eluent solvent
system MeOH/CH2Cl2, yielded 17 fractions (AN-F1 to AN-F17). Separation of fraction
AN-F4 using reverse phase (RP) silica-coated TLC plates with a mobile phase of
H2O:MeOH (1:5) yielded 1-(4-hydroxyphenyl)propan-1-one (23) and oxyanin B (24).
Fractional crystallization of AN-F8 with MeOH/CHCl3 (1:1) yielded crystals of luteolin
(25) as the major chemical constituent of a plant. Purification of fraction AN-F14 using
RP silica gel column chromatography with an isocratic mobile phase of MeOH (100%)
furnished luteolin-7-O-β-D-glucopyranoside (26).
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11.2.5.2. Characterisation data for each compound
(3R,6R)-Linalool oxide acetate (19).
Colourless oil (1.2 g). LR-ESI-MS (m/z): 213 [M+H+]. LR-EI-MS (m/z): 212
(100%), 197, 195, 154, 153, 136, 114, 101, 94, 79, 68, 43. 1H-NMR (CDCl3, 500
MHz):  4.63 (1H, m, H-3), 2.16-2.09 (2H, m, H-4), 1.59-1.83 (2H, m, H-5), 5.92-6.02
(1H, m, H-7), 4.96-5.02 (2H, m, H-8), 1.17 (3H, s, H-9), 1.15 (3H, s, H-10), 1.20 (3H,
s, H-11), 2.02 (3H, s, H-13).

13

C-NMR (125 MHz, CDCl3):  74.1 (C-2), 76.0 (C-3),

31.8 (C-4), 22.2 (C-5), 73.5 (C-6), 146.0 (C-7), 110.7 (C-8), 31.3 (C-9), 21.9 (C-10),
29.3 (C-11), 170.4 (C-12), 21.2 (C-13). These 1H-NMR and

13

C-NMR spectroscopic

data agreed with those of (3R,6R)-linalool oxide acetate reported in the literature
(Chanotiya et al., 2005).

Chamazulene (20)
Dark blue coloured oil (2.6 mg). LR-ESI-MS (m/z): 185 [M+H+]. LR-EI-MS
(m/z): 184, 183, 169 (100%), 155, 153, 141, 128, 115, 77, 63, 51, 41, 39. 1H-NMR
(CDCl3, 500 MHz):  7.61 (1H, br s, H-2), 7.21 (1H, br s, H-3), 6.98 (1H, d, J = 10.5
Hz, H-5), 7.38 (1H, d, J = 10.0 Hz, H-6), 8.15 (1H, br s, H-8), 2.82 (3H, s, H-13 (Me)),
2.65 (3H, s, H-14 (Me)), 2.84 (2H, br s, H-11), 1.34 (3H, t, J = 8.0 Hz, H-12).

13

C-

NMR (125 MHz, CDCl3):  125.1 (C-1), 136.4 (C-2), 112.7 (C-3), 144.2 (C-4), 124.9
(C-5), 136.1 (C-6), 135.7 (C-7), 134.7 (C-8), 137.5 (C-9), 138.0 (C-10), 33.8 (C-11),
17.3 (H-12 (Me)), 24.1 (C-13 (Me), 12.8 (C-14 (Me)). These 1H-NMR and

13

C-NMR

spectroscopic data agreed with those of chamazulene reported in the literature (Adam
and Zapp, 1998; Carret et al., 2005; Cruz et al., 2006). .

(E)-2-(2,4-Hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (21)
Colourless liquid (87.0 mg). LR-ESI-MS (m/z): 201 [M+H+]. LR-EI-MS (m/z):
200 (M+) (100%), 185, 170, 157, 141, 128, 115, 102, 76. 1H-NMR (CDCl3, 500 MHz):
 1.98 (3H, s, H-1), 4.92 (1H, br s, H-6), 6.69 (1H, d, J = 5.7, H-8), 6.21 (1H, t, J = 5.0,
H-9), 2.00-2.30 (4H, m, H-11/12), 3.87-4.20 (2H, m, H-13).

13

C-NMR (125 MHz,

CDCl3, APT):  4.9 (C-1), 80.8 (C-2), 65.4 (C-3), 79.1 (C-4), 70.9 (C-5), 79.0 (C-6),
167.3 (C-7), 127.6 (C-8), 135.4 (C-9), 121.2 (C-10), 35.8 (C-11), 24.7 (C-12), 69.9 (C13). The 1H-NMR and

13

C-NMR spectroscopic data agreed with those of the (E)-

spiroether reported in the literature (Chanotiya et al., 2005).
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(Z)-2-(2,4-Hexadinylidene)-1,6-dioxaspiro[4,4]non-3-ene (22)
Colourless liquid (6.7 mg). LR-ESI-MS (m/z): 201 [M+H+]. LR-EI-MS (m/z):
200 (M+) (base peak), 185, 170, 157, 141, 128, 115, 102, 76.

1

H-NMR (CDCl3, 500

MHz):  1.99 (3H, s, H-1), 4.59 (1H, br s, H-6), 6.22 (1H, d, J = 5.5 Hz, H-8), 6.15
(1H, d, J = 5.5 Hz, H-9), 2.00-2.35 (4H, m, H-11/12), 3.97-4.25 (2H, m, H-13).

13

C-

NMR (125 MHz, CDCl3, APT):  4.7 (C-1), 78.4 (C-2), 65.1 (C-3), 76.7 (C-4), 70.7
(C-5), 80.5 (C-6), 167.1 (C-7), 127.4 (C-8), 135.2 (C-9), 121.0 (C-10), 35.5 (C-11),
24.5 (C-12), 69.6 (C-13). The 1H-NMR and

13

C-NMR spectroscopic data agreed with

those of the (Z)-spiroether reported in the literature (Chanotiya et al., 2005).

p-Hydroxyacetophenone (23)
Creamy white solid (11.3 mg). LR-EI-MS (m/z): 136 (M+), 121 (100%), 107, 93,
77, 65, 39 which matched the ion fragmentation pattern of p-hydroxyacetophenone
(NIST08s.LIB, Entry # 6281, CAS:99-93-4, RetIndex:1250). 1H-NMR (CDCl3, 500
MHz):  1.25 (3H, br s), 2.56 (2H, br s), 3.50 (1H, br s, OH), 6.88 (2H, d, J = 8.5 Hz),
7.90 (2H, d, J = 8.5 Hz). These 1H-NMR spectroscopic data agreed with those in the
literature (Makadia et al., 2011).

Oxyanin B (24)
Pale yellow solid (18.6 mg). LR-ESI-MS (m/z): 361 [M+H+]. LR-EI-MS (m/z):
360 (M+), 345, 327, 317, 299, 274, 246, 207, 164, 151, 135, 69. 1H NMR (500 MHz,
DMSO-d6):  6.52 (1H, s, H-8), 6.94 (1H, d, J = 8.5 Hz, H-3′), 7.54 (1H, d, J = 8.5 Hz,
H-2′), 7.61 (1H, s, H-6′), 3.49 (1H, bs, C(6)-OH), 12.73 (1H, bs, C(5)-OH), 3.73 (3H, s,
C(7)-OMe), 3.77 (3H, s, C(3)-OMe), 3.83 (3H, s, C(3′)-OMe).

13

C NMR (125 MHz,

DMSO-d6):  55.7 (C(4′)-OMe), 59.7 (C(3)-OMe), 59.8 (C(7)-OMe), 94.2 (C-8), 104.3
(C-10), 112.0 (C-6′), 115.6 (C-3′), 120.8 (C-1′), 122.1 (C-2′), 131.3 (C-7), 137.3 (C-3),
147.4 (C-4′), 149.7 (C-5′), 151.7 (C-6), 152.2 (C-5), 155.2 (C-2), 177.9 (C-4). The 1HNMR spectroscopic data agreed with those of oxyanin B reported in the literature
(Malan and Roux, 1979). The

13

C-NMR spectroscopic data for this compound are

reported here for the first time.
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Luteolin (25)
White solid (618.0 mg). LR-ESI-MS (m/z): 281 [M+H+]. LR-EI-MS (m/z): 286
(M+), 277, 258, 229, 153 (100%), 124, 96, 77, 69. 1H NMR (500 MHz, CD3OD):  6.19
(1H, br s), 6.41 (1H, br s), 6.51 (1H, br s), 6.88 (1H, d, J = 9.0 Hz), 7.35 (1H, s), 7.36
(1H, s). 13C NMR (125 MHz, CD3OD):  183.8 (C-4), 166.3 (C-2), 166.1 (C-7), 163.2
(C-5), 159.4 (C-9), 150.9 (C-4), 147.1 (C-3), 123.6 (C-6), 120.2 (C-1), 116.7 (C-5),
114.1 (C-2), 103.8 (C-10), 103.8 (C-3), 100.1 (C-6), 94.9 (C-8). It is the major
chemical constituent of the plant and its 1H-NMR and

13

C-NMR spectroscopic data

agreed with those of luteolin reported in the literature (Peters et al., 1986); Jung et al.,
2009).

Luteolin-7-O-β-D-glucopyranoside (26)
Faint yellow powder (41.3 mg). LR-ESI-MS (m/z): 449 (M+H+). LR-EI-MS
(m/z): 448, 281, 207, 191, 147, 133, 84, 73, 66, 44. 1H NMR (500 MHz, DMSO): 
7.44 (1H, dd, J = 8.5, 2.5 Hz, H-6′), 7.40 (1H, s, H-2′), 6.88 (1H, d, J = 8.0 Hz, H-5′),
6.77 (1H, d, J = 2.0 Hz, H-8), 6.74 (1H, s, H-3), 6.43 (1H, d, J = 2.0 Hz, H-6), 5.07
(1H, d, J = 7.0 Hz, glc-1), 3.14-3.70 (6H, m, glc-2 to glc-6).

13

C NMR (125 MHz,

DMSO):  181.9 (C-4), 164.5 (C-2), 162.9 (C-7), 161.1 (C-5), 156.9 (C-9), 150.0 (C4′), 145.8 (C-3′), 121.3 (C-1′), 119.1 (C-6′), 115.9 (C-5′), 113.5 (C-2′), 105.3 (C-10),
103.1 (C-3), 99.8 (glc-1), 99.5 (C-6), 94.7 (C-8), 77.1 (glc-5), 76.4 (glc-3), 73.1 (glc-2),
69.5 (glc-4), 60.6 (glc-6). These 1H-NMR and 13C-NMR spectroscopic data agreed with
those of luteolin-7-O-β-D-glucopyranoside reported in the literature (Wang et al.,
2003).

11.2.6. Experimental section of Chapter 7 (M. simplicifolia)
11.2.6.1. Phytochemical analysis of the EO and MeOH extract
The hydro-distillation of the dried aerial parts of M. simplicifolia (250 g) yielded
0.5% w/w of a pale green liquid EO which solidified (white) upon standing. The EO
was analysed for its chemical constituents using GC and GC-MS which identified 37
compounds as listed in Table 7.1 of Chapter 7. Subsequently, the air-dried plant
material was powered and was repeatedly extracted with methanol which yielded 60 g
of crude MeOH extract. The MeOH extract was acidified with 5% HCl and then
extracted with CH2Cl2 that yielded 9.8 g of CH2Cl2 extract. The remaining acidified
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aqueous solution was basified (pH 9-12) with NH4OH solution and then extracted with
CHCl3 which furnished 446 mg of CHCl3 extract.
Focusing on the alkaloids, the crude basic CHCl3 extract was subjected to initial
flash column chromatography (CC) over silica gel (120 g, 200-300 mesh), eluting with
a gradient solvent system of MeOH-CHCl3 (in a v/v% ratio of 0:100, 2:98, 4:96, 6:94,
8:92, 10:90, 20:80, 30:70, 50:50), which yielded fractions CHCl3-F1 to CHCl3-F8.
Fractions CHCl3-F7 and CHCl3-F8 were combined and separated by CC with a gradient
solvent system of MeOH-CHCl3 (200 mL, v/v% ratio of 20:80, 30:70) to obtain subfractions CHCl3-F78.1 to CHCl3-F78.5. Final separation of sub-fraction CHCl3-78.4
using PTLC and the mobile phase system of MeOH-CHCl3 (v/v ratio of 15:85) yielded
a new protoberberine type alkaloid, compound 27 which we named as simplicifolianine
after the plant name. Fractions CHCl3-F5 and CHCl3-F6 were combined and separated
using CC (gradient eluant, MeOH-CHCl3) followed by preparative thin layer
chromatography (PTLC) (mobile phase, MeOH-CHCl3 (4:96, 100 mL)) and this
yielded compound 1 which was identified as protopine. Fraction CHCl3-F1 upon final
separation using PTLC and CHCl3 as the mobile phase, and recrystallization using
MeOH/CHCl3 yielded compound 29 as small needles which was identified as
norsanguinarine.
Similarly, the crude acidic CH2Cl2 extract was separated using the flash CC on
silica gel eluting with a gradient solvent system of MeOH-CH2Cl2 (in a v/v% ratio of
0:100, 0.5:99.5, 1.5:98.5, 2.5:97.5, 3.5:96.5, 5:95, 10:90, 20:80, 50:50) which yielded
fractions CH2Cl2-F1 to CH2Cl2-F18. Fraction CH2Cl2-F4 upon crystallization from
CHCl3-MeOH (1:1) gave crystals of compound 30 which was identified as
dihydrosanguinarine. Fraction CH2Cl2-F10 upon separation using CC with a gradient
solvent system of MeOH-CH2Cl2 (in a v/v ratio of 0:100, 0.5:99.5, 1:99, 2:98, 5:95,
10:90, 100:0) gave sub-fractions CH2Cl2-F10.1 to CH2Cl2-F10.4. Crystallization of the
sub-fraction CH2Cl2-F10.1 from CHCl3-MeOH (97:3) furnished a crystalline
compound 31 which was identified as 6-methoxydihydrosanguinarine. The mother
liquor, from which compound 30 was obtained, was purified by CC eluting with CHCl3
(100%) to obtain five sub-fractions CH2Cl2-F4.1 to CH2Cl2-F4.5. The sub-fractions
CH2Cl2-F4.4 and CH2Cl2-F4.5 were combined and repeatedly separated. Final
separation of fraction CH2Cl2-F4.45.3.1 by PTLC (CHCl3-ethyl acetate-MeOH in v/v
ratio of 90:8:2), yielded compound 32 which was identified as oxysanguinarine.
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The structures of dihydrosanguinarine (30) and 6-methoxysanguinarine (31) were
confirmed by single crystal X-ray crystallographic analysis. Atomic coordinates, bond
lengths and angles and displacement parameters have been deposited at the Cambridge
Crystallographic Data Centre (CCDC no. 929725, 929726).

11.2.6.2. Characterisation data for each compound
Protopine (1)
White powder and prisms (63.5 mg, CHCl3/MeOH): The LR-ESI-MS, LR-EI1

MS, H- and 13C-NMR spectroscopic data were same as described in the experimental
section for Chapters 4 and 5.

Simplicifolianine (27) (Patent application number: BT/PT/13/04).
Light brown amorphous solid (3.0 mg). mp: 170.8-171.3 oC. LR-ESI-MS (m/z):
380 [M+]. LR-EI-MS (m/z): 380 [M+], 364, 350, 336, 308, 280, 228, 207, 191, 167, 149
(80%), 129, 111. HR-ESI-MS (m/z): 380.1130 [M]+ (380.1134 calc. for C21H18NO6).
1

H-NMR and 13C-NMR: see Table 7.1.

Norsanguinarine (29)
White feathery solid (3.0 mg). LR-ESI-MS (m/z): 318 [M+H+]. LR-EI-MS (m/z):
317 [M+, 100%], 288, 259, 230, 201, 174, 157. HR-ESI-MS (molecular formula):
C19H11NO4. 1H NMR (500 MHz, CDCl3):  7.25, (1H, s, H-1), 8.68 (1H, s, H-4), 9.45
(1H, s, H-6), 7.46 (1H, d, J = 10.0 Hz, H-9), 8.15 (1H, d, J = 10.0 Hz, H-10), 8.31 (1H,
d, J = 10.0 Hz, H-11), 7.85 (1H, d, J = 10.0 Hz, H-12), 6.13 (2H, s, H-13), 6.29 (2H, s,
H-14).

13

C NMR (125 MHz, CDCl3):  104.5 (C-1), 148.4 (C-2), 148.7 (C-3), 102.4

(C-4), 129.4 (C-4a), 140.0 (C-4b), 144.9 (C-6), 112.8 (C-6a), 143.7 (C-7), 145.3 (C-8),
113.7 (C-9), 115.7 (C-10), 128.2 (C-10a), 120.5 (C-10b), 118.5 (C-11), 127.5 (C-12),
129.9 (H-12a), 101.5 (C-13), 102.8 (C-14). These

1

H-NMR and

13

C-NMR

spectroscopic data agreed with those reported for norsanguinarine (Tousek et. al.,
2004).

Dihydrosanguinarine 30
Colourless crystals (11.6 mg, CHCl3/MeOH). LR-ESI-MS (m/z): 334 [M+H+].
LR-EI-MS (m/z): 333 [M+], 332 (100%), 317, 274, 260, 166, 151, 137, 122, 108, 94.
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HR-ESI-MS (molecular formula): C20H15NO4. 1H NMR (500 MHz, CDCl3):  7.10,
(1H, s, H-1), 7.66 (1H, s, H-4), 4.19 (1H, s, H-6), 6.85 (1H, d, J = 8.0 Hz, H-9), 7.30
(1H, d, J = 8.0 Hz, H-10), 7.69 (1H, d, J = 8.5 Hz, H-11), 7.48 (1H, d, J = 8.5 Hz, H12), 6.04 (2H, s, H-13), 6.03 (2H, s, H-14), 2.62 (3H, s, N-Me).

13

C NMR (125 MHz,

CDCl3):  104.3 (C-1), 148.8 (C-2), 147.5 (C-3), 100.7 (C-4), 126.5 (C-4a), 142.5 (C4b), 48.4 (C-6), 113.6 (C-6a), 144.3 (C-7), 147.2 (C-8), 107.2 (C-9), 116.18 (C-10),
127.3 (C-10a), 124.3 (C-10b), 120.3 (C-11), 123.9 (C-12), 131.0 (H-12a), 101.0 (C-13),
101.3 (C-14), 41.5 (N-Me). These 1H-NMR and

13

C-NMR spectroscopic data agreed

with those reported for dihydrosanguinarine (30) (Williams and Ellis, 1993; Choi et al.,
2010; Miao et. al, 2011; Yao et al., 2011). Crystal data for compound 30: C20H15NO4,
Mr 333.34, T = 200K, triclinic, Pī, a = 9.3269 (2) Å, b = 10.2708 (2) Å, c = 17.5397 (3)
Å, β = 100.3950 (12)°, V = 1536.33 (5) Å3, Z = 4, F(000) = 696, Dx = 1.441 g cm–3, μ =
0.10 mm–1, specimen = 0.47 × 0.34 × 0.26 mm (colourless block). 40000 reflections
were measured to 2θmax = 60° and merged to 8969 unique data. Final R = 0.066 [for
7763 reflections with F2 > 2σ(F2)], wR = 0.194 (all data), S = 1.02.

6-Methoxydihydrosanguinarine (31)
Colourless crystals (3.3 mg, CHCl3/MeOH). LR-ESI-MS (m/z): 364 [M+H+]. LREI-MS (m/z): 363 [M+], 332 (100%), 317, 274, 201, 166, 147, 137, 115, 101, 94. HRESI-MS (molecular formula): C21H17NO5. 1H NMR (500 MHz, CDCl3):  7.12, (1H, s,
H-1), 7.69 (1H, s, H-4), 5.37 (1H, s, H-6), 6.93 (1H, d, J = 8.0 Hz, H-9), 7.41 (1H, d, J
= 8.5 Hz, H-10), 7.76 (1H, d, J = 8.5 Hz, H-11), 7.48 (1H, d, J = 8.5 Hz, H-12), 6.06
(2H, s, H-13), 6.11 (2H, s, H-14), 2.74 (3H, s, N-Me), 3.45 (3H, s, OMe).

13

C NMR

(125 MHz, CDCl3):  104.6 (C-1), 147.4 (C-2), 148.2 (C-3), 100.5 (C-4), 126.8 (C-4a),
138.5 (C-4b), 85.8 (C-6), 113.1 (C-6a), 145.4 (C-7), 147.6 (C-8), 108.8 (C-9), 116.3
(C-10), 125.7 (C-10a), 122.7 (C-10b), 120.1 (C-11), 123.7 (C-12), 131.2 (H-12a), 101.0
(C-13), 101.7 (C-14), 40.6 (N-Me), 54.0 (OMe). These 1H-NMR and

13

C-NMR

spectroscopic data agreed with those reported for 6-methoxysanguinarine in the
literature (Zhang et al., 1995; Dostal et al., 1998; Choi et al., 2010; Miao et al., 2011).
Crystal data for compound 31: C21H17NO5, Mr 363.37, T = 200K, monoclinic, P21/n, a
= 12.3894 (3) Å, b = 7.7519 (1) Å, c = 18.2571 (4) Å, β = 103.7510 (11)°, V = 1703.18
(6) Å3, Z = 4, F(000) = 760, Dx = 1.417 g cm–3, μ = 0.10 mm–1, specimen = 0.59 × 0.22
× 0.10 mm (pale brown plate). 35751 reflections were measured to 2θmax = 55° and
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merged to 3876 unique data. Final R = 0.040 [for 2968 reflections with F2 > 2σ(F2)],
wR = 0.103 (all data), S = 0.98.

Oxysanguinarine (32)
Grey amorphous powder (2.5 mg). LR-ESI-MS (m/z): 348 [M+H+]. LR-EI-MS
(m/z): 347 [M+, 100%], 318, 302, 289, 274, 260, 246, 232, 203, 188, 173, 159, 137,
115, 102. HR-ESI-MS (molecular formula): C29H25NO5. 1H NMR (500 MHz, CDCl3):
 7.16, (1H, s, H-1), 7.57 (1H, s, H-4), 7.23 (1H, d, J = 8.0 Hz, H-9), 7.75 (1H, d, J =
8.5 Hz, H-10), 7.97 (1H, d, J = 9.0 Hz, H-11), 7.54 (1H, d, J = 8.5 Hz, H-12), 6.09 (2H,
s, H-13), 6.27 (2H, s, H-14), 3.90 (3H, s, N-Me). 13C NMR (125 MHz, CDCl3):  104.6
(C-1), 147.0 (C-2), 147.1 (C-3), 102.4 (C-4), 122.8 (C-4a), 135.7 (C-4b), 163.0 (C-6),
118.6 (C-6a), 147.8 (C-7), 148.0 (C-8), 113.1 (C-9), 115.4 (C-10), 129.0 (C-10a), 113.2
(C-10b), 118.6 (C-11), 123.5 (C-12), 131.8 (H-12a), 101.5 (C-13), 102.8 (C-14), 40.7
(N-Me). These 1H-NMR and

13

C-NMR spectroscopic data agreed with those reported

for oxysanguinarine (Williams and Ellis, 1993; Miao et al., 2011).

11.2.7. Experimental section of Chapter 8 (P. amabile)
11.2.7.1. Phytochemical analysis of the EO and MeOH extract
The dried plant material (250 g) was powdered and hydro-distilled for EO using
the Clevenger apparatus which yielded a pleasant and smooth smelling EO (1.8 mL).
The equipment, general protocols and isolation techniques were carried out as
described in the general experimental section. Fifty two components were identified
(Table 8.2, Chapter 8) by GC/GC-MS analysis including MS library matching and
Kovats retention indices (KI) comparisons with Adams (1995). The EO (383.0 mg) was
initially column chromatographed on a silica gel (120 g, 200-300 mesh) eluting with a
gradient solvent system of CHCl3-petroleum spirit (v/v ratio of 0:100, 5:95, 10:90,
15:85, 20:80, 30:70, 50:50, 70:30, 100:0) to obtain nine fractions, PAoil-1 to PAoil-9.
Further separation of PAoil-1, using reverse phase preparative silica gel plates with a
solvent system of H2O-MeOH (1:9) yielded (E)-isomyristicin (37) as the major
constituent of oil. Eluting fraction PAoil-5 with isocratic or fixed ratio solvent system
of petroleum spirit-CHCl3 (1:9) on a normal phase silica gel column furnished (E)isoapiol (38) and methyl eugenol (39). Separation of fraction PAoil-8 on a preparative
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silica plate using the solvent system of diethyl ether-petroleum spirit (3:7), furnished
(E)-isoelemicin (40).
Subsequent to the analysis of an EO of P. amabile, its dried powdered material
was extracted with MeOH which yielded crude MeOH extract (190.0 g). The crude
MeOH extract was dissolved in MeOH/water (1:9) and fractionated first with hexane
and petroleum spirit to obtain their respective extracts. The remaining aqueous portion
was acidified with HCl (5%) and fractionated with CH2Cl2 to obtain the acidic extract.
The aqueous component was again basified with NH4OH to pH 9-12 and then
fractionated with CHCl3 to obtain a basic CHCl3 extract followed by EtOAc and nbutanol giving EtOAc and BuOH extracts, respectively. The remaining aqueous layer
was dried to obtain H2O extract. Each of these extracts (50-100 mg) was used for
determining their biological activities. The initial purification was focused on the most
active CHCl3 extract (13.3 g) using the silica gel CC and the gradient eluent solvent
system of MeOH-CH2Cl2 (500 mL, v/v ratio as 0:100, 5:95, 10:90, 15:85, 50:50) which
yielded 13 fractions, CHCl3-F1 to CHCl3-F13). Separation of fraction CHCl3-5 using
PTLC plates with CH2Cl2 (100%) as an isocratic solvent system, yielded compounds
37-40 (Figure 8.1) which were also isolated earlier from its EO. Fraction CHCl3-F7 was
separated using the same method and solvent system as above which furnished psoralen
(41), bergapten (42) (as major compound) and isoimperatorin (43). Fraction CHCl3-F10
upon separation using preparative TLC plates with MeOH-CHCl3 (1:19) as the solvent
system yielded isopimpinellin (44), oxypeucedanin hydrate (45) and oxypeucedanin
methanolate (46). From the acidic petroleum spirit, CH2Cl2, and EtOAc, same
compounds were obtained.

11.2.7.2. Characterisation data for each compound
(E)-Isomyristicin (37)
Colourless oil (185.3 mg). LR-ESI-MS (m/z): 193 [M+H+]. LR-EI-MS (m/z): 192
(100%), 177, 165, 161, 147, 131, 119, 103, 91, 77, 65, 53, 39. 1H NMR (500 MHz,
CDCl3):  6.45 (1H, s, H-2), 6.55 (1H, s, H-6), 6.29 (1H, d, J = 15.6 Hz, H-1'), 6.07
(1H, m, H-2'), 1.84 (3H, d, J = 6.6 Hz, H-3'), 5.91 (2H, s), 3.87 (3H, s, OMe). 13C NMR
(125 MHz, CDCl3):  133.2 (C-1), 99.7 (C-2), 143.7 (C-3), 134.5 (C-4), 149.3 (C-5),
106.2 (C-6), 131.0 (C-1'), 124.8 (C-2'), 18.6 (C-3'), 101.5 (OCH2O), 56.7 (OMe). These
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1

H-NMR and 13C-NMR spectroscopic data agreed with those of isomyristicin reported

in the literature (Antunes et al., 1995; Enqiquez et al., 1980).

(E)-Isoapiol (38)
Liquid (30.7 mg). LR-ESI-MS (m/z): 222 [M+H+]. LR-EI-MS (m/z): 222
(100%), 207, 191, 177, 163, 149, 134, 121, 106, 91, 77, 65, 53, 39. 1H NMR (500 MHz,
CDCl3):  6.62 (1H, br s, H-6), 6.59 (1H, d, J = 16.0 Hz, H-1'), 6.06 (1H, m, H-2'), 1.88
(3H, d, J = 7.0 Hz, H-3'), 5.89 (2H, br s, OCH2O), 4.01 (3H, s, C-3-OMe), 3.75 (3H, s,
C-2-OMe).

13

C NMR (125 MHz, CDCl3):  124.9 (C-1), 125.1 (C-2), 137.5 (C-3),

136.4 (C-4), 143.8 (C-5), 98.3 (C-6), 124.7 (C-1'), 145.0 (C-2'), 18.7 (C-3'), 101.1
(OCH2O), 60.0 (C-3-OMe), 61.4 (C-2-OMe). These

1

H-NMR and

13

C-NMR

spectroscopic data agreed with those of isoapiol reported in the literature (Jakupovic
and Eid, 1987).

Methyl eugenol (39)
Colourless oil (44.7 mg). LR-ESI-MS (m/z): 179 [M+H+]. LR-EI-MS (m/z): 178
(100%), 163, 147, 135, 115, 107, 91, 77, 57, 41. 1H NMR (500 MHz, CDCl3):  6.716.80 (3H, m, H-2, H-5 and H-6), 3.34 (2H, d, J = 6.5 Hz, H-1'), 5.96 (1H, m, H-2'),
5.05-5.11 (2H, m, H-3'), 3.86 (3H, s, OMe), 3.88 (3H, s, OMe).

13

C NMR (125 MHz,

CDCl3):  120.4 (C-1), 111.8 (C-2), 147.3 (C-3), 148.8 (C-4), 111.2 (C-5), 132.6 (C-6),
39.7 (C-1'), 137.7 (C-2'), 115.6 (C-3'), 55.9 (OMe), 55.7 (OMe). These 1H-NMR and
13

C-NMR spectroscopic data agreed with those of methyl eugenol reported in the

literature (Miyazawa and Kohno, 2005).

(E)-Isoelemicin (40)
Colourless oil (3.4 mg). LR-ESI-MS (m/z): 209 [M+H+]. LR-ESI-MS (m/z): 208
[M+]. 1H NMR (500 MHz, CDCl3):  6.55 (2H, s), 6.31 (1H, d, J = 15.5 Hz), 6.13 (1H,
dq, J = 15.5, 6.5 Hz), 1.87 (3H, d, J = 6.5 Hz), 3.87 (6H, s), 3.83 (3H, s). This 1H-NMR
spectroscopic data agreed with those of (E)-isoelemicin reported in the literature
(Enqiquez et al., 1980).
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Psoralen (41)
White needles (23.8 mg, fromMeOH/CHCl3 (1:1)). LR-ESI-MS (m/z): 187
[M+H+]. LR-EI-MS (m/z): 186 [M+] (100%), 158, 130, 102, 93, 76, 102, 76, 63, 51. 1H
NMR (500 MHz, CDCl3):  6.37 (1H, d, J = 9.5 Hz, H-3), 7.81 (1H, d, J = 9.5 Hz, H4), 7.68 (1H, d, J = 5.5 Hz, H-5), 6.84 (1H, br s, H-8), 7.79 (1H, s, H-2'), 7.48 (1H, s,
H-3'). 13C NMR (125 MHz, CDCl3):  160.9 (C-2), 115.4 (C-3), 124.8 (C-4), 106.3 (C4a), 146.8 (C-5), 119.8 (C-6), 156.3 (C-7), 99.8 (C-8), 152.5 (C-8a), 144.0 (C-2'), 114.6
(C-3'). These 1H-NMR and 13C-NMR spectroscopic data agreed with those of psoralen
reported in the literature (Jiangning et al., 2005).

Bergapten (42)
Clear crystals (2.5 g, from MeOH/CHCl3 (1:1)). LR-ESI-MS (m/z): 217
[M+H+]. LR-EI-MS (m/z): 216 [M+], 202 (100%), 192, 173, 158, 145, 131, 118, 102,
89, 74, 69, 63, 51. 1H NMR (500 MHz, CDCl3):  6.27 (1H, d, J = 9.5 Hz, H-3), 8.15
(1H, d, J = 10.0 Hz, H-4), 7.12 (1H, s, H-8), 7.59 (1H, d, J = 2.5 Hz, H-2'), 7.02 (1H, d,
J = 2.0 Hz, H-3'), 4.27 (3H, s, 5-OMe).

13

C NMR (125 MHz, CDCl3):  161.4 (C-2),

112.7 (C-3), 139.4 (C-4), 106.6 (C-4a), 149.7 (C-5), 112.9 (C-6), 158.5 (C-7), 93.9 (C8), 152.9 (C-8a), 144.9 (C-2'), 105.2 (C-3'), 60.3 (5-OMe). These 1H-NMR and

13

C-

NMR spectroscopic data agreed with those of bergapten reported in the literature
(O’Neill et al., 2013; Kawaii et al., 1999).

Isoimperatorin (43)
Clear crystals (143.1 mg, from MeOH/CHCl3 (1:3)). LR-ESI-MS (m/z): 271
+

[M+H ]. LR-EI-MS (m/z): 270 [M+], 202 (100%), 174, 158, 145, 131, 118, 103, 89, 69,
51. 1H NMR (500 MHz, CDCl3):  6.26 (1H, d, J = 10.0 Hz, H-3), 8.15 (1H, d, J = 9.5
Hz, H-4), 7.14 (1H, s, H-8), 7.59 (1H, d, J = 2.0, Hz, H-2'), 6.95 (1H, d, J = 1.0 Hz, H3'), 4.91 (2H, d, J = 7.5 Hz, H-1"), 5.53 (1H, t, J = 7.0 Hz, H-2"), 1.80 (3H, s, 4"-Me),
1.70 (3H, s, 5"-Me).

13

C NMR (125 MHz, CDCl3):  161.4 (C-2), 112.7 (C-3), 139.6

(C-4), 107.6 (C-4a), 149.1 (C-5), 114.3 (C-6), 158.1 (C-7), 94.3 (C-8), 152.6 (C-9),
145.0 (C-2'), 105.2 (C-3'), 69.9 (C-1"), 119.3 (C-2"), 139.8 (C-3"), 25.9 (C-4"), 18.4
(C-5"). These 1H-NMR and

13

C-NMR spectroscopic data agreed with those of

isoimperatorin reported in the literature (Tian et al., 2013; Jackson et al., 1990).
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Isopimpinellin (44)
Faint yellow solid (93.8 mg). LR-ESI-MS (m/z): 247 [M+H+]. LR-EI-MS (m/z):
246 [M+], 232 (100%), 216, 202, 188, 173, 160, 148, 139, 116, 194, 91, 74, 60, 50. 1H
NMR (500 MHz, CDCl3):  6.30 (1H, d, J = 10.0 Hz, H-3), 8.13 (1H, d, J = 10.0 Hz,
H-4), 7.63 (1H, d, J = 2.5, Hz, H-2'), 7.00 (1H, d, J = 2.5 Hz, H-3'), 4.17 (3H, s, OMe),
4.16 (3H, s, OMe). 13C NMR (125 MHz, CDCl3):  160.5 (C-2), 112.8 (C-3), 139.5 (C4), 107.6 (C-4a), 144.4 (C-5), 114.7 (C-6), 150.1 (C-7), 127.4 (C-8), 143.7 (C-8a),
145.2 (C-2'), 105.2 (C-3'), 61.7 and 60.9 (OMe). These 1H-NMR and

13

C-NMR

spectroscopic data agreed with those of isopimpinellin reported in the literature (Yoo et
al., 2002).

Oxypeucedanin hydrate (45)
Light yellowish needles (109.7 mg, from MeOH/CHCl3(1:2)). LR-ESI-MS (m/z):
305 [M+H+]. LR-EI-MS (m/z): 304 [M+], 244, 215, 202 (100%), 174, 145, 118, 89, 59,
51. 1H NMR (500 MHz, CDCl3):  6.26 (1H, d, J = 9.5 Hz, H-3), 8.17 (1H, d, J = 10.0
Hz, H-4), 7.15 (1H, br s, H-8), 7.60 (1H, d, J = 2.0, Hz, H-2'), 6.99 (1H, s, H-3'), 4.49
(2H, dq, 2.5, 7.5, 10.0 Hz, H-1"), 3.91 (2H, dd, 2.5, 7.5 Hz, H-2"), 1.36 (3H, s, 3"-Me),
1.31 (3H, s, 3"-Me).

13

C NMR (125 MHz, CDCl3):  161.3 (C-2), 113.1 (C-3), 139.2

(C-4), 107.3 (C-4a), 148.6 (C-5), 114.3 (C-6), 158.2 (C-7), 94.8 (C-8), 152.5 (C-8a),
145.3 (C-2'), 104.8 (C-3'), 74.5 (C-1"), 76.6 (C-2"), 71.8 (C-3"), 26.7 (3"-Me), 25.2
(3"-Me). These 1H-NMR and

13

C-NMR spectroscopic data agreed with those of

isopimpinellin reported in the literature (Fujioka et al., 1999).

Oxypeucedanin methanolate (46)
White amorphous solid (295.2 mg). LR-ESI-MS (m/z): 319 [M+H+]. LR-EI-MS
(m/z): 318 [M+], 286, 215, 202 (100%), 185, 174, 157, 145, 118, 99, 85, 73, 59, 51. 1H
NMR (500 MHz, CDCl3):  6.26 (1H, d, J = 9.5 Hz, H-3), 8.23 (1H, d, J = 9.5 Hz, H4), 7.15 (1H, d, J = 6.0 Hz, H-8), 7.61 (1H, d, J = 2.0, Hz, H-2'), 7.00 (1H, s, H-3'),
4.49 (2H, dq, J = 2.5, 9.5 Hz, H-1"), 3.96 (1H, dd, J = 2.5, 7.5 Hz, H-2"), 3.28 (3H, s,
3"-OMe), 1.27 (3H, s, 3"-Me), 1.24 (3H, s, 3"-Me).

13

C NMR (125 MHz, CDCl3): 

161.4 (C-2), 112.9 (C-3), 139.5 (C-4), 107.4 (C-4a), 148.9 (C-5), 114.1 (C-6), 158.2
(C-7), 94.6 (C-8), 152.7 (C-8a), 145.1 (C-2'), 105.0 (C-3'), 74.4 (C-1"), 76.1 (C-2"),
71.4 (C-C"), 20.7 (3"-Me), 20.9 (3"-Me), 49.4 (3"-OMe), These 1H-NMR and
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NMR spectroscopic data agreed with those of oxypeucedanin methanolate reported in
the literature (Fujioka et al., 1999).

11.2.8. Experimental section of Chapter 9 (A. laciniatum)
11.2.8.1. Phytochemical analysis of the MeOH extract
The dried roots of A. laciniatum was powdered and extracted with MeOH to
generate the crude MeOH extract (165 g). This extract was dissolved in MeOH/water
(1:9) and then acidified with 5% HCl and fractionated with CH2Cl2 to give the acidic
fraction (coded as DCM-1, (6.2 g)). The aqueous part was basified with NH4OH to pH
9-12 and then fractionated with CH2Cl2 to give the basic extract (coded as DCM-2, (2.4
g)) followed by ethyl acetate and n-butanol to give the respective EtOAc (0.11g) and
BuOH extracts (1.7 g). The initial purification of the DCM-1 extract by using the silica
gel packed CC and the gradient eluent solvent system of CH2Cl2/MeOH (100 mL, v/v
ratio as 0:100, 10:90, 20:80, 30:70, 50:50) yielded eight fractions, DCM-1-F1 to DCM1-F8. Further separation of fraction DCM-1-F4 using PTLC plates with the solvent
system of MeOH-CH2Cl2-NH4OH (2:23:6 drops) furnished a white solid which upon
crystallization with CHCl3/MeOH (1:1) gave prisms. This compound was identified as
pseudaconitine (72) through NMR spectroscopic analysis. Separation of fraction DCM1-F8 using the PTLC plates with the solvent system of MeOH-CH2Cl2-NH4OH (1:9:6
drops) yielded 14-veratroylpseudaconine (73).
Similarly, another fraction DCM-2 was subjected to a silica gel packed CC and
the gradient eluent solvent system of CH2Cl2/MeOH (100 mL, v/v ratio as 0:100, 1:99,
2:98, 4:96, 8:92, 15:85, 30:70) yielded eight fractions, DCM-2-F1 to DCM-2-F8.
Fraction DCM-2-F2 when dried furnished amorphous white solid which was identified
as 14-O-acetylneoline (74). Fraction DCM-2-F3 upon drying under reduced pressure
yielded neoline (75). Fraction DCM-2-F7 (105.0 mg) was further separated using
PTLC plates with the solvent system of MeOH-CH2Cl2 (2:23) which gave senbusine A
(76). Their structures were first elucidated using 1D and 2D NMR spectroscopic data
and then confirmed by comparing with the relevant literature (see Chapter 9 for the
details). The EtOAc and BuOH extracts were not analysed here due to time constraints.
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11.2.8.2. Characterisation data of each compound
Pseudaconitine (72)
Prismic crystals (1.9 g, from CHCl3/MeOH, (1:1)). LR-ESI-MS (m/z): 690
[M+H+]. LR-EI-MS (m/z): 689 [M+], 675, 658, 642, 629, 614, 598, 585, 464, 432, 330,
266, 252, 236, 202, 182, 178, 165, 137,86, 75, 58, 45. 1H NMR (500 MHz, CDCl3): 
3.04-3.20 (1H, m, H-1), 1.95-2.11 (1H, m, Ha-2), 2.25-2.45 (1H, m, Hb-2), 3.79 (1H, m,
H-3), 2.10-2.16 (1H, m, H-5), 4.03 (1H, d, J = 6.5 Hz, H-6), 2.90 (1H, m, H-7), 2.892.95 (1H, m, H-9), 2.10-2.15 (1H, m, H-10), 2.55-2.63 (2H, m, H-12), 4.87 (1H, d, J =
4.5 Hz, H-14), 2.40-2.55 (1H, m, Ha-15), 3.06-3.14 (1H, m, Hb-15), 3.38-3.41 (1H, t, J
= 7.5, H-16), 3.02 (1H, br s, H-17), 3.51-3.53 (1H, m, Ha-18), 3.62-3.65 (1H, m, Hb18), 2.25-2.45 (1H, m, Ha-19), 2.90-2.96 (1H, m, Hb-19), 2.35-2.60 (2H, m, H-20), 1.13
(3H, t, J = 7.0 Hz, 21-Me), 3.26 (3H, s, 1-OMe), 3.17 (3H, s, 6-OMe), 3.54 (3H, s, 16OMe), 3.30 (3H, s, 18-OMe), 3.91 (3H, s, 3'-OMe), 3.94 (3H, s, 4'-OMe), 1.34 (3H, s,
8-OAc), 2.10 (1H, s, 3-OH), 3.85 (1H, s, 13-OH), 7.62 (1H, s, H-2'), 6.90 (1H, d, J =
8.5, H-5'), 7.70 (1H, d, J = 8.0, H-6'). This 1H-NMR spectroscopic data agreed with
those of pseudaconitine reported in the literature (Hanuman and Katz, 1993).

14-Veratroylpseudaconine (73)
Amorphous white solid (28.7 mg). LR-ESI-MS (m/z): 648 [M+H+]. LR-EI-MS
(m/z): 647 [M+], 631, 616, 599, 557, 435, 182, 165, 149, 125, 111, 97, 71, 57, 41. HRESI-MS (molecular formula): C34H49NO11. 1H NMR (500 MHz, CDCl3):  3.13 (1H,
dd, J = 6.5 Hz, H-1), 2.04-2.11 (1H, m, Ha-2), 2.26-2.46 (1H, m, Hb-2), 3.64-3.77 (1H,
m, H-3), 2.04-2.11 (1H, m, H-5), 4.07 (1H, d, J = 6.5 Hz, H-6), 2.46-2.52 (1H, m, H-7),
2.52-2.57 (1H, m, H-9), 2.04-2.11 (1H, m, H-10), 2.03-2.11 (1H, m, Ha-12), 2.31-2.57
(1H, m, Hb-12), 5.12 (1H, d, J = 5.5 Hz, H-14), 2.27-2.41 (1H, m, Ha-15), 2.51-2.64
(1H, m, Hb-15), 3.33-3.38 (1H, m, H-16), 3.01 (1H, br s, H-17), 3.64-3.77 (2H, m, H18), 2.43-2.45 (1H, m, Ha-19), 2.88-3.07 (1H, m, Hb-19), 2.39-2.57 (2H, m, H-20), 1.11
(3H, t, J = 7.0 Hz, 21-Me), 3.28 (3H, s, 1-OMe), 3.25 (3H, s, 6-OMe), 3.42 (3H, s, 16OMe), 3.31 (3H, s, 18-OMe), 3.93 (3H, s, 3'-OMe), 3.94 (3H, s, 4'-OMe), 2.06 (1H, br
s, 3-OH), 2.27 (1H, s, 8-OH), 3.67 (1H, s, 13-OH), 7.60 (1H, br s, H-2'), 6.90 (1H, d, J
= 8.5, H-5'), 7.67 (1H, d, J = 8.5, H-6').

13

C NMR (125 MHz, CDCl3):  82.7 (C-1),

33.7 (C-2), 72.1 (C-4), 42.5 (C-4), 48.0 (C-5), 82.6 (C-6), 53.6 (C-7), 74.0 (C-8), 47.9
(C-9), 42.1 (C-10), 50.4 (C-11), 35.8 (C-12), 76.0 (C-13), 79.9 (C-14), 42.2 (C-15),
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83.3 (C-16), 62.0 (C-17), 77.5 (C-18), 47.6 (C-19), 49.1 (C-20), 13.6 (C-21), 56.0 (C1'), 57.7 (C-6'), 58.5 (C-16'), 59.3 (C-18'), 166.5 (O=C), 122.5 (C-1), 110.5 (C-2),
148.8 (C-3), 153.3 (C-4), 112.3 (C-5), 123.9 (C-6), 56.2 (C-3'), 56.0 (C-4'). These 1HNMR and APT spectroscopic data agreed with those of 14-veratroylpseudaconine
reported from another species, A. ferox (Hanuman and Katz, 1993) and A. falconeri
(Taylor and Francis, 2013).

14-O-Acetylneoline (74)
Amorphous white solid (46.9 mg). LR-ESI-MS (m/z): 690 [M+H+]. HR-EI-MS
(molecular formula): C26H41NO7. 1H NMR (500 MHz, CDCl3):  3.69 (1H, br s, H-1),
1.50-1.63 (2H, m, H-2), 1.57-1.63 (2H, m, H-3), 2.19 (1H, d, J = 7.0, H-5), 4.11 (1H,
d, J = 6.0 Hz, H-6), 2.00 (1H, s, H-7), 2.24 (1H, t, J = 5.5 Hz, H-9), 2.60-2.63 (1H, m,
H-10), 1.77-1.81 (2H, m, H-12), 2.30-2.35 (1H, m, H-13), 4.85 (1H, t, J = 4.0 Hz, H14), 1.88-1.93 (1H, m, Ha-15), 2.30-2.32 (1H, m, Hb-15), 3.29-3.30 (1H, m, H-16), 2.67
(1H, s, H-17), 3.23-3.62 (2H, d, J = 8.0 Hz, H-18), 2.31-2.69 (2H, m, H-19), 2.45-2.58
(2H, m, H-20), 1.13 (3H, t, J = 7.0 Hz, 21-Me), 3.34 (3H, s, 6-OMe), 3.26 (3H, s, 16OMe), 3.32 (3H, s, 18-OMe), 2.06 (3H, s, OCO-Me). 13C NMR (125 MHz, CDCl3): 
72.2 (C-1), 29.4 (C-2), 30.0 (C-4), 30.2 (C-4), 44.5 (C-5), 83.4 (C-6), 52.7(C-7), 74.7
(C-8), 46.2 (C-9), 36.7 (C-10), 49.7 (C-11), 29.6 (C-12), 43.4 (C-13), 77.2 (C-14), 42.7
(C-15), 82.0 (C-16), 63.4 (C-17), 80.2 (C-18), 57.1 (C-19), 48.4 (C-20), 13.1 (C-21),
58.1 (6-OMe), 56.2 (16-OMe), 59.3 (18-OMe), 21.3 (OCO-Me), 170.5 (O-C-OMe).
These

1

H-NMR and

13

C-NMR spectroscopic data agreed with those of 14-O-

acetylneoline isolated from aphids, Brachycaudus aconiti which lives and feeds on A.
napellus (Liu et al., 1996).

Neoline (75)
Pale yellow powder (428.5 mg). LR-ESI-MS (m/z): 438 [M+H+]. LR-EI-MS
(m/z): 437 [M+]. HR-EI-MS (molecular formula): C24H39NO6. 1H NMR (500 MHz,
CDCl3):  3.66 (1H, br s, H-1), 1.46-1.61 (1H, m, Ha-2), 1.88-1.97 (1H, m, Hb-2), 1.461.61 (2H, m, H-3), 2.17 (1H, d, J = 7.0 Hz, H-5), 4.15-4.17 (1H, m, H-6), 2.05 (1H, br
s, H-7), 2.16-2.22 (1H, m, H-9), 1.80-1.98 (1H, m, H-10), 1.60-1.75 (1H, m, Ha-12),
1.96-2.07 (1H, m, Hb-12), 2.29-2.33 (2H, m, H-13), 4.83 (1H, t, J = 4.0 Hz, H-14), 7.38
(14-OH), 2.08-2.15 (1H, m, Ha-15), 2.34-2.50 (1H, m, Hb-15), 3.29-3.35 (1H, m, H-16),
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2.66 (1H, br s, H-17), 3.63 (2H, d, J = 8.0 Hz, H-18), 3.25-3.29 (1H, m, Ha-19), 2.292.33 (1H, m, Hb-19), 2.66-2.71 (2H, m, H-20), 1.12 (3H, t, J = 7.5 Hz, 21-Me), 3.32
(3H, s, 6-OMe), 3.34 (3H, s, 16-OMe), 3.34 (3H, s, 18-OMe). These 1H-NMR
spectroscopic data agreed with those of neoline isolated from A. ferox (Hanuman and
Katz, 1994).

Senbusine A (76)
Amorphous power (13.8 mg). LR-ESI-MS (m/z): 424 [M+H+]. LR-EI-MS (m/z):
423 [M+]. 1H NMR (500 MHz, CDCl3):  3.66 (1H, br s, H-1), 1.49-1.61 (1H, m, Ha-2),
1.83-1.93 (1H, m, Hb-2), 1.49-1.61 (2H, m, H-3), 2.10 (1H, br s, H-5), 4.20 (1H, br s,
H-6), 1.93 (1H, br s, H-7), 2.18 (1H, br s, H-9), 1.86-1.90 (1H, m, H-10), 1.64-1.74
(1H, m, Ha-12), 2.02-2.09 (1H, m, Hb-12), 2.27-2.34 (2H, m, H-13), 4.78 (1H, d, J =
6.0 Hz, H-14), 2.02-2.09 (2H, m, H-15), 3.25-3.37 (1H, m, H-16), 2.66 (1H, br s, H17), 3.31-3.42 (2H, m, H-18), 3.66-3.72 (1H, m, Ha-19), 2.32-2.38 (1H, m, Hb-19),
2.80-2.52 (2H, m, H-20), 1.14 (3H, t, J = 7.0 Hz, 21-Me), 3.34 (3H, s, 16-OMe), 3.33
(3H, s, 18-OMe).

13

C NMR (125 MHz, CDCl3):  72.3 (C-1), 29.4 (C-2), 29.9 (C-4),

38.0 (C-4), 48.4 (C-5), 73.2 (C-6), 55.6 (C-7), 75.3 (C-8), 46.0 (C-9), 44.3 (C-10), 50.0
(C-11), 29.6 (C-12), 40.4 (C-13), 75.9 (C-14), 42.5 (C-15), 82.0 (C-16), 64.0 (C-17),
80.6 (C-18), 57.2 (C-19), 48.6 (C-20), 13.2 (C-21), 56.5 (16-OMe), 59.4 (18-OMe).
These 1H-NMR and also its APT spectroscopic data agreed with those of senbusine A
isolated from A. carmichaeli and A. ferox (Konno et al., 1982; Hanuman and Katz,
1994).
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